<SEC-DOCUMENT>0000926617-17-000049.txt : 20170811
<SEC-HEADER>0000926617-17-000049.hdr.sgml : 20170811
<ACCEPTANCE-DATETIME>20170811160219
ACCESSION NUMBER:		0000926617-17-000049
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		34
CONFORMED PERIOD OF REPORT:	20170630
FILED AS OF DATE:		20170811
DATE AS OF CHANGE:		20170811

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			VERMILLION, INC.
		CENTRAL INDEX KEY:			0000926617
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		IRS NUMBER:				330595156
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-34810
		FILM NUMBER:		171024995

	BUSINESS ADDRESS:	
		STREET 1:		12117 BEE CAVES ROAD BUILDING THREE
		STREET 2:		SUITE 100
		CITY:			AUSTIN
		STATE:			TX
		ZIP:			78738
		BUSINESS PHONE:		512-519-0400

	MAIL ADDRESS:	
		STREET 1:		12117 BEE CAVES ROAD BUILDING THREE
		STREET 2:		SUITE 100
		CITY:			AUSTIN
		STATE:			TX
		ZIP:			78738

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CIPHERGEN BIOSYSTEMS INC
		DATE OF NAME CHANGE:	20000316

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ABIOTIC SYSTEMS
		DATE OF NAME CHANGE:	19950407
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>c617-20170630x10q.htm
<DESCRIPTION>10-Q
<TEXT>
<!--HTML document created with Certent Disclosure Management 6.8.4.2-->
<!--Created on: 8/11/2017 2:59:05 PM-->
<html>
	<head>
		<title>
			2017-06-30 10Q Q2
		</title>
	</head>
	<body><div style="margin-left:72pt;margin-right:72pt;">
		<p style="margin:0pt 0pt 8pt;border-top:2pt double #000000 ;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 2pt">
			<a name="_GoBack"></a><font style="display: inline;font-weight:bold;font-size:2pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 8pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 16pt">
			<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:16pt;">UNITED STATES</font>
		</p>
		<p style="margin:0pt 0pt 8pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 16pt">
			<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:16pt;">SECURITIES AND EXCHANGE COMMISSION</font>
		</p>
		<p style="margin:0pt 0pt 8pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 11pt">
			<font style="display: inline;font-family:Times New Roman;font-weight:bold;">W</font><font style="display: inline;font-family:Times New Roman;font-weight:bold;">ASHINGTON</font><font style="display: inline;font-family:Times New Roman;font-weight:bold;">, &nbsp;</font><font style="display: inline;font-family:Times New Roman;font-weight:bold;">DC</font><font style="display: inline;font-family:Times New Roman;font-weight:bold;"> 20549</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 11pt">
			<font style="display: inline;font-family:Times New Roman;text-decoration:underline;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 8pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 16pt">
			<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:16pt;">FORM 10-Q</font>
		</p>
		<p style="margin:0pt 0pt 8pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 11pt">
			<font style="display: inline;font-family:Times New Roman;text-decoration:underline;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 8pt;font-family:Calibri;line-height:107.92%;font-size: 11pt">
			<font style="display: inline;font-family:Times New Roman;font-weight:bold;">(Mark One)</font>
		</p>
		<p style="margin:0pt 0pt 8pt;font-family:Calibri;line-height:107.92%;font-size: 4pt">
			<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:4pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;border-bottom:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">&#x2611;</font><font style="display: inline;font-weight:bold;"> &nbsp;&nbsp;&nbsp; </font><font style="display: inline;font-weight:bold;">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15</font><font style="display: inline;font-weight:bold;">(d) </font><font style="display: inline;font-weight:bold;">OF THE SECURITIES EXCHANGE ACT OF 1934</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 4pt">
			<font style="text-indent:0pt;margin-left:0pt; padding-right:347.35pt;"></font><font style="text-indent:0pt;margin-left:0pt; padding-right:4pt;text-align:left"><font style="display: inline;font-weight:bold;font-size:4pt;"></font></font>
		</p>
		<p style="margin:0pt;text-align:center;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">For the quarterly period ended </font><font style="display: inline;font-weight:bold;">June 30</font><font style="display: inline;font-weight:bold;">, &nbsp;</font><font style="display: inline;font-weight:bold;">201</font><font style="display: inline;font-weight:bold;">7</font>
		</p>
		<p style="margin:0pt;text-align:center;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:center;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">OR</font>
		</p>
		<p style="margin:0pt;text-align:center;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">&#x2610;</font><font style="display: inline;font-weight:bold;"> &nbsp;&nbsp;&nbsp; </font><font style="display: inline;font-weight:bold;">TRANSITION REPORT </font><font style="display: inline;font-weight:bold;">PURSUANT TO</font><font style="display: inline;font-weight:bold;">&nbsp;</font><font style="display: inline;font-weight:bold;">SECTION 13 OR 15</font><font style="display: inline;font-weight:bold;">(d) </font><font style="display: inline;font-weight:bold;">OF THE SECURITIES EXCHANGE ACT OF 1934</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 4pt">
			<font style="display: inline;font-weight:bold;font-size:4pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-align:center;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">For the transition period from ______ to ______</font>
		</p>
		<p style="margin:0pt;text-align:center;border-top:1pt none #D9D9D9 ;line-height:100%;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 8pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 11pt">
			<font style="display: inline;font-family:Times New Roman;font-weight:bold;">Commission </font><font style="display: inline;font-family:Times New Roman;font-weight:bold;">f</font><font style="display: inline;font-family:Times New Roman;font-weight:bold;">ile </font><font style="display: inline;font-family:Times New Roman;font-weight:bold;">n</font><font style="display: inline;font-family:Times New Roman;font-weight:bold;">umber:&nbsp;&nbsp;001-34810</font>
		</p>
		<p style="margin:0pt 0pt 8pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 11pt">
			<font style="display: inline;font-family:Times New Roman;text-decoration:underline;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 8pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 11pt">
			<font style="display: inline;font-family:Times New Roman;"><img src="c617-20170630x10qg001.jpg" style="width: 2.572917in; height: 0.6041667in" alt="Picture 17"></font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 41.66%;margin-left:0pt;">
			<tr>
				<td valign="middle" style="width:100.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size: 1pt">
						<font style="display: inline;font-family:Times New Roman;font-size:1pt;">&#xFEFF;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:100.00%;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:115%;font-family:Calibri;font-size: 1pt">
						<font style="display: inline;font-family:Times New Roman;font-size:1pt;">&#xFEFF;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:100.00%;height:4.05pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:115%;font-family:Calibri;font-size: 1pt">
						<font style="display: inline;font-family:Times New Roman;font-size:1pt;">&#xFEFF;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:100.00%;height:36.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:115%;text-align:center;font-family:Calibri;font-size: 20pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:20pt;">Vermillion, Inc.</font></p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:100.00%;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:115%;text-align:center;font-family:Calibri;font-size: 11pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;">(Exact Name of Registrant as Specified in Its Charter)</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt 0pt 8pt;font-family:Calibri;line-height:107.92%;font-size: 11pt">
			<font style="display: inline;font-family:Times New Roman;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 8pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 11pt">
			<font style="display: inline;font-family:Times New Roman;text-decoration:underline;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="middle" style="width:56.44%;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:115%;font-family:Calibri;height:1.00pt;overflow:hidden;font-size: 1pt">
						<font style="display: inline;font-family:Times New Roman;font-size:1pt;">&#xFEFF;</font></p>
				</td>
				<td valign="middle" style="width:02.32%;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:115%;font-family:Calibri;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:41.24%;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:115%;font-family:Calibri;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:56.44%;height:12.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:115%;text-align:center;font-family:Calibri;font-size: 9pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:9pt;">Delaware </font></p>
				</td>
				<td valign="middle" style="width:02.32%;height:12.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:115%;text-align:center;font-family:Calibri;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:41.24%;height:12.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:115%;text-align:center;font-family:Calibri;font-size: 9pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:9pt;">33-0595156 </font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:56.44%;height:12.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:115%;text-align:center;font-family:Calibri;font-size: 9pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:9pt;">(State or </font><font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:9pt;">Other Jurisdiction</font><font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:9pt;"> of </font><font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:9pt;">Incorporation or Organization</font><font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:9pt;">)</font></p>
				</td>
				<td valign="top" style="width:02.32%;height:12.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:115%;text-align:center;font-family:Calibri;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:41.24%;height:12.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:115%;text-align:center;font-family:Calibri;font-size: 9pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:9pt;">(I.R.S. Employer Identification No.)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:56.44%;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:115%;text-align:center;font-family:Calibri;font-size: 9pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:9pt;">12117 Bee Caves Road, Building Three, Suite 100, Austin, Texas </font></p>
				</td>
				<td valign="bottom" style="width:02.32%;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:115%;text-align:center;font-family:Calibri;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:41.24%;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:115%;text-align:center;font-family:Calibri;font-size: 9pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:9pt;">78738</font></p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:56.44%;height:12.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:115%;text-align:center;font-family:Calibri;font-size: 9pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:9pt;">(Address of </font><font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:9pt;">Principal Executive Offices</font><font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:9pt;">)</font></p>
				</td>
				<td valign="middle" style="width:02.32%;height:12.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:115%;text-align:center;font-family:Calibri;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:41.24%;height:12.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:115%;text-align:center;font-family:Calibri;font-size: 9pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:9pt;">(Zip Code)</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt 0pt 8pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 4pt">
			<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:4pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 8pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 11pt">
			<font style="display: inline;font-family:Times New Roman;font-weight:bold;">(512) 519-0400</font>
		</p>
		<p style="margin:0pt 0pt 8pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 9pt">
			<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:9pt;">(Registrant&#x2019;s </font><font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:9pt;">Telephone Number, Including Area Code</font><font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:9pt;text-decoration:underline;">)</font>
		</p>
		<p style="margin:0pt 0pt 8pt;font-family:Calibri;line-height:107.92%;font-size: 5pt">

		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;"></font><font style="display: inline;">1</font><font style="display: inline;"></font>

		</p>

		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt">

			&nbsp;

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<p style="margin:0pt 0pt 8pt;font-family:Calibri;line-height:107.92%;;font-size: 5pt"><font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:5pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 8pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 11pt">
			<font style="display: inline;font-family:Times New Roman;text-decoration:underline;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 8pt;font-family:Calibri;line-height:107.92%;font-size: 4pt">
			<font style="display: inline;font-family:Times New Roman;font-size:4pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 8pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.&nbsp;&nbsp;Yes&nbsp;</font><font style="display: inline;font-size:10pt;">&#x2611;</font><font style="display: inline;">&nbsp;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">No&nbsp;</font><font style="display: inline;font-size:10pt;">&#x2610;</font>
		</p>
		<p style="margin:0pt 0pt 8pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 8pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (&#xA7;232.405 of this </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">chapter</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">) during the preceding 12 months (or for </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">such </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">shorter period that the registrant was required to submit and post such files).&nbsp;&nbsp;Yes&nbsp;</font><font style="display: inline;font-size:10pt;">&#x2611;</font><font style="display: inline;">&nbsp;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">No&nbsp;</font><font style="display: inline;font-size:10pt;">&#x2610;</font>
		</p>
		<p style="margin:0pt 0pt 8pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 8pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company</font><a name="_cp_text_1_5"></a><font style="display: inline;font-family:Times New Roman;font-size:10pt;">, or an emerging growth company</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">.&nbsp;&nbsp;See the definitions of &#x201C;large accelerated filer,&#x201D; &#x201C;accelerated filer</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">,</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">&#x201D;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">&nbsp;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">&#x201C;smaller reporting </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">company,&#x201D; and &#x201C;emerging growth </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">company&#x201D; in Rule 12b-2 of the Exchange Act.&nbsp;&nbsp;(Check </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">one</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">):</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 5pt">
			<font style="display: inline;font-size:5pt;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;margin-left:0pt;">
			<tr>
				<td valign="top" style="width:297.00pt;height:1.00pt;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size: 5pt">
						<font style="display: inline;font-family:Times New Roman;font-size:5pt;">&#xFEFF;</font></p>
				</td>
				<td valign="top" style="width:180.00pt;height:1.00pt;padding:0pt 5.4pt;">
					<p style="margin:0pt 0pt 10pt;line-height:115%;font-family:Calibri;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:297.00pt;padding:0pt 5.4pt;">
					<p style="margin:0pt;line-height:115%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">Large accelerated filer </font><font style="display: inline;">&#x2610;</font></p>
				</td>
				<td valign="top" style="width:180.00pt;padding:0pt 5.4pt;">
					<p style="margin:0pt;line-height:115%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">Accelerated filer </font><font style="display: inline;">&#x2610;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:297.00pt;padding:0pt 5.4pt;">
					<p style="margin:0pt;line-height:115%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 5pt">
						<font style="display: inline;font-size:5pt;">&#xFEFF;</font></p>
				</td>
				<td valign="top" style="width:180.00pt;padding:0pt 5.4pt;">
					<p style="margin:0pt;line-height:115%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:297.00pt;padding:0pt 5.4pt;">
					<p style="margin:0pt;line-height:115%;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">Non-accelerated filer&nbsp; </font><font style="display: inline;">&#x2610;</font></p>
				</td>
				<td valign="top" style="width:180.00pt;padding:0pt 5.4pt;">
					<p style="margin:0pt;line-height:115%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">Smaller reporting company </font><font style="display: inline;">&#x2611;</font></p>
					<p style="margin:0pt;line-height:115%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
					<p style="margin:0pt;line-height:115%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">Emergin</font><font style="display: inline;">g</font><font style="display: inline;"> growth</font><font style="display: inline;"> company </font><font style="display: inline;">&#x2610;</font></p>
					<p style="margin:0pt;line-height:115%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<a name="_cp_text_1_13"></a><font style="display: inline;background-color: #FFFFFF;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.</font><font style="display: inline;background-color: #FFFFFF;">&nbsp;</font><font style="display: inline;">&#x2610;</font>
		</p>
		<p style="margin:0pt 0pt 8pt;font-family:Calibri;line-height:107.92%;font-size: 4pt">
			<font style="display: inline;font-family:Times New Roman;font-size:4pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;border-bottom:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Indicate</font><font style="display: inline;"> by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&nbsp;&nbsp;Yes&nbsp;</font><font style="display: inline;">&#x2610;</font><font style="display: inline;">&nbsp;No&nbsp;</font><font style="display: inline;">&#x2611;</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 5pt">
			<font style="display: inline;font-size:5pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Indicate by check mark whether the registrant has filed all documents and reports required to be filed by Sections 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court.&nbsp; </font><font style="display: inline;">Yes&nbsp;</font><font style="display: inline;">&#x2611;</font><font style="display: inline;">&nbsp;No&nbsp;</font><font style="display: inline;">&#x2610;</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 5pt">
			<font style="display: inline;font-size:5pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">As of </font><font style="display: inline;">July 31</font><font style="display: inline;">, &nbsp;</font><font style="display: inline;">201</font><font style="display: inline;">7</font><font style="display: inline;">, the </font><font style="display: inline;">registrant</font><font style="display: inline;"> had </font><font style="display: inline;">56,164,082</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">shares of common stock, par value $0.001 per share, outstanding.</font>
		</p>
		<p style="margin:0pt;border-bottom:2pt double #000000 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 8pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 11pt">
			<font style="display: inline;font-family:Times New Roman;font-weight:bold;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 8pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 11pt">

		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;"></font><font style="display: inline;">2</font><font style="display: inline;"></font>

		</p>

		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt">

			&nbsp;

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<p style="margin:0pt 0pt 8pt;text-align:center;font-family:Calibri;line-height:107.92%;;font-size: 11pt"><font style="display: inline;font-family:Times New Roman;font-weight:bold;color:#000000;">VERMILLION, INC.</font>
		</p>
		<p style="margin:0pt 0pt 8pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 11pt">
			<font style="display: inline;font-family:Times New Roman;font-weight:bold;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 8pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 11pt">
			<font style="display: inline;font-family:Times New Roman;font-weight:bold;color:#000000;">FORM 10-Q</font>
		</p>
		<p style="margin:0pt 0pt 8pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 11pt">
			<font style="display: inline;font-family:Times New Roman;font-weight:bold;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 8pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 11pt">
			<font style="display: inline;font-family:Times New Roman;font-weight:bold;color:#000000;">Table of Contents</font>
		</p>
		<p style="margin:0pt 0pt 8pt;font-family:Calibri;line-height:107.92%;font-size: 11pt">
			<font style="display: inline;font-family:Times New Roman;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 8pt;font-family:Calibri;line-height:107.92%;font-size: 1pt">
			<font style="display: inline;font-family:Times New Roman;font-size:1pt;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:09.62%;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:115%;font-family:Calibri;height:1.00pt;overflow:hidden;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:81.00%;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:115%;font-family:Calibri;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.38%;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:115%;font-family:Calibri;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:09.62%;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:115%;font-family:Calibri;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:81.00%;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:115%;font-family:Calibri;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.38%;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:115%;text-align:right;font-family:Calibri;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;text-decoration:underline;">Page</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:09.62%;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:115%;font-family:Calibri;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">&#xFEFF;</font><a href="#Financial_Information"><font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">PART I</font></a><font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:81.00%;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:115%;font-family:Calibri;font-size: 10pt">
						<a href="#Financial_Information"><font style="display: inline;font-family:Times New Roman;font-size:10pt;">Financial Information</font></a></p>
				</td>
				<td valign="bottom" style="width:09.38%;background-color: #CCEEFF;height:12.75pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">4&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:09.62%;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:115%;font-family:Calibri;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">&#xFEFF;</font><a href="#Balance_Sheet"><font style="display: inline;font-family:Times New Roman;font-size:10pt;">Item 1</font></a></p>
				</td>
				<td valign="bottom" style="width:81.00%;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:115%;font-family:Calibri;font-size: 10pt">
						<a href="#Balance_Sheet"><font style="display: inline;font-family:Times New Roman;font-size:10pt;">Financial Statements</font></a></p>
				</td>
				<td valign="bottom" style="width:09.38%;height:12.75pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">4&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:09.62%;background-color: #CCEEFF;height:28.35pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:115%;font-family:Calibri;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:81.00%;background-color: #CCEEFF;height:28.35pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 6pt;line-height:115%;font-family:Calibri;font-size: 10pt">
						<a href="#Balance_Sheet"><font style="display: inline;font-family:Times New Roman;font-size:10pt;">Condensed Consolidated Balance Sheets as of </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">June 30</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">, 201</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">7</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> and December 31, 201</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">6</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> (unaudited)</font></a></p>
				</td>
				<td valign="bottom" style="width:09.38%;background-color: #CCEEFF;height:28.35pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">4&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:09.62%;height:26.55pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:115%;font-family:Calibri;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:81.00%;height:26.55pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 6pt;line-height:115%;font-family:Calibri;font-size: 10pt">
						<a href="#Operations"><font style="display: inline;font-family:Times New Roman;font-size:10pt;">Condensed Consolidated Statements of Operations for the three</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> and six </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">months</font></a><font style="display: inline;">&nbsp;</font><a href="#Operations"><font style="display: inline;font-family:Times New Roman;font-size:10pt;">ended </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">June </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">3</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">0</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">, 201</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">7</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> and 201</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">6</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> (unaudited)</font></a></p>
				</td>
				<td valign="bottom" style="width:09.38%;height:26.55pt;color:#000000;font-family:Times New Roman;font-size:11pt;text-align:right;" nowrap="nowrap">5&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:09.62%;background-color: #CCEEFF;height:25.65pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:115%;font-family:Calibri;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:81.00%;background-color: #CCEEFF;height:25.65pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 6pt;line-height:115%;font-family:Calibri;font-size: 10pt">
						<a href="#Cash_Flows"><font style="display: inline;font-family:Times New Roman;font-size:10pt;">Condensed Consolidated Statements of Cash Flows for the </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">six </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">months ended </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">June </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">3</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">0</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">, 201</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">7</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> and 201</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">6</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> (unaudited)</font></a></p>
				</td>
				<td valign="bottom" style="width:09.38%;background-color: #CCEEFF;height:25.65pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">6&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:09.62%;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:115%;font-family:Calibri;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:81.00%;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 6pt;line-height:115%;font-family:Calibri;font-size: 10pt">
						<a href="#Notes_To_Statements"><font style="display: inline;font-family:Times New Roman;font-size:10pt;">Notes to Condensed Consolidated Financial Statements (unaudited)</font></a></p>
				</td>
				<td valign="bottom" style="width:09.38%;height:12.75pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">7&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:09.62%;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:115%;font-family:Calibri;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">&#xFEFF;</font><a href="#Item_2"><font style="display: inline;font-family:Times New Roman;font-size:10pt;">Item 2</font></a></p>
				</td>
				<td valign="bottom" style="width:81.00%;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:115%;font-family:Calibri;font-size: 10pt">
						<a href="#Item_2"><font style="display: inline;font-family:Times New Roman;font-size:10pt;">Management's Discussion and Analysis of Financial Condition and Results of Operations</font></a></p>
				</td>
				<td valign="bottom" style="width:09.38%;background-color: #CCEEFF;height:12.75pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">13&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:09.62%;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:115%;font-family:Calibri;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">&#xFEFF;</font><a href="#Item_3"><font style="display: inline;font-family:Times New Roman;font-size:10pt;">Item 3</font></a></p>
				</td>
				<td valign="bottom" style="width:81.00%;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:115%;font-family:Calibri;font-size: 10pt">
						<a href="#Item_3"><font style="display: inline;font-family:Times New Roman;font-size:10pt;">Quantitative and Qualitative Disclosures About Market Risk</font></a></p>
				</td>
				<td valign="bottom" style="width:09.38%;height:12.75pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">23&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:09.62%;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:115%;font-family:Calibri;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">&#xFEFF;</font><a href="#Item_4"><font style="display: inline;font-family:Times New Roman;font-size:10pt;">Item 4</font></a></p>
				</td>
				<td valign="bottom" style="width:81.00%;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:115%;font-family:Calibri;font-size: 10pt">
						<a href="#Item_4"><font style="display: inline;font-family:Times New Roman;font-size:10pt;">Controls and Procedures</font></a></p>
				</td>
				<td valign="bottom" style="width:09.38%;background-color: #CCEEFF;height:12.75pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">23&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:09.62%;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:115%;font-family:Calibri;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">&#xFEFF;</font><a href="#Part_II"><font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">PART II</font></a></p>
				</td>
				<td valign="bottom" style="width:81.00%;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:115%;font-family:Calibri;font-size: 10pt">
						<a href="#Part_II"><font style="display: inline;font-family:Times New Roman;font-size:10pt;">Other Information</font></a></p>
				</td>
				<td valign="bottom" style="width:09.38%;height:12.75pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">24&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:09.62%;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:115%;font-family:Calibri;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">&#xFEFF;</font><a href="#Part_II_Item_1"><font style="display: inline;font-family:Times New Roman;font-size:10pt;">Item 1</font></a></p>
				</td>
				<td valign="bottom" style="width:81.00%;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:115%;font-family:Calibri;font-size: 10pt">
						<a href="#Part_II_Item_1"><font style="display: inline;font-family:Times New Roman;font-size:10pt;">Legal Proceedings</font></a></p>
				</td>
				<td valign="bottom" style="width:09.38%;background-color: #CCEEFF;height:12.75pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">24&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:09.62%;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:115%;font-family:Calibri;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">&#xFEFF;</font><a href="#Part_II_Item_1A"><font style="display: inline;font-family:Times New Roman;font-size:10pt;">Item 1A</font></a></p>
				</td>
				<td valign="bottom" style="width:81.00%;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:115%;font-family:Calibri;font-size: 10pt">
						<a href="#Part_II_Item_1A"><font style="display: inline;font-family:Times New Roman;font-size:10pt;">Risk Factors</font></a></p>
				</td>
				<td valign="bottom" style="width:09.38%;height:12.75pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">24&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:09.62%;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:115%;font-family:Calibri;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">&#xFEFF;</font><a href="#Part_II_Item_6"><font style="display: inline;font-family:Times New Roman;font-size:10pt;">Item 6</font></a></p>
				</td>
				<td valign="bottom" style="width:81.00%;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:115%;font-family:Calibri;font-size: 10pt">
						<a href="#Part_II_Item_6"><font style="display: inline;font-family:Times New Roman;font-size:10pt;">Exhibits</font></a></p>
				</td>
				<td valign="bottom" style="width:09.38%;background-color: #CCEEFF;height:12.75pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">25&nbsp;
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="bottom" style="width:90.62%;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:115%;font-family:Calibri;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">&#xFEFF;</font><a href="#Signatures"><font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">SIGNATURES</font></a></p>
				</td>
				<td valign="bottom" style="width:09.38%;height:12.75pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">26&nbsp;
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt 0pt 8pt;font-family:Calibri;line-height:107.92%;font-size: 11pt">
			<font style="display: inline;font-family:Times New Roman;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 8pt;font-family:Calibri;line-height:107.92%;font-size: 11pt">
			<font style="display: inline;font-family:Times New Roman;font-style:italic;">Vermillion</font><font style="display: inline;font-family:Times New Roman;font-style:italic;">,</font><font style="display: inline;font-family:Times New Roman;font-style:italic;"> OVA1</font><font style="display: inline;font-family:Times New Roman;font-style:italic;"> and </font><font style="display: inline;font-family:Times New Roman;font-style:italic;">Overa</font><font style="display: inline;font-family:Times New Roman;font-style:italic;"> are registered trademarks of Vermillion, Inc.</font>
		</p>
		<p style="margin:0pt 0pt 8pt;font-family:Calibri;line-height:107.92%;font-size: 11pt">
			<font style="display: inline;font-family:Times New Roman;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:center;font-family:Times New Roman;font-weight:bold;font-size: 9pt">

		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;"></font><font style="display: inline;">3</font><font style="display: inline;"></font>

		</p>

		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt">

			&nbsp;

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<p style="margin:0pt;line-height:100%;text-align:center;font-family:Times New Roman;font-weight:bold;;font-size: 9pt"><a name="Financial_Information"></a><font style="display: inline;font-size:9.5pt;">PART I - FINANCIAL INFORMATION</font>
		</p>
		<p style="margin:0pt 0pt 8pt 40pt;text-indent: -40pt;font-family:Calibri;line-height:107.92%;font-size: 9pt">
			<font style="display: inline;font-family:Times New Roman;font-size:9.5pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 40pt;text-indent: -40pt;font-family:Calibri;line-height:107.92%;font-size: 9pt">
			<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:9.5pt;">ITEM 1.</font><font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:9.5pt;;font-size: 9pt;font-family:Calibri;text-indent:0pt;margin-left:0pt;padding:0pt 14.8pt 0pt 0pt;"></font><font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:9.5pt;"></font><font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:9.5pt;">FINANCIAL STATEMENTS</font>
		</p>
		<p style="margin:0pt 0pt 0pt 40pt;text-indent: -40pt;font-family:Calibri;line-height:107.92%;font-size: 9pt">
			<font style="display: inline;font-family:Times New Roman;font-size:9.5pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:center;font-family:Calibri;font-size: 9pt">
			<a name="Balance_Sheet"></a><font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:9.5pt;">Vermillion, Inc. </font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:center;font-family:Calibri;font-size: 9pt">
			<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:9.5pt;">Condensed </font><font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:9.5pt;">Consolidated Balance Sheets</font>
		</p>
		<p style="margin:0pt 0pt 0pt 40pt;line-height:100%;text-indent: -40pt;text-align:center;font-family:Calibri;font-size: 9pt">
			<font style="display: inline;font-family:Times New Roman;font-size:9.5pt;">(Amounts in Thousands, Except Share and Par Value Amounts)</font>
		</p>
		<p style="margin:0pt 0pt 0pt 40pt;line-height:100%;text-indent: -40pt;text-align:center;font-family:Calibri;font-size: 9pt">
			<font style="display: inline;font-family:Times New Roman;font-size:9.5pt;">(Unaudited)</font>
		</p>
		<p style="margin:0pt;font-family:Calibri;line-height:107.92%;font-size: 1pt">
			<font style="display: inline;font-family:Times New Roman;font-size:1pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;font-family:Calibri;line-height:107.92%;font-size: 1pt">
			<font style="display: inline;font-family:Times New Roman;font-size:1pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;font-family:Calibri;line-height:107.92%;font-size: 1pt">
			<font style="display: inline;font-family:Times New Roman;font-size:1pt;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:71.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size: 1pt">
						<font style="display: inline;font-size:1pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:71.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;">&#xFEFF;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 9pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:9pt;">June 30,</font></p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 9pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:9pt;">December 31,</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:71.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;">&#xFEFF;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 9pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:9pt;">2017</font></p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 9pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:9pt;">2016</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:71.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 9pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:9pt;">Assets</font></p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:71.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 9pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:9pt;">Current assets:</font></p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:71.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 18pt;font-family:Calibri;line-height:107.92%;font-size: 9pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:9pt;">Cash and cash equivalents </font></p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 9pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:9pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">6,028&nbsp;
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 9pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:9pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">5,242&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:71.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 18pt;font-family:Calibri;line-height:107.92%;font-size: 9pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:9pt;">Accounts receivable </font></p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 6pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">214&nbsp;
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">275&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:71.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 18pt;font-family:Calibri;line-height:107.92%;font-size: 9pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:9pt;">Prepaid expenses and other current assets </font></p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 6pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">269&nbsp;
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">498&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:71.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 18pt;font-family:Calibri;line-height:107.92%;font-size: 9pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:9pt;">Inventories</font></p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 6pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">102&nbsp;
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">93&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:71.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 18pt;font-family:Calibri;line-height:107.92%;font-size: 9pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:9pt;">Total current assets </font></p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 6pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">6,613&nbsp;
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">6,108&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:71.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 9pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:9pt;">Property and equipment, net </font></p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">1,549&nbsp;
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">1,911&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:71.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 9pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:9pt;">Other assets</font></p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">11&nbsp;
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 9pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:9pt;"> &nbsp;-</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:71.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 18pt;font-family:Calibri;line-height:107.92%;font-size: 9pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:9pt;">Total assets</font></p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 9pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:9pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">8,173&nbsp;
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 9pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:9pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">8,019&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:71.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 18pt;font-family:Calibri;line-height:107.92%;font-size: 9pt">
						<font style="display: inline;color:#000000;font-size:9pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.02%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.02%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:71.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 9pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:9pt;">Liabilities and Stockholders&#x2019; Equity</font></p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:71.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 9pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:9pt;">Current liabilities:</font></p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:71.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 18pt;font-family:Calibri;line-height:107.92%;font-size: 9pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:9pt;">Accounts payable </font></p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 9pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:9pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">300&nbsp;
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 9pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:9pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">881&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:71.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 18pt;font-family:Calibri;line-height:107.92%;font-size: 9pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:9pt;">Accrued liabilities </font></p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 6pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">1,541&nbsp;
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">1,464&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:71.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 18pt;font-family:Calibri;line-height:107.92%;font-size: 9pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:9pt;">Short-term debt</font></p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 6pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">188&nbsp;
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">182&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:71.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 18pt;font-family:Calibri;line-height:107.92%;font-size: 9pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:9pt;">Other current liabilities</font></p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 6pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">32&nbsp;
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">34&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:71.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 18pt;font-family:Calibri;line-height:107.92%;font-size: 9pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:9pt;">Total current liabilities </font></p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 6pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">2,061&nbsp;
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">2,561&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:71.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 9pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:9pt;">Non-current liabilities:</font></p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:71.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 18pt;font-family:Calibri;line-height:107.92%;font-size: 9pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:9pt;">Long-term debt</font></p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 6pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">1,538&nbsp;
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">1,667&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:71.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 18pt;font-family:Calibri;line-height:107.92%;font-size: 9pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:9pt;">Other non-current liabilities</font></p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 6pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">47&nbsp;
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">29&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:71.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 18pt;font-family:Calibri;line-height:107.92%;font-size: 9pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:9pt;">Total liabilities </font></p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 6pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">3,646&nbsp;
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">4,257&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:71.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 9pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:9pt;">Commitments and contingencies (Note 3)</font></p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:71.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 9pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:9pt;">Stockholders&#x2019; equity:</font></p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:71.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 18pt;font-family:Calibri;line-height:107.92%;font-size: 9pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:9pt;">Common stock, par value $0.001 per share, 150,000,000 shares authorized at</font></p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 6pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:71.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 24pt;font-family:Calibri;line-height:107.92%;font-size: 9pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:9pt;">June 30, 2017 and December&nbsp;31, 2016; 56,164,082 and 52,328,492 shares</font></p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 6pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:71.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 24pt;font-family:Calibri;line-height:107.92%;font-size: 9pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:9pt;">issued and outstanding at June 30, 2017 and December&nbsp;31, 2016, </font></p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 12pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:71.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 24pt;font-family:Calibri;line-height:107.92%;font-size: 9pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:9pt;">respectively</font></p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 12pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">56&nbsp;
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">52&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:71.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 18pt;font-family:Calibri;line-height:107.92%;font-size: 9pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:9pt;">Additional paid-in capital </font></p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 6pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">395,060&nbsp;
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">389,266&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:71.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 18pt;font-family:Calibri;line-height:107.92%;font-size: 9pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:9pt;">Accumulated deficit </font></p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 6pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">(390,589)
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">(385,556)
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:71.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 18pt;font-family:Calibri;line-height:107.92%;font-size: 9pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:9pt;">Total stockholders&#x2019; equity</font></p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 6pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">4,527&nbsp;
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">3,762&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:71.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 18pt;font-family:Calibri;line-height:107.92%;font-size: 9pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:9pt;">Total liabilities and stockholders&#x2019; equity</font></p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 9pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:9pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">8,173&nbsp;
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.22%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 9pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:9pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:9pt;text-align:right;" nowrap="nowrap">8,019&nbsp;
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt 0pt 8pt;font-family:Calibri;line-height:107.92%;font-size: 11pt">
			<font style="display: inline;font-family:Times New Roman;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 8pt;text-indent:36pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 11pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">See accompanying notes to the unaudited </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">condensed </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">consolidated financial statements.</font>
		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;"></font><font style="display: inline;">4</font><font style="display: inline;"></font>

		</p>

		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt">

			&nbsp;

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<p style="margin:0pt 0pt 8pt;text-indent:36pt;text-align:center;font-family:Calibri;line-height:107.92%;;font-size: 11pt"><font style="display: inline;font-family:Times New Roman;"></font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<a name="Operations"></a><font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">Vermillion, Inc.</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">Condensed </font><font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">Consolidated Statements of Operations</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">(Amounts in Thousands, Except Share and Per Share Amounts)</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">(Unaudited)</font>
		</p>
		<p style="margin:0pt 0pt 8pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;font-family:Calibri;line-height:107.92%;font-size: 1pt">
			<font style="display: inline;font-family:Times New Roman;font-size:1pt;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:42.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size: 1pt">
						<font style="display: inline;font-size:1pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:42.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;color:#000000;font-size:10pt;">&#xFEFF;</font></p>
				</td>
				<td colspan="5" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:10pt;">Three Months Ended June 30, </font></p>
				</td>
				<td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="5" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:10pt;">Six Months Ended June 30, </font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:42.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;color:#000000;font-size:10pt;">&#xFEFF;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:10pt;">2017</font></p>
				</td>
				<td valign="bottom" style="width:01.44%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:10pt;">2016</font></p>
				</td>
				<td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:10pt;">2017</font></p>
				</td>
				<td valign="bottom" style="width:01.44%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:10pt;">2016</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:42.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">Revenue:</font></p>
				</td>
				<td valign="bottom" style="width:01.32%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:42.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 12pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">Product</font></p>
				</td>
				<td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">860&nbsp;
				</td>
				<td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">554&nbsp;
				</td>
				<td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">1,538&nbsp;
				</td>
				<td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">1,059&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:42.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 12pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">Service</font></p>
				</td>
				<td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">38&nbsp;
				</td>
				<td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">155&nbsp;
				</td>
				<td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">86&nbsp;
				</td>
				<td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">155&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:42.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">Total revenue</font></p>
				</td>
				<td valign="bottom" style="width:01.32%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">898&nbsp;
				</td>
				<td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">709&nbsp;
				</td>
				<td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">1,624&nbsp;
				</td>
				<td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">1,214&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:42.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">Cost of revenue:</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;font-size:5pt;vertical-align:super;line-height:107.92%">(1)</font></p>
				</td>
				<td valign="bottom" style="width:01.32%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:42.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 12pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">Product</font></p>
				</td>
				<td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 6pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">428&nbsp;
				</td>
				<td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">527&nbsp;
				</td>
				<td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">850&nbsp;
				</td>
				<td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">1,055&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:42.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 12pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">Service</font></p>
				</td>
				<td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 6pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">266&nbsp;
				</td>
				<td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">60&nbsp;
				</td>
				<td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">571&nbsp;
				</td>
				<td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">60&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:42.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">Total cost of revenue</font></p>
				</td>
				<td valign="bottom" style="width:01.32%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">694&nbsp;
				</td>
				<td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">587&nbsp;
				</td>
				<td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">1,421&nbsp;
				</td>
				<td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">1,115&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:42.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">Gross profit</font></p>
				</td>
				<td valign="bottom" style="width:01.32%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">204&nbsp;
				</td>
				<td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">122&nbsp;
				</td>
				<td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">203&nbsp;
				</td>
				<td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">99&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:42.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">Operating expenses:</font></p>
				</td>
				<td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:42.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 12pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">Research and development</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;font-size:5pt;vertical-align:super;line-height:107.92%">(2)</font></p>
				</td>
				<td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 6pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">268&nbsp;
				</td>
				<td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">564&nbsp;
				</td>
				<td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">493&nbsp;
				</td>
				<td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">1,498&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:42.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 12pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">Sales and marketing</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;font-size:5pt;vertical-align:super;line-height:107.92%">(3)</font></p>
				</td>
				<td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 6pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">1,041&nbsp;
				</td>
				<td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">1,628&nbsp;
				</td>
				<td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">2,064&nbsp;
				</td>
				<td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">3,908&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:42.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 12pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">General and administrative</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;font-size:5pt;vertical-align:super;line-height:107.92%">(4)</font></p>
				</td>
				<td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 6pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:15.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">1,241&nbsp;
				</td>
				<td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:15.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">1,691&nbsp;
				</td>
				<td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:15.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">2,648&nbsp;
				</td>
				<td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:15.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:15.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">3,350&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:42.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">Total operating expenses </font></p>
				</td>
				<td valign="bottom" style="width:01.32%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 6pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">2,550&nbsp;
				</td>
				<td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">3,883&nbsp;
				</td>
				<td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">5,205&nbsp;
				</td>
				<td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">8,756&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:42.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">Loss from operations </font></p>
				</td>
				<td valign="bottom" style="width:01.32%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(2,346)
				</td>
				<td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(3,761)
				</td>
				<td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(5,002)
				</td>
				<td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(8,657)
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:42.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">Interest income (expense), net </font></p>
				</td>
				<td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(10)
				</td>
				<td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(8)
				</td>
				<td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(22)
				</td>
				<td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(5)
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:42.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">Other income (expense), net </font></p>
				</td>
				<td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(4)
				</td>
				<td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">20&nbsp;
				</td>
				<td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(9)
				</td>
				<td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">16&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:42.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">Net loss </font></p>
				</td>
				<td valign="bottom" style="width:01.32%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(2,360)
				</td>
				<td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(3,749)
				</td>
				<td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(5,033)
				</td>
				<td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(8,646)
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:42.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">Net loss per share - basic and diluted </font></p>
				</td>
				<td valign="bottom" style="width:01.32%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.02%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(0.04)
				</td>
				<td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.02%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(0.07)
				</td>
				<td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.02%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(0.09)
				</td>
				<td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.02%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(0.17)
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:42.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:39.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">Weighted average common shares used to compute basic and diluted net loss per common share </font></p>
				</td>
				<td valign="bottom" style="width:01.32%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:39.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 6pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:39.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">56,113,917&nbsp;
				</td>
				<td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:39.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:39.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:39.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">52,151,440&nbsp;
				</td>
				<td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:39.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:39.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:39.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">55,123,977&nbsp;
				</td>
				<td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:39.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:39.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:39.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">52,132,288&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:42.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:39.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">Non-cash stock-based compensation expense included in cost of revenue and operating expenses:</font></p>
				</td>
				<td valign="bottom" style="width:01.32%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:39.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.02%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:39.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:39.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:39.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.02%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:39.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:39.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:39.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.02%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:39.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:39.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:39.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.02%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:39.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:42.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">(1)&nbsp;&nbsp;Cost of revenue</font></p>
				</td>
				<td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">40&nbsp;
				</td>
				<td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">22&nbsp;
				</td>
				<td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">79&nbsp;
				</td>
				<td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">46&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:42.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">(2)&nbsp;&nbsp;Research and development</font></p>
				</td>
				<td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">2&nbsp;
				</td>
				<td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">22&nbsp;
				</td>
				<td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">5&nbsp;
				</td>
				<td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">53&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:42.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">(3)&nbsp;&nbsp;Sales and marketing</font></p>
				</td>
				<td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">40&nbsp;
				</td>
				<td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">14&nbsp;
				</td>
				<td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">77&nbsp;
				</td>
				<td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">56&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:42.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">(4)&nbsp;&nbsp;General and administrative</font></p>
				</td>
				<td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">295&nbsp;
				</td>
				<td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">319&nbsp;
				</td>
				<td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">510&nbsp;
				</td>
				<td valign="bottom" style="width:01.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">445&nbsp;
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt 0pt 8pt;font-family:Calibri;line-height:107.92%;font-size: 11pt">
			<font style="display: inline;font-family:Times New Roman;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 8pt;text-indent:14.4pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">See accompanying notes to the unaudited </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">condensed </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">consolidated financial statements.</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 11pt">

		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;"></font><font style="display: inline;">5</font><font style="display: inline;"></font>

		</p>

		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt">

			&nbsp;

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<p style="margin:0pt;text-align:center;font-family:Calibri;line-height:107.92%;;font-size: 11pt"><font style="display: inline;font-family:Times New Roman;"></font><a name="Cash_Flows"></a><font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">Vermillion, Inc.</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">Condensed </font><font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">Consolidated Statements of Cash Flows</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">(Amounts in Thousands)</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">(Unaudited)</font>
		</p>
		<p style="margin:0pt 0pt 8pt;font-family:Calibri;line-height:107.92%;font-size: 1pt">
			<font style="display: inline;font-family:Times New Roman;font-size:1pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 8pt;font-family:Calibri;line-height:107.92%;font-size: 1pt">
			<font style="display: inline;font-family:Times New Roman;font-size:1pt;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:68.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size: 1pt">
						<font style="display: inline;font-size:1pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:68.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;color:#000000;font-size:10pt;">&#xFEFF;</font></p>
				</td>
				<td colspan="5" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:10pt;">Six Months Ended</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:68.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;color:#000000;font-size:10pt;">&#xFEFF;</font></p>
				</td>
				<td colspan="5" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:10pt;">June 30,</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:68.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;color:#000000;font-size:10pt;">&#xFEFF;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:10pt;">2017</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:10pt;">2016</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:68.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:10pt;">Cash flows from operating activities:</font></p>
				</td>
				<td valign="bottom" style="width:01.32%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.04%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.32%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.04%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:68.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">Net loss </font></p>
				</td>
				<td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:13.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(5,033)
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:13.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(8,646)
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:68.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">Adjustments to reconcile net loss to net cash used in operating activities:</font></p>
				</td>
				<td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:68.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 18pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">Depreciation and amortization </font></p>
				</td>
				<td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 6pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">401&nbsp;
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 6pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">323&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:68.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 18pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">Stock-based compensation expense </font></p>
				</td>
				<td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 6pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">671&nbsp;
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 6pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">600&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:68.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 18pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">Loss on sale and disposal of property and equipment</font></p>
				</td>
				<td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 6pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">4&nbsp;
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 6pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">3&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:68.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">Changes in operating assets and liabilities:</font></p>
				</td>
				<td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:68.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 18pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">Accounts receivable </font></p>
				</td>
				<td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">61&nbsp;
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 6pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(156)
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:68.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 18pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">Prepaid expenses and other assets </font></p>
				</td>
				<td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 6pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">218&nbsp;
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 6pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">233&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:68.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 18pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">Inventories</font></p>
				</td>
				<td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 6pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(9)
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 6pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">7&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:68.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 18pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">Accounts payable, accrued liabilities and other liabilities</font></p>
				</td>
				<td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 6pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(504)
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 6pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(835)
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:68.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 18pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">Deferred revenue </font></p>
				</td>
				<td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 6pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 3.25pt 0.05pt 0pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"> &nbsp;-</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 6pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">16&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:68.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">Net cash used in operating activities </font></p>
				</td>
				<td valign="bottom" style="width:01.32%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.04%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(4,191)
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.32%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.04%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(8,455)
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:68.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:10pt;">Cash flows from investing activities:</font></p>
				</td>
				<td valign="bottom" style="width:01.32%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.04%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.32%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.04%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:68.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 18pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">Purchase of property and equipment</font></p>
				</td>
				<td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 6pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(43)
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 6pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(1,054)
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:68.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">Net cash used in investing activities</font></p>
				</td>
				<td valign="bottom" style="width:01.32%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.04%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(43)
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.32%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.04%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(1,054)
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:68.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:10pt;">Cash flows from financing activities:</font></p>
				</td>
				<td valign="bottom" style="width:01.32%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.04%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.32%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.04%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:68.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:25.50pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 18pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">Proceeds from private placement offering of common stock, net of issuance costs</font></p>
				</td>
				<td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:25.50pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:25.50pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">5,127&nbsp;
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:25.50pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:25.50pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:25.50pt;padding:0pt;">
					<p style="margin:0pt 3.25pt 0.05pt 0pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"> &nbsp;-</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:68.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 18pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">Proceeds from issuance of DECD loan, net of issuance costs</font></p>
				</td>
				<td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 3.25pt 0.05pt 0pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"> &nbsp;-</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">1,966&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:68.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 18pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">Principal repayment of DECD loan</font></p>
				</td>
				<td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(92)
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(28)
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:68.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 18pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">Repayment of capital lease obligations</font></p>
				</td>
				<td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(15)
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(14)
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:68.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 18pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">Proceeds from issuance of common stock from exercise of stock options</font></p>
				</td>
				<td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 3.25pt 0.05pt 0pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"> &nbsp;-</font></p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">5&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:68.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">Net cash provided by financing activities </font></p>
				</td>
				<td valign="bottom" style="width:01.32%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.04%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">5,020&nbsp;
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.32%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.04%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">1,929&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:68.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">Net increase (decrease) in cash and cash equivalents </font></p>
				</td>
				<td valign="bottom" style="width:01.32%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.04%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">786&nbsp;
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.32%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.04%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(7,580)
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:68.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">Cash and cash equivalents, beginning of period </font></p>
				</td>
				<td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">5,242&nbsp;
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">18,642&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:68.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">Cash and cash equivalents, end of period </font></p>
				</td>
				<td valign="bottom" style="width:01.32%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:13.04%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">6,028&nbsp;
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.32%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:13.04%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">11,062&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:68.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">Supplemental disclosure of cash flow information:</font></p>
				</td>
				<td valign="bottom" style="width:01.32%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.04%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.32%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.04%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:68.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 18pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">Cash paid during the period for interest</font></p>
				</td>
				<td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">24&nbsp;
				</td>
				<td valign="bottom" style="width:02.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">10&nbsp;
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt 0pt 8pt;font-family:Calibri;line-height:107.92%;font-size: 11pt">
			<font style="display: inline;font-family:Times New Roman;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:14.4pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 11pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">See accompanying notes to the unaudited </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">condensed </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">consolidated financial statements</font><font style="display: inline;font-family:Times New Roman;">.</font>
		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;"></font><font style="display: inline;">6</font><font style="display: inline;"></font>

		</p>

		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt">

			&nbsp;

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<p style="margin:0pt;text-indent:14.4pt;text-align:center;font-family:Calibri;line-height:107.92%;;font-size: 11pt"><font style="display: inline;font-family:Times New Roman;"></font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<a name="Notes_To_Statements"></a><font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">Vermillion, Inc.</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">Notes to </font><font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">Condensed </font><font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">Consolidated Financial Statements</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">(Unaudited)</font>
		</p>
		<p style="margin:0pt 0pt 8pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 11pt">
			<font style="display: inline;font-family:Times New Roman;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 8pt 40pt;text-indent: -40pt;font-family:Calibri;line-height:107.92%;font-size: 11pt">
			<font style="display: inline;font-family:Times New Roman;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">1.&nbsp;&nbsp; </font><font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">ORGANIZATION, BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING AND REPORTING POLICIES</font>
		</p>
		<p style="margin:0pt 0pt 8pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;">Organization </font>
		</p>
		<p style="margin:4.5pt 0pt 0pt 4.5pt;text-indent:31.5pt;line-height:100%;font-family:Arial Unicode MS;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">Vermillion, Inc. (&#x201C;Vermillion&#x201D;; Vermillion and its wholly-owned subsidiaries are collectively referred to as the &#x201C;Company</font><a name="_cp_text_1_15"></a><font style="display: inline;font-family:Times New Roman;font-size:10pt;">,&#x201D; &#x201C;we&#x201D; or &#x201C;our</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">&#x201D;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">) i</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">s incorporated in the state of Delaware, and is engaged in the business of developing and commercializing diagnostic tests for </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">gynecologic</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> disease. The Company sells OVA1&#x2122; </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">and Overa&#x2122; </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">risk of malignancy test</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">s</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> for </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">ovarian cancer</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> (&#x201C;OVA1&#x201D;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> and &#x201C;Overa</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">,</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">&#x201D;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> respectively</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">) through Vermillion&#x2019;s wholly-owned&nbsp;Clinical Laboratory Improvement Amendments of 1988 (&#x201C;CLIA&#x201D;) certified clinical laboratory, ASPiRA LABS, Inc. (&#x201C;ASPiRA LABS&#x201D;)</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">. &nbsp;</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">The Company also offer</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">s</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"> in-vitro diagnostic (&#x201C;IVD&#x201D;) trial services to third-party customers through its wholly-owned subsidiary, ASPiRA IVD, Inc. (&#x201C;ASPiRA IVD&#x201D;), which </font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">commenced operations </font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">in </font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">June</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"> 2016. </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">ASPiRA IVD </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">is</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> a specialized</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">, CLIA certified,</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> laboratory provider dedicated to meeting the unique testing needs of IVD manufacturers seeking to commercialize&nbsp;high-complexity&nbsp;assays. </font>
		</p>
		<p style="margin:9pt 0pt 3pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;">Going Concern</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">The Company has incurred significant net losses and negative cash flows from operations since inception, and as a result has an accumulated deficit of approximat</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">ely </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">$</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">390</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">,</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">5</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">89</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">,000</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> &nbsp;a</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">t &nbsp;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">June 30</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">, 201</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">7</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">. The Company </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">also </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">expects to incur a net loss </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">and negative cash flows from operations </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">for</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">&nbsp;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">the remainder of </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">201</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">7</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">. The Company&#x2019;s management believes that successful achievement of the </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">Company&#x2019;s </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">business objectives will require additional financing.&nbsp;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">Given these conditions, there is substantial doubt about the Company&#x2019;s ability to continue as a going concern. The </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">condensed </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">consolidated financial statements have been prepared on a going concern basis and do not include any adjustments that might result from these uncertainties. </font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">The Company expects to raise capital through a variety of sources, which may include </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">the exercise of common stock warrants</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">, &nbsp;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">equity </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">offerings, debt financing</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">, collaborati</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">ons</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">, licensing arrangements, </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">grants and government funding and strategic alliances</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">. However, additional funding may not be available when needed or on terms acceptable to the Company. If the Company is unable to obtain additional capital, it may not be able to continue sales and marketing, research and development, or other operations on the scope or scale of current activity and that could have a material adverse effect on </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">the Company&#x2019;s</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">&nbsp;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">business, results of operations and financial condition.</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">As discussed in Note </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">4</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">, on February 17, 2017, the Company completed a private placement pursuant to which certain investors purchased Vermillion common stock and warrants to purchase shares of</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> Vermillion</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> common stock for net proceeds of approximately $</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">5,1</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">27</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">,000</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> after deducting offering expenses.</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">As discussed in Note 3, </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">i</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">n March 2016, the Company entered into an agreement (the &#x201C;Loan Agreement&#x201D;) pursuant to which it may borrow up to </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">$4,000,000</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> from the State of Connecticut Department of Economic and Community Development (the &#x201C;DECD&#x201D;). </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">An initial disbursement of </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">$2,000,000</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> was made to the Company </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">i</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">n April 2016 under the Loan Agreement.&nbsp;The Loan Agreement provides that the remaining </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">$2,000,000</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> will be </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">disbursed </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">if and when the Company achieves certain future milestones.</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:5pt 0pt;text-indent:36pt;line-height:100%;font-family:Arial Unicode MS;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 8pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;">Basis of Presentation </font>
		</p>
		<p style="margin:6pt 0pt;text-indent:36pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">The accompanying unaudited </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">condensed </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201C;GAAP&#x201D;) for interim financial information and with the instructions to Form 10-Q and </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">Article</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">&nbsp;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">8-03</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the </font>
		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;"></font><font style="display: inline;">7</font><font style="display: inline;"></font>

		</p>

		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt">

			&nbsp;

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<p style="margin:6pt 0pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"><font style="display: inline;font-family:Times New Roman;font-size:10pt;">opinion of management of the Company, all adjustments, consisting of normal recurring adjustments necessary for the fair statement of results for the periods presented, have been included. The results of operations of any interim period are not necessarily indicative of the results of operations for the full year or any other interim period. </font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">The unaudited </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">condensed </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">consolidated financial statements and related disclosures have been prepared with the presumption that users of the interim unaudited </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">condensed </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">consolidated financial statements have read or have access to the audited consolidated financial statements for the preceding fiscal year. The </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">condensed </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">consolidated balance sheet at December&nbsp;31,&nbsp;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">201</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">6</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">&nbsp;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">included in this report has been derived from the audited consolidated financial statements at that date but does not include all the information and footnotes required by GAAP. Accordingly, these unaudited </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">condensed </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended December 31, </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">201</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">6</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">, included in Vermillion&#x2019;s Annual Report on Form 10-K which was filed with the Securities and Exchange Commission on March </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">3</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">1</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">, &nbsp;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">201</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">7</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> (the &#x201C;201</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">6</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> Annual Report&#x201D;)</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">.</font>
		</p>
		<p style="margin:6pt 0pt 0pt;line-height:100%;text-indent:36pt;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimated results.</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:6pt 0pt 0pt;line-height:100%;text-indent:36pt;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 8pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;">Significant Acco</font><font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;">unting and Reporting Policies </font>
		</p>
		<p style="margin:0pt 0pt 2.25pt 10pt;line-height:normal;text-indent:26pt;text-align:justify;text-justify:inter-ideograph;border-bottom:1pt none #D9D9D9 ;font-family:Arial Unicode MS;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;background-color: #FFFFFF;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 2.25pt 10pt;line-height:normal;text-indent: -10pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Arial Unicode MS;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;background-color: #FFFFFF;">Revenue Recognition</font>
		</p>
		<p style="margin:0pt 0pt 2.25pt 10pt;line-height:normal;text-indent: -10pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Arial Unicode MS;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;background-color: #FFFFFF;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 2.25pt 10pt;line-height:normal;text-indent: -10pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Arial Unicode MS;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;text-decoration:underline;background-color: #FFFFFF;">Product Revenue</font>
		</p>
		<p style="margin:0pt 0pt 2.25pt 10pt;line-height:normal;text-indent: -10pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Arial Unicode MS;font-size: 8pt">
			<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:8.5pt;background-color: #FFFFFF;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:normal;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Arial Unicode MS;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;background-color: #FFFFFF;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;background-color: #FFFFFF;;font-size: 10pt;font-family:Arial Unicode MS;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;background-color: #FFFFFF;">The Company has adopted ASC 954-605,</font><font style="font-family:Times New Roman;display: inline;">&nbsp;</font><font style="display: inline;font-family:Times New Roman;font-style:italic;color:#000000;font-size:10pt;background-color: #FFFFFF;">Health Care Entities&#x2014;Revenue Recognition</font><font style="display: inline;font-family:Times New Roman;font-style:italic;color:#000000;font-size:10pt;background-color: #FFFFFF;">,</font><font style="display: inline;font-family:Times New Roman;font-style:italic;color:#000000;font-size:10pt;background-color: #FFFFFF;">&nbsp;</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;background-color: #FFFFFF;">as </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">revenue from laboratory services has become significant to the </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">C</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">ompany</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;background-color: #FFFFFF;">.</font><font style="font-family:Times New Roman;display: inline;">&nbsp;</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;background-color: #FFFFFF;">The Company's </font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;background-color: #FFFFFF;">product </font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;background-color: #FFFFFF;">revenue is generated by performing diagnostic services using its OVA1</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;background-color: #FFFFFF;"> and Overa</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;background-color: #FFFFFF;"> test</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;background-color: #FFFFFF;">s</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;background-color: #FFFFFF;">,</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;background-color: #FFFFFF;"> and the service is completed upon the delivery of test results to the prescribing physician. The Company recognizes revenue related to billings for Medicare and commercial payers on an accrual basis, net of contractual and other adjustments, when amounts that will ultimately be realized can be estimated. Until a contract has been negotiated with a commercial payer or governmental program, the OVA1</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;background-color: #FFFFFF;"> and Overa</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;background-color: #FFFFFF;"> test</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;background-color: #FFFFFF;">s</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;background-color: #FFFFFF;"> may or may not be covered by these entities' existing reimbursement policies. In addition, patients do not enter into direct agreements with the Company that commit them to pay any portion of the cost of the tests in the event that their insurance declines to reimburse the Company. In the absence of an agreement with the patient or other clearly enforceable legal right to demand payment from the patient, the related revenue is only recognized upon cash receipt.</font>
		</p>
		<p style="margin:0pt;line-height:normal;border-top:1pt none #D9D9D9 ;font-family:Arial Unicode MS;font-size: 8pt">
			<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:8.5pt;background-color: #FFFFFF;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">E</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">stimates of amounts that </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">the Company </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">will ultimately realize require significant judgment by management. Some patients have out-of-pocket costs for amounts not covered by their insurance carrier, and the Company may bill the patient directly for these amounts in the form of co-payments and co-insurance in accordance with the </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">patient&#x2019;s</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> health plan. Some payers may not cover the OVA1 </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">and Overa </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">test</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">s</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> as ordered by the prescribing physician under their reimbursement policies. The Company pursues reimbursement from such patients on a case-by-case basis. In the absence of contracted reimbursement coverage or the ability to estimate the amount that will ultimately be realized for the Company's services, revenue is recognized when cash is received.</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;background-color: #FFFFFF;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 8pt;text-indent:36pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">&nbsp;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">See discussion of </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">FASB ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606) (&#x201C;ASU No. 2014-09&#x201D;)</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> included in Recent Accounting Pronouncements below</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">. &nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 8pt;text-indent:36pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 2.25pt 10pt;line-height:normal;text-indent: -10pt;text-align:justify;text-justify:inter-ideograph;border-bottom:1pt none #D9D9D9 ;font-family:Arial Unicode MS;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;background-color: #FFFFFF;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 2.25pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Arial Unicode MS;font-size: 10pt">

		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;"></font><font style="display: inline;">8</font><font style="display: inline;"></font>

		</p>

		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt">

			&nbsp;

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<p style="margin:0pt 0pt 2.25pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Arial Unicode MS;;font-size: 10pt"><font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;text-decoration:underline;background-color: #FFFFFF;">Service Revenue</font>
		</p>
		<p style="margin:0pt 0pt 2.25pt 10pt;line-height:normal;text-indent: -10pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;font-family:Arial Unicode MS;font-size: 8pt">
			<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:8.5pt;background-color: #FFFFFF;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">The Company&#x2019;s service revenue is generated by performing</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> IVD trial services </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">for</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> third-party customers. </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">In accordance with SAB Topic 13, service revenue is recognized when the following revenue recognition criteria are met: (1)&nbsp;persuasive evidence of an arrangement exists; (2)&nbsp;delivery has occurred or services have been rendered; (3)&nbsp;the fee is fixed or determinable; and (4)&nbsp;collectability is reasonably assured.</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">See discussion of ASU No. 2014-09 included in Recent Accounting Pronouncements below</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">.</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;background-color: #FFFFFF;">The Company has made no </font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;background-color: #FFFFFF;">other </font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;background-color: #FFFFFF;">significant</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> changes in its critical accounting policies and estimates from those disclosed in </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">the 201</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">6</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> Annual Report</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">.</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 8pt;text-indent:36pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;text-decoration:underline;background-color: #FFFFFF;">Recent Accounting Pronouncements</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">In March 2016, the </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">Financial Accounting Standards Board</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">&nbsp;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">(&#x201C;FASB&#x201D;) </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">issued ASU 2016-09, Improvements to Employee Share-Based Payment Accounting (</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">Topic 718), Compensation - Stock Compensation</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> (&#x201C;ASU 2016-09&#x201D;)</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">. The new guidance simplifies several aspects of the accounting for share-based payments, including immediate recognition of all excess tax benefits and deficiencies in the income statement, changing the threshold to qualify for equity classification up to the employees' maximum statutory tax rates, allowing an entity-wide accounting policy election to either estimate the number of awards that are expected to vest or account for forfeitures as they occur, and clarifying the classification on the statement of cash flows for the excess tax benefit and employee taxes paid when an employer withholds shares for tax-withholding purposes. ASU 2016-09 is effective for annual reporting periods beginning after December 15, 2016 and interim periods within that reporting period. The adoption of this standard is not expected to have a material effect on our financial statements</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">.</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 8pt;text-indent:36pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">In May 2014, the FASB issued ASU No. 2014-09</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">, Revenue from Contracts with Customers (Topic 606) (&#x201C;ASU 2014-09&#x201D;),</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> which</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> removes inconsistencies and weaknesses in revenue requirements, provides a more robust framework for addressing revenue issues, improves comparability of revenue recognition practices across entities, industries, jurisdictions and capital markets, provides more useful information to users of financial statements through improved disclosure requirements and simplifies the preparation of financial statements by reducing the number of requirements to which an entity must refer. This guidance requires that an entity depict the consideration by applying a five-step analysis in determining when and how revenue is recognized. The new model will require revenue recognition to depict the transfer of promised goods or services to customers in an amount that reflects the consideration a company expects to receive in exchange for those goods or services. On April 1, 2015, the FASB voted for a one-year deferral of the effective date of the new revenue recognition standard, ASU No. 2014-09.&nbsp;On July 15, 2015, the FASB affirmed these changes, which requires public entities to apply the amendments in ASU 2014-09 for annual reporting beginning after December 15, 2017. Early adoption is permitted beginning after December 31, 2016, the original effective date in ASU 2014-09.</font>
		</p>
		<p style="margin:0pt 0pt 8pt;text-indent:36pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;"> The Company is in the early stages of its analysis of the effect </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">ASU 2014-09</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> will have on its Service Revenue, but expects to complete its analysis during the second half of 2017.</font>
		</p>
		<p style="margin:0pt 0pt 8pt;text-indent:36pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">The Company is also in the early stages of its analysis of</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> the effect </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">ASU 2014-09</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> will have on</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">&nbsp;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">its Product Revenue and also expects to complete this analysis in the second half of 2017. Revenue that is recognized upon the ultimate receipt of cash under the Company&#x2019;s existing revenue recognition policy will have to be reassessed under the new standard. The next step in the Company&#x2019;s implementation process is to review its patient account population to determine the appropriate distribution of patient accounts </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;text-decoration:underline;">by payer</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> &nbsp;(</font><font style="display: inline;font-family:Times New Roman;font-style:italic;font-size:10pt;">i.e.</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">, Medicare, patient pay, other third-party payer, </font><font style="display: inline;font-family:Times New Roman;font-style:italic;font-size:10pt;">etc</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">.) into portfolios with similar collection experience that, when evaluated for collectability, will result in a materially consistent revenue amount for such portfolios as if each patient account were evaluated on a contract-by-contract basis.</font>
		</p>
		<p style="margin:0pt 0pt 8pt;text-indent:36pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">The Company has not yet determined if it plans to utilize the full retrospective or modified retrospective method of adoption, but anticipates adopting the new standard in the first quarter of 2018.</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">

		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;"></font><font style="display: inline;">9</font><font style="display: inline;"></font>

		</p>

		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt">

			&nbsp;

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<p style="margin:0pt;text-indent:36pt;font-family:Calibri;line-height:107.92%;;font-size: 10pt"><font style="display: inline;font-family:Times New Roman;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 8pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-indent:36pt;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">2</font><font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">.&nbsp;&nbsp;&nbsp;AGREEMENTS WITH QUEST DIAGNOSTICS INCORPORATED</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;line-height:100%;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;line-height:100%;font-family:Arial Unicode MS;font-size: 12pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">I</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">n March 2015, the Company entered into a commercial agreement with Quest Diagnostics</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">,</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">&nbsp;</font><a name="_cp_text_1_39"></a><font style="display: inline;font-family:Times New Roman;font-size:10pt;">Incorporated (&#x201C;Quest Diagnostics&#x201D;)</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">. Pursuant to this agreement</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">, &nbsp;</font><a name="_cp_text_1_40"></a><font style="display: inline;font-family:Times New Roman;font-size:10pt;">all OVA1 U.S. testing services for </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">Quest Diagnostics </font><a name="_cp_text_1_42"></a><font style="display: inline;font-family:Times New Roman;font-size:10pt;">customers were transferred to</font><font style="display: inline;font-family:Times New Roman;">&nbsp;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">Vermillion&#x2019;s</font><font style="display: inline;font-family:Times New Roman;">&nbsp;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">wholly-owned subsidiary, ASPiRA LABS,</font><font style="display: inline;font-family:Times New Roman;">&nbsp;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">as of August 2015. Pursuant to this agreement, as amended as of March 11, 2017, Quest Diagnostics has agreed to provide </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">blood draw and logistics support by transporting specimens from its clients to ASPiRA LABS for testing through at least March 11, 201</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">8</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> in exchange for a market value fee. Per the terms of </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">this</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> agreement, the Company will not offer to existing or future Quest Diagnostics customers tests that Quest Diagnostics offers. </font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-indent:36pt;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:10pt;">3.</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"> &nbsp; </font><font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">COMMITMENT</font><font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">S</font><font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;"> AND CONTINGENCIES</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;">Development Loan</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Arial Unicode MS;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">On March 22, 2016, the Company entered into the </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">Loan </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">Agreement, pursuant to which the Company may borrow up to </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">$4,000,000</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> from the DECD.&nbsp;Proceeds from the </font><a name="_cp_text_1_48"></a><font style="display: inline;font-family:Times New Roman;font-size:10pt;">$2,000,000</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> April 2016 initial disbursement under the Loan Agreement </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">were</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> utilized primarily to fund the build-out, information technology infrastructure and other costs related to the Company&#x2019;s Trumbull, Connecticut facility and operations.&nbsp;The loan bears interest at a fixed rate of </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">2.0%</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> per annum and requires equal monthly payments of principal and interest until maturity, </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">which occurs </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">on</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">&nbsp;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">April 15, 2026</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">.&nbsp;As security for the loan, the Company has granted the DECD a blanket security interest in the Company&#x2019;s personal and intellectual property.&nbsp;The DECD&#x2019;s security interest in the Company&#x2019;s intellectual property may be subordinated to a qualified institutional lender.&nbsp;Under the terms of the </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">Loan </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">Agreement, the Company may be eligible for forgiveness of up to </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">$2,000,000</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> of the </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">principal amount of the loan if the Company achieves certain job creation and retention milestones by March 1, 2018.&nbsp;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">Conversely, i</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">f the Company is unable to meet these job creation </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">milestones, namely, hiring </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">40</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> full time employees with a specified average annual salary within the allotted timeframe </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">and </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">retaining those employees for a </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">two</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">-</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">year period </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">or </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">does not maintain the Company&#x2019;s Connecticut operations for a period of</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">&nbsp;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">10</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> years, the DECD may require early repayment of a portion or all of the loan</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> plus a penalty of </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">5%</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">.</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Arial Unicode MS;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">&nbsp; &nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Arial Unicode MS;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">As discussed above, a</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">n initial disbursement of </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">$2,000,000</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">&nbsp;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">was</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> made to the Company</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> on April 15, 2016</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> under the Loan Agreement</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">.&nbsp;The </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">Loan </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">Agreement provides that the remaining </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">$2,000,000</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> will be </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">disbursed</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">&nbsp;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">if and when the Company achieves certain future milestones. The loan may be prepaid at any time without premium or penalty</font><a name="T7"></a><a name="T8"></a><a name="T9"></a><font style="display: inline;font-family:Times New Roman;font-size:10pt;">.</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;border-top:1pt none #D9D9D9 ;line-height:100%;font-family:Arial Unicode MS;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;">Operating Leases</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-indent:36pt;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">The Company leases facilities to support its business of discovering, developing and commercializing diagnostic tests in the fields of gynecologic disease</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">. The Company&#x2019;s</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> principal facility</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">,</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">&nbsp;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">including</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">&nbsp;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">the </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">CLIA laboratory </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">used by ASPiRA LABS</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">,</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> is </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">located in Austin, Texas</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">,</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> and </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">the </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">CLIA laboratory </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">used by ASPiRA IVD is located </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">in Trumbull, Connecticut</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">. &nbsp;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">The</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> Austin, Texas lease </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">include</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">s</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">&nbsp;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">an aggregate annual base rent of </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">$</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">85</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">,000</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> and annual estimated common area charges, taxes and insurance of </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">$</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">46</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">,000</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> and</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> expires on </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">January</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> 31, 201</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">9</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">.</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> &nbsp; &nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-indent:36pt;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">In October 2015, the Company entered a lease agreement for a facility in Trumbull, Connecticut. The lease </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">required</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> initial payments for the buildout of leasehold improvements to the office space, which </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">were</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> approximately </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">$</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">596</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">,000</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">. The term of the lease is </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">five</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> years beginning after the initial date of occupancy </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">i</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">n January</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">&nbsp;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">2016 and a rent abatement period of </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">five</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> months. The lease includes an aggregate annual base rent of </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">$32,000</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> and annual estimated common area charges, taxes and insurance of </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">$9</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">5</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">,000</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">. &nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-indent:36pt;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">Building rent</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> for the three months ended</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">&nbsp;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">June 30</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">, 2017</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> and </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">201</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">6</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">&nbsp;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">totaled </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">$</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">6</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">2</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">,000</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> and </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">$</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">5</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">3</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">,000</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">, respectively. </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">Building rent</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> for the </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">six </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">months ended</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> June 30, 2017</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> and </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">201</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">6</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> totaled </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">$</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">123</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">,000</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> and </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">$104,000</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">, respectively. </font>
		</p>
		<p style="margin:0pt;line-height:100%;text-indent:36pt;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;">Capital Lease</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-indent:36pt;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">In April 2015, the Company lease</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">d</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">&nbsp;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">a</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> laboratory instrument for a total initial payment of </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">$</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">125</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">,000</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> and ongoing payments of approximately </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">$</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">3</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">,</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">5</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">00</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> per month for </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">36</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> months after delivery. The agreement also requires </font>
		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;"></font><font style="display: inline;">10</font><font style="display: inline;"></font>

		</p>

		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt">

			&nbsp;

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt"><font style="display: inline;font-family:Times New Roman;font-size:10pt;">minimum annual purchases of reagents from the manufacturer of the equipment.</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> The laboratory instrument was placed into service on July 1, 2015. </font>
		</p>
		<p style="margin:0pt;line-height:100%;text-indent:36pt;font-family:Calibri;font-size: 11pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">The accumulated amortization of assets under capital lease obligations was </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">$</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">155</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">,000</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> and </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">$</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">77</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">,000</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> as of </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">June 30</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">, &nbsp;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">201</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">7</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">&nbsp;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">and </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">201</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">6</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">, respectively. The </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">net book value of assets under capital lease obligations was </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">$</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">77</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">,000</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> and </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">$</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">1</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">55</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">,000</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> as</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> of</font><font style="display: inline;">&nbsp;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">June 30</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">, 2017</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> and </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">2016</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">, respectively</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">. &nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-indent:36pt;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;">Non-cancelable </font><font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;">Royalty</font><font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;"> Obligations</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Arial Unicode MS;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">The Company </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">is a party to an amended</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> research collaboration agreement with The Johns Hopkins University School of Medicine </font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">under which the Company license</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">s</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"> certain of its intellectual property</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">. &nbsp;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">Under </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">the terms of the amended research collaboration agreement, Vermillion is required to pay the greater of </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">4%</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> royalties on net sales of diagnostic tests using the assigned patents or annual minimum royalties of </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">$57,500</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">. &nbsp;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">Royalty expense for the three months ended </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">June 30</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">, 2017</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> and </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">201</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">6</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">&nbsp;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">totalled </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">$</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">34</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">,000</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> and </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">$</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">2</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">2</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">,000</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">,</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> respectively. </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">Royalty expense for the </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">six </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">months ended </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">June 30, 2017</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> and 201</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">6</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> totalled </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">$</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">63</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">,000</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> and </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">$42,000</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">,</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> respectively.</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;border-top:1pt none #D9D9D9 ;line-height:100%;font-family:Arial Unicode MS;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">&nbsp;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 6pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">4.&nbsp;&nbsp; </font><font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">STOCKHOLDERS&#x2019; EQUITY</font>
		</p>
		<p style="margin:0pt 0pt 10pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;">2017 Private Placement</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font>
		</p>
		<p style="margin:0pt 0pt 10pt;text-indent:36pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">On February 17, 2017, the Company completed a private placement pursuant to which certain investors purchased </font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">3,747,125</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> shares of Vermillion common stock at a price of </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">$1.40</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> per share. Vermillion also issued warrants to purchase shares of </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">Vermillion </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">common stock at a price of </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">$0.125</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> per warrant share in the private placement. Net proceeds of the private placement were approximately $</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">5,1</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">27</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">,000</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> after deducting offering expenses. The warrants are exercisable for </font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">2,810,338</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> shares of Vermillion common stock at </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">$1.80</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> per share. </font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">The warrants may be exercised from time to time beginning August 17, 2017 and expire on the fifth anniversary of the date of issuance </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">or, if earlier, five business days after Vermillion delivers notice that the closing price per share of its common stock exceeded the exercise price for 20 consecutive trading days during the exercise period</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">.</font>
		</p>
		<p style="margin:0pt 0pt 3pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">The sale</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> of common stock and issuance of warrants qualified for equity treatment under GAAP. The respective values of the warrants and common stock were calculated using their relative fair values and classified under common stock and additional paid-in capital. The value ascribed to the warrants is </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">$804,000</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> and to the common stock is approximately </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">$4,296,000</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">.</font>
		</p>
		<p style="margin:0pt 0pt 3pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 3pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;">2010 Stock Incentive Plan</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">The Company&#x2019;s employees, directors, and consultants are eligible to receive awards under the Vermillion, Inc. </font><a name="_cp_text_4_18"></a><font style="display: inline;font-family:Times New Roman;font-size:10pt;">Second Amended and Restated </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">2010 Stock Incentive Plan (the &#x201C;2010 Plan&#x201D;). The 2010 Plan permits the granting of a variety of awards, including stock options, share appreciation rights, restricted shares, restricted share units, unrestricted shares, deferred share units, performance and cash-settled awards, and dividend equivalent rights. The 2010 Plan provides for issuance of up to </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">8,122,983</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> shares of Vermillion common stock, subject to adjustment as provided in the 2010 Plan.</font>
		</p>
		<p style="margin:0pt 0pt 3pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;">Stock-Based Compensation</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-indent:36pt;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">During the </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">six</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">&nbsp;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">months ended </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">June 30</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">, 2017</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">, the Company awarded to Vermillion&#x2019;s non-employee directors </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">131</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">,</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">250</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> shares of restricted stock under the 2010 Plan having a fair value of approximately </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">$</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">281</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">,000</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> as payment for services </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">to be </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">rendered in </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">2017</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">.&nbsp;These shares of restricted stock vest</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">ed</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">&nbsp;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">50%</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> on June 1, </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">201</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">7,</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">&nbsp;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">and </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">will vest </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">25%</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> on</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> each of</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> September 1, 201</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">7</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> and</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">&nbsp;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">December 1, </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">2017</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">.</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">&nbsp;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">The Company also issued to certain consultants </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">22,841</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> shares of restricted stock </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">under </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">the 2010 Plan having a fair value of </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">approximately </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">$</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">39</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">,000</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">.</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-indent:36pt;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-indent:36pt;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">During the </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">three </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">months ended </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">June 30</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">, 2017</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">, the Company issued to certain consultants </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">9,213</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> shares of restricted stock under the 2010 Plan having a fair value of approximately </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">$19,000</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">.</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> The Company </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">did not</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> make any awards of restricted stock to non-employee directors during the three months ended June 30, 201</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">7</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">.&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-indent:36pt;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-indent:36pt;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">During the </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">six</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">&nbsp;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">months ended </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">June 30</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">, 2017</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">, t</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">he Company </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">also </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">granted certain consultants options to purchase </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">7</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">0,000</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> shares of Vermillion common stock with an exercise price of </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">$</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">2.14</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> per share.&nbsp;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">&nbsp;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">The Company also granted certain officers</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> and</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> employees options to </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">purchase approximately </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">916</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">,000</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> shares of Vermillion common </font>
		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;"></font><font style="display: inline;">11</font><font style="display: inline;"></font>

		</p>

		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt">

			&nbsp;

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt"><font style="display: inline;font-family:Times New Roman;font-size:10pt;">stock with an exercise price of </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">$</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">2.14</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> per share.&nbsp;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">These stock options generally vest </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">25%</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> on each of the four&nbsp;anniversaries of the grant date.</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">&nbsp;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> In addition, the C</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">ompany granted certain officers and </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">employees</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> options to purchase</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">&nbsp;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">25</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">0,000</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> shares of Vermillion common stock with an exercise price of </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">approximately </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">$</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">2.14</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> per</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> share with performance-based vesting based on certain metrics through December 31, 201</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">7</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">.</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">&nbsp;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">These options vest </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">25%</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> on each of the four&nbsp;anniversaries of the grant date if the performance-based metrics are met.</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-indent:36pt;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-indent:36pt;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">During the three months ended June 30, 201</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">7</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">, the Company granted certain officers and employees options to purchase </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">14,500</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> shares of Vermillion common stock with an exercise price of </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">$1.83</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> per share.&nbsp;These stock options vest </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">25%</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> on each of the four&nbsp;anniversaries of the vesting commencement date for each such stock option.&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-indent:36pt;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">The allocation of employee stock-based compensation expense by functional area for the three</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">&nbsp;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">and six </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">months ended </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">June 30</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">, 2017</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">&nbsp;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">and </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">2016 </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">was as follows:</font>
		</p>
		<p style="margin:0pt;font-family:Calibri;line-height:107.92%;font-size: 1pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:38.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size: 1pt">
						<font style="display: inline;font-size:1pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:38.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;color:#000000;font-size:10pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="5" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:10pt;">Three Months Ended June 30,</font></p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="5" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:10pt;">Six Months Ended June 30,</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:38.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:10pt;text-decoration:underline;">(in thousands)</font></p>
				</td>
				<td valign="top" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:10pt;">2017</font></p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:10pt;">2016</font></p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:10pt;">2017</font></p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:10pt;">2016</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:38.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">Cost of revenue</font></p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.10%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">20&nbsp;
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.10%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">22&nbsp;
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.10%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">40&nbsp;
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.10%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">46&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:38.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">Research and development </font></p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">2&nbsp;
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">22&nbsp;
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">5&nbsp;
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">53&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:38.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">Sales and marketing </font></p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">38&nbsp;
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">14&nbsp;
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">70&nbsp;
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">56&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:38.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">General and administrative</font></p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">283&nbsp;
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">320&nbsp;
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">414&nbsp;
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">425&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:38.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">Total </font></p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.10%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">343&nbsp;
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.10%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">378&nbsp;
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.10%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">529&nbsp;
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.10%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">580&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:38.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;color:#000000;font-size:10pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.10%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.10%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.10%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.10%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt 0pt 8pt;font-family:Calibri;line-height:107.92%;font-size: 11pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;font-family:Calibri;line-height:107.92%;font-size: 1pt">
			<font style="display: inline;font-size:1pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;font-family:Calibri;line-height:107.92%;font-size: 1pt">
			<font style="display: inline;font-size:1pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;font-family:Calibri;line-height:107.92%;font-size: 1pt">
			<font style="display: inline;font-size:1pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;font-family:Calibri;line-height:107.92%;font-size: 1pt">
			<font style="display: inline;font-size:1pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;font-family:Calibri;line-height:107.92%;font-size: 1pt">
			<font style="display: inline;font-size:1pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;font-family:Calibri;line-height:107.92%;font-size: 1pt">
			<font style="display: inline;font-size:1pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;font-family:Calibri;line-height:107.92%;font-size: 1pt">
			<font style="display: inline;font-size:1pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;font-family:Calibri;line-height:107.92%;font-size: 1pt">
			<font style="display: inline;font-size:1pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;font-family:Calibri;line-height:107.92%;font-size: 1pt">
			<font style="display: inline;font-family:Times New Roman;font-size:1pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;font-family:Calibri;line-height:107.92%;font-size: 1pt">
			<font style="display: inline;font-family:Times New Roman;font-size:1pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">5.&nbsp;&nbsp; </font><font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">LOSS PER SHARE</font>
		</p>
		<p style="margin:0pt 0pt 8pt;text-indent:36pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">The Company calculates basic loss per share using the weighted ave</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">rage number of shares </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">of Vermillion common stock </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">outstanding during the period. Because the Company is in a net loss position, diluted loss per share is calculated using the </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">weighted average number of shares of </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">Vermillion </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">common stock outstanding and excludes the effects of </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">11,662,280</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">&nbsp;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">an</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">d &nbsp;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">7,808,044</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> po</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">tential shares of</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> Vermillion</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> common stock as of </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">June 30</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">, 2017</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">&nbsp;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">and </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">201</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">6</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">, respectively, that are anti-dilutive. Potential shares of </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">Vermillion </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">common stock include incremental shares of </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">Vermillion </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">common stock issuable upon the exercise of outstanding warrants</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">, stock options and unvested restricted stock units.</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 8pt;text-indent:36pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 8pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 8pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">

		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;"></font><font style="display: inline;">12</font><font style="display: inline;"></font>

		</p>

		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt">

			&nbsp;

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<p style="margin:0pt 0pt 8pt;font-family:Calibri;line-height:107.92%;;font-size: 10pt"><font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;"></font>
		</p>
		<p style="margin:0pt 0pt 8pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<a name="Item_2"></a><font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">ITEM 2.</font><font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;"> &nbsp;MANAGEMENT&#x2019;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</font>
		</p>
		<p style="margin:0pt 0pt 3pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;">Forward</font><font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;">-</font><font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;">Looking Statements </font>
		</p>
		<p style="margin:0pt 0pt 8pt;text-indent:29.5pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">This Quarterly Report on Form 10-Q contains forward-looking statements, as defined in the Private Securities Litigation Refo</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">rm Act of 1995. </font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:29.5pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">These statements involve a number of risks and uncertainties. Words such as &#x201C;may,&#x201D; &#x201C;expects,&#x201D; &#x201C;intends,&#x201D; &#x201C;anticipates,&#x201D; &#x201C;believes,&#x201D; &#x201C;estimates,&#x201D; &#x201C;plans,&#x201D; &#x201C;seeks,&#x201D; &#x201C;could,&#x201D; &#x201C;should,&#x201D; &#x201C;continue,&#x201D; &#x201C;will,&#x201D; &#x201C;potential,&#x201D; &#x201C;projects&#x201D; and similar expressions are intended to identify such forward-looking statements. Readers are cautioned that these forward-looking statements speak only as of the date on which th</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">is Quarterly Report on Form 10-Q</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> is filed with the </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">Securities and Exchange Commission (&#x201C;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">SEC</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">&#x201D;)</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">, and, except as required by law, </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">Vermillion, Inc. (&#x201C;Vermillion&#x201D; and together with its subsidiaries, the &#x201C;Company</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">,</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">&#x201D; &#x201C;we</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">,</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">&#x201D; &#x201C;our</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">,</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">&#x201D; or &#x201C;us&#x201D;) does</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> not assume any obligation to update, amend or clarify them to reflect events, new information or circumstances occurring after such date.</font>
		</p>
		<p style="margin:0pt 0pt 4pt;text-indent:29.5pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">Examples of forward-looking statements regarding our business include the following:</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="punctuation-wrap:hanging;line-height:100%;vertical-align:baseline;font-family:Calibri;font-size: 10pt;margin:0pt 0pt 6pt;">
				<font style="margin:0pt 0pt 6pt;font-family:Symbol;color:#000000;font-size:8pt;punctuation-wrap:hanging;line-height:100%;vertical-align:baseline;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="punctuation-wrap:hanging;line-height:100%;vertical-align:baseline;font-family:Calibri;font-size: 10pt;margin:0pt 0pt 6pt;">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">projections or expectations regarding our future </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">test volumes, </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">revenue</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">, cost of revenue, operating expenses, cash flow, </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">results of operations and financial condition;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="punctuation-wrap:hanging;line-height:100%;font-family:Calibri;font-size: 10pt;margin:0pt 0pt 6pt;">
				<font style="margin:0pt 0pt 6pt;font-family:Symbol;color:#000000;font-size:8pt;punctuation-wrap:hanging;line-height:100%;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="punctuation-wrap:hanging;line-height:100%;font-family:Calibri;font-size: 10pt;margin:0pt 0pt 6pt;">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">our plan to broaden our commercial focus from ovarian cancer to differential diagnosis of women with a range of gynecological disorders;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="punctuation-wrap:hanging;line-height:100%;font-family:Calibri;font-size: 10pt;margin:0pt 0pt 6pt;">
				<font style="margin:0pt 0pt 6pt;font-family:Symbol;color:#000000;font-size:8pt;punctuation-wrap:hanging;line-height:100%;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="punctuation-wrap:hanging;line-height:100%;font-family:Calibri;font-size: 10pt;margin:0pt 0pt 6pt;">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">our planned business strategy and the anticipated timing of the implementation thereof;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="punctuation-wrap:hanging;line-height:100%;vertical-align:baseline;font-family:Calibri;font-size: 10pt;margin:0pt 0pt 6pt;">
				<font style="margin:0pt 0pt 6pt;font-family:Symbol;color:#000000;font-size:8pt;punctuation-wrap:hanging;line-height:100%;vertical-align:baseline;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="punctuation-wrap:hanging;line-height:100%;vertical-align:baseline;font-family:Calibri;font-size: 10pt;margin:0pt 0pt 6pt;">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">plans with respect to our market expansion and growth, including plans to market Overa outside the United States;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="punctuation-wrap:hanging;line-height:100%;vertical-align:baseline;font-family:Calibri;font-size: 10pt;margin:0pt 0pt 6pt;">
				<font style="margin:0pt 0pt 6pt;font-family:Symbol;color:#000000;font-size:8pt;punctuation-wrap:hanging;line-height:100%;vertical-align:baseline;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="punctuation-wrap:hanging;line-height:100%;vertical-align:baseline;font-family:Calibri;font-size: 10pt;margin:0pt 0pt 6pt;">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">plans to develop new algorithms and molecular diagnostic tests;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">&nbsp;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="punctuation-wrap:hanging;line-height:100%;vertical-align:baseline;font-family:Calibri;font-size: 10pt;margin:0pt 0pt 6pt;">
				<font style="margin:0pt 0pt 6pt;font-family:Symbol;color:#000000;font-size:8pt;punctuation-wrap:hanging;line-height:100%;vertical-align:baseline;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="punctuation-wrap:hanging;line-height:100%;vertical-align:baseline;font-family:Calibri;font-size: 10pt;margin:0pt 0pt 6pt;">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">plans to develop a product or tool combining an OVA1 with results of a symptom index;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="punctuation-wrap:hanging;line-height:100%;vertical-align:baseline;font-family:Calibri;font-size: 10pt;margin:0pt 0pt 6pt;">
				<font style="margin:0pt 0pt 6pt;font-family:Symbol;color:#000000;font-size:8pt;punctuation-wrap:hanging;line-height:100%;vertical-align:baseline;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="punctuation-wrap:hanging;line-height:100%;vertical-align:baseline;font-family:Calibri;font-size: 10pt;margin:0pt 0pt 6pt;">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">plans to establish our own payer coverage for OVA1 and Overa; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="punctuation-wrap:hanging;line-height:100%;vertical-align:baseline;font-family:Calibri;font-size: 10pt;margin:0pt 0pt 6pt;">
				<font style="margin:0pt 0pt 6pt;font-family:Symbol;color:#000000;font-size:8pt;punctuation-wrap:hanging;line-height:100%;vertical-align:baseline;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="punctuation-wrap:hanging;line-height:100%;vertical-align:baseline;font-family:Calibri;font-size: 10pt;margin:0pt 0pt 6pt;">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">intentions to address clinical questions related to early disease detection, treatment response, monitoring of disease progression, prognosis and other issues in the fields of oncology and women&#x2019;s health;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="punctuation-wrap:hanging;line-height:100%;vertical-align:baseline;font-family:Calibri;font-size: 10pt;margin:0pt 0pt 6pt;">
				<font style="margin:0pt 0pt 6pt;font-family:Symbol;color:#000000;font-size:8pt;punctuation-wrap:hanging;line-height:100%;vertical-align:baseline;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="punctuation-wrap:hanging;line-height:100%;vertical-align:baseline;font-family:Calibri;font-size: 10pt;margin:0pt 0pt 6pt;">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">plans to leverage infrastructure and enhance our pipeline of future technologies by fostering relationships with in vitro diagnostic (&#x201C;IVD&#x201D;) companies;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="punctuation-wrap:hanging;line-height:100%;vertical-align:baseline;font-family:Calibri;font-size: 11pt;margin:0pt 0pt 6pt;">
				<font style="margin:0pt 0pt 6pt;font-family:Symbol;color:#000000;font-size:8pt;punctuation-wrap:hanging;line-height:100%;vertical-align:baseline;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="punctuation-wrap:hanging;line-height:100%;vertical-align:baseline;font-family:Calibri;font-size: 11pt;margin:0pt 0pt 6pt;">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">plans with respect to ASPiRA IVD, Inc. (&#x201C;ASPiRA IVD&#x201D;);</font><font style="display: inline;color:#000000;">&nbsp;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="punctuation-wrap:hanging;line-height:100%;vertical-align:baseline;font-family:Calibri;font-size: 10pt;margin:0pt 0pt 6pt;">
				<font style="margin:0pt 0pt 6pt;font-family:Symbol;color:#000000;font-size:8pt;punctuation-wrap:hanging;line-height:100%;vertical-align:baseline;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="punctuation-wrap:hanging;line-height:100%;vertical-align:baseline;font-family:Calibri;font-size: 10pt;margin:0pt 0pt 6pt;">
			<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">expected service revenue growth based on ASPiRA IVD;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="punctuation-wrap:hanging;line-height:100%;font-family:Calibri;font-size: 10pt;margin:0pt 0pt 6pt;">
				<font style="margin:0pt 0pt 6pt;font-family:Symbol;color:#000000;font-size:8pt;punctuation-wrap:hanging;line-height:100%;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="punctuation-wrap:hanging;line-height:100%;font-family:Calibri;font-size: 10pt;margin:0pt 0pt 6pt;">
			<a name="_cp_blt_1_60"></a><a name="_cp_text_1_61"></a><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">e</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">xpected license revenue in future periods;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="punctuation-wrap:hanging;line-height:100%;vertical-align:baseline;color:#00C000;font-family:Calibri;font-size: 10pt;margin:0pt 0pt 6pt;">
				<font style="margin:0pt 0pt 6pt;font-family:Symbol;color:#000000;font-size:8pt;punctuation-wrap:hanging;line-height:100%;vertical-align:baseline;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="punctuation-wrap:hanging;line-height:100%;vertical-align:baseline;color:#00C000;font-family:Calibri;font-size: 10pt;margin:0pt 0pt 6pt;">
			<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">our planned focus</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;"> on the execution of five core strategic business drivers in ovarian cancer diagnostics and specialized laboratory services to address unmet medical needs for women faced with gynecologic disease and other conditions and the continued development of our business;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="punctuation-wrap:hanging;line-height:100%;vertical-align:baseline;font-family:Calibri;font-size: 10pt;margin:0pt 0pt 6pt;">
				<font style="margin:0pt 0pt 6pt;font-family:Symbol;color:#000000;font-size:8pt;punctuation-wrap:hanging;line-height:100%;vertical-align:baseline;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="punctuation-wrap:hanging;line-height:100%;vertical-align:baseline;font-family:Calibri;font-size: 10pt;margin:0pt 0pt 6pt;">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">anticipated efficacy of our products, product </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">development activities and product innovations;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="punctuation-wrap:hanging;line-height:100%;vertical-align:baseline;font-family:Calibri;font-size: 10pt;margin:0pt 0pt 6pt;">
				<font style="margin:0pt 0pt 6pt;font-family:Symbol;color:#000000;font-size:8pt;punctuation-wrap:hanging;line-height:100%;vertical-align:baseline;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="punctuation-wrap:hanging;line-height:100%;vertical-align:baseline;font-family:Calibri;font-size: 10pt;margin:0pt 0pt 6pt;">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">expected competition in the markets in which we compete;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="punctuation-wrap:hanging;line-height:100%;vertical-align:baseline;font-family:Calibri;font-size: 10pt;margin:0pt 0pt 6pt;">
				<font style="margin:0pt 0pt 6pt;font-family:Symbol;color:#000000;font-size:8pt;punctuation-wrap:hanging;line-height:100%;vertical-align:baseline;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="punctuation-wrap:hanging;line-height:100%;vertical-align:baseline;font-family:Calibri;font-size: 10pt;margin:0pt 0pt 6pt;">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">plans with respect to ASPiRA LABS, Inc. (&#x201C;ASPiRA LABS&#x201D;)</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="punctuation-wrap:hanging;line-height:100%;vertical-align:baseline;font-family:Calibri;font-size: 10pt;margin:0pt 0pt 6pt;">
				<font style="margin:0pt 0pt 6pt;font-family:Symbol;color:#000000;font-size:8pt;punctuation-wrap:hanging;line-height:100%;vertical-align:baseline;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="punctuation-wrap:hanging;line-height:100%;vertical-align:baseline;font-family:Calibri;font-size: 10pt;margin:0pt 0pt 6pt;">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">expectations regarding future services provided by Quest Diagnostics Incorporated (&#x201C;Quest Diagnostics&#x201D;);</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="punctuation-wrap:hanging;line-height:100%;font-family:Calibri;font-size: 10pt;margin:0pt 0pt 6pt;">
				<font style="margin:0pt 0pt 6pt;font-family:Symbol;color:#000000;font-size:8pt;punctuation-wrap:hanging;line-height:100%;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="punctuation-wrap:hanging;line-height:100%;font-family:Calibri;font-size: 10pt;margin:0pt 0pt 6pt;">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">plans to expand our ovar</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">ian cancer franchise beyond OVA1, including with respect to Overa and OvaX;</font></p></td></tr></table></div>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;"></font><font style="display: inline;">13</font><font style="display: inline;"></font>

		</p>

		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt">

			&nbsp;

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="punctuation-wrap:hanging;line-height:100%;font-family:Calibri;font-size: 10pt;margin:0pt 0pt 6pt;">
				<font style="margin:0pt 0pt 6pt;font-family:Symbol;color:#000000;font-size:8pt;punctuation-wrap:hanging;line-height:100%;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="punctuation-wrap:hanging;line-height:100%;font-family:Calibri;font-size: 10pt;margin:0pt 0pt 6pt;">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">plans regarding the commercialization of Overa;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="punctuation-wrap:hanging;line-height:100%;font-family:Calibri;font-size: 10pt;margin:0pt 0pt 6pt;">
				<font style="margin:0pt 0pt 6pt;font-family:Symbol;color:#000000;font-size:8pt;punctuation-wrap:hanging;line-height:100%;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="punctuation-wrap:hanging;line-height:100%;font-family:Calibri;font-size: 10pt;margin:0pt 0pt 6pt;">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">plans to develop and perform laboratory development tests (&#x201C;LDTs&#x201D;);</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="punctuation-wrap:hanging;line-height:100%;color:#00C000;font-family:Calibri;font-size: 10pt;margin:0pt 0pt 6pt;">
				<font style="margin:0pt 0pt 6pt;font-family:Symbol;color:#000000;font-size:8pt;punctuation-wrap:hanging;line-height:100%;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="punctuation-wrap:hanging;line-height:100%;color:#00C000;font-family:Calibri;font-size: 10pt;margin:0pt 0pt 6pt;">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">plans with respect to the Company&#x2019;s pelvic mass registry</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">, including</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;"> anticipated sources of funding</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">; &nbsp;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="punctuation-wrap:hanging;line-height:100%;color:#00C000;font-family:Calibri;font-size: 10pt;margin:0pt 0pt 6pt;">
				<font style="margin:0pt 0pt 6pt;font-family:Symbol;color:#000000;font-size:8pt;punctuation-wrap:hanging;line-height:100%;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="punctuation-wrap:hanging;line-height:100%;color:#00C000;font-family:Calibri;font-size: 10pt;margin:0pt 0pt 6pt;">
			<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">anticipated effects on reimbursement for OVA1 from changes to Novitas Solutions&#x2019; administrative requirements;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="punctuation-wrap:hanging;line-height:100%;color:#000000;font-family:Calibri;font-size: 10pt;margin:0pt 0pt 6pt;">
				<font style="margin:0pt 0pt 6pt;font-family:Symbol;color:#000000;font-size:8pt;punctuation-wrap:hanging;line-height:100%;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="punctuation-wrap:hanging;line-height:100%;color:#000000;font-family:Calibri;font-size: 10pt;margin:0pt 0pt 6pt;">
			<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">expectations regarding</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;"> the Company&#x2019;s monitoring and combining multiple protein biomarkers to create diagnostic tests to aid physicians considering treatment options for patients with complex diseases, and the Company&#x2019;s future development of new In Vitro Diagnostic Multivariate Index Assays</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;"> (IVDMIA</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">);</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="punctuation-wrap:hanging;line-height:100%;vertical-align:baseline;font-family:Calibri;font-size: 10pt;margin:0pt 0pt 6pt;">
				<font style="margin:0pt 0pt 6pt;font-family:Symbol;color:#000000;font-size:8pt;punctuation-wrap:hanging;line-height:100%;vertical-align:baseline;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="punctuation-wrap:hanging;line-height:100%;vertical-align:baseline;font-family:Calibri;font-size: 10pt;margin:0pt 0pt 6pt;">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">expectations regarding </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">existing and future collaborations and partnerships</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">, including OVA1 and Overa distribution agreements</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="punctuation-wrap:hanging;line-height:100%;vertical-align:baseline;font-family:Calibri;font-size: 10pt;margin:0pt 0pt 6pt;">
				<font style="margin:0pt 0pt 6pt;font-family:Symbol;color:#000000;font-size:8pt;punctuation-wrap:hanging;line-height:100%;vertical-align:baseline;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="punctuation-wrap:hanging;line-height:100%;vertical-align:baseline;font-family:Calibri;font-size: 10pt;margin:0pt 0pt 6pt;">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">plans regarding future publications;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="punctuation-wrap:hanging;line-height:100%;vertical-align:baseline;text-decoration:none;color:#000000;font-family:Calibri;font-size: 10pt;margin:0pt 0pt 6pt;">
				<font style="margin:0pt 0pt 6pt;font-family:Symbol;color:#000000;font-size:8pt;punctuation-wrap:hanging;line-height:100%;vertical-align:baseline;text-decoration:none;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="punctuation-wrap:hanging;line-height:100%;vertical-align:baseline;text-decoration:none;color:#000000;font-family:Calibri;font-size: 10pt;margin:0pt 0pt 6pt;">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">our </font><font style="color:#00C000;display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;text-decoration:none;">continued ability to comply with applicable governmental regulations</font><font style="color:#00C000;display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;text-decoration:none;">, &nbsp;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">expectations regarding </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">pending regulatory submissions and plans to seek regulatory approvals for our tests outside the United States</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="punctuation-wrap:hanging;line-height:100%;vertical-align:baseline;text-decoration:none;color:#000000;font-family:Calibri;font-size: 10pt;margin:0pt 0pt 6pt;">
				<font style="margin:0pt 0pt 6pt;font-family:Symbol;color:#000000;font-size:8pt;punctuation-wrap:hanging;line-height:100%;vertical-align:baseline;text-decoration:none;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="punctuation-wrap:hanging;line-height:100%;vertical-align:baseline;text-decoration:none;color:#000000;font-family:Calibri;font-size: 10pt;margin:0pt 0pt 6pt;">
			<font style="color:#00C000;display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;text-decoration:none;">our ability to obtain and maintain the regulatory approvals required to market Overa in other countries;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="punctuation-wrap:hanging;line-height:100%;vertical-align:baseline;font-family:Calibri;font-size: 10pt;margin:0pt 0pt 6pt;">
				<font style="margin:0pt 0pt 6pt;font-family:Symbol;color:#000000;font-size:8pt;punctuation-wrap:hanging;line-height:100%;vertical-align:baseline;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="punctuation-wrap:hanging;line-height:100%;vertical-align:baseline;font-family:Calibri;font-size: 10pt;margin:0pt 0pt 6pt;">
			<font style="color:#00C000;display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;text-decoration:none;">our continued ability to expand and protect our intellectual property portfolio;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="punctuation-wrap:hanging;line-height:100%;vertical-align:baseline;font-family:Calibri;font-size: 10pt;margin:0pt 0pt 6pt;">
				<font style="margin:0pt 0pt 6pt;font-family:Symbol;color:#000000;font-size:8pt;punctuation-wrap:hanging;line-height:100%;vertical-align:baseline;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="punctuation-wrap:hanging;line-height:100%;vertical-align:baseline;font-family:Calibri;font-size: 10pt;margin:0pt 0pt 6pt;">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">anticipated </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">liquidity and capital requirements</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="punctuation-wrap:hanging;line-height:100%;vertical-align:baseline;font-family:Calibri;font-size: 10pt;margin:0pt 0pt 6pt;">
				<font style="margin:0pt 0pt 6pt;font-family:Symbol;color:#000000;font-size:8pt;punctuation-wrap:hanging;line-height:100%;vertical-align:baseline;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="punctuation-wrap:hanging;line-height:100%;vertical-align:baseline;font-family:Calibri;font-size: 10pt;margin:0pt 0pt 6pt;">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">anticipated future losses and our ability to continue as a going concern;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">&nbsp;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="punctuation-wrap:hanging;line-height:100%;vertical-align:baseline;font-family:Calibri;font-size: 10pt;margin:0pt 0pt 6pt;">
				<font style="margin:0pt 0pt 6pt;font-family:Symbol;color:#000000;font-size:8pt;punctuation-wrap:hanging;line-height:100%;vertical-align:baseline;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="punctuation-wrap:hanging;line-height:100%;vertical-align:baseline;font-family:Calibri;font-size: 10pt;margin:0pt 0pt 6pt;">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">expectations regarding the second disbursement from our financing arrangement with</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;"> the State of Connecticut Department of Economic and Community Development (the &#x201C;DECD&#x201D;);</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="punctuation-wrap:hanging;line-height:100%;vertical-align:baseline;font-family:Calibri;font-size: 10pt;margin:0pt 0pt 6pt;">
				<font style="margin:0pt 0pt 6pt;font-family:Symbol;color:#000000;font-size:8pt;punctuation-wrap:hanging;line-height:100%;vertical-align:baseline;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="punctuation-wrap:hanging;line-height:100%;vertical-align:baseline;font-family:Calibri;font-size: 10pt;margin:0pt 0pt 6pt;">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">expected expenditures, including the expected decrease in expenses related to research and development in 2017;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="punctuation-wrap:hanging;line-height:100%;vertical-align:baseline;font-family:Calibri;font-size: 10pt;margin:0pt 0pt 6pt;">
				<font style="margin:0pt 0pt 6pt;font-family:Symbol;color:#000000;font-size:8pt;punctuation-wrap:hanging;line-height:100%;vertical-align:baseline;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="punctuation-wrap:hanging;line-height:100%;vertical-align:baseline;font-family:Calibri;font-size: 10pt;margin:0pt 0pt 6pt;">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">our ability to use our net operating loss carryforwards;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="punctuation-wrap:hanging;line-height:100%;vertical-align:baseline;font-family:Calibri;font-size: 10pt;margin:0pt 0pt 6pt;">
				<font style="margin:0pt 0pt 6pt;font-family:Symbol;color:#000000;font-size:8pt;punctuation-wrap:hanging;line-height:100%;vertical-align:baseline;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="punctuation-wrap:hanging;line-height:100%;vertical-align:baseline;font-family:Calibri;font-size: 10pt;margin:0pt 0pt 6pt;">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">expected market adoption of our diagnostic tests, including OVA1 and Overa; </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="punctuation-wrap:hanging;line-height:100%;vertical-align:baseline;font-family:Calibri;font-size: 10pt;margin:0pt 0pt 6pt;">
				<font style="margin:0pt 0pt 6pt;font-family:Symbol;color:#000000;font-size:8pt;punctuation-wrap:hanging;line-height:100%;vertical-align:baseline;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="punctuation-wrap:hanging;line-height:100%;vertical-align:baseline;font-family:Calibri;font-size: 10pt;margin:0pt 0pt 6pt;">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">expectations regarding our </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">ability</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;"> to launch new products developed, licensed, co-marketed or acquired;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="punctuation-wrap:hanging;line-height:100%;vertical-align:baseline;font-family:Calibri;font-size: 10pt;margin:0pt 0pt 6pt;">
				<font style="margin:0pt 0pt 6pt;font-family:Symbol;color:#000000;font-size:8pt;punctuation-wrap:hanging;line-height:100%;vertical-align:baseline;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="punctuation-wrap:hanging;line-height:100%;vertical-align:baseline;font-family:Calibri;font-size: 10pt;margin:0pt 0pt 6pt;">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">expectations regarding raising capital and the amount of financing anticipated to be required to fund our planned operations; and</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="punctuation-wrap:hanging;line-height:100%;vertical-align:baseline;font-family:Calibri;font-size: 10pt;margin:0pt 0pt 6pt;">
				<font style="margin:0pt 0pt 6pt;font-family:Symbol;color:#000000;font-size:8pt;punctuation-wrap:hanging;line-height:100%;vertical-align:baseline;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="punctuation-wrap:hanging;line-height:100%;vertical-align:baseline;font-family:Calibri;font-size: 10pt;margin:0pt 0pt 6pt;">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">expect</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">ations regarding</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;"> reimbursement for our products, and our ability to obtain such reimbursement, from third-party payers such as private insurance companies and government insurance plans.</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 4pt;text-indent:29.5pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;"> &nbsp;&nbsp;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;;font-size: 10pt;font-family:Calibri;text-indent:0pt;margin-left:0pt;padding:0pt 23.5pt 0pt 0pt;"></font><font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;"></font><font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;"></font>
		</p>
		<p style="margin:0pt 0pt 3pt;line-height:100%;font-family:Calibri;font-size: 11pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;;font-size: 11pt;font-family:Calibri;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-family:Times New Roman;color:#000000;"></font><font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">Forward-looking statements are subject to significant risks and uncertainties, including </font><a name="_cp_text_66_155"></a><font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">those discussed </font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">in Part I, Item 1A &#x201C;Risk Factors&#x201D; of </font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">our Annual Report on Form 10-K for the year ended December 31, </font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">201</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">6</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">&nbsp;</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">(our &#x201C;</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">201</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">6</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">&nbsp;</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">Annual Repo</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">rt&#x201D;) </font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">and </font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">Part II, Item 1A. &#x201C;Risk Factors&#x201D; of our</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">&nbsp;</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">Quarterly Report</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"> on Form 10-</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">Q</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"> for the three months ended March 31, 2017 (our &#x201C;2017 First Quarterly Report&#x201D;)</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">,</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;"> that could cause actual results to differ materially from those projected in such forward-looking statements due to various </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">factors, including our ability to increase the volume of OVA1 </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">or Overa </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">sales; our ability to market our test through sales channels other than Quest Diagnostics </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">Incorporated (&#x201C;Quest Diagnostics&#x201D;) </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">including ASPiRA LABS; failures by third-party payers to reimburse OVA1</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;"> or Overa</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;"> or changes or variances in reimbursement rates; </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">our ability to secure additional capital on acceptable terms to execute our business plan</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">; our ability to commercialize </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">OVA1 </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">and/or </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">O</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">vera</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">&nbsp;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">both within and </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">outside the United States; in the event that we succeed in commercializing </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">OVA1 </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">and/or </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">O</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">vera</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;"> outside the United States, the political, economic and other conditions affecting other countries (including foreign exchange rates); our ability to develop and commercialize additional diagnostic products and achieve market acceptance with respect to these products; our ability to compete successfully; our ability to obtain any regulatory approval required for our </font>
		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;"></font><font style="display: inline;">14</font><font style="display: inline;"></font>

		</p>

		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt">

			&nbsp;

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<p style="margin:0pt 0pt 3pt;line-height:100%;font-family:Calibri;;font-size: 11pt"><font style="display: inline;font-family:Times New Roman;font-size:10pt;">future diagnostic products; our or our suppliers&#x2019; ability to comply with </font><a name="_cp_text_4_157"></a><font style="display: inline;font-family:Times New Roman;font-size:10pt;">United States Food and Drug Administration (&#x201C;FDA&#x201D;) </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">requirements for production, marketing and post-market monitoring of our products; </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">additional costs that may be required to make </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">further improvements to our manufacturing operations; </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">our ability to maintain sufficient or acceptable supplies of immunoassay kits from our suppliers; our ability to continue to develop, protect and promote our proprietary technologies; future litigation against us, including infringement of intellectual property and product liability exposure; our ability to retain key employees; business interruptions; legislative actions resulting in higher compliance costs; changes in healthcare policy; our ability to comply with environmental laws; our ability to generate sufficient demand for ASPiRA LABS&#x2019; services to cover its operating costs; our ability to comply with the additional laws and regulations that apply to us in connection with the operation of ASPiRA LABS; our ability to </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">comply with FDA regulations that relate to our products and to </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">obtain any FDA clearance or approval required to develop and perform </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">laboratory-developed tests (&#x201C;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">LDTs</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">&#x201D;)</font><a name="_cp_text_1_164"></a><font style="display: inline;font-family:Times New Roman;font-size:10pt;">; ASPiRA IVD&#x2019;s </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">lack of operating history; ASPiRA IVD&#x2019;s </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">ability to generate and maintain business; fluctuations over time with respect to ASPiRA IVD&#x2019;s operating results; ASPiRA IVD&#x2019;s ability to enter into profitable contracts; ASPiRA IVD&#x2019;s ability to maintain effective information systems without significant interruption; ASPiRA IVD&#x2019;s ability to perform its services in compliance with contractual requirements, regulatory standards and ethical considerations</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">; and our ability to continue as a going concern.</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">. &nbsp;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">&nbsp;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 3pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 3pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;">Overview </font>
		</p>
		<p style="margin:5pt 0pt;line-height:normal;text-indent:36pt;border-bottom:1pt none #D9D9D9 ;font-family:Arial Unicode MS;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">Our vision is to&nbsp;drive&nbsp;the advancement of women&#x2019;s health by providing innovative methods to detect, monitor and manage the treatment of both benign and malignant </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">gynecologic</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> disease, with our primary focus being diseases of the female pelvic cavity.</font>
		</p>
		<p style="margin:5pt 0pt;line-height:normal;text-indent:36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Arial Unicode MS;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">We have expanded our corporate strategy with the goal of transforming Vermillion from a technology license company to a diagnostic service and bio-analytic solutions provider.&nbsp;Our plan is to broaden our commercial focus from ovarian cancer to differential diagnosis of women with a range of </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">gynecologic</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">al</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> disorders. Our strategy is being deployed in three phases.&nbsp;The three phases </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">are a rebuild phase, which was completed in the&nbsp;third&nbsp;quarter of 2015, a transformation phase, which</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> is</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">&nbsp;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">now </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">virtually </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">complete except for continuing expansion of payer coverage</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">, and a market expansion and growth phase, which we expect to begin </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">in </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">the near future</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">.&nbsp;&nbsp;</font>
		</p>
		<p style="margin:5pt 0pt;line-height:normal;text-indent:36pt;border-top:1pt none #D9D9D9 ;font-family:Arial Unicode MS;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">During the first phase, we expanded our leadership team by hiring several new senior leaders including a chief executive officer.&nbsp;&nbsp;In addition, we expanded our commercial strategy, reestablished medical and advisory support, rebuilt our patient advocacy strategy and established a billing system and a payer strategy outside of our relationship with Quest Diagnostics.&nbsp;&nbsp;During the second phase, </font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">we completed the process of obtaining licensure of ASPiRA LABS </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">in all of the states that require licenses, are in the process of establishing our own payer coverage for OVA1, </font><font style="font-weight:bold;display: inline;font-family:Times New Roman;font-weight:normal;font-size:10pt;">Multivariate Index Assay</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> (MIA), and launched a second-generation OVA1 test, trademarked Overa, </font><font style="font-weight:bold;display: inline;font-family:Times New Roman;font-weight:normal;font-size:10pt;">Multivariate Index Assay, 2</font><font style="font-weight:bold;display: inline;font-family:Times New Roman;font-weight:normal;font-size:10pt;font-size:5pt;vertical-align:super;line-height:normal">nd</font><font style="font-weight:bold;display: inline;font-family:Times New Roman;font-weight:normal;font-size:10pt;"> Generation</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> (MIA2G), on a targeted basis.&nbsp;&nbsp;In the third phase, we </font><a name="_cp_text_1_10"></a><font style="display: inline;font-family:Times New Roman;font-size:10pt;">plan to fully commercialize </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">OVA1</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> and </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">Overa by utilizing </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">the full national licensure of ASPiRA LABS, select laboratories for distribution, managed care coverage in select markets, </font><a name="_cp_text_1_12"></a><font style="display: inline;font-family:Times New Roman;font-size:10pt;">our </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">sales force and </font><a name="_cp_text_4_15"></a><font style="display: inline;font-family:Times New Roman;font-size:10pt;">existing customer base</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">.&nbsp;&nbsp;Unlike OVA1, Overa uses a global testing platform, which will allow Overa to </font><a name="_cp_text_4_17"></a><font style="display: inline;font-family:Times New Roman;font-size:10pt;">be deployed </font><a name="_cp_text_1_18"></a><font style="display: inline;font-family:Times New Roman;font-size:10pt;">internationally.&nbsp;&nbsp;We initiated the targeted launch of Overa in October 2016 with two key accounts converting from OVA1 to Overa. In October 2015, we announced registration of the CE mark for and clearance to market Overa in the European Union.&nbsp;&nbsp;We also plan to </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">develop an LDT</font><a name="_cp_text_1_20"></a><font style="display: inline;font-family:Times New Roman;font-size:10pt;">&nbsp;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">product series</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">, which we refer to internally as OvaX.&nbsp; We anticipate that OvaX will include not only biomarkers, but also clinical risk factors, other diagnostics and patient history data in order to boost predictive value.</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:5pt 0pt;line-height:normal;text-indent:36pt;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">We are dedicated to the discovery, development and commercialization of novel high-value diagnostic and bio-analytical solutions that help physicians diagnose, treat and improve outcomes for women. Our tests are intended to </font><a name="_cp_text_1_885"></a><font style="display: inline;font-family:Times New Roman;font-size:10pt;">detect, characterize and stage disease, and to </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">help guide decisions regarding patient treatment, which may include decisions to refer patients to specialists, to perform additional testing, or to assist in monitoring response to therapy. A distinctive feature of our approach is to combine multiple biomarkers, other modalities and diagnostics, clinical risk factors and patient data into a single, reportable index score that has higher diagnostic accuracy than its constituents. We concentrate on our development of novel diagnostic tests for gynecologic disease, with an initial focus on ovarian cancer. We also intend to address clinical questions related to early disease detection, treatment response, monitoring of disease progression, prognosis and others through collaborations with leading academic and research institutions.</font>
		</p>
		<p style="margin:5pt 0pt;line-height:normal;text-indent:36pt;border-bottom:1pt none #D9D9D9 ;font-family:Arial Unicode MS;font-size: 10pt">
			<a name="_cp_text_4_890"></a>
		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;"></font><font style="display: inline;">15</font><font style="display: inline;"></font>

		</p>

		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt">

			&nbsp;

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<p style="margin:5pt 0pt;line-height:normal;text-indent:36pt;border-bottom:1pt none #D9D9D9 ;font-family:Arial Unicode MS;;font-size: 10pt"><font style="display: inline;font-family:Times New Roman;font-size:10pt;">Our initial product, OVA1, </font><a name="_cp_text_1_891"></a><font style="display: inline;font-family:Times New Roman;font-size:10pt;">is a blood test designed to, in addition to a physician&#x2019;s clinical assessment of a woman with a pelvic mass, identify women who are at high risk of having a malignant ovarian </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">tumor</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> prior to planned surgery. </font><a name="_cp_text_4_892"></a><font style="display: inline;font-family:Times New Roman;font-size:10pt;">The FDA cleared OVA1 in September 2009</font><a name="_cp_text_1_893"></a><font style="display: inline;font-family:Times New Roman;font-size:10pt;">, and we commercially launched OVA1 in March 2010. We have </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">launched on a targeted basis</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">&nbsp;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">a second-generation biomarker panel known as Overa, which is intended to maintain our product&#x2019;s high sensitivity while improving specificity. We received FDA clearance for Overa </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">i</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">n March 2016. Overa uses the Roche </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">cobas</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> 6000 platform</font><a name="_cp_text_1_894"></a><font style="display: inline;font-family:Times New Roman;font-size:10pt;">. &nbsp;</font>
		</p>
		<p style="margin:5pt 0pt;line-height:normal;text-indent:36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Arial Unicode MS;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">In June 2014, Vermillion launched ASPiRA LABS, a Clinical Laboratory Improvements Amendments of 1988 (&#x201C;CLIA&#x201D;) certified national laboratory based in Austin, Texas, which specializes in applying biomarker-based technologies to address critical needs in the management of </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">gynecologic</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> cancers and disease. ASPiRA LABS provides expert diagnostic services using a state-of-the-art biomarker-based diagnostic algorithm to </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">aid in </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">clinical decision making and advance personalized treatment plans. The lab currently processes our OVA1 </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">and Overa </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">test</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">s</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">, and </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">w</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">e plan to develop and perform LDTs at ASPiRA LABS</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> in the future</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">.&nbsp;ASPiRA LABS holds a CLIA Certificate of Registration and a state laboratory license in California, Maryland, New York, Pennsylvania and Rhode Island. </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">Our Florida license is in process of renewal</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">,</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> which is expected shortly. </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">The </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">Centers</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> for Medicare &amp; Medicaid Services issued a provider number to ASPiRA LABS in March 2015.</font>
		</p>
		<p style="margin:5pt 0pt;line-height:normal;text-indent:36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Arial Unicode MS;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">In 2016, we creat</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">ed</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"> a new service within the ASPiRA channel strategy, &#x201C;an ASPiRA </font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">IVD Services </font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">Program&#x201D;. In April 201</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">6</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">,</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"> we formed ASPiRA IVD </font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">to</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">&nbsp;</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">offer IVD </font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">t</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">rial services to thi</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">rd</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">-</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">party customers. </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">A</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">SPiRA</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> IVD </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">is</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> a specialized laboratory provider dedicated to meeting the unique testing needs of IVD manufacturers </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">seeking to </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">commercializ</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">e</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">&nbsp;high-complexity&nbsp;assays.&nbsp;A</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">SPiRA</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> IVD </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">was built </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">around a core of laboratory&nbsp;expertise and a</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">n</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> FDA-compliant quality system</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">, &nbsp;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">and strives to</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> deliver accurate and reliable&nbsp;results to its third-party customers suitable for&nbsp;FDA submission</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">. &nbsp;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">ASPiRA IVD </font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">received</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"> &nbsp;a</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"> CLIA laboratory </font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">license </font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">in June 2016 </font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">and commence</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">d</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"> operations</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"> in </font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">the </font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">second </font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">quarter of 2016</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">.</font>
		</p>
		<p style="margin:5pt 0pt;line-height:normal;text-indent:36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Arial Unicode MS;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">In this program, we </font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">also </font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">plan to leverage </font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">our </font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">existing infrastructure </font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">and </font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">enhance our pipeline of future technologies by fostering relationships with IVD companies who are developing new diagnostics including companion diagnostics platforms. We believe this </font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">plan </font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">will allow us to continue to be innovative in evaluating potential diagnostics. Our goal with the addition of this line of business is to invest in our short</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">-</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">term and long</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">-</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">term enterprise value while leveraging </font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">our </font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">specimen bank, database, FDA experience, laboratory informatics and operating efficiency.</font>
		</p>
		<p style="margin:5pt 0pt;line-height:normal;text-indent:36pt;border-top:1pt none #D9D9D9 ;font-family:Arial Unicode MS;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;">Strategy:</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Arial Unicode MS;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">We are focused on the execution of </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">five </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">core strategic business drivers in ovarian cancer diagnostics </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">and specialized laboratory services </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">to build long-term value for our investors: </font>
		</p>
		<p style="margin:0pt;text-indent:36pt;border-top:1pt none #D9D9D9 ;line-height:100%;font-family:Arial Unicode MS;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;"></font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="punctuation-wrap:hanging;line-height:100%;vertical-align:baseline;font-family:Calibri;font-size: 10pt;margin:0pt 0pt 6pt;">
				<font style="margin:0pt 0pt 6pt;font-family:Symbol;color:#000000;font-size:8pt;punctuation-wrap:hanging;line-height:100%;vertical-align:baseline;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="punctuation-wrap:hanging;line-height:100%;vertical-align:baseline;font-family:Calibri;font-size: 10pt;margin:0pt 0pt 6pt;">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">Maximizing the existing OVA1 opportunity in the United States by taking the lead in payer coverage and commercialization of OVA1. This strategy included the launch of a </font><a name="_cp_text_66_187"></a><font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">CLIA</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;"> certified clinical laboratory, ASPiRA LABS, in June 2014;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="punctuation-wrap:hanging;line-height:100%;vertical-align:baseline;font-family:Calibri;font-size: 10pt;margin:0pt 0pt 6pt;">
				<font style="margin:0pt 0pt 6pt;font-family:Symbol;color:#000000;font-size:8pt;punctuation-wrap:hanging;line-height:100%;vertical-align:baseline;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="punctuation-wrap:hanging;line-height:100%;vertical-align:baseline;font-family:Calibri;font-size: 10pt;margin:0pt 0pt 6pt;">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">Improving OVA1 specificity and expanding the distribution platform by launching Overa, a next generation biomarker panel, on a targeted basis while building the clinical utility and health economics foundation of both OVA1 and Overa, which we believe may allow for better domestic market penetration and international expansion (FDA cl</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">earance for Overa was received </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">i</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">n March</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;"> 2016);</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="punctuation-wrap:hanging;line-height:100%;vertical-align:baseline;font-family:Calibri;font-size: 10pt;margin:0pt 0pt 6pt;">
				<font style="margin:0pt 0pt 6pt;font-family:Symbol;color:#000000;font-size:8pt;punctuation-wrap:hanging;line-height:100%;vertical-align:baseline;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="punctuation-wrap:hanging;line-height:100%;vertical-align:baseline;font-family:Calibri;font-size: 10pt;margin:0pt 0pt 6pt;">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">Leveraging our existing database and specimen bank while building the largest specimen and data repository of gynecologic pelvic mass patients worldwide;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="punctuation-wrap:hanging;line-height:100%;vertical-align:baseline;font-family:Calibri;font-size: 10pt;margin:0pt 0pt 6pt;">
				<font style="margin:0pt 0pt 6pt;font-family:Symbol;color:#000000;font-size:8pt;punctuation-wrap:hanging;line-height:100%;vertical-align:baseline;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="punctuation-wrap:hanging;line-height:100%;vertical-align:baseline;font-family:Calibri;font-size: 10pt;margin:0pt 0pt 6pt;">
			<font style="color:#00C000;display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;text-decoration:none;">Expanding our product offerings to additional pelvic disease conditions such as endometriosis and polycystic ovarian syndrome by adding additional gynecologic bio-analytic solutions involving biomarkers, other modalities (</font><font style="color:#00C000;display: inline;font-family:Times New Roman;font-style:italic;color:#000000;font-size:10pt;text-decoration:none;">e.g.</font><font style="color:#00C000;display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;text-decoration:none;">, imaging), clinical risk factors and patient data to aid diagnosis and risk stratification of women presenting with a pelvic mass disease; and</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="punctuation-wrap:hanging;line-height:100%;vertical-align:baseline;font-family:Calibri;font-size: 10pt;margin:0pt 0pt 6pt;">
				<font style="margin:0pt 0pt 6pt;font-family:Symbol;color:#000000;font-size:8pt;punctuation-wrap:hanging;line-height:100%;vertical-align:baseline;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="punctuation-wrap:hanging;line-height:100%;vertical-align:baseline;font-family:Calibri;font-size: 10pt;margin:0pt 0pt 6pt;">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">Expanding our customer offerings with the launch of our ASPiRA IVD laboratory services.</font></p></td></tr></table></div>
		<p style="margin:5pt 0pt;text-indent:36pt;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Arial Unicode MS;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:5pt 0pt;line-height:normal;text-indent:36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Arial Unicode MS;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">We believe that these business drivers will contribute significantly to addressing unmet medical needs for women faced with </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">gynecologic</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;"> disease and other conditions and the continued development of our business.</font>
		</p>
		<p style="margin:5pt 0pt;line-height:normal;text-indent:36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Arial Unicode MS;font-size: 10pt">

		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;"></font><font style="display: inline;">16</font><font style="display: inline;"></font>

		</p>

		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt">

			&nbsp;

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<p style="margin:5pt 0pt;line-height:normal;text-indent:36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Arial Unicode MS;;font-size: 10pt"><font style="display: inline;font-family:Times New Roman;font-size:10pt;">OVA1 addresses a clear clinical need, namely the pre</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">-</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">surgical identification of women who are at high risk of having a malignant ovarian tumor. Numerous studies have documented the benefit of referral of these women to gynecologic oncologists for their initial surgery. Prior to the clearance of OVA1, no blood test had been cleared by the FDA for physicians to use in the pre</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">-</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">surgical management of ovarian adnexal masses. OVA1 is a qualitative serum test that utilizes five well-established biomarkers and proprietary software cleared as part of the OVA1 510(k) to determine the likelihood of malignancy in women over age 18, with a pelvic mass for whom surgery is planned. OVA1 should not be used without an independent clinical/radiological evaluation and is not intended to be a screening test or to determine whether a patient should proceed to surgery. Incorrect use of OVA1 carries the risk of unnecessary testing, surgery and delayed diagnosis. </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">&nbsp;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">OVA1 was developed through large pre-clinical studies in collaboration with numerous academic medical centers encompassing over 2,500 clinical samples. OVA1 was fully validated in a prospective multi-center clinical trial encompassing 27 sites reflective of the diverse nature of the clinical centers at which ovarian adnexal masses are evaluated.</font>
		</p>
		<p style="margin:5pt 0pt;line-height:normal;text-indent:36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Arial Unicode MS;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">Novitas Solutions, the Medicare contractor that has jurisdiction over claims submitted by Quest Diagnostics for OVA1, covers and reimburses for&nbsp;OVA1. &nbsp;This local coverage determination from Novitas Solutions&nbsp;should essentially provide national coverage for patients enrolled in Medicare as well as Medicare Advantage health plans. However, ASPiRA</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"> LABS</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">&nbsp;</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">initially</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">&nbsp;</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">experienced difficulty in obtaining payment from Novitas Solutions for most claims submitted due to Novitas Solutions&#x2019;&nbsp;administrative requirements. </font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">In October 2016, Novitas Solutions updated its administrative requirements for OVA1 reimbursement</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"> which has</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"> improve</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">d</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"> our ability to obtain reimbursement for OVA1 from Novitas Solutions.</font>
		</p>
		<p style="margin:5pt 0pt;line-height:normal;text-indent:36pt;border-top:1pt none #D9D9D9 ;font-family:Arial Unicode MS;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">In October 2016, we launched our pelvic mass specimen and data repository and began the collection of </font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">In</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">stitutional </font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">Review Board</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">&nbsp;</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">patient consents for collection and cataloguing of serum samples for future research purposes.</font>
		</p>
		<p style="margin:0pt 0pt 8pt;text-indent:36pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">In November 2016, The American College of Obstetricians and Gynecologists ("ACOG&#x201D;) issued Practice Bulletin Number 174 which included OVA1 as a &#x201C;Multivaria</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">te</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"> Index Assay&#x201D;. This bulletin outlines ACOG's &#x201C;new&#x201D; clinical management guidelines for adnexal mass management.&nbsp; </font>
		</p>
		<p style="margin:0pt 0pt 8pt;text-indent:36pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">These new clinical management guideline</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">s</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> replace the July 2007 version, Practice Bulletin 83. </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">Practice Bulletins summarize current information on techniques and clinical management issues for the practice of obstetrics and gynecology. Practice Bulletins are evidence-based documents</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">,</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> and recommendations are based on the evidence.</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> This is also the only clinical management tool used for </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">adnexal masses</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">. Guidelines do not exist for </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">adnexal masses</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">, only Practice Bulletins. Guidelines do exist, however, for </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">ovarian cancer </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">management.&nbsp;&nbsp; </font>
		</p>
		<p style="margin:5pt 0pt;line-height:normal;text-indent:36pt;border-bottom:1pt none #D9D9D9 ;font-family:Arial Unicode MS;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">The Practice Bulletin recommends that obstetricians and gynecologists evaluating women with adnexal masses </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">who</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> do not meet Level A criteria of a low risk transvaginal ultrasound should proceed with Level B clinical guidelines. </font><font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">Level B guidelines state that the physician </font><font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">may</font><font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;"> use risk assessment tools such as existing CA125 technology or OVA1 (&#x201C;Multivariate Index Assay&#x201D;) as listed in the bulletin</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">. Based on this, OVA1 has now achieved parity with CA125 as a Level B recommendation for the management of adnexal masses, but OVA1 is the only recommended Level B tool </font><font style="display: inline;font-family:Times New Roman;font-style:italic;font-size:10pt;">that has FDA clearance for use</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> assessing ovarian cancer risk in adnexal masses.</font>
		</p>
		<p style="margin:5pt 0pt;line-height:normal;text-indent:36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Arial Unicode MS;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">In December 2016, we received an FDA Clarification Letter regarding OVA1 and Overa. This letter was in reference to the September 7, 2016 FDA Safety Communication advising women and their physicians against the use of ovarian cancer screening tests for asymptomatic women.</font>
		</p>
		<p style="margin:5pt 0pt;line-height:normal;text-indent:36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Arial Unicode MS;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">In order to avoid any confusion, as well as to document the FDA position on OVA1 and Overa, Jeffrey Shuren, M.D</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">.</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">, J.D</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">.</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">, Director for the Center for Devices and Radiological Health at the FDA, sent a letter to Vermillion, dated December 21, 2016. In the letter, Dr. Shuren stated: </font>
		</p>
		<p style="margin:5pt 36pt;line-height:normal;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Arial Unicode MS;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">We agree that this safety communication does not apply to Vermillion&#x2019;s FDA-cleared tests, OVA1 (MIA) and Overa (MIA2G), which are not screening tests for ovarian cancer.</font>
		</p>
		<p style="margin:5pt 36pt;line-height:normal;border-top:1pt none #D9D9D9 ;font-family:Arial Unicode MS;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">FDA cleared OVA1 (MIA) and Overa (MIA2G) as aids to further assess the likelihood that malignancy is present when the physician&#x2019;s independent clinical and radiological evaluation does not indicate malignancy. The intended uses of the two assays are the same&#x2014;to help physicians more reliably identify which patients would benefit from consultation with or referral to a gynecologic oncologist. OVA1 (MIA) and Overa (MIA2G) are indicated for women who present with an adnexal mass.</font>
		</p>
		<p style="margin:0pt 0pt 8pt;text-indent:36pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">

		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;"></font><font style="display: inline;">17</font><font style="display: inline;"></font>

		</p>

		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt">

			&nbsp;

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<p style="margin:0pt 0pt 8pt;text-indent:36pt;font-family:Calibri;line-height:107.92%;;font-size: 10pt"><font style="display: inline;font-family:Times New Roman;font-size:10pt;">In March 2015, we </font><a name="_cp_text_4_32"></a><font style="display: inline;font-family:Times New Roman;font-size:10pt;">entered into a </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">new commercial agreement</font><a name="_cp_text_1_34"></a><font style="display: inline;font-family:Times New Roman;font-size:10pt;">&nbsp;</font><a name="_cp_text_1_36"></a><font style="display: inline;font-family:Times New Roman;font-size:10pt;">with Quest Diagnostics.&nbsp;&nbsp;Pursuant to </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">this agreement</font><a name="_cp_text_1_37"></a><font style="display: inline;font-family:Times New Roman;font-size:10pt;">, all OVA1 U.S. testing services for Quest Diagnostics customers were transferred to Vermillion&#x2019;s wholly-owned subsidiary</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">, ASPiRA LABS, as of August 10, 2015.&nbsp;&nbsp;Pursuant to this agreement, as amended as of March 11, 2017, Quest Diagnostics </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">has agreed</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> to provide blood draw and logistics support by transporting specimens from its clients to ASPiRA LABS for testing through at least March 11, 2018 in exchange for a market value fee.</font><a name="_cp_text_1_32"></a><font style="display: inline;font-family:Times New Roman;font-size:10pt;">&nbsp;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> &nbsp;Per the terms of </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">this</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> agreement, we will not offer </font><a name="_cp_text_1_73"></a><font style="display: inline;font-family:Times New Roman;font-size:10pt;">to existing or future Quest Diagnostics customers </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">CA</font><a name="_cp_text_1_74"></a><font style="display: inline;font-family:Times New Roman;font-size:10pt;">&nbsp;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">125</font><a name="_cp_text_1_75"></a><font style="display: inline;font-family:Times New Roman;font-size:10pt;">-</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">II or other tests that Quest Diagnostics offers.&nbsp; </font>
		</p>
		<p style="margin:5pt 0pt;line-height:normal;text-indent:36pt;font-family:Arial Unicode MS;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">&nbsp;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 8pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;">Critical Accounting Policies and Estimates</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">There have been no </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">material changes to our critical accounting policies and estimates </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">from those </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">disclosed in Item 7 of our </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">2016 </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">Annual Report</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">.</font>
		</p>
		<p style="margin:0pt 0pt 8pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 8pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;">Results of Operations - Three Months Ended </font><font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;">June 30</font><font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;">, 2017</font><font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;">&nbsp;</font><font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;">Compared to Three Months Ended </font><font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;">June 30</font><font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;">, &nbsp;</font><font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;">201</font><font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;">6</font>
		</p>
		<p style="margin:0pt 0pt 8pt;text-indent:36pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">The selected summary financial and operating data of the Company for the three months ended </font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">June 30</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">, 2017</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">&nbsp;</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">and </font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">201</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">6</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">&nbsp;</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">were as follows:</font>
		</p>
		<p style="margin:0pt;font-family:Calibri;line-height:107.92%;font-size: 1pt">
			<font style="display: inline;font-family:Times New Roman;font-size:1pt;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="middle" style="width:45.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size: 1pt">
						<font style="display: inline;font-size:1pt;">&#xFEFF;</font></p>
				</td>
				<td valign="middle" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:45.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;color:#000000;font-size:10pt;">&#xFEFF;</font></p>
				</td>
				<td valign="top" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="5" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:10pt;">Three Months Ended June 30,</font></p>
				</td>
				<td valign="bottom" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="4" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:10pt;">Increase (Decrease) </font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:45.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:10pt;text-decoration:underline;">(dollars in thousands)</font></p>
				</td>
				<td valign="bottom" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:10pt;">2017</font></p>
				</td>
				<td valign="bottom" style="width:02.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:10pt;">2016</font></p>
				</td>
				<td valign="bottom" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:10pt;">Amount </font></p>
				</td>
				<td valign="bottom" style="width:02.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.34%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:10pt;">% &nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:45.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">Revenue:</font></p>
				</td>
				<td valign="middle" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.38%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:11.96%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.38%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.96%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.38%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.36%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.34%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:45.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 12pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">Product </font></p>
				</td>
				<td valign="bottom" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 6pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">860&nbsp;
				</td>
				<td valign="middle" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="middle" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">554&nbsp;
				</td>
				<td valign="middle" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="middle" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">306&nbsp;
				</td>
				<td valign="middle" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:09.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">55&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:45.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 12pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">Service</font></p>
				</td>
				<td valign="bottom" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 6pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">38&nbsp;
				</td>
				<td valign="middle" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">155&nbsp;
				</td>
				<td valign="middle" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(117)
				</td>
				<td valign="middle" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:09.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(75)
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:45.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 24pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">Total revenue</font></p>
				</td>
				<td valign="middle" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 12pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.38%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 12pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.96%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">898&nbsp;
				</td>
				<td valign="middle" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.38%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 12pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:11.96%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">709&nbsp;
				</td>
				<td valign="middle" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.38%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 12pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:09.36%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">189&nbsp;
				</td>
				<td valign="middle" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:09.34%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">27&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:45.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">Cost of revenue:</font></p>
				</td>
				<td valign="middle" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:09.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:45.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 12pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">Product </font></p>
				</td>
				<td valign="bottom" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 6pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 6pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">428&nbsp;
				</td>
				<td valign="middle" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 6pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">527&nbsp;
				</td>
				<td valign="middle" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 6pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(99)
				</td>
				<td valign="middle" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:09.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(19)
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:45.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 12pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">Service</font></p>
				</td>
				<td valign="bottom" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 6pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 6pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">266&nbsp;
				</td>
				<td valign="middle" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 6pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">60&nbsp;
				</td>
				<td valign="middle" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 6pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">206&nbsp;
				</td>
				<td valign="middle" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:09.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">343&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:45.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 24pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">Total cost of revenue</font></p>
				</td>
				<td valign="middle" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 12pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.38%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 12pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.96%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">694&nbsp;
				</td>
				<td valign="middle" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.38%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 12pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:11.96%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">587&nbsp;
				</td>
				<td valign="middle" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.38%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 12pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:09.36%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">107&nbsp;
				</td>
				<td valign="middle" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:09.34%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">18&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:45.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 24pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">Gross profit </font></p>
				</td>
				<td valign="middle" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 12pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.38%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 12pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.96%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">204&nbsp;
				</td>
				<td valign="middle" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.38%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 12pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:11.96%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">122&nbsp;
				</td>
				<td valign="middle" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.38%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 12pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:09.36%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">82&nbsp;
				</td>
				<td valign="middle" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:09.34%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">67&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:45.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">Operating expenses:</font></p>
				</td>
				<td valign="middle" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:09.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:45.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 12pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">Research and development </font></p>
				</td>
				<td valign="bottom" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 6pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 6pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">268&nbsp;
				</td>
				<td valign="middle" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 6pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">564&nbsp;
				</td>
				<td valign="middle" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 6pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(296)
				</td>
				<td valign="middle" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:09.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(52)
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:45.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 12pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">Sales and marketing </font></p>
				</td>
				<td valign="bottom" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 6pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 6pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">1,041&nbsp;
				</td>
				<td valign="middle" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 6pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">1,628&nbsp;
				</td>
				<td valign="middle" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 6pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(587)
				</td>
				<td valign="middle" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:09.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(36)
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:45.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 12pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">General and administrative </font></p>
				</td>
				<td valign="bottom" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 6pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 6pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">1,241&nbsp;
				</td>
				<td valign="middle" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 6pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">1,691&nbsp;
				</td>
				<td valign="middle" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 6pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(450)
				</td>
				<td valign="middle" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:09.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(27)
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:45.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 24pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">Total operating expenses</font></p>
				</td>
				<td valign="bottom" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 12pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.38%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 12pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.96%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">2,550&nbsp;
				</td>
				<td valign="middle" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.38%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 12pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:11.96%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">3,883&nbsp;
				</td>
				<td valign="middle" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.38%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 12pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:09.36%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(1,333)
				</td>
				<td valign="middle" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:09.34%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(34)
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:45.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">Loss from operations</font></p>
				</td>
				<td valign="middle" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 12pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.38%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 12pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.96%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(2,346)
				</td>
				<td valign="middle" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.38%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 12pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:11.96%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(3,761)
				</td>
				<td valign="middle" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.38%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 12pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:09.36%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">1,415&nbsp;
				</td>
				<td valign="middle" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:09.34%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(38)
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:45.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">Interest income (expense), net </font></p>
				</td>
				<td valign="middle" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(10)
				</td>
				<td valign="middle" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(8)
				</td>
				<td valign="middle" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(2)
				</td>
				<td valign="middle" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:09.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">25&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:45.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">Other income (expense), net </font></p>
				</td>
				<td valign="middle" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(4)
				</td>
				<td valign="middle" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">20&nbsp;
				</td>
				<td valign="middle" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(24)
				</td>
				<td valign="middle" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:09.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(120)
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:45.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">Net loss </font></p>
				</td>
				<td valign="middle" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.38%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.96%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(2,360)
				</td>
				<td valign="middle" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.38%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.96%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(3,749)
				</td>
				<td valign="middle" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.38%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:09.36%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">1,389&nbsp;
				</td>
				<td valign="middle" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:09.34%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(37)
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt 0pt 6pt;line-height:100%;text-indent:36pt;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 6pt;line-height:100%;text-indent:36pt;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;">Product Revenue</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">.&nbsp;&nbsp;Product revenue was $</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">860</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">,000 fo</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">r the three months ended </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">June 30</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">, 2017</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">&nbsp;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">compared to $</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">554</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">,000 for t</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">he same period in </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">201</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">6</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">. &nbsp;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">Revenue for ASPiRA LABS is being recognized when the OVA1 test is being performed or </font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;background-color: #FFFFFF;">when amounts that will ultimately be realized can be estimated</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">. All other ASPiRA LABS revenue is being recognized on a cash basis and thus recognition of revenue lags the performance of some OVA1 tests.</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">&nbsp;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">The </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">55</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">% product revenue growth is due to </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">improvement in the average unit price received per test compared to the same quarter in the prior year. The increase in average unit price was driven by an</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> increase in client bill contracts</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">, expansion of positive medical policy and contracting with payers, and</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">&nbsp;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">improved billing and collection practices.</font>
		</p>
		<p style="margin:0pt 0pt 6pt;line-height:100%;text-indent:36pt;font-family:Calibri;font-size: 12pt">

		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;"></font><font style="display: inline;">18</font><font style="display: inline;"></font>

		</p>

		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt">

			&nbsp;

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<p style="margin:0pt 0pt 6pt;line-height:100%;text-indent:36pt;font-family:Calibri;;font-size: 12pt"><font style="display: inline;font-family:Times New Roman;font-size:10pt;">The number of OVA1 tests performed </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">in</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">crea</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">sed </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">3</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">% to approximately </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">2,418</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">&nbsp;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">OVA1 tests during the three months ended </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">June 30</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">, 2017</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> compared to approximately </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">2,</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">345</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">&nbsp;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">OVA1 tests for the same period in </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">201</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">6</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">. &nbsp;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> &nbsp;We expect test volume and, to a lesser extent, product revenue to decrease in the third quarter of 2017 due </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">primarily </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">to the loss of one </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">client bill </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">customer</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> and </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">also </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">some</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> summer seasonality.</font><font style="display: inline;color:#000000;font-size:12pt;">&nbsp;</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">We expect the direct volume loss from the client bill customer to be between 5% and 10% in the third quarter relative to volume in the second quarter of 2017.</font>
		</p>
		<p style="margin:0pt 0pt 6pt;line-height:100%;text-indent:36pt;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;">Service Revenue</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">.&nbsp;&nbsp;Service revenu</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">e was $</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">3</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">8</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">,</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">000 for</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> the three months ended </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">June 30</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">, 2017</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> compared to $155,000 for the same period in 2016</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">, a decrease of 75%</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">. &nbsp;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">Service revenue will vary from quarter to quarter based on the size of ongoing customer projects.</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">&nbsp;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">Revenue for ASPiRA IVD is being recognized once </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">certain </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">revenue recognition criteria has been met</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> (see Note 1</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> to</font><a name="_cp_text_1_104"></a><font style="display: inline;font-family:Times New Roman;font-size:10pt;">&nbsp;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">the financial statements included in Part I, Item I of this Form 10-Q</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">)</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">.</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">&nbsp;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">We expect service revenue to </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">increase</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">&nbsp;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">in the </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">third </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">quarter of 201</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">7</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">.</font>
		</p>
		<p style="margin:0pt 0pt 6pt;line-height:100%;text-indent:36pt;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;">Cost of Revenue</font><font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;"> - Product</font><font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;">.</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> &nbsp;Cost of product revenue was $</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">4</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">28</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">,</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">000 for the three months ended </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">June 30</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">, 2017 </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">compared to $</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">527</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">,000 for the same period in </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">201</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">6</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">, representing a decrease of </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">1</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">9</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">%</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> due to </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">operating efficiencies</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> compared to the prior year quarter</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">.</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">&nbsp;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">We expect the cost of product revenue to remain consistent </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">with </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">second</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">&nbsp;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">quarter 201</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">7</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> levels </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">in the </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">third </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">quarter of 201</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">7</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">.</font>
		</p>
		<p style="margin:0pt 0pt 6pt;line-height:100%;text-indent:36pt;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;">Cost of Revenue</font><font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;"> - Service</font><font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;">.</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> &nbsp; &nbsp;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">Cost of service revenue was $</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">266</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">,000 f</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">or the three months ended </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">June 30</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">, 2017</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> compared to $60,000 for the same period in 2016</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">.</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">&nbsp;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">ASPiRA IVD </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">did </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">not </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">commenc</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">e</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> operations </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">until </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">June</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">&nbsp;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">2016</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> and thus</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> the second quarter of 2016</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> included only one month of expense compared to a full quarter of expense in 2017</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">. &nbsp;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">We expect the cost of service revenue to </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">remain consistent</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">&nbsp;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">with </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">second</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> quarter 2017 levels</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> in the </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">third </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">quarter of 201</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">7</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">.</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> &nbsp; &nbsp;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 8pt;text-indent:36pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;">Research and Development Expenses</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">.&nbsp;&nbsp;Research and development expenses represent costs incurred to develop our technology and carry out clinical studies, and include personnel-related expenses, regulatory costs, reagents and supplies used in research and development laboratory work, infrastructure expenses, contract services and other outside costs. Research and development expenses for the three months ended </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">June 30</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">, 2017</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">&nbsp;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">de</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">creased </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">$</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">296</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">,000, or </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">52</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">%</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">,</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> compared to the same period in </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">201</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">6</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">. &nbsp;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">This </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">decrease </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">was primar</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">ily due to </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">a reduction in </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">personnel </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">and personnel related </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">expenses</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> due to </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">the clearance of Overa in March 2016</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">.</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> We expect research and development expense</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">s</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> to </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">remain consistent </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">with </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">second </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">quarter 201</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">7</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> levels </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">in the </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">third </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">quarter of </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">201</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">7</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">.</font>
		</p>
		<p style="margin:0pt 0pt 6pt;line-height:100%;text-indent:36pt;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;">Sales and Marketing Expenses</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">.&nbsp;&nbsp;Our sales and marketing expenses consist primarily of personn</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">el-related expenses, education and promotional expenses, and infrastructure expenses. These expenses include the costs of educating physicians, laboratory personnel and other healthcare professionals regarding OVA1</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> and Overa</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">. Sales and marketing expenses also include the costs of sponsoring continuing medical education, medical meeting participation, and dissemination of scientific and health economic publications. Sales and marketing expenses </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">for the three months ended</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">&nbsp;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">June 30</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">, 2017</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">&nbsp;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">decreased </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">$</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">5</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">8</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">7</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">,000, </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">or</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> 36</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">%,</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> compared to the same period in </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">201</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">6</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">. &nbsp;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">Th</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">is </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">decrease </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">was primarily </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">due to </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">a reduction in personnel </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">and personnel </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">expenses and decreases in </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">consulting </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">and marketing </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">services</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">. We expect sales and marketing expenses to </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">increase modestly over the remainder of 2017 as we focus efforts on the commercialization of OVA1 and Overa</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">.</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-indent:36pt;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;">General and Administrative Expenses</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">.&nbsp;&nbsp;General and administrative expenses consist primarily of personnel-related expenses, professional fees and other costs, including legal, finance and accounting expenses and other infrastructure expens</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">es. </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">General and administrative expenses for the three months ended </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">June 30</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">, 2017</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">&nbsp;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">decreased </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">by $</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">450</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">,000, or </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">2</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">7</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">%, </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">compared to the same period in </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">201</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">6</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">. &nbsp;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">The </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">decrease </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">was primarily due to </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">the reduction of </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">consulting services</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> and ASPiRA IVD start-up expenses in 2016 not </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">being </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">repeated in 2017</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">.</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">&nbsp;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">We expect general and administrative expenses to </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">remain consistent with </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">second</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">&nbsp;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">quarter 2017 levels </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">in the </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">third </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">quarter of 201</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">7</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">.</font>
		</p>
		<p style="margin:0pt 0pt 8pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 8pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">

		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;"></font><font style="display: inline;">19</font><font style="display: inline;"></font>

		</p>

		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt">

			&nbsp;

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<p style="margin:0pt 0pt 8pt;font-family:Calibri;line-height:107.92%;;font-size: 10pt"><font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;"></font>
		</p>
		<p style="margin:0pt 0pt 8pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;">Results of Operations </font><font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;">&#x2013;</font><font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;">&nbsp;</font><font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;">Six </font><font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;">Months Ended </font><font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;">June 30, 2017</font><font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;"> Compared to </font><font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;">Six </font><font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;">Months Ended </font><font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;">June 30</font><font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;">, 201</font><font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;">6</font>
		</p>
		<p style="margin:0pt 0pt 8pt;text-indent:36pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">The selected summary financial and operating data of the Company for the </font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">six </font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">months ended </font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">June 30, 2017</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"> and 201</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">6</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"> were as follows:</font>
		</p>
		<p style="margin:0pt;font-family:Calibri;line-height:107.92%;font-size: 1pt">
			<font style="display: inline;font-family:Times New Roman;font-size:1pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-indent:36pt;font-family:Calibri;font-size: 1pt">
			<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:1pt;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="middle" style="width:45.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size: 1pt">
						<font style="display: inline;font-size:1pt;">&#xFEFF;</font></p>
				</td>
				<td valign="middle" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:45.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;color:#000000;font-size:10pt;">&#xFEFF;</font></p>
				</td>
				<td valign="top" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="5" valign="top" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:10pt;">Six Months Ended June 30,</font></p>
				</td>
				<td valign="top" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="4" valign="top" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:10pt;">Increase (Decrease) </font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:45.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:10pt;text-decoration:underline;">(dollars in thousands)</font></p>
				</td>
				<td valign="bottom" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="top" style="width:00.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:10pt;">2017</font></p>
				</td>
				<td valign="top" style="width:02.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="top" style="width:00.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:10pt;">2016</font></p>
				</td>
				<td valign="top" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="top" style="width:00.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:10pt;">Amount </font></p>
				</td>
				<td valign="top" style="width:02.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:09.34%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:10pt;">% &nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:45.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">Revenue:</font></p>
				</td>
				<td valign="middle" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.38%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:11.96%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.38%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.96%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.38%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.36%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.34%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:45.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 12pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">Product </font></p>
				</td>
				<td valign="bottom" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 6pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="middle" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">1,538&nbsp;
				</td>
				<td valign="middle" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="middle" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">1,059&nbsp;
				</td>
				<td valign="middle" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="middle" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">479&nbsp;
				</td>
				<td valign="middle" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:09.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">45&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:45.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 12pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">Service</font></p>
				</td>
				<td valign="bottom" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 6pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">86&nbsp;
				</td>
				<td valign="middle" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">155&nbsp;
				</td>
				<td valign="middle" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(69)
				</td>
				<td valign="middle" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:09.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(45)
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:45.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 12pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">License </font></p>
				</td>
				<td valign="bottom" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 6pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 6pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 3.25pt 0.05pt 0pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"> &nbsp;-</font></p>
				</td>
				<td valign="middle" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 6pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 3.25pt 0.05pt 0pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"> &nbsp;-</font></p>
				</td>
				<td valign="middle" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 6pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 3.25pt 0.05pt 0pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"> &nbsp;-</font></p>
				</td>
				<td valign="middle" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:09.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 3.25pt 0.05pt 0pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"> &nbsp;-</font></p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:45.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 24pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">Total revenue</font></p>
				</td>
				<td valign="middle" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.38%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:11.96%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">1,624&nbsp;
				</td>
				<td valign="middle" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.38%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:11.96%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">1,214&nbsp;
				</td>
				<td valign="middle" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.38%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:09.36%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">410&nbsp;
				</td>
				<td valign="middle" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:09.34%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">34&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:45.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">Cost of revenue:</font></p>
				</td>
				<td valign="middle" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:09.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:45.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 12pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">Product </font></p>
				</td>
				<td valign="bottom" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 6pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 6pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">850&nbsp;
				</td>
				<td valign="middle" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 6pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">1,055&nbsp;
				</td>
				<td valign="middle" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 6pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(205)
				</td>
				<td valign="middle" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:09.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(19)
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:45.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 12pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">Service</font></p>
				</td>
				<td valign="bottom" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 6pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 6pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">571&nbsp;
				</td>
				<td valign="middle" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 6pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">60&nbsp;
				</td>
				<td valign="middle" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 6pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">511&nbsp;
				</td>
				<td valign="middle" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:09.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">852&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:45.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 24pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">Total cost of revenue</font></p>
				</td>
				<td valign="middle" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.38%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:11.96%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">1,421&nbsp;
				</td>
				<td valign="middle" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.38%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:11.96%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">1,115&nbsp;
				</td>
				<td valign="middle" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.38%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:09.36%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">306&nbsp;
				</td>
				<td valign="middle" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:09.34%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">27&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:45.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 24pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">Gross profit </font></p>
				</td>
				<td valign="middle" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.38%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:11.96%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">203&nbsp;
				</td>
				<td valign="middle" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.38%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:11.96%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">99&nbsp;
				</td>
				<td valign="middle" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.38%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:09.36%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">104&nbsp;
				</td>
				<td valign="middle" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:09.34%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">105&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:45.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">Operating expenses:</font></p>
				</td>
				<td valign="middle" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:09.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:45.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 12pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">Research and development </font></p>
				</td>
				<td valign="bottom" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 6pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 6pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">493&nbsp;
				</td>
				<td valign="middle" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 6pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">1,498&nbsp;
				</td>
				<td valign="middle" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 6pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(1,005)
				</td>
				<td valign="middle" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:09.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(67)
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:45.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 12pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">Sales and marketing </font></p>
				</td>
				<td valign="bottom" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 6pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 6pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">2,064&nbsp;
				</td>
				<td valign="middle" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 6pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">3,908&nbsp;
				</td>
				<td valign="middle" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 6pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(1,844)
				</td>
				<td valign="middle" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:09.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(47)
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:45.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 12pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">General and administrative </font></p>
				</td>
				<td valign="bottom" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 6pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 6pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">2,648&nbsp;
				</td>
				<td valign="middle" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 6pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">3,350&nbsp;
				</td>
				<td valign="middle" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 6pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(702)
				</td>
				<td valign="middle" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:09.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(21)
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:45.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 24pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">Total operating expenses</font></p>
				</td>
				<td valign="bottom" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 6pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.38%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 6pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:11.96%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">5,205&nbsp;
				</td>
				<td valign="middle" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.38%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 6pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:11.96%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">8,756&nbsp;
				</td>
				<td valign="middle" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.38%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt 6pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:09.36%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(3,551)
				</td>
				<td valign="middle" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:09.34%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(41)
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:45.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">Loss from operations</font></p>
				</td>
				<td valign="middle" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.38%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:11.96%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(5,002)
				</td>
				<td valign="middle" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.38%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:11.96%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(8,657)
				</td>
				<td valign="middle" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.38%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:09.36%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">3,655&nbsp;
				</td>
				<td valign="middle" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:09.34%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(42)
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:45.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">Interest income (expense), net </font></p>
				</td>
				<td valign="middle" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(22)
				</td>
				<td valign="middle" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(5)
				</td>
				<td valign="middle" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(17)
				</td>
				<td valign="middle" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:09.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">340&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:45.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">Other income (expense), net</font></p>
				</td>
				<td valign="middle" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(9)
				</td>
				<td valign="middle" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:11.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">16&nbsp;
				</td>
				<td valign="middle" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:09.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(25)
				</td>
				<td valign="middle" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:09.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(156)
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:45.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">Net loss </font></p>
				</td>
				<td valign="middle" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.38%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:11.96%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(5,033)
				</td>
				<td valign="middle" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.38%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:11.96%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(8,646)
				</td>
				<td valign="middle" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.38%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:09.36%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">3,613&nbsp;
				</td>
				<td valign="middle" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:09.34%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(42)
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt 0pt 6pt;line-height:100%;text-indent:36pt;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 6pt;line-height:100%;text-indent:36pt;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;">Product Revenue</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">.&nbsp;&nbsp;Product revenue was $</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">1,538</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">,000 fo</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">r the </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">six</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> months ended </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">June 30, 2017</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> compared to $</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">1,059</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">,000 for t</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">he same period in </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">201</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">6</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">. &nbsp;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">Revenue for ASPiRA LABS is being recognized when the OVA1 test is being performed or </font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;background-color: #FFFFFF;">when amounts that will ultimately be realized can be estimated</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">. All other ASPiRA LABS revenue is being recognized on a cash basis and thus recognition of revenue lags the performance of some OVA1 tests.</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> The </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">45</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">% product revenue growth is due to improvement in the average unit price received per test compared to the same quarter in the prior year. The increase in average unit price was driven by an increase in client bill contracts, expansion of positive medical policy and contracting with payers, and improved billing and collection practices.</font>
		</p>
		<p style="margin:0pt 0pt 6pt;line-height:100%;text-indent:36pt;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">The number of OVA1 tests performed </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">in</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">crea</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">sed </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">2</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">% to approximately </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">4,711</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> OVA1 tests during the </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">six</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> months ended </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">June 30, 2017</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> compared to approximately </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">4,610</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> OVA1 tests for the same period in 201</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">6</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">. &nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 6pt;line-height:100%;text-indent:36pt;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;">Service Revenue</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">.&nbsp;&nbsp;Service revenu</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">e was $</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">86</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">,</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">000 for</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> the </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">six</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> months ended </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">June 30, 2017 compared to $155,000 for the same period in 2016</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">, a decrease of 45%</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">. &nbsp;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">Service revenue will vary from quarter to quarter based on the size of ongoing customer projects.</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">&nbsp;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">Revenue for ASPiRA IVD is being recognized once </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">certain </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">revenue recognition criteria has been met</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> (see Note 1</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> to</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">&nbsp;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">the financial statements included in Part I, Item I of this Form 10-Q</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">)</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">. &nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 6pt;line-height:100%;text-indent:36pt;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;">Cost of Revenue</font><font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;"> - Product</font><font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;">.</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> &nbsp;Cost of product revenue was $</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">85</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">0</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">,</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">000 for the </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">six</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> months ended </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">June 30, 2017 </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">compared to $</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">1,055</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">,000 for the same period in 201</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">6, representing a decrease of </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">19</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">% due to operating efficiencies compared to the prior year.</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 6pt;line-height:100%;text-indent:36pt;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;">Cost of Revenue - Service.</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> &nbsp;Cost of service revenue was $</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">571</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">,000 f</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">or the </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">six</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> months ended </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">June 30, 2017 compared to $60,000 for the same period in 2016</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">. &nbsp;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">ASPiRA IVD did not commence operations until June 2016 and thus included only one month of expense compared to two full quarters of expense in 2017</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">.</font>
		</p>
		<p style="margin:0pt 0pt 8pt;text-indent:36pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;">Research and Development Expenses</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">.&nbsp;&nbsp;Research and development expenses represent costs incurred to develop our technology and carry out clinical studies, and include personnel-related expenses, regulatory costs, </font>
		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;"></font><font style="display: inline;">20</font><font style="display: inline;"></font>

		</p>

		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt">

			&nbsp;

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<p style="margin:0pt 0pt 8pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"><font style="display: inline;font-family:Times New Roman;font-size:10pt;">reagents and supplies used in research and development laboratory work, infrastructure expenses, contract services and other outside costs. Research and development expenses</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">&nbsp;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">through March 2016 </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">also include</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">d</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> costs related to activities performed under contracts with our collaborators and strategic partners. Research and development expenses for the </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">six</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> months ended </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">June 30, 2017</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> decreased </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">$</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">1,</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">005</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">,000, or</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> 67</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">%</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">,</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> compared to the same period in 201</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">6</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">. &nbsp;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">This decrease was primarily due to the expiration of our collaboration agreement with The Johns Hopkins </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">University </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">School of Medicine </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">in March 2016 as well as</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> lower personnel and personnel related expenses due to </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">the clearance of Overa in March 2016</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">.</font>
		</p>
		<p style="margin:0pt 0pt 6pt;line-height:100%;text-indent:36pt;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;">Sales and Marketing Expenses</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">.&nbsp;&nbsp;Our sales and marketing expenses consist primarily of personn</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">el-related expenses, education and promotional expenses, and infrastructure expenses. These expenses include the costs of educating physicians, laboratory personnel and other healthcare professionals regarding OVA1</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> and Overa</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">. Sales and marketing expenses also include the costs of sponsoring continuing medical education, medical meeting participation, and dissemination of scientific and health economic publications. Sales and marketing expenses for the </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">six</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> months ended</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> June 30, 2017</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> decreased </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">$</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">1,8</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">4</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">4</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">,000, or </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">47</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">%,</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> compared to the same period in 201</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">6</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">. &nbsp;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">Th</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">is </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">decrease </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">was primarily </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">due to </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">a reduction in personnel </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">and personnel </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">expenses and decreases in </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">consulting and marketing services</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> compared to the prior year period</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">.</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-indent:36pt;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;">General and Administrative Expenses</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">.&nbsp;&nbsp;General and administrative expenses consist primarily of personnel-related expenses, professional fees and other costs, including legal, finance and accounting expenses and other infrastructure expens</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">es. </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">General and administrative expenses for the </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">six</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> months ended </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">June 30, 2017</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> decreased by $</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">702</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">,000, or </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">21</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">%, compared to the same period in 201</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">6</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">. The decrease was primarily due to </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">the reduction of consulting services and ASPiRA IVD start-up expenses in 2016 not</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> being</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> repeated in 2017</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">.</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-indent:36pt;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 3pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 3pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;">Liquidity and Capital Resources </font>
		</p>
		<p style="margin:4.5pt 0pt 8pt;text-indent:36pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">We plan to continue to expend resources selling and marketing OVA1</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> and </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">Overa</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">, operating our IVD trial services business</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> and developing additional diagnostic tests</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> and service capabilities</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">. &nbsp;</font>
		</p>
		<p style="margin:9pt 0pt 8pt;text-indent:36pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">We have incurred significant net losses and negative cash flows from operations since inception. At </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">June 30</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">, 2017</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">, we had an accumulated deficit of </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">$</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">390</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">,</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">5</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">89</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">,000</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> and stockholders&#x2019; equity of $</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">4,5</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">2</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">7</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">,</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">000</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">. As of </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">June 30</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">, 2017</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">, we had $</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">6,028</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">,000</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> of cash and cash equivalents and </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">$</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">2,061</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">,000</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> of current liabilities.</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> Working capital was </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">$</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">4,</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">5</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">52</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">,000 and </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">$</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">3,547</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">,000 at</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">&nbsp;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">June 30</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">, 2017</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> and December&nbsp;31,&nbsp;201</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">6</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">, respectively</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">.</font>
		</p>
		<p style="margin:9pt 0pt 8pt;text-indent:36pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">O</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">n February 17, 2017, the Company completed a private placement pursuant to which certain investors purchased Vermillion common stock </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">and </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">warrants to purchase shares of </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">Vermillion </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">common stock </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">for n</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">et procee</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">ds of</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> approximately $</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">5,1</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">27</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">,000 after deducting offering expenses.</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">I</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">n March 2016, </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">we</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> entered into an agreement pursuant to which </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">we</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> may borrow up to $4,000,000 from the DECD. </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">We received an initial disbursement</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> of $2,000,000 </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">i</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">n April 2016</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> under this agreement</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">. The remaining $2,000,000 will be </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">disbursed</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> if and when </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">we</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> achieve certain future milestones.</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">&nbsp;</font><a name="_cp_text_1_117"></a><font style="display: inline;font-family:Times New Roman;font-size:10pt;">See Note 3 </font><a name="_cp_text_4_118"></a><font style="display: inline;font-family:Times New Roman;font-size:10pt;">to the </font><a name="_cp_text_1_119"></a><font style="display: inline;font-family:Times New Roman;font-size:10pt;">financial statements included in Part I, Item I of this Form 10-Q for information regarding such milestones.</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">We</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> expect to incur a net loss </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">and negative cash flows from operations </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">in </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">the remainder of </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">201</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">7</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">. &nbsp;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">Our</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> management believes that successful achievement of </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">our</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> business objectives will require additional financing.&nbsp;Given these conditions, there is substantial doubt about </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">our</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> ability to continue as a going concern. The </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">condensed </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">consolidated financial statements have been prepared on a going concern basis and do not include any adjustments that might result from these uncertainties. </font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">The Company expects to raise capital through a variety of sources, which may include </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">the exercise of common stock warrants, </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">equity </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">offerings, debt financing</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">, collaborati</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">ons</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">, licensing arrangements, </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">grants and government funding and strategic alliances</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">. &nbsp;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> However, additional funding may not be available when needed or on terms acceptable to the Company. If the Company is unable to obtain additional capital, it may not be able to continue sales and marketing, research and development, or other operations on the scope or scale of current activity and that could have a material adverse effect on </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">the Company&#x2019;s</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">&nbsp;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">business, results of operations and financial condition.</font>
		</p>
		<p style="margin:9pt 0pt 8pt;text-indent:36pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">

		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;"></font><font style="display: inline;">21</font><font style="display: inline;"></font>

		</p>

		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt">

			&nbsp;

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<p style="margin:9pt 0pt 8pt;text-indent:36pt;font-family:Calibri;line-height:107.92%;;font-size: 10pt"><font style="display: inline;font-family:Times New Roman;font-size:10pt;">Net cash used in operating activit</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">ies was $</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">4,191</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">,000</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> for the</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> six</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">&nbsp;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">months ended </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">June 30</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">, &nbsp;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">201</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">7</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">,</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">&nbsp;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">resulting primarily from the net loss reported of $</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">5,03</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">3</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">,000</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">&nbsp;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">a</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">nd </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">changes in accounts payable, accrued and other liabilities of $</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">504</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">,000 </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">partially offset by</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> stock compensation expense of $</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">671</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">,000</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">,</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> depreciation and amortization of $</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">401</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">,000</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> and prepaid expenses of $</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">21</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">8</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">,000</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">.</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">Net cash used in operating activities was $</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">8,455</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">,000 for the </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">six </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">months ended </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">June 30</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">, 2016 resulting primarily from the net loss reported of $</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">8,646</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">,000 and changes in accounts payable, accrued and other liabilities of $</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">835</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">,000 partially offset by stock compensation expense of $</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">600</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">,000 and depreciation and amortization of $</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">323</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">,000.</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">Net cash used in investing activities was $</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">43</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">,000 and $</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">1,0</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">54</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">,000 for the </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">six</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">&nbsp;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">months ended </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">June 30</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">, 2017 </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">and </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">201</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">6</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">, respectively. </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">Th</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">e</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">&nbsp;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">costs in 2016</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">&nbsp;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">resulted from purchases of property and equipment</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> for the ASPiRA IVD lab</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">oratory</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">.</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">Net cash </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">provided by</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> financing activities was </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">$</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">5,</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">020</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">,</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">000 for</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> the </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">six</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">&nbsp;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">months ended </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">June 30</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">, 2017</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">, which</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">&nbsp;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">consisted primarily of proceeds from the </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">sale</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> of </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">Vermillion </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">common stock</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> in our February 2017 private placement</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">, net of issuance costs</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">.</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">Net cash </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">provided </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">by </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">financing activities of $</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">1,9</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">29</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">,000 for the </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">six </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">months ended </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">June 30</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">, 2016</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">&nbsp;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">consisted primarily of proceeds from the DECD loan.</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">&nbsp;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> &nbsp;&nbsp;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> &nbsp; &nbsp;</font>
		</p>
		<p style="margin:9pt 0pt 8pt;text-indent:36pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">Our future liquidity and capital requirements will depend upon many factors, including, among others: &nbsp;&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="punctuation-wrap:hanging;line-height:100%;vertical-align:baseline;font-family:Calibri;font-size: 10pt;margin:0pt 0pt 6pt;">
				<font style="margin:0pt 0pt 6pt;font-family:Symbol;color:#000000;font-size:8pt;punctuation-wrap:hanging;line-height:100%;vertical-align:baseline;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="punctuation-wrap:hanging;line-height:100%;vertical-align:baseline;font-family:Calibri;font-size: 10pt;margin:0pt 0pt 6pt;">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">resources devoted to sales, marketing and distribution capabilities;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="punctuation-wrap:hanging;line-height:100%;vertical-align:baseline;font-family:Calibri;font-size: 10pt;margin:0pt 0pt 6pt;">
				<font style="margin:0pt 0pt 6pt;font-family:Symbol;color:#000000;font-size:8pt;punctuation-wrap:hanging;line-height:100%;vertical-align:baseline;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="punctuation-wrap:hanging;line-height:100%;vertical-align:baseline;font-family:Calibri;font-size: 10pt;margin:0pt 0pt 6pt;">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">the rate of </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">OVA1 </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">and Overa </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">product adoption by physicians and patients;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="punctuation-wrap:hanging;line-height:100%;vertical-align:baseline;font-family:Calibri;font-size: 10pt;margin:0pt 0pt 6pt;">
				<font style="margin:0pt 0pt 6pt;font-family:Symbol;color:#000000;font-size:8pt;punctuation-wrap:hanging;line-height:100%;vertical-align:baseline;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="punctuation-wrap:hanging;line-height:100%;vertical-align:baseline;font-family:Calibri;font-size: 10pt;margin:0pt 0pt 6pt;">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">the insurance payer community&#x2019;s acceptance of and reimbursement for OVA1</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;"> and Overa</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="punctuation-wrap:hanging;line-height:100%;vertical-align:baseline;font-family:Calibri;font-size: 10pt;margin:0pt 0pt 6pt;">
				<font style="margin:0pt 0pt 6pt;font-family:Symbol;color:#000000;font-size:8pt;punctuation-wrap:hanging;line-height:100%;vertical-align:baseline;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="punctuation-wrap:hanging;line-height:100%;vertical-align:baseline;font-family:Calibri;font-size: 10pt;margin:0pt 0pt 6pt;">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">the successful </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">targeted </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">launch of </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">O</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">vera</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="punctuation-wrap:hanging;line-height:100%;vertical-align:baseline;font-family:Calibri;font-size: 10pt;margin:0pt 0pt 6pt;">
				<font style="margin:0pt 0pt 6pt;font-family:Symbol;color:#000000;font-size:8pt;punctuation-wrap:hanging;line-height:100%;vertical-align:baseline;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="punctuation-wrap:hanging;line-height:100%;vertical-align:baseline;font-family:Calibri;font-size: 10pt;margin:0pt 0pt 6pt;">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">resources devoted to our IVD </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">trials </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">laboratory and services;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="punctuation-wrap:hanging;line-height:100%;vertical-align:baseline;font-family:Calibri;font-size: 10pt;margin:0pt 0pt 6pt;">
				<font style="margin:0pt 0pt 6pt;font-family:Symbol;color:#000000;font-size:8pt;punctuation-wrap:hanging;line-height:100%;vertical-align:baseline;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="punctuation-wrap:hanging;line-height:100%;vertical-align:baseline;font-family:Calibri;font-size: 10pt;margin:0pt 0pt 6pt;">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">the </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">revenue generated by</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;"> our IVD trial services business;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="punctuation-wrap:hanging;line-height:100%;vertical-align:baseline;font-family:Calibri;font-size: 10pt;margin:0pt 0pt 6pt;">
				<font style="margin:0pt 0pt 6pt;font-family:Symbol;color:#000000;font-size:8pt;punctuation-wrap:hanging;line-height:100%;vertical-align:baseline;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="punctuation-wrap:hanging;line-height:100%;vertical-align:baseline;font-family:Calibri;font-size: 10pt;margin:0pt 0pt 6pt;">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">our plans to acquire or invest in other products, technologies and businesses; and</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="punctuation-wrap:hanging;line-height:100%;vertical-align:baseline;font-family:Calibri;font-size: 10pt;margin:0pt 0pt 6pt;">
				<font style="margin:0pt 0pt 6pt;font-family:Symbol;color:#000000;font-size:8pt;punctuation-wrap:hanging;line-height:100%;vertical-align:baseline;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="punctuation-wrap:hanging;line-height:100%;vertical-align:baseline;font-family:Calibri;font-size: 10pt;margin:0pt 0pt 6pt;">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">the market price of our common stock.</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 8pt;text-indent:36pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">We have significant net operating loss (&#x201C;NOL&#x201D;) </font><a name="_cp_text_1_41"></a><font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">carryforwards </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">as of </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">June 30</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">, 2017</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;"> for which a full valuation allowance has been provided due to our history of operating losses. Section 382 of the Internal Revenue Code of 1986, as amended, as well as similar state provisions</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">&nbsp;</font><a name="_cp_text_1_141"></a><font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">may restrict our </font><a name="_cp_text_4_142"></a><font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">ability to use our </font><a name="_cp_text_4_143"></a><font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">NOL credit carryforwards </font><a name="_cp_text_4_144"></a><font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">due to ownership change limitations occurring in the past or that could occur in the future</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">. These ownership changes may also limit the amount of NOL credit carryforwards that can be utilized annually to offset future taxable income and tax, respectively. </font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;line-height:100%;font-family:Arial Unicode MS;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">In connection with </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">a</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;"> private placement </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">offering of common stock and warrants we completed in May 2013, we </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">entered into a stockholders agreement </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">which, among other things, gives two of the primary investors in that offering the right </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">to participate in any future equity offerings </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">by the Company </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">on the same price and terms as other investors.&nbsp;In addition, the stockholders agreement prohibits </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">us</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;"> from taking </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">certain </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">material actions without the consent of at least one of the two primary investors</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;"> in that offering</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">.&nbsp;These material actions include: </font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="punctuation-wrap:hanging;line-height:100%;vertical-align:baseline;font-family:Calibri;font-size: 10pt;margin:0pt 0pt 6pt;">
				<font style="margin:0pt 0pt 6pt;font-family:Symbol;color:#000000;font-size:8pt;punctuation-wrap:hanging;line-height:100%;vertical-align:baseline;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="punctuation-wrap:hanging;line-height:100%;vertical-align:baseline;font-family:Calibri;font-size: 10pt;margin:0pt 0pt 6pt;">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">Making any acquisition with value greater than $2 million;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="punctuation-wrap:hanging;line-height:100%;vertical-align:baseline;font-family:Calibri;font-size: 10pt;margin:0pt 0pt 6pt;">
				<font style="margin:0pt 0pt 6pt;font-family:Symbol;color:#000000;font-size:8pt;punctuation-wrap:hanging;line-height:100%;vertical-align:baseline;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="punctuation-wrap:hanging;line-height:100%;vertical-align:baseline;font-family:Calibri;font-size: 10pt;margin:0pt 0pt 6pt;">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">Offering, selling or issuing any securities senior to Vermillion&#x2019;s common stock or any securities that are convertible into or exchangeable or exercisable for securities ranking senior to Vermillion&#x2019;s common stock;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="punctuation-wrap:hanging;line-height:100%;vertical-align:baseline;font-family:Calibri;font-size: 10pt;margin:0pt 0pt 6pt;">
				<font style="margin:0pt 0pt 6pt;font-family:Symbol;color:#000000;font-size:8pt;punctuation-wrap:hanging;line-height:100%;vertical-align:baseline;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="punctuation-wrap:hanging;line-height:100%;vertical-align:baseline;font-family:Calibri;font-size: 10pt;margin:0pt 0pt 6pt;">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">Taking any action that would result in a change in control of </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">the Company</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;"> or an insolvency event;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;"> and</font></p></td></tr></table></div>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;"></font><font style="display: inline;">22</font><font style="display: inline;"></font>

		</p>

		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt">

			&nbsp;

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="punctuation-wrap:hanging;line-height:100%;vertical-align:baseline;font-family:Calibri;font-size: 10pt;margin:0pt 0pt 6pt;">
				<font style="margin:0pt 0pt 6pt;font-family:Symbol;color:#000000;font-size:8pt;punctuation-wrap:hanging;line-height:100%;vertical-align:baseline;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="punctuation-wrap:hanging;line-height:100%;vertical-align:baseline;font-family:Calibri;font-size: 10pt;margin:0pt 0pt 6pt;">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">Paying or declaring dividends on any securities of the Company or distributing any assets of the Company other than in the ordinary course of business or repurchasing any outstanding securities of the Company</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">.</font></p></td></tr></table></div>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Arial Unicode MS;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">&nbsp; &nbsp;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;"></font>
		</p>
		<p style="margin:0pt;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;line-height:100%;font-family:Arial Unicode MS;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">The</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;"> foregoing</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;"> rights terminate for each stockholder when that stockholder ceases to beneficially own less than 50% of the shares and warrants (taking into account shares issued upon exercise of the warrants), in the aggregate, tha</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">t</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;"> were purchased at the closing of the </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">2013 </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">private placement.</font>
		</p>
		<p style="margin:0pt 0pt 8pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 8pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;color:#000000;">Off-Balance Sheet Arrangements </font>
		</p>
		<p style="margin:0pt 0pt 8pt;text-indent:36pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">As of </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">June 30</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">, 2017</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">, we had no off-balance sheet arrangements that are reasonably likely to have a current or future material effect on our </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">condensed </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">consolidated financial condition, results of operations, liquidity, capital expenditures or capital resources.</font>
		</p>
		<p style="margin:0pt 0pt 8pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="middle" style="width:09.00%;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="middle" style="width:91.00%;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 10pt;line-height:115%;font-family:Calibri;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:09.00%;padding:0pt;">
					<p style="margin:0pt;line-height:115%;font-family:Calibri;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">&#xFEFF;</font><a name="Item_3"></a><font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;color:#000000;">ITEM&nbsp;3.</font></p>
				</td>
				<td valign="top" style="width:91.00%;padding:0pt;">
					<p style="margin:5pt 0pt;line-height:115%;font-family:Calibri;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;color:#000000;">QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;text-indent:36pt;font-family:Calibri;line-height:107.92%;font-size: 1pt">
			<font style="display: inline;font-family:Times New Roman;font-size:1pt;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 8pt;text-indent:36pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">Per Item 305(e) of Regulation S-K, </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">the </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">information</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">&nbsp;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">called for by this Item 3</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;"> is not required.</font>
		</p>
		<p style="margin:0pt 0pt 8pt;text-indent:36pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="middle" style="width:09.00%;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="middle" style="width:91.00%;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 10pt;line-height:115%;font-family:Calibri;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:09.00%;padding:0pt;">
					<p style="margin:0pt;line-height:115%;font-family:Calibri;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">&#xFEFF;</font><a name="Item_4"></a><font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;color:#000000;">ITEM&nbsp;4.</font></p>
				</td>
				<td valign="top" style="width:91.00%;padding:0pt;">
					<p style="margin:5pt 0pt;line-height:115%;font-family:Calibri;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;color:#000000;">CONTROLS AND PROCEDURES </font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt 0pt 3pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;color:#000000;">Evaluation of disclosure controls and procedures. </font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">Our senior management is responsible for establishing and maintaining a system of disclosure controls and procedures (as defined in Rule 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the &#x201C;Exchange Act&#x201D;)) designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC&#x2019;s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by an issuer in the reports that it files or submits under the Exchange Act is accumulated and communicated to the issuer&#x2019;s management, including its principal executive officer and principal financial officer, or</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;"> persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. Management, including our Chief Executive Officer and Chief Accounting Officer, performed an evaluation of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">June 30</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">, &nbsp;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">201</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">7</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">. Based on this evaluation, our Chief Executive Officer and Chief Accounting Officer have concluded that as of </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">June 30</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">, &nbsp;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">201</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">7</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">, our disclosure controls and procedures were effective.</font>
		</p>
		<p style="margin:0pt 0pt 8pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 8pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;color:#000000;">Changes in internal controls over financial reporting. </font>
		</p>
		<p style="margin:0pt 0pt 3pt;text-indent:36pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;color:#000000;">There was no change in our internal control over financial reporting that occurred during the period covered by this Quarterly Report on Form 10-Q that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting. </font>
		</p>
		<p style="margin:0pt 0pt 8pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 8pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 8pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 8pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">

		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;"></font><font style="display: inline;">23</font><font style="display: inline;"></font>

		</p>

		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt">

			&nbsp;

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<p style="margin:0pt 0pt 8pt;font-family:Calibri;line-height:107.92%;;font-size: 10pt"><font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;"></font>
		</p>
		<p style="margin:0pt 0pt 8pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<a name="Part_II"></a><font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">PART II</font><font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;"> - OTHER INFORMATION</font>
		</p>
		<p style="margin:0pt 0pt 8pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:540.00pt;margin-left:0pt;">
			<tr>
				<td valign="middle" style="width:09.00%;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">&#xFEFF;</font></p>
				</td>
				<td valign="middle" style="width:491.40pt;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 10pt;line-height:115%;font-family:Calibri;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:09.00%;padding:0pt;">
					<p style="margin:0pt;line-height:115%;font-family:Calibri;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">&#xFEFF;</font><a name="Part_II_Item_1"></a><font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">ITEM&nbsp;1.</font></p>
				</td>
				<td valign="top" style="width:491.40pt;padding:0pt;">
					<p style="margin:5pt 0pt;line-height:115%;font-family:Calibri;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">LEGAL PROCEEDINGS </font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;text-indent:36pt;font-family:Calibri;line-height:107.92%;font-size: 1pt">
			<font style="display: inline;font-family:Times New Roman;font-size:1pt;">&#xFEFF;</font>
		</p>
		<p style="margin:4.5pt 0pt 8pt;text-indent:36pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">In the ordinary course of business, we may periodically become subject to legal proceedings and claims arising in connection with ongoing business activities. The results of litigation and claims cannot be predicted with certainty, and unfavorable resolutions are possible and could materially and adversely affect our results of operations, cash </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">flows and financial position. In addition, regardless of the outcome, litigation could have an adverse impact on us because of defense costs, diversion of management resources and other factors. While the outcome of these proceedings and claims cannot be predicted with certainty, there are no matters, as of </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">June 30</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">, &nbsp;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">201</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">7</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">, that, in the opinion of management, will have a material adverse effect on our financial position, results of operations or cash flows.</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:1031.40pt;margin-left:0pt;">
			<tr>
				<td valign="middle" style="width:04.72%;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size: 10pt">
						<font style="color:#0000FF;border-bottom-style:double;border-bottom-width:2pt;font-family:Times New Roman;font-weight:bold;font-size:10pt;height:100%;text-indent:0pt;">&#xFEFF;</font></p>
				</td>
				<td valign="top" style="width:47.64%;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 10pt;line-height:115%;font-family:Calibri;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:47.64%;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 10pt;line-height:115%;font-family:Calibri;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:04.72%;padding:0pt;">
					<p style="margin:0pt;line-height:115%;font-family:Calibri;font-size: 10pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:47.64%;padding:0pt;">
					<p style="margin:5pt 0pt;line-height:115%;font-family:Calibri;font-size: 11pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:47.64%;padding:0pt;">
					<p style="margin:5pt 0pt;line-height:115%;font-family:Calibri;font-size: 11pt">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt">
			<a name="Part_II_Item_1A"></a><font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">ITEM 1A. RISK FACTORS</font>
		</p>
		<p style="margin:0pt 0pt 8pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Arial Unicode MS;font-size: 10pt">
			<a name="_cp_text_1_506"></a><font style="display: inline;font-family:Times New Roman;font-style:italic;font-size:10pt;">There have b</font><font style="display: inline;font-family:Times New Roman;font-style:italic;font-size:10pt;">een no material changes to our risk factors from those disclosed under &#x201C;Risk Factors&#x201D; in Part I, Item 1A of our </font><font style="display: inline;font-family:Times New Roman;font-style:italic;font-size:10pt;">201</font><font style="display: inline;font-family:Times New Roman;font-style:italic;font-size:10pt;">6</font><font style="display: inline;font-family:Times New Roman;font-style:italic;font-size:10pt;">&nbsp;</font><font style="display: inline;font-family:Times New Roman;font-style:italic;font-size:10pt;">Annual </font><font style="display: inline;font-family:Times New Roman;font-style:italic;font-size:10pt;">Report</font><font style="display: inline;font-family:Times New Roman;font-style:italic;font-size:10pt;">&nbsp;</font><font style="display: inline;font-family:Times New Roman;font-style:italic;font-size:10pt;">and </font><font style="display: inline;font-family:Times New Roman;font-style:italic;font-size:10pt;">Part II, Item 1A of our </font><font style="display: inline;font-family:Times New Roman;font-style:italic;font-size:10pt;">2017 First Quarterly Report</font><font style="display: inline;font-family:Times New Roman;font-style:italic;font-size:10pt;">. The risks and uncertainties described in our </font><font style="display: inline;font-family:Times New Roman;font-style:italic;font-size:10pt;">2016</font><font style="display: inline;font-family:Times New Roman;font-style:italic;font-size:10pt;">&nbsp;</font><font style="display: inline;font-family:Times New Roman;font-style:italic;font-size:10pt;">Annual Report </font><font style="display: inline;font-family:Times New Roman;font-style:italic;font-size:10pt;">and </font><font style="display: inline;font-family:Times New Roman;font-style:italic;font-size:10pt;">2017 First Quarterly Report</font><font style="display: inline;font-family:Times New Roman;font-style:italic;font-size:10pt;">&nbsp;</font><font style="display: inline;font-family:Times New Roman;font-style:italic;font-size:10pt;">are not the only ones we face. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also materially adversely affect our business, financial condition or results of operations. </font>
		</p>
		<p style="margin:0pt;text-indent:36pt;border-top:1pt none #D9D9D9 ;line-height:100%;font-family:Arial Unicode MS;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-style:italic;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 8pt;font-family:Calibri;line-height:107.92%;font-size: 11pt">
			<font style="display: inline;">&#xFEFF;</font><a name="s659B07563D6954FC985ABD225000E85"></a><a name="_cp_text_4_584"></a><a name="_cp_text_4_789"></a>
		</p>
		<p style="margin:0pt 0pt 8pt;font-family:Calibri;line-height:107.92%;font-size: 11pt">

		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;"></font><font style="display: inline;">24</font><font style="display: inline;"></font>

		</p>

		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt">

			&nbsp;

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<p style="margin:0pt 0pt 8pt;font-family:Calibri;line-height:107.92%;;font-size: 11pt"><font style="display: inline;font-family:Times New Roman;font-weight:bold;"></font>
		</p>
		<p style="margin:0pt 0pt 8pt 40.5pt;text-indent: -40.5pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">ITEM 6.&nbsp;&nbsp;&nbsp;EXHIBI</font><a name="Part_II_Item_6"></a><font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">TS</font>
		</p>
		<p style="margin:4.5pt 0pt 0pt;line-height:100%;font-family:Arial Unicode MS;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">(a)&nbsp;&nbsp;&nbsp;The following exhibits are filed or incorporated by reference with this report as indicated below: </font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 101.26%;margin-left:0pt;">
			<tr>
				<td valign="middle" style="width:43.85pt;height:0.90pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:115%;font-family:Calibri;height:0.90pt;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">&#xFEFF;</font></p>
				</td>
				<td valign="middle" style="width:05.45pt;height:0.90pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:115%;font-family:Calibri;height:0.90pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:172.70pt;height:0.90pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:115%;font-family:Calibri;height:0.90pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:04.25pt;height:0.90pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:115%;font-family:Calibri;height:0.90pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="middle" style="width:32.65pt;height:0.90pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:115%;font-family:Calibri;height:0.90pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:04.25pt;height:0.90pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:115%;font-family:Calibri;height:0.90pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:47.20pt;height:0.90pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:115%;font-family:Calibri;height:0.90pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:04.25pt;height:0.90pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:115%;font-family:Calibri;height:0.90pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:32.65pt;height:0.90pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:115%;font-family:Calibri;height:0.90pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:04.25pt;height:0.90pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:115%;font-family:Calibri;height:0.90pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="middle" style="width:80.20pt;height:0.90pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:115%;font-family:Calibri;height:0.90pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:04.25pt;height:0.90pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:115%;font-family:Calibri;height:0.90pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:37.95pt;height:0.90pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:115%;font-family:Calibri;height:0.90pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:43.85pt;height:9.40pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:115%;text-align:center;font-family:Calibri;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">Exhibit</font></p>
				</td>
				<td valign="middle" style="width:05.45pt;height:9.40pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:115%;font-family:Calibri;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:172.70pt;height:9.40pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:115%;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:04.25pt;height:9.40pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:115%;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="9" valign="middle" style="width:205.45pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:9.40pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:115%;text-align:center;font-family:Calibri;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">Incorporated by Reference </font></p>
				</td>
				<td valign="middle" style="width:04.25pt;height:9.40pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:115%;text-align:center;font-family:Calibri;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:37.95pt;height:9.40pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:115%;text-align:center;font-family:Calibri;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">Filed</font></p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:43.85pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:9.40pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:115%;text-align:center;font-family:Calibri;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">Number</font></p>
				</td>
				<td valign="middle" style="width:05.45pt;height:9.40pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:115%;font-family:Calibri;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:172.70pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:9.40pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:115%;text-align:center;font-family:Calibri;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">Exhibit Description </font></p>
				</td>
				<td valign="middle" style="width:04.25pt;height:9.40pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:115%;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:29.80pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:9.40pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:115%;text-align:center;font-family:Calibri;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">Form </font></p>
				</td>
				<td colspan="2" valign="middle" style="width:07.10pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:9.40pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:115%;text-align:center;font-family:Calibri;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:47.20pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:9.40pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:115%;text-align:center;font-family:Calibri;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">File No. </font></p>
				</td>
				<td valign="middle" style="width:04.25pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:9.40pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:115%;text-align:center;font-family:Calibri;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:32.65pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:9.40pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:115%;text-align:center;font-family:Calibri;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">Exhibit </font></p>
				</td>
				<td valign="middle" style="width:04.25pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:9.40pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:115%;text-align:center;font-family:Calibri;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:75.55pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:9.40pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:115%;text-align:center;font-family:Calibri;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">Filing Date </font></p>
				</td>
				<td valign="middle" style="width:04.65pt;height:9.40pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:115%;text-align:center;font-family:Calibri;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="middle" style="width:42.20pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:9.40pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:115%;text-align:center;font-family:Calibri;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">Herewith </font></p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:43.85pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:7.90pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:115%;font-family:Calibri;height:7.90pt;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">&#xFEFF;</font></p>
				</td>
				<td valign="middle" style="width:05.45pt;height:7.90pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:115%;font-family:Calibri;height:7.90pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:172.70pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:7.90pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:115%;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;height:7.90pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:04.25pt;height:7.90pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:115%;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;height:7.90pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:29.80pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:7.90pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:115%;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;height:7.90pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="middle" style="width:07.10pt;height:7.90pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:115%;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;height:7.90pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:47.20pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:7.90pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:115%;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;height:7.90pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:04.25pt;height:7.90pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:115%;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;height:7.90pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:32.65pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:7.90pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:115%;text-align:right;font-family:Calibri;height:7.90pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:04.25pt;height:7.90pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:115%;text-align:right;font-family:Calibri;height:7.90pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:75.55pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:7.90pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:115%;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;height:7.90pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:04.65pt;height:7.90pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:115%;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;height:7.90pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="middle" style="width:42.20pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:7.90pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:115%;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;height:7.90pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:43.85pt;background-color: #CCEEFF;height:38.25pt;padding:0pt;">
					<p style="margin:0pt 3.25pt 0.05pt 0pt;line-height:115%;font-family:Calibri;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">3.1</font></p>
				</td>
				<td valign="top" style="width:05.45pt;background-color: #CCEEFF;height:38.25pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:115%;font-family:Calibri;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:172.70pt;background-color: #CCEEFF;height:38.25pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:115%;font-family:Calibri;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">Fourth Amended and Restated Certificate</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> of Incorporation of Vermillion, Inc. dated January&nbsp;22, 2010</font></p>
				</td>
				<td valign="middle" style="width:04.25pt;background-color: #CCEEFF;height:38.25pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:115%;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:29.80pt;background-color: #CCEEFF;height:38.25pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:115%;text-align:right;font-family:Calibri;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">8-K</font></p>
				</td>
				<td colspan="2" valign="top" style="width:07.10pt;background-color: #CCEEFF;height:38.25pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:115%;font-family:Calibri;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:47.20pt;background-color: #CCEEFF;height:38.25pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:115%;text-align:right;font-family:Calibri;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">000-31617</font></p>
				</td>
				<td valign="top" style="width:04.25pt;background-color: #CCEEFF;height:38.25pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:115%;font-family:Calibri;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:32.65pt;background-color: #CCEEFF;height:38.25pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">3.1&nbsp;
				</td>
				<td valign="top" style="width:04.25pt;background-color: #CCEEFF;height:38.25pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:115%;text-align:right;font-family:Calibri;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:75.55pt;background-color: #CCEEFF;height:38.25pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:115%;text-align:right;font-family:Calibri;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">January&nbsp;25, 2010</font></p>
				</td>
				<td valign="top" style="width:04.65pt;background-color: #CCEEFF;height:38.25pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:115%;text-align:right;font-family:Calibri;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="middle" style="width:42.20pt;background-color: #CCEEFF;height:38.25pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:115%;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:43.85pt;height:39.79pt;padding:0pt;">
					<p style="margin:0pt 3.25pt 0.05pt 0pt;line-height:115%;font-family:Calibri;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">3.2</font></p>
				</td>
				<td valign="top" style="width:05.45pt;height:39.79pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:115%;font-family:Calibri;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:172.70pt;height:39.79pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:115%;font-family:Calibri;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">Certificate of Amendment of Fourth Amended and Restated Certificate of Incorporation, effective June 19, 2014</font></p>
				</td>
				<td valign="middle" style="width:04.25pt;height:39.79pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:115%;font-family:Calibri;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:29.80pt;height:39.79pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:115%;text-align:right;font-family:Calibri;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">10-Q</font></p>
				</td>
				<td colspan="2" valign="top" style="width:07.10pt;height:39.79pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:115%;font-family:Calibri;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:47.20pt;height:39.79pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:115%;text-align:right;font-family:Calibri;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">001-34810</font></p>
				</td>
				<td valign="top" style="width:04.25pt;height:39.79pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:115%;font-family:Calibri;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:32.65pt;height:39.79pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">3.2&nbsp;
				</td>
				<td valign="top" style="width:04.25pt;height:39.79pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:115%;text-align:right;font-family:Calibri;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:75.55pt;height:39.79pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:115%;text-align:right;font-family:Calibri;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">August 14, 2014</font></p>
				</td>
				<td valign="top" style="width:04.65pt;height:39.79pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:115%;text-align:right;font-family:Calibri;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="middle" style="width:42.20pt;height:39.79pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:115%;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:43.85pt;background-color: #CCEEFF;height:27.05pt;padding:0pt;">
					<p style="margin:0pt 3.25pt 0.05pt 0pt;line-height:115%;font-family:Calibri;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">3.3</font></p>
				</td>
				<td valign="top" style="width:05.45pt;background-color: #CCEEFF;height:27.05pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:115%;font-family:Calibri;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:172.70pt;background-color: #CCEEFF;height:27.05pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:115%;font-family:Calibri;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">Fifth Amended and Restated Bylaws of Vermillion, Inc., effective June 19, 2014</font></p>
					<p style="margin:0pt 0pt 0.05pt;line-height:115%;font-family:Calibri;overflow: hidden;">
						&nbsp;</p>
					<p style="margin:0pt 0pt 0.05pt;line-height:115%;font-family:Calibri;overflow: hidden;">
						&nbsp;</p>
					<p style="margin:0pt 0pt 0.05pt;line-height:115%;font-family:Calibri;overflow: hidden;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:04.25pt;background-color: #CCEEFF;height:27.05pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:115%;font-family:Calibri;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:29.80pt;background-color: #CCEEFF;height:27.05pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:115%;text-align:right;font-family:Calibri;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">10-Q</font></p>
				</td>
				<td colspan="2" valign="top" style="width:07.10pt;background-color: #CCEEFF;height:27.05pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:115%;font-family:Calibri;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:47.20pt;background-color: #CCEEFF;height:27.05pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:115%;text-align:right;font-family:Calibri;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">001-34810</font></p>
				</td>
				<td valign="top" style="width:04.25pt;background-color: #CCEEFF;height:27.05pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:115%;font-family:Calibri;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:32.65pt;background-color: #CCEEFF;height:27.05pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">3.3&nbsp;
				</td>
				<td valign="top" style="width:04.25pt;background-color: #CCEEFF;height:27.05pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:115%;text-align:right;font-family:Calibri;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:75.55pt;background-color: #CCEEFF;height:27.05pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:115%;text-align:right;font-family:Calibri;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">August 14, 2014</font></p>
				</td>
				<td valign="top" style="width:04.65pt;background-color: #CCEEFF;height:27.05pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:115%;text-align:right;font-family:Calibri;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="middle" style="width:42.20pt;background-color: #CCEEFF;height:27.05pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:115%;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:43.85pt;height:41.40pt;padding:0pt;">
					<p style="margin:0pt 3.25pt 0.05pt 0pt;line-height:115%;font-family:Calibri;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">31.1</font></p>
				</td>
				<td valign="top" style="width:05.45pt;height:41.40pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:115%;font-family:Calibri;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:172.70pt;height:41.40pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:115%;font-family:Calibri;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">Certification of the Chief Executive Officer Pursuant to Section</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> 302 of the Sarbanes-Oxley Act of 2002</font></p>
				</td>
				<td valign="middle" style="width:04.25pt;height:41.40pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:115%;font-family:Calibri;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:29.80pt;height:41.40pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:115%;text-align:right;font-family:Calibri;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="top" style="width:07.10pt;height:41.40pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:115%;font-family:Calibri;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:47.20pt;height:41.40pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:115%;text-align:right;font-family:Calibri;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:04.25pt;height:41.40pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:115%;font-family:Calibri;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:32.65pt;height:41.40pt;padding:0pt;">
					<p style="margin:0pt 3.25pt 0.05pt 0pt;line-height:115%;text-align:right;font-family:Calibri;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:04.25pt;height:41.40pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:115%;text-align:right;font-family:Calibri;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:75.55pt;height:41.40pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:115%;text-align:right;font-family:Calibri;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:04.65pt;height:41.40pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:115%;text-align:right;font-family:Calibri;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="top" style="width:42.20pt;height:41.40pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:115%;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">&nbsp;</font><font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">&#x221A;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:43.85pt;background-color: #CCEEFF;height:40.50pt;padding:0pt;">
					<p style="margin:0pt 3.25pt 0.05pt 0pt;line-height:115%;font-family:Calibri;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">31.2</font></p>
				</td>
				<td valign="top" style="width:05.45pt;background-color: #CCEEFF;height:40.50pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:115%;font-family:Calibri;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:172.70pt;background-color: #CCEEFF;height:40.50pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:115%;font-family:Calibri;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">Certification of the Chief Accounting Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</font></p>
				</td>
				<td valign="middle" style="width:04.25pt;background-color: #CCEEFF;height:40.50pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:115%;font-family:Calibri;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:29.80pt;background-color: #CCEEFF;height:40.50pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:115%;text-align:right;font-family:Calibri;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="middle" style="width:07.10pt;background-color: #CCEEFF;height:40.50pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:115%;font-family:Calibri;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:47.20pt;background-color: #CCEEFF;height:40.50pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:115%;text-align:right;font-family:Calibri;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:04.25pt;background-color: #CCEEFF;height:40.50pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:115%;font-family:Calibri;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:32.65pt;background-color: #CCEEFF;height:40.50pt;padding:0pt;">
					<p style="margin:0pt 3.25pt 0.05pt 0pt;line-height:115%;text-align:right;font-family:Calibri;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:04.25pt;background-color: #CCEEFF;height:40.50pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:115%;text-align:right;font-family:Calibri;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:75.55pt;background-color: #CCEEFF;height:40.50pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:115%;text-align:right;font-family:Calibri;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:04.65pt;background-color: #CCEEFF;height:40.50pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:115%;text-align:right;font-family:Calibri;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="top" style="width:42.20pt;background-color: #CCEEFF;height:40.50pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:115%;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">&nbsp;</font><font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">&#x221A;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:43.85pt;height:67.50pt;padding:0pt;">
					<p style="margin:0pt 3.25pt 0.05pt 0pt;line-height:115%;font-family:Calibri;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">32.1</font></p>
				</td>
				<td valign="top" style="width:05.45pt;height:67.50pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:115%;font-family:Calibri;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:172.70pt;height:67.50pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:115%;font-family:Calibri;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">Certification of the Chief Executive Officer and Chief Accounting Officer </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</font></p>
				</td>
				<td valign="middle" style="width:04.25pt;height:67.50pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:115%;font-family:Calibri;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:29.80pt;height:67.50pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:115%;text-align:right;font-family:Calibri;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="middle" style="width:07.10pt;height:67.50pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:115%;font-family:Calibri;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:47.20pt;height:67.50pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:115%;text-align:right;font-family:Calibri;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:04.25pt;height:67.50pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:115%;font-family:Calibri;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:32.65pt;height:67.50pt;padding:0pt;">
					<p style="margin:0pt 3.25pt 0.05pt 0pt;line-height:115%;text-align:right;font-family:Calibri;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:04.25pt;height:67.50pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:115%;text-align:right;font-family:Calibri;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:75.55pt;height:67.50pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:115%;text-align:right;font-family:Calibri;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:04.65pt;height:67.50pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:115%;text-align:right;font-family:Calibri;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="top" style="width:42.20pt;height:67.50pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:115%;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;"> (1)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:43.85pt;background-color: #CCEEFF;height:9.44pt;padding:0pt;">
					<p style="margin:0pt 3.25pt 0.05pt 0pt;line-height:115%;font-family:Calibri;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">101</font></p>
				</td>
				<td valign="middle" style="width:05.45pt;background-color: #CCEEFF;height:9.44pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:115%;font-family:Calibri;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:172.70pt;background-color: #CCEEFF;height:9.44pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:115%;font-family:Calibri;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">Interactive Data Files</font></p>
				</td>
				<td valign="bottom" style="width:04.25pt;background-color: #CCEEFF;height:9.44pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:115%;font-family:Calibri;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:29.80pt;background-color: #CCEEFF;height:9.44pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:115%;text-align:right;font-family:Calibri;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="middle" style="width:07.10pt;background-color: #CCEEFF;height:9.44pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:115%;font-family:Calibri;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:47.20pt;background-color: #CCEEFF;height:9.44pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:115%;text-align:right;font-family:Calibri;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:04.25pt;background-color: #CCEEFF;height:9.44pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:115%;font-family:Calibri;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:32.65pt;background-color: #CCEEFF;height:9.44pt;padding:0pt;">
					<p style="margin:0pt 3.25pt 0.05pt 0pt;line-height:115%;text-align:right;font-family:Calibri;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:04.25pt;background-color: #CCEEFF;height:9.44pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:115%;text-align:right;font-family:Calibri;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:75.55pt;background-color: #CCEEFF;height:9.44pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:115%;text-align:right;font-family:Calibri;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:04.65pt;background-color: #CCEEFF;height:9.44pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:115%;text-align:right;font-family:Calibri;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="top" style="width:42.20pt;background-color: #CCEEFF;height:9.44pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:115%;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">&nbsp;</font><font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">&#x221A;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt 0pt 8pt;font-family:Calibri;line-height:107.92%;font-size: 11pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 8pt;border-bottom:1.5pt solid #000000 ;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:540.00pt;margin-left:0pt;">
			<tr>
				<td valign="top" style="width:04.00%;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">&#xFEFF;</font></p>
				</td>
				<td valign="top" style="width:96.00%;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 10pt;line-height:115%;font-family:Calibri;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:04.00%;padding:0pt;">
					<p style="margin:0pt;line-height:115%;font-family:Calibri;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">(1)</font></p>
				</td>
				<td valign="top" style="width:96.00%;padding:0pt;">
					<p style="margin:0pt;line-height:115%;font-family:Calibri;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">Furnished herewith</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:04.00%;height:4.65pt;padding:0pt;">
					<p style="margin:0pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">&#xFEFF;</font></p>
				</td>
				<td valign="top" style="width:96.00%;height:4.65pt;padding:0pt;">
					<p style="margin:0pt;line-height:115%;font-family:Calibri;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt 0pt 8pt 36pt;text-indent: -36pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 8pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">

		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;"></font><font style="display: inline;">25</font><font style="display: inline;"></font>

		</p>

		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt">

			&nbsp;

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<p style="margin:0pt 0pt 8pt;font-family:Calibri;line-height:107.92%;;font-size: 10pt"><font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;"></font>
		</p>
		<p style="margin:0pt 0pt 8pt 36pt;text-indent: -36pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<a name="Signatures"></a><font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">SIGNATURES</font>
		</p>
		<p style="margin:0pt 0pt 8pt;font-family:Calibri;line-height:107.92%;font-size: 11pt">
			<font style="display: inline;font-family:Times New Roman;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 8pt;text-indent:36pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">Pursuant to the requirements of the </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">Securities </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">Exchange Act</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> of 1934</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</font>
		</p>
		<p style="margin:0pt 0pt 8pt;font-family:Calibri;line-height:107.92%;font-size: 11pt">
			<font style="display: inline;font-family:Times New Roman;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:216.00pt;height:1.00pt;padding:0pt 5.4pt;">
					<p style="margin:0pt;line-height:115%;font-family:Calibri;height:1.00pt;overflow:hidden;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:268.55pt;height:1.00pt;padding:0pt 5.4pt;">
					<p style="margin:0pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:216.00pt;padding:0pt 5.4pt;">
					<p style="margin:0pt;line-height:115%;font-family:Calibri;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:268.55pt;padding:0pt 5.4pt;">
					<p style="margin:0pt;line-height:115%;font-family:Calibri;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">Vermillion, Inc.</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:216.00pt;padding:0pt 5.4pt;">
					<p style="margin:0pt;line-height:115%;font-family:Calibri;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">Date:&nbsp; </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">August </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">11</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">, 2017</font></p>
				</td>
				<td valign="bottom" style="width:268.55pt;padding:0pt 5.4pt;">
					<p style="margin:0pt;line-height:115%;font-family:Calibri;font-size: 11pt">
						&nbsp;</p>
					<p style="margin:0pt;line-height:115%;font-family:Calibri;font-size: 11pt">
						&nbsp;</p>
					<p style="margin:0pt;line-height:115%;border-bottom:1pt solid #000000 ;font-family:Calibri;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">/s/ Valerie B. Palmieri</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;;font-size: 10pt;font-family:Calibri;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"></font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"></font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:216.00pt;padding:0pt 5.4pt;">
					<p style="margin:0pt;line-height:115%;font-family:Calibri;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:268.55pt;padding:0pt 5.4pt;">
					<p style="margin:0pt;line-height:115%;font-family:Calibri;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">Valerie B. Palmieri</font></p>
					<p style="margin:0pt;line-height:115%;font-family:Calibri;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">President and Chief </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">Executive Officer</font></p>
					<p style="margin:0pt;line-height:115%;font-family:Calibri;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">(Principal Executive Officer)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:216.00pt;padding:0pt 5.4pt;">
					<p style="margin:0pt;line-height:115%;font-family:Calibri;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">Date:&nbsp; </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">August </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">11</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">, 2017</font></p>
				</td>
				<td valign="bottom" style="width:268.55pt;padding:0pt 5.4pt;">
					<p style="margin:0pt;line-height:115%;font-family:Calibri;font-size: 11pt">
						&nbsp;</p>
					<p style="margin:0pt;line-height:115%;font-family:Calibri;font-size: 11pt">
						&nbsp;</p>
					<p style="margin:0pt;line-height:115%;border-bottom:1pt solid #000000 ;font-family:Calibri;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">/s/ Eric J. Schoen</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;;font-size: 10pt;font-family:Calibri;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"></font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"></font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:216.00pt;padding:0pt 5.4pt;">
					<p style="margin:0pt;line-height:115%;font-family:Calibri;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:268.55pt;padding:0pt 5.4pt;">
					<p style="margin:0pt;line-height:115%;font-family:Calibri;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">Eric J. Schoen</font></p>
					<p style="margin:0pt;line-height:115%;font-family:Calibri;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">Senior </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">Vice President, Finance and Chief Accounting Officer</font></p>
					<p style="margin:0pt;line-height:115%;font-family:Calibri;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">(Principal Financial Officer)</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Calibri;line-height:107.92%;font-size: 1pt">
			<font style="display: inline;font-family:Times New Roman;font-size:1pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 8pt;font-family:Calibri;line-height:107.92%;font-size: 1pt">
			<font style="display: inline;font-family:Times New Roman;font-size:1pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 8pt;font-family:Calibri;line-height:107.92%;font-size: 11pt">
			<font style="display: inline;font-family:Times New Roman;">&#xFEFF;</font>
		</p>
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:0pt;text-align:center;line-height:100%;font-family:Times New Roman;font-size: 10pt">

			<font style="display: inline;"></font><font style="display: inline;">26</font><font style="display: inline;"></font>

		</p>

		<p style="margin:0pt;line-height:100%;font-family:Times New Roman;font-size: 10pt">

			&nbsp;

		</p>

</div><hr size="3" style="color:#999999" width="100%" align="center"></hr>
	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>c617-20170630xex31_1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!--HTML document created with Certent Disclosure Management 6.8.4.2-->
<!--Created on: 8/11/2017 2:59:22 PM-->
<html>
	<head>
		<title>
			Exhibit 31.1
		</title>
	</head>
	<body><div style="margin-left:72pt;margin-right:72pt;">
		<p style="margin:0pt 0pt 8pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 11pt">
			<a name="_GoBack"></a><font style="display: inline;font-weight:bold;">Exhibit 31.1</font>
		</p>
		<p style="margin:0pt 0pt 8pt;font-family:Calibri;line-height:107.92%;font-size: 11pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 8pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 11pt">
			<font style="display: inline;font-weight:bold;">Certification of the Chief Executive Officer Pursuant to Section 302 of</font>
		</p>
		<p style="margin:0pt 0pt 8pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 11pt">
			<font style="display: inline;font-weight:bold;">The Sarbanes-Oxley Act Of 2002</font>
		</p>
		<p style="margin:0pt 0pt 8pt;font-family:Calibri;line-height:107.92%;font-size: 11pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 8pt;font-family:Calibri;line-height:107.92%;font-size: 11pt">
			<font style="display: inline;">I, Valerie B. Palmieri, certify that:</font>
		</p>
		<p style="margin:0pt 0pt 8pt;font-family:Calibri;line-height:107.92%;font-size: 11pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;font-size: 11pt;margin:0pt;">
				<font style="margin:0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:10pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;;"> 1.</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;font-size: 11pt;margin:0pt;">
			<font style="display: inline;color:#000000;">I have reviewed this quarterly report on Form 10-Q of Vermillion, Inc.;</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 8pt;font-family:Calibri;line-height:107.92%;font-size: 11pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;font-size: 11pt;margin:0pt;">
				<font style="margin:0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:10pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;;"> 2.</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;font-size: 11pt;margin:0pt;">
			<font style="display: inline;color:#000000;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 8pt;font-family:Calibri;line-height:107.92%;font-size: 11pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;font-size: 11pt;margin:0pt;">
				<font style="margin:0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:10pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;;"> 3.</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;font-size: 11pt;margin:0pt;">
			<font style="display: inline;color:#000000;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 8pt;font-family:Calibri;line-height:107.92%;font-size: 11pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;font-size: 11pt;margin:0pt;">
				<font style="margin:0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:10pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;;"> 4.</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;font-size: 11pt;margin:0pt;">
			<font style="display: inline;color:#000000;">The registrant&#x2019;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 8pt;font-family:Calibri;line-height:107.92%;font-size: 11pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 8pt 36pt;text-indent: -18pt;font-family:Calibri;line-height:107.92%;font-size: 11pt">
			<font style="display: inline;color:#000000;">(a)&nbsp;&nbsp;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font>
		</p>
		<p style="margin:0pt 0pt 8pt;font-family:Calibri;line-height:107.92%;font-size: 11pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 8pt 36pt;text-indent: -18pt;font-family:Calibri;line-height:107.92%;font-size: 11pt">
			<font style="display: inline;color:#000000;">(b)&nbsp;&nbsp;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font>
		</p>
		<p style="margin:0pt 0pt 8pt;font-family:Calibri;line-height:107.92%;font-size: 11pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 8pt 36pt;text-indent: -18pt;font-family:Calibri;line-height:107.92%;font-size: 11pt">
			<font style="display: inline;color:#000000;">(c)&nbsp;&nbsp;Evaluated the effectiveness of the registrant&#x2019;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font>
		</p>
		<p style="margin:0pt 0pt 8pt;font-family:Calibri;line-height:107.92%;font-size: 11pt">

		</p>
		<p><font size="1"> </font></p><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<p style="margin:0pt 0pt 8pt;font-family:Calibri;line-height:107.92%;;font-size: 11pt"><font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 8pt 36pt;text-indent: -18pt;font-family:Calibri;line-height:107.92%;font-size: 11pt">
			<font style="display: inline;">(d)&nbsp;&nbsp;Disclosed in this report any change in the registrant&#x2019;s internal control over financial reporting that occurred during the registrant&#x2019;s most recent fiscal quarter (the registrant&#x2019;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#x2019;s internal control over financial reporting; and</font>
		</p>
		<p style="margin:0pt 0pt 8pt;font-family:Calibri;line-height:107.92%;font-size: 11pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;font-size: 11pt;margin:0pt;">
				<font style="margin:0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:10pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;;"> 5.</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;font-size: 11pt;margin:0pt;">
			<font style="display: inline;color:#000000;">The registrant&#x2019;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#x2019;s auditors and the audit committee of the registrant&#x2019;s board of directors (or persons performing the equivalent functions):</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 8pt;font-family:Calibri;line-height:107.92%;font-size: 11pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 8pt 36pt;text-indent: -18pt;font-family:Calibri;line-height:107.92%;font-size: 11pt">
			<font style="display: inline;color:#000000;">(a)&nbsp;&nbsp;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#x2019;s ability to record, process, summarize and report financial information; and</font>
		</p>
		<p style="margin:0pt 0pt 8pt;font-family:Calibri;line-height:107.92%;font-size: 11pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 8pt 36pt;text-indent: -18pt;font-family:Calibri;line-height:107.92%;font-size: 11pt">
			<font style="display: inline;color:#000000;">(b)&nbsp;&nbsp;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#x2019;s internal control over financial reporting.</font>
		</p>
		<p style="margin:0pt 0pt 8pt;font-family:Calibri;line-height:107.92%;font-size: 11pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:216.00pt;height:1.00pt;padding:0pt 5.4pt;">
					<p style="margin:0pt;line-height:115%;font-family:Calibri;height:1.00pt;overflow:hidden;font-size: 1pt">
						<font style="display: inline;font-size:1pt;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:261.00pt;height:1.00pt;padding:0pt 5.4pt;">
					<p style="margin:0pt;line-height:115%;font-family:Calibri;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:216.00pt;padding:0pt 5.4pt;">
					<p style="margin:0pt;line-height:115%;font-family:Calibri;font-size: 11pt">
						<font style="display: inline;color:#000000;">Date:&nbsp; </font><font style="display: inline;color:#000000;">August </font><font style="display: inline;color:#000000;">11</font><font style="display: inline;color:#000000;">, 2017</font></p>
				</td>
				<td valign="bottom" style="width:261.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt 5.4pt;">
					<p style="margin:0pt;line-height:115%;font-family:Calibri;font-size: 11pt">
						&nbsp;</p>
					<p style="margin:0pt;line-height:115%;font-family:Calibri;font-size: 11pt">
						<font style="display: inline;color:#000000;">/s/ Valerie B. Palmieri</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:216.00pt;padding:0pt 5.4pt;">
					<p style="margin:0pt;line-height:115%;font-family:Calibri;font-size: 11pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:261.00pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 5.4pt;">
					<p style="margin:0pt;line-height:115%;font-family:Calibri;font-size: 11pt">
						<font style="display: inline;color:#000000;">Valerie B. Palmieri</font></p>
					<p style="margin:0pt;line-height:115%;font-family:Calibri;font-size: 11pt">
						<font style="display: inline;color:#000000;">President and Chief Executive Officer</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt 0pt 8pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 8pt;font-family:Calibri;line-height:107.92%;font-size: 11pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p><font size="1"> </font></p><hr size="3" style="color:#999999" width="100%" align="center"></hr>
	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>c617-20170630xex31_2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!--HTML document created with Certent Disclosure Management 6.8.4.2-->
<!--Created on: 8/11/2017 2:59:26 PM-->
<html>
	<head>
		<title>
			Exhibit 31.2
		</title>
	</head>
	<body><div style="margin-left:72pt;margin-right:72pt;">
		<p style="margin:0pt;text-align:right;line-height:100%;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<a name="_GoBack"></a><font style="display: inline;font-weight:bold;font-style:normal;font-size:10pt;">Exhibit 31.2</font>
		</p>
		<p style="margin:0pt 0pt 8pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 8pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 11pt">
			<font style="display: inline;font-weight:bold;">Certification of the Chief Accounting Officer Pursuant to Section 302 of</font>
		</p>
		<p style="margin:0pt 0pt 8pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 11pt">
			<font style="display: inline;font-weight:bold;">The Sarbanes-Oxley Act Of 2002</font>
		</p>
		<p style="margin:0pt 0pt 8pt;font-family:Calibri;line-height:107.92%;font-size: 11pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 8pt;font-family:Calibri;line-height:107.92%;font-size: 11pt">
			<font style="display: inline;">I, Eric J. Schoen, certify that:</font>
		</p>
		<p style="margin:0pt 0pt 8pt;font-family:Calibri;line-height:107.92%;font-size: 11pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;font-size: 11pt;margin:0pt;">
				<font style="margin:0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:10pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;;"> 1.</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;font-size: 11pt;margin:0pt;">
			<font style="display: inline;color:#000000;">I have reviewed this quarterly report on Form 10-Q of Vermillion, Inc.;</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 8pt;font-family:Calibri;line-height:107.92%;font-size: 11pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;font-size: 11pt;margin:0pt;">
				<font style="margin:0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:10pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;;"> 2.</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;font-size: 11pt;margin:0pt;">
			<font style="display: inline;color:#000000;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 8pt;font-family:Calibri;line-height:107.92%;font-size: 11pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;font-size: 11pt;margin:0pt;">
				<font style="margin:0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:10pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;;"> 3.</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;font-size: 11pt;margin:0pt;">
			<font style="display: inline;color:#000000;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 8pt;font-family:Calibri;line-height:107.92%;font-size: 11pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;font-size: 11pt;margin:0pt;">
				<font style="margin:0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:10pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;;"> 4.</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;font-size: 11pt;margin:0pt;">
			<font style="display: inline;color:#000000;">The registrant&#x2019;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 8pt;font-family:Calibri;line-height:107.92%;font-size: 11pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 8pt 36pt;text-indent: -18pt;font-family:Calibri;line-height:107.92%;font-size: 11pt">
			<font style="display: inline;color:#000000;">(a)&nbsp;&nbsp;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font>
		</p>
		<p style="margin:0pt 0pt 8pt;font-family:Calibri;line-height:107.92%;font-size: 11pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 8pt 36pt;text-indent: -18pt;font-family:Calibri;line-height:107.92%;font-size: 11pt">
			<font style="display: inline;color:#000000;">(b)&nbsp;&nbsp;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font>
		</p>
		<p style="margin:0pt 0pt 8pt;font-family:Calibri;line-height:107.92%;font-size: 11pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 8pt 36pt;text-indent: -18pt;font-family:Calibri;line-height:107.92%;font-size: 11pt">
			<font style="display: inline;color:#000000;">(c)&nbsp;&nbsp;Evaluated the effectiveness of the registrant&#x2019;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font>
		</p>
		<p style="margin:0pt 0pt 8pt 36pt;font-family:Calibri;line-height:107.92%;font-size: 11pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 8pt 36pt;text-indent: -18pt;font-family:Calibri;line-height:107.92%;font-size: 11pt">

		</p>
		<p><font size="1"> </font></p><hr size="3" style="color:#999999" width="100%" align="center"></hr><p style="page-break-after:always">&nbsp;</p>
		<p style="margin:0pt 0pt 8pt 36pt;text-indent: -18pt;font-family:Calibri;line-height:107.92%;;font-size: 11pt"><font style="display: inline;">(d)&nbsp;&nbsp;Disclosed in this report any change in the registrant&#x2019;s internal control over financial reporting that occurred during the registrant&#x2019;s most recent fiscal quarter (the registrant&#x2019;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#x2019;s internal control over financial reporting; and</font>
		</p>
		<p style="margin:0pt 0pt 8pt;font-family:Calibri;line-height:107.92%;font-size: 11pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;font-size: 11pt;margin:0pt;">
				<font style="margin:0pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-size:10pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;;"> 5.</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;font-size: 11pt;margin:0pt;">
			<font style="display: inline;color:#000000;">The registrant&#x2019;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#x2019;s auditors and the audit committee of the registrant&#x2019;s board of directors (or persons performing the equivalent functions):</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 8pt;font-family:Calibri;line-height:107.92%;font-size: 11pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 8pt 36pt;text-indent: -18pt;font-family:Calibri;line-height:107.92%;font-size: 11pt">
			<font style="display: inline;color:#000000;">(a)&nbsp;&nbsp;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#x2019;s ability to record, process, summarize and report financial information; and</font>
		</p>
		<p style="margin:0pt 0pt 8pt;font-family:Calibri;line-height:107.92%;font-size: 11pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 8pt 36pt;text-indent: -18pt;font-family:Calibri;line-height:107.92%;font-size: 11pt">
			<font style="display: inline;color:#000000;">(b)&nbsp;&nbsp;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#x2019;s internal control over financial reporting.</font>
		</p>
		<p style="margin:0pt 0pt 8pt 36pt;text-indent: -18pt;font-family:Calibri;line-height:107.92%;font-size: 11pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:216.00pt;height:3.15pt;padding:0pt 5.4pt;">
					<p style="margin:0pt;line-height:115%;font-family:Calibri;height:3.15pt;font-size: 1pt">
						<font style="display: inline;font-size:1pt;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:261.00pt;height:3.15pt;padding:0pt 5.4pt;">
					<p style="margin:0pt;line-height:115%;font-family:Calibri;height:3.15pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:216.00pt;padding:0pt 5.4pt;">
					<p style="margin:0pt;line-height:115%;font-family:Calibri;font-size: 11pt">
						<font style="display: inline;color:#000000;">Date:&nbsp; </font><font style="display: inline;color:#000000;">August </font><font style="display: inline;color:#000000;">11</font><font style="display: inline;color:#000000;">, 2017</font></p>
				</td>
				<td valign="bottom" style="width:261.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt 5.4pt;">
					<p style="margin:0pt;line-height:115%;font-family:Calibri;font-size: 11pt">
						<font style="display: inline;color:#000000;">/s/ Eric J. Schoen</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:216.00pt;padding:0pt 5.4pt;">
					<p style="margin:0pt;line-height:115%;font-family:Calibri;font-size: 11pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:261.00pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 5.4pt;">
					<p style="margin:0pt;line-height:115%;font-family:Calibri;font-size: 11pt">
						<font style="display: inline;color:#000000;">Eric J. Schoen</font></p>
					<p style="margin:0pt;line-height:115%;font-family:Calibri;font-size: 11pt">
						<font style="display: inline;color:#000000;">Senior </font><font style="display: inline;color:#000000;">Vice President, Finance and Chief Accounting Officer</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt 0pt 8pt;font-family:Calibri;line-height:107.92%;font-size: 11pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 8pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;font-size:10pt;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 8pt;font-family:Calibri;line-height:107.92%;font-size: 11pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p><font size="1"> </font></p><hr size="3" style="color:#999999" width="100%" align="center"></hr>
	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>c617-20170630xex32_1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!--HTML document created with Certent Disclosure Management 6.8.4.2-->
<!--Created on: 8/11/2017 2:59:31 PM-->
<html>
	<head>
		<title>
			Exhibit 32.1
		</title>
	</head>
	<body><div style="margin-left:72pt;margin-right:72pt;">
		<p style="margin:0pt 0pt 8pt;text-align:right;font-family:Calibri;line-height:107.92%;font-size: 11pt">
			<a name="_GoBack"></a><font style="display: inline;font-weight:bold;">Exhibit 32.1</font>
		</p>
		<p style="margin:0pt 0pt 8pt;font-family:Calibri;line-height:107.92%;font-size: 11pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 8pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 11pt">
			<font style="display: inline;font-weight:bold;">Certification of the Chief Executive Officer and </font><font style="display: inline;font-weight:bold;">Senior </font><font style="display: inline;font-weight:bold;">Vice President, Finance and Chief Accounting Officer</font><font style="display: inline;">&nbsp;</font><font style="display: inline;font-weight:bold;">Pursuant to 18 U.S.C. Section 1350,</font>
		</p>
		<p style="margin:0pt 0pt 8pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 11pt">
			<font style="display: inline;font-weight:bold;">as Adopted </font><font style="display: inline;font-weight:bold;">Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</font>
		</p>
		<p style="margin:0pt 0pt 8pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 11pt">
			<font style="display: inline;font-weight:bold;">with Respect to the Quarterly Report on Form 10-Q</font>
		</p>
		<p style="margin:0pt 0pt 8pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 11pt">
			<font style="display: inline;font-weight:bold;">for the Period Ended </font><font style="display: inline;font-weight:bold;">June 30</font><font style="display: inline;font-weight:bold;">, 2017</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 8pt;font-family:Calibri;line-height:107.92%;font-size: 11pt">
			<font style="display: inline;">Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, Chapter 63 of Title 18, United States Code), each of the undersigned officers of Vermillion, Inc., a </font><font style="display: inline;">Delaware</font><font style="display: inline;"> corporation (the &#x201C;Company&#x201D;), does hereby certify, to the best of such officer&#x2019;s knowledge, that:</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;font-size: 11pt;margin:0pt;">
				<font style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;font-size:11pt;;"> 1.</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;font-size: 11pt;margin:0pt;">
			<font style="display: inline;color:#000000;">The Company&#x2019;s quarterly report on Form 10-Q for the period ended </font><font style="display: inline;color:#000000;">June 30</font><font style="display: inline;color:#000000;">, 2017</font><font style="display: inline;color:#000000;">, (the &#x201C;Form 10-Q&#x201D;) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 8pt;font-family:Calibri;line-height:107.92%;font-size: 11pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;font-size: 11pt;margin:0pt;">
				<font style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;font-size:11pt;;"> 2.</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;font-size: 11pt;margin:0pt;">
			<font style="display: inline;color:#000000;">Information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 8pt;font-family:Calibri;line-height:107.92%;font-size: 11pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;margin-left:0.9pt;">
			<tr>
				<td valign="bottom" style="width:216.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:3.00pt;padding:0pt 5.4pt;">
					<p style="margin:0pt;line-height:115%;font-family:Calibri;height:3.00pt;font-size: 1pt">
						<font style="display: inline;font-size:1pt;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="top" style="width:261.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:3.00pt;padding:0pt 5.4pt;">
					<p style="margin:0pt;line-height:115%;font-family:Calibri;height:3.00pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:216.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 5.4pt;">
					<p style="margin:0pt;line-height:115%;font-family:Calibri;font-size: 11pt">
						<font style="display: inline;color:#000000;">Date:&nbsp; </font><font style="display: inline;color:#000000;">August </font><font style="display: inline;color:#000000;">11</font><font style="display: inline;color:#000000;">, 2017</font></p>
				</td>
				<td valign="top" style="width:261.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt 5.4pt;">
					<p style="margin:0pt;line-height:115%;font-family:Calibri;font-size: 11pt">
						<font style="display: inline;color:#000000;">/s/ Valerie B. Palmieri</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:216.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 5.4pt;">
					<p style="margin:0pt;line-height:115%;font-family:Calibri;font-size: 11pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="top" style="width:261.00pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 5.4pt;">
					<p style="margin:0pt;line-height:115%;font-family:Calibri;font-size: 11pt">
						<font style="display: inline;color:#000000;">Valerie B. Palmieri</font></p>
					<p style="margin:0pt;line-height:115%;font-family:Calibri;font-size: 11pt">
						<font style="display: inline;color:#000000;">President and Chief Executive Officer</font></p>
					<p style="margin:0pt;line-height:115%;font-family:Calibri;font-size: 11pt">
						<font style="display: inline;color:#000000;">(Principal Executive Officer)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:216.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 5.4pt;">
					<p style="margin:0pt;line-height:115%;font-family:Calibri;font-size: 11pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="top" style="width:261.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 5.4pt;">
					<p style="margin:0pt;line-height:115%;font-family:Calibri;font-size: 11pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:216.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 5.4pt;">
					<p style="margin:0pt;line-height:115%;font-family:Calibri;font-size: 11pt">
						<font style="display: inline;color:#000000;">Date:&nbsp; </font><font style="display: inline;color:#000000;">August </font><font style="display: inline;color:#000000;">11</font><font style="display: inline;color:#000000;">, 2017</font></p>
				</td>
				<td valign="top" style="width:261.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt 5.4pt;">
					<p style="margin:0pt;line-height:115%;font-family:Calibri;font-size: 11pt">
						<font style="display: inline;color:#000000;">/s/ Eric J. Schoen</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:216.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 5.4pt;">
					<p style="margin:0pt;line-height:115%;font-family:Calibri;font-size: 11pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="top" style="width:261.00pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 5.4pt;">
					<p style="margin:0pt;line-height:115%;font-family:Calibri;font-size: 11pt">
						<font style="display: inline;color:#000000;">Eric J. Schoen</font></p>
					<p style="margin:0pt;line-height:115%;font-family:Calibri;font-size: 11pt">
						<font style="display: inline;color:#000000;">Senior </font><font style="display: inline;color:#000000;">Vice President, Finance and Chief Accounting Officer</font></p>
					<p style="margin:0pt;line-height:115%;font-family:Calibri;font-size: 11pt">
						<font style="display: inline;color:#000000;">(Principal Financial Officer)</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt 0pt 8pt;font-family:Calibri;line-height:107.92%;font-size: 11pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 8pt;font-family:Calibri;line-height:107.92%;font-size: 11pt">
			<font style="display: inline;color:#000000;">The certification set forth above is being furnished as an Exhibit solely pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and is not being filed as part of the Form 10-Q or as a separate disclosure document of the Company or the certifying officers.</font>
		</p>
		<p><font size="1"> </font></p><hr size="3" style="color:#999999" width="100%" align="center"></hr>
	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>c617-20170630x10qg001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 c617-20170630x10qg001.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_X0!*17AI9@  34T *@    @  P$:  4
M   !    ,@$;  4    !    .@$H  ,    !  (         E@    $   "6
M     0  _^T +%!H;W1O<VAO<" S+C  .$))30/M       0 )8    !  $
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M!0$! 0$! 0           0(#! 4&!P@)"@O_Q "U$  " 0,# @0#!04$!
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M ***,T %%&:,T %%%&: "BC-% !111F@ HHHS0 4444 %%%% !1110 4444
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MZ,C@$DJ6*Y;;N/E[?\%!KCPG_P %6=4^$&M7T*^%K[3;.RT\,D:_8]5:+[0
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M^CJ#S6=\6_V,_A7\=7FF\5> O#.K7=Q\LEXUDD=V?^VZ8D'X-7@WC#_@AO\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
*HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>6
<FILENAME>c617-20170630.xml
<DESCRIPTION>EX-101.INS
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created by Certent Disclosure Management 6.8.4.2 -->
<!--Based on XBRL 2.1-->
<!--Created on: 8/11/2017 2:59:11 PM-->
<xbrl xmlns="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:us-gaap="http://fasb.org/us-gaap/2017-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:vrml="http://www.vermillion.com/20170630" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:schemaRef xlink:type="simple" xlink:href="c617-20170630.xsd" />
  <!--Context Section-->
  <context id="Duration_1_1_2017_To_6_30_2017_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_AssetsHeldUnderCapitalLeasesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000926617</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:AssetsHeldUnderCapitalLeasesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-06-30</endDate>
    </period>
  </context>
  <context id="Duration_4_1_2017_To_6_30_2017_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_vrml_StockOptionPlanTwentyTenMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_vrml_ExercisePriceEMember_us-gaap_TitleOfIndividualAxis_vrml_CertainOfficersAndEmployeesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000926617</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vrml:StockOptionPlanTwentyTenMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">vrml:ExercisePriceEMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">vrml:CertainOfficersAndEmployeesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-04-01</startDate>
      <endDate>2017-06-30</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2017_To_6_30_2017_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_PlanNameAxis_vrml_StockOptionPlanTwentyTenMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_vrml_ExercisePriceDMember_us-gaap_TitleOfIndividualAxis_vrml_CertainOfficersAndEmployeesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000926617</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vrml:StockOptionPlanTwentyTenMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">vrml:ExercisePriceDMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">vrml:CertainOfficersAndEmployeesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-06-30</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2017_To_6_30_2017_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_vrml_StockOptionPlanTwentyTenMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_vrml_ExercisePriceCMember_us-gaap_TitleOfIndividualAxis_vrml_CertainOfficersAndEmployeesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000926617</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vrml:StockOptionPlanTwentyTenMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">vrml:ExercisePriceCMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">vrml:CertainOfficersAndEmployeesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-06-30</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2017_To_6_30_2017_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_vrml_StockOptionPlanTwentyTenMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_vrml_ExercisePriceBMember_us-gaap_TitleOfIndividualAxis_vrml_CertainConsultantsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000926617</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vrml:StockOptionPlanTwentyTenMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">vrml:ExercisePriceBMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">vrml:CertainConsultantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-06-30</endDate>
    </period>
  </context>
  <context id="As_Of_6_30_2017_us-gaap_PlanNameAxis_vrml_StockOptionPlanTwentyTenMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000926617</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vrml:StockOptionPlanTwentyTenMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-06-30</instant>
    </period>
  </context>
  <context id="Duration_4_1_2017_To_6_30_2017_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_vrml_StockOptionPlanTwentyTenMember_us-gaap_TitleOfIndividualAxis_vrml_NonEmployeeDirectorsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000926617</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vrml:StockOptionPlanTwentyTenMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">vrml:NonEmployeeDirectorsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-04-01</startDate>
      <endDate>2017-06-30</endDate>
    </period>
  </context>
  <context id="Duration_4_1_2017_To_6_30_2017_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_vrml_StockOptionPlanTwentyTenMember_us-gaap_TitleOfIndividualAxis_vrml_CertainConsultantsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000926617</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vrml:StockOptionPlanTwentyTenMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">vrml:CertainConsultantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-04-01</startDate>
      <endDate>2017-06-30</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2017_To_6_30_2017_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_vrml_StockOptionPlanTwentyTenMember_us-gaap_TitleOfIndividualAxis_vrml_NonEmployeeDirectorsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000926617</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vrml:StockOptionPlanTwentyTenMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">vrml:NonEmployeeDirectorsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-06-30</endDate>
    </period>
  </context>
  <context id="As_Of_6_30_2017_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_PlanNameAxis_vrml_StockOptionPlanTwentyTenMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_vrml_ExercisePriceDMember_us-gaap_TitleOfIndividualAxis_vrml_CertainOfficersAndEmployeesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000926617</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vrml:StockOptionPlanTwentyTenMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">vrml:ExercisePriceDMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">vrml:CertainOfficersAndEmployeesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-06-30</instant>
    </period>
  </context>
  <context id="As_Of_6_30_2017_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_vrml_StockOptionPlanTwentyTenMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_vrml_ExercisePriceEMember_us-gaap_TitleOfIndividualAxis_vrml_CertainOfficersAndEmployeesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000926617</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vrml:StockOptionPlanTwentyTenMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">vrml:ExercisePriceEMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">vrml:CertainOfficersAndEmployeesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-06-30</instant>
    </period>
  </context>
  <context id="As_Of_6_30_2017_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_vrml_StockOptionPlanTwentyTenMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_vrml_ExercisePriceCMember_us-gaap_TitleOfIndividualAxis_vrml_CertainOfficersAndEmployeesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000926617</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vrml:StockOptionPlanTwentyTenMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">vrml:ExercisePriceCMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">vrml:CertainOfficersAndEmployeesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-06-30</instant>
    </period>
  </context>
  <context id="As_Of_6_30_2017_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_vrml_StockOptionPlanTwentyTenMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_vrml_ExercisePriceBMember_us-gaap_TitleOfIndividualAxis_vrml_CertainConsultantsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000926617</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vrml:StockOptionPlanTwentyTenMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">vrml:ExercisePriceBMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">vrml:CertainConsultantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-06-30</instant>
    </period>
  </context>
  <context id="Duration_1_1_2017_To_6_30_2017_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_vrml_StockOptionPlanTwentyTenMember_us-gaap_TitleOfIndividualAxis_vrml_CertainConsultantsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000926617</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vrml:StockOptionPlanTwentyTenMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">vrml:CertainConsultantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-06-30</endDate>
    </period>
  </context>
  <context id="Duration_4_1_2017_To_6_30_2017_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_vrml_StockOptionPlanTwentyTenMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_vrml_ExercisePriceEMember_us-gaap_TitleOfIndividualAxis_vrml_CertainOfficersAndEmployeesMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000926617</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vrml:StockOptionPlanTwentyTenMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">vrml:ExercisePriceEMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">vrml:CertainOfficersAndEmployeesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-04-01</startDate>
      <endDate>2017-06-30</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2017_To_6_30_2017_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_vrml_StockOptionPlanTwentyTenMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_vrml_ExercisePriceDMember_us-gaap_TitleOfIndividualAxis_vrml_CertainOfficersAndEmployeesMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000926617</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vrml:StockOptionPlanTwentyTenMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">vrml:ExercisePriceDMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">vrml:CertainOfficersAndEmployeesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-06-30</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2017_To_6_30_2017_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_vrml_StockOptionPlanTwentyTenMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_vrml_ExercisePriceCMember_us-gaap_TitleOfIndividualAxis_vrml_CertainOfficersAndEmployeesMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000926617</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vrml:StockOptionPlanTwentyTenMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">vrml:ExercisePriceCMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">vrml:CertainOfficersAndEmployeesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-06-30</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2017_To_6_30_2017_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_vrml_StockOptionPlanTwentyTenMember_us-gaap_TitleOfIndividualAxis_vrml_NonEmployeeDirectorsMember_us-gaap_VestingAxis_vrml_VestingPercentageDateMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000926617</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vrml:StockOptionPlanTwentyTenMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">vrml:NonEmployeeDirectorsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:VestingAxis">vrml:VestingPercentageDateMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-06-30</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2017_To_6_30_2017_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_vrml_StockOptionPlanTwentyTenMember_us-gaap_TitleOfIndividualAxis_vrml_NonEmployeeDirectorsMember_us-gaap_VestingAxis_vrml_VestingPercentageDateCMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000926617</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vrml:StockOptionPlanTwentyTenMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">vrml:NonEmployeeDirectorsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:VestingAxis">vrml:VestingPercentageDateCMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-06-30</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2017_To_6_30_2017_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_vrml_StockOptionPlanTwentyTenMember_us-gaap_TitleOfIndividualAxis_vrml_NonEmployeeDirectorsMember_us-gaap_VestingAxis_vrml_VestingPercentageDateBMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000926617</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vrml:StockOptionPlanTwentyTenMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">vrml:NonEmployeeDirectorsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:VestingAxis">vrml:VestingPercentageDateBMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-06-30</endDate>
    </period>
  </context>
  <context id="Duration_4_15_2016_To_4_15_2016_us-gaap_DebtInstrumentAxis_vrml_DecdMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000926617</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrml:DecdMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-04-15</startDate>
      <endDate>2016-04-15</endDate>
    </period>
  </context>
  <context id="Duration_4_1_2015_To_4_30_2015_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_AssetsHeldUnderCapitalLeasesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000926617</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:AssetsHeldUnderCapitalLeasesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-04-01</startDate>
      <endDate>2015-04-30</endDate>
    </period>
  </context>
  <context id="Duration_10_1_2015_To_10_31_2015_us-gaap_LeaseArrangementTypeAxis_vrml_TrumbullConnecticutFacilityMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000926617</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">vrml:TrumbullConnecticutFacilityMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-10-01</startDate>
      <endDate>2015-10-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2017_To_6_30_2017_us-gaap_LeaseArrangementTypeAxis_vrml_TrumbullConnecticutFacilityMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000926617</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">vrml:TrumbullConnecticutFacilityMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-06-30</endDate>
    </period>
  </context>
  <context id="As_Of_10_31_2015_us-gaap_LeaseArrangementTypeAxis_vrml_TrumbullConnecticutFacilityMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000926617</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">vrml:TrumbullConnecticutFacilityMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-10-31</instant>
    </period>
  </context>
  <context id="Duration_1_1_2017_To_6_30_2017_us-gaap_LeaseArrangementTypeAxis_vrml_AustinTexasFacilityMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000926617</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">vrml:AustinTexasFacilityMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-06-30</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2017_To_6_30_2017_us-gaap_DebtInstrumentAxis_vrml_DecdMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000926617</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrml:DecdMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-06-30</endDate>
    </period>
  </context>
  <context id="As_Of_3_22_2016_us-gaap_DebtInstrumentAxis_vrml_DecdMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000926617</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">vrml:DecdMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-03-22</instant>
    </period>
  </context>
  <context id="Duration_4_1_2017_To_6_30_2017">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000926617</identifier>
    </entity>
    <period>
      <startDate>2017-04-01</startDate>
      <endDate>2017-06-30</endDate>
    </period>
  </context>
  <context id="Duration_4_1_2016_To_6_30_2016">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000926617</identifier>
    </entity>
    <period>
      <startDate>2016-04-01</startDate>
      <endDate>2016-06-30</endDate>
    </period>
  </context>
  <context id="As_Of_2_17_2017">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000926617</identifier>
    </entity>
    <period>
      <instant>2017-02-17</instant>
    </period>
  </context>
  <context id="As_Of_6_30_2016">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000926617</identifier>
    </entity>
    <period>
      <instant>2016-06-30</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2015">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000926617</identifier>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="As_Of_4_30_2015_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_AssetsHeldUnderCapitalLeasesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000926617</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:AssetsHeldUnderCapitalLeasesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-04-30</instant>
    </period>
  </context>
  <context id="Duration_1_1_2016_To_6_30_2016">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000926617</identifier>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-06-30</endDate>
    </period>
  </context>
  <context id="Duration_4_1_2017_To_6_30_2017_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingAndMarketingExpenseMember_us-gaap_PlanNameAxis_vrml_EmployeeStockBasedCompensationMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000926617</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vrml:EmployeeStockBasedCompensationMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-04-01</startDate>
      <endDate>2017-06-30</endDate>
    </period>
  </context>
  <context id="Duration_4_1_2017_To_6_30_2017_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_PlanNameAxis_vrml_EmployeeStockBasedCompensationMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000926617</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vrml:EmployeeStockBasedCompensationMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-04-01</startDate>
      <endDate>2017-06-30</endDate>
    </period>
  </context>
  <context id="Duration_4_1_2017_To_6_30_2017_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_PlanNameAxis_vrml_EmployeeStockBasedCompensationMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000926617</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vrml:EmployeeStockBasedCompensationMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-04-01</startDate>
      <endDate>2017-06-30</endDate>
    </period>
  </context>
  <context id="Duration_4_1_2017_To_6_30_2017_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_us-gaap_PlanNameAxis_vrml_EmployeeStockBasedCompensationMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000926617</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vrml:EmployeeStockBasedCompensationMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-04-01</startDate>
      <endDate>2017-06-30</endDate>
    </period>
  </context>
  <context id="Duration_4_1_2017_To_6_30_2017_us-gaap_PlanNameAxis_vrml_EmployeeStockBasedCompensationMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000926617</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vrml:EmployeeStockBasedCompensationMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-04-01</startDate>
      <endDate>2017-06-30</endDate>
    </period>
  </context>
  <context id="Duration_4_1_2017_To_6_30_2017_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingAndMarketingExpenseMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000926617</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-04-01</startDate>
      <endDate>2017-06-30</endDate>
    </period>
  </context>
  <context id="Duration_4_1_2017_To_6_30_2017_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000926617</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-04-01</startDate>
      <endDate>2017-06-30</endDate>
    </period>
  </context>
  <context id="Duration_4_1_2017_To_6_30_2017_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000926617</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-04-01</startDate>
      <endDate>2017-06-30</endDate>
    </period>
  </context>
  <context id="Duration_4_1_2017_To_6_30_2017_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000926617</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-04-01</startDate>
      <endDate>2017-06-30</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2017_To_6_30_2017_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingAndMarketingExpenseMember_us-gaap_PlanNameAxis_vrml_EmployeeStockBasedCompensationMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000926617</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vrml:EmployeeStockBasedCompensationMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-06-30</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2017_To_6_30_2017_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_PlanNameAxis_vrml_EmployeeStockBasedCompensationMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000926617</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vrml:EmployeeStockBasedCompensationMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-06-30</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2017_To_6_30_2017_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_PlanNameAxis_vrml_EmployeeStockBasedCompensationMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000926617</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vrml:EmployeeStockBasedCompensationMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-06-30</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2017_To_6_30_2017_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_us-gaap_PlanNameAxis_vrml_EmployeeStockBasedCompensationMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000926617</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vrml:EmployeeStockBasedCompensationMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-06-30</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2017_To_6_30_2017_us-gaap_PlanNameAxis_vrml_EmployeeStockBasedCompensationMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000926617</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vrml:EmployeeStockBasedCompensationMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-06-30</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2017_To_6_30_2017_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingAndMarketingExpenseMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000926617</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-06-30</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2017_To_6_30_2017_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000926617</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-06-30</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2017_To_6_30_2017_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000926617</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-06-30</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2017_To_6_30_2017_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000926617</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-06-30</endDate>
    </period>
  </context>
  <context id="Duration_4_1_2016_To_6_30_2016_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingAndMarketingExpenseMember_us-gaap_PlanNameAxis_vrml_EmployeeStockBasedCompensationMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000926617</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vrml:EmployeeStockBasedCompensationMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-04-01</startDate>
      <endDate>2016-06-30</endDate>
    </period>
  </context>
  <context id="Duration_4_1_2016_To_6_30_2016_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_PlanNameAxis_vrml_EmployeeStockBasedCompensationMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000926617</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vrml:EmployeeStockBasedCompensationMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-04-01</startDate>
      <endDate>2016-06-30</endDate>
    </period>
  </context>
  <context id="Duration_4_1_2016_To_6_30_2016_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_PlanNameAxis_vrml_EmployeeStockBasedCompensationMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000926617</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vrml:EmployeeStockBasedCompensationMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-04-01</startDate>
      <endDate>2016-06-30</endDate>
    </period>
  </context>
  <context id="Duration_4_1_2016_To_6_30_2016_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_us-gaap_PlanNameAxis_vrml_EmployeeStockBasedCompensationMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000926617</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vrml:EmployeeStockBasedCompensationMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-04-01</startDate>
      <endDate>2016-06-30</endDate>
    </period>
  </context>
  <context id="Duration_4_1_2016_To_6_30_2016_us-gaap_PlanNameAxis_vrml_EmployeeStockBasedCompensationMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000926617</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vrml:EmployeeStockBasedCompensationMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-04-01</startDate>
      <endDate>2016-06-30</endDate>
    </period>
  </context>
  <context id="Duration_4_1_2016_To_6_30_2016_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingAndMarketingExpenseMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000926617</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-04-01</startDate>
      <endDate>2016-06-30</endDate>
    </period>
  </context>
  <context id="Duration_4_1_2016_To_6_30_2016_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000926617</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-04-01</startDate>
      <endDate>2016-06-30</endDate>
    </period>
  </context>
  <context id="Duration_4_1_2016_To_6_30_2016_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000926617</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-04-01</startDate>
      <endDate>2016-06-30</endDate>
    </period>
  </context>
  <context id="Duration_4_1_2016_To_6_30_2016_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000926617</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-04-01</startDate>
      <endDate>2016-06-30</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2016_To_6_30_2016_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingAndMarketingExpenseMember_us-gaap_PlanNameAxis_vrml_EmployeeStockBasedCompensationMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000926617</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vrml:EmployeeStockBasedCompensationMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-06-30</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2016_To_6_30_2016_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_PlanNameAxis_vrml_EmployeeStockBasedCompensationMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000926617</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vrml:EmployeeStockBasedCompensationMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-06-30</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2016_To_6_30_2016_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_PlanNameAxis_vrml_EmployeeStockBasedCompensationMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000926617</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vrml:EmployeeStockBasedCompensationMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-06-30</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2016_To_6_30_2016_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_us-gaap_PlanNameAxis_vrml_EmployeeStockBasedCompensationMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000926617</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vrml:EmployeeStockBasedCompensationMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-06-30</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2016_To_6_30_2016_us-gaap_PlanNameAxis_vrml_EmployeeStockBasedCompensationMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000926617</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vrml:EmployeeStockBasedCompensationMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-06-30</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2016_To_6_30_2016_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingAndMarketingExpenseMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000926617</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-06-30</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2016_To_6_30_2016_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000926617</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-06-30</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2016_To_6_30_2016_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000926617</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-06-30</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2016_To_6_30_2016_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000926617</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-06-30</endDate>
    </period>
  </context>
  <context id="As_Of_6_30_2017_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_AssetsHeldUnderCapitalLeasesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000926617</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:AssetsHeldUnderCapitalLeasesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-06-30</instant>
    </period>
  </context>
  <context id="As_Of_6_30_2016_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_AssetsHeldUnderCapitalLeasesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000926617</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:AssetsHeldUnderCapitalLeasesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-06-30</instant>
    </period>
  </context>
  <context id="As_Of_6_30_2017">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000926617</identifier>
    </entity>
    <period>
      <instant>2017-06-30</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2016">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000926617</identifier>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="As_Of_7_31_2017">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000926617</identifier>
    </entity>
    <period>
      <instant>2017-07-31</instant>
    </period>
  </context>
  <context id="Duration_1_1_2017_To_6_30_2017">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000926617</identifier>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-06-30</endDate>
    </period>
  </context>
  <!--Unit Section-->
  <unit id="Unit16">
    <measure>vrml:item</measure>
  </unit>
  <unit id="Unit15">
    <measure>vrml:employee</measure>
  </unit>
  <unit id="Unit14">
    <measure>xbrli:pure</measure>
  </unit>
  <unit id="Unit13">
    <divide>
      <unitNumerator>
        <measure>iso4217:USD</measure>
      </unitNumerator>
      <unitDenominator>
        <measure>xbrli:shares</measure>
      </unitDenominator>
    </divide>
  </unit>
  <unit id="Unit12">
    <measure>iso4217:USD</measure>
  </unit>
  <unit id="Unit1">
    <measure>xbrli:shares</measure>
  </unit>
  <!--Tuple Section-->
  <!--Element Section-->
  <dei:AmendmentFlag contextRef="Duration_1_1_2017_To_6_30_2017">false</dei:AmendmentFlag>
  <dei:CurrentFiscalYearEndDate contextRef="Duration_1_1_2017_To_6_30_2017">--12-31</dei:CurrentFiscalYearEndDate>
  <dei:DocumentFiscalPeriodFocus contextRef="Duration_1_1_2017_To_6_30_2017">Q2</dei:DocumentFiscalPeriodFocus>
  <dei:DocumentFiscalYearFocus contextRef="Duration_1_1_2017_To_6_30_2017">2017</dei:DocumentFiscalYearFocus>
  <dei:DocumentPeriodEndDate contextRef="Duration_1_1_2017_To_6_30_2017">2017-06-30</dei:DocumentPeriodEndDate>
  <dei:DocumentType contextRef="Duration_1_1_2017_To_6_30_2017">10-Q</dei:DocumentType>
  <dei:EntityCentralIndexKey contextRef="Duration_1_1_2017_To_6_30_2017">0000926617</dei:EntityCentralIndexKey>
  <dei:EntityCommonStockSharesOutstanding contextRef="As_Of_7_31_2017" unitRef="Unit1" decimals="INF">56164082</dei:EntityCommonStockSharesOutstanding>
  <dei:EntityFilerCategory contextRef="Duration_1_1_2017_To_6_30_2017">Smaller Reporting Company</dei:EntityFilerCategory>
  <dei:EntityRegistrantName contextRef="Duration_1_1_2017_To_6_30_2017">VERMILLION, INC.</dei:EntityRegistrantName>
  <us-gaap:AccountsPayableCurrent contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="-3">881000</us-gaap:AccountsPayableCurrent>
  <us-gaap:AccountsPayableCurrent contextRef="As_Of_6_30_2017" unitRef="Unit12" decimals="-3">300000</us-gaap:AccountsPayableCurrent>
  <us-gaap:AccountsReceivableNetCurrent contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="-3">275000</us-gaap:AccountsReceivableNetCurrent>
  <us-gaap:AccountsReceivableNetCurrent contextRef="As_Of_6_30_2017" unitRef="Unit12" decimals="-3">214000</us-gaap:AccountsReceivableNetCurrent>
  <us-gaap:AccruedLiabilitiesCurrent contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="-3">1464000</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:AccruedLiabilitiesCurrent contextRef="As_Of_6_30_2017" unitRef="Unit12" decimals="-3">1541000</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="As_Of_6_30_2016_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_AssetsHeldUnderCapitalLeasesMember" unitRef="Unit12" decimals="0">77000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="As_Of_6_30_2017_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_AssetsHeldUnderCapitalLeasesMember" unitRef="Unit12" decimals="0">155000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
  <us-gaap:AdditionalPaidInCapital contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="-3">389266000</us-gaap:AdditionalPaidInCapital>
  <us-gaap:AdditionalPaidInCapital contextRef="As_Of_6_30_2017" unitRef="Unit12" decimals="-3">395060000</us-gaap:AdditionalPaidInCapital>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="Duration_1_1_2016_To_6_30_2016_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember" unitRef="Unit12" decimals="-3">46000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="Duration_1_1_2016_To_6_30_2016_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember" unitRef="Unit12" decimals="-3">445000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="Duration_1_1_2016_To_6_30_2016_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="Unit12" decimals="-3">53000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="Duration_1_1_2016_To_6_30_2016_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingAndMarketingExpenseMember" unitRef="Unit12" decimals="-3">56000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="Duration_1_1_2016_To_6_30_2016_us-gaap_PlanNameAxis_vrml_EmployeeStockBasedCompensationMember" unitRef="Unit12" decimals="-3">580000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="Duration_1_1_2016_To_6_30_2016_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_us-gaap_PlanNameAxis_vrml_EmployeeStockBasedCompensationMember" unitRef="Unit12" decimals="-3">46000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="Duration_1_1_2016_To_6_30_2016_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_PlanNameAxis_vrml_EmployeeStockBasedCompensationMember" unitRef="Unit12" decimals="-3">425000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="Duration_1_1_2016_To_6_30_2016_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_PlanNameAxis_vrml_EmployeeStockBasedCompensationMember" unitRef="Unit12" decimals="-3">53000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="Duration_1_1_2016_To_6_30_2016_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingAndMarketingExpenseMember_us-gaap_PlanNameAxis_vrml_EmployeeStockBasedCompensationMember" unitRef="Unit12" decimals="-3">56000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="Duration_4_1_2016_To_6_30_2016_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember" unitRef="Unit12" decimals="-3">22000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="Duration_4_1_2016_To_6_30_2016_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember" unitRef="Unit12" decimals="-3">319000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="Duration_4_1_2016_To_6_30_2016_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="Unit12" decimals="-3">22000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="Duration_4_1_2016_To_6_30_2016_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingAndMarketingExpenseMember" unitRef="Unit12" decimals="-3">14000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="Duration_4_1_2016_To_6_30_2016_us-gaap_PlanNameAxis_vrml_EmployeeStockBasedCompensationMember" unitRef="Unit12" decimals="-3">378000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="Duration_4_1_2016_To_6_30_2016_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_us-gaap_PlanNameAxis_vrml_EmployeeStockBasedCompensationMember" unitRef="Unit12" decimals="-3">22000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="Duration_4_1_2016_To_6_30_2016_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_PlanNameAxis_vrml_EmployeeStockBasedCompensationMember" unitRef="Unit12" decimals="-3">320000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="Duration_4_1_2016_To_6_30_2016_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_PlanNameAxis_vrml_EmployeeStockBasedCompensationMember" unitRef="Unit12" decimals="-3">22000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="Duration_4_1_2016_To_6_30_2016_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingAndMarketingExpenseMember_us-gaap_PlanNameAxis_vrml_EmployeeStockBasedCompensationMember" unitRef="Unit12" decimals="-3">14000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="Duration_1_1_2017_To_6_30_2017_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember" unitRef="Unit12" decimals="-3">79000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="Duration_1_1_2017_To_6_30_2017_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember" unitRef="Unit12" decimals="-3">510000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="Duration_1_1_2017_To_6_30_2017_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="Unit12" decimals="-3">5000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="Duration_1_1_2017_To_6_30_2017_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingAndMarketingExpenseMember" unitRef="Unit12" decimals="-3">77000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="Duration_1_1_2017_To_6_30_2017_us-gaap_PlanNameAxis_vrml_EmployeeStockBasedCompensationMember" unitRef="Unit12" decimals="-3">529000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="Duration_1_1_2017_To_6_30_2017_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_us-gaap_PlanNameAxis_vrml_EmployeeStockBasedCompensationMember" unitRef="Unit12" decimals="-3">40000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="Duration_1_1_2017_To_6_30_2017_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_PlanNameAxis_vrml_EmployeeStockBasedCompensationMember" unitRef="Unit12" decimals="-3">414000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="Duration_1_1_2017_To_6_30_2017_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_PlanNameAxis_vrml_EmployeeStockBasedCompensationMember" unitRef="Unit12" decimals="-3">5000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="Duration_1_1_2017_To_6_30_2017_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingAndMarketingExpenseMember_us-gaap_PlanNameAxis_vrml_EmployeeStockBasedCompensationMember" unitRef="Unit12" decimals="-3">70000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="Duration_4_1_2017_To_6_30_2017_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember" unitRef="Unit12" decimals="-3">40000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="Duration_4_1_2017_To_6_30_2017_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember" unitRef="Unit12" decimals="-3">295000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="Duration_4_1_2017_To_6_30_2017_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="Unit12" decimals="-3">2000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="Duration_4_1_2017_To_6_30_2017_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingAndMarketingExpenseMember" unitRef="Unit12" decimals="-3">40000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="Duration_4_1_2017_To_6_30_2017_us-gaap_PlanNameAxis_vrml_EmployeeStockBasedCompensationMember" unitRef="Unit12" decimals="-3">343000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="Duration_4_1_2017_To_6_30_2017_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_us-gaap_PlanNameAxis_vrml_EmployeeStockBasedCompensationMember" unitRef="Unit12" decimals="-3">20000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="Duration_4_1_2017_To_6_30_2017_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_PlanNameAxis_vrml_EmployeeStockBasedCompensationMember" unitRef="Unit12" decimals="-3">283000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="Duration_4_1_2017_To_6_30_2017_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_PlanNameAxis_vrml_EmployeeStockBasedCompensationMember" unitRef="Unit12" decimals="-3">2000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="Duration_4_1_2017_To_6_30_2017_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingAndMarketingExpenseMember_us-gaap_PlanNameAxis_vrml_EmployeeStockBasedCompensationMember" unitRef="Unit12" decimals="-3">38000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Duration_1_1_2016_To_6_30_2016" unitRef="Unit1" decimals="INF">7808044</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Duration_1_1_2017_To_6_30_2017" unitRef="Unit1" decimals="INF">11662280</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:Assets contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="-3">8019000</us-gaap:Assets>
  <us-gaap:Assets contextRef="As_Of_6_30_2017" unitRef="Unit12" decimals="-3">8173000</us-gaap:Assets>
  <us-gaap:AssetsCurrent contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="-3">6108000</us-gaap:AssetsCurrent>
  <us-gaap:AssetsCurrent contextRef="As_Of_6_30_2017" unitRef="Unit12" decimals="-3">6613000</us-gaap:AssetsCurrent>
  <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="Duration_1_1_2017_To_6_30_2017">&lt;div&gt; &lt;div style="margin-left:0pt;margin-right:0pt;"&gt;
		&lt;p style="margin:0pt 0pt 8pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;"&gt;Basis of Presentation &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:6pt 0pt;text-indent:36pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&amp;#x201C;GAAP&amp;#x201D;) for interim financial information and with the instructions to Form 10-Q and Article 8-03 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management of the Company, all adjustments, consisting of normal recurring adjustments necessary for the fair statement of results for the periods presented, have been included. The results of operations of any interim period are not necessarily indicative of the results of operations for the full year or any other interim period. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 6pt;text-indent:36pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;The unaudited condensed consolidated financial statements and related disclosures have been prepared with the presumption that users of the interim unaudited condensed consolidated financial statements have read or have access to the audited consolidated financial statements for the preceding fiscal year. The condensed consolidated balance sheet at December&amp;nbsp;31,&amp;nbsp;2016 included in this report has been derived from the audited consolidated financial statements at that date but does not include all the information and footnotes required by GAAP. Accordingly, these unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended December 31, 2016, included in Vermillion&amp;#x2019;s Annual Report on Form 10-K which was filed with the Securities and Exchange Commission on March 3&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;1&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;, 2017 (the &amp;#x201C;2016 Annual Report&amp;#x201D;).&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:6pt 0pt 0pt;line-height:100%;text-indent:36pt;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimated results.&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;
	&lt;/div&gt; &lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
  <us-gaap:CapitalLeasesContingentRentalPaymentsDue contextRef="As_Of_4_30_2015_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_AssetsHeldUnderCapitalLeasesMember" unitRef="Unit12" decimals="0">3500</us-gaap:CapitalLeasesContingentRentalPaymentsDue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="As_Of_12_31_2015" unitRef="Unit12" decimals="-3">18642000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="As_Of_6_30_2016" unitRef="Unit12" decimals="-3">11062000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="-3">5242000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="As_Of_6_30_2017" unitRef="Unit12" decimals="-3">6028000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="Duration_1_1_2016_To_6_30_2016" unitRef="Unit12" decimals="-3">-7580000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="Duration_1_1_2017_To_6_30_2017" unitRef="Unit12" decimals="-3">786000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="As_Of_2_17_2017" unitRef="Unit13" decimals="INF">1.80</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="As_Of_2_17_2017" unitRef="Unit1" decimals="INF">2810338</us-gaap:ClassOfWarrantOrRightOutstanding>
  <us-gaap:CommitmentsAndContingencies xsi:nil="true" contextRef="As_Of_12_31_2016" unitRef="Unit12" />
  <us-gaap:CommitmentsAndContingencies xsi:nil="true" contextRef="As_Of_6_30_2017" unitRef="Unit12" />
  <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="Duration_1_1_2017_To_6_30_2017">&lt;div&gt; &lt;div style="margin-left:0pt;margin-right:0pt;"&gt;
		&lt;p style="margin:0pt;line-height:100%;text-indent:36pt;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:10pt;"&gt;3.&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt; &amp;nbsp; &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;"&gt;COMMITMENT&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;"&gt;S&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;"&gt; AND CONTINGENCIES&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;"&gt;Development Loan&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:36pt;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Arial Unicode MS;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;On March 22, 2016, the Company entered into the &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;Loan &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;Agreement, pursuant to which the Company may borrow up to &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;$4,000,000&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; from the DECD.&amp;nbsp;Proceeds from the &lt;/font&gt;&lt;a name="_cp_text_1_48"&gt;&lt;/a&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;$2,000,000&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; April 2016 initial disbursement under the Loan Agreement &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;were&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; utilized primarily to fund the build-out, information technology infrastructure and other costs related to the Company&amp;#x2019;s Trumbull, Connecticut facility and operations.&amp;nbsp;The loan bears interest at a fixed rate of &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;2.0%&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; per annum and requires equal monthly payments of principal and interest until maturity, which occurs on &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;April 15, 2026&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;.&amp;nbsp;As security for the loan, the Company has granted the DECD a blanket security interest in the Company&amp;#x2019;s personal and intellectual property.&amp;nbsp;The DECD&amp;#x2019;s security interest in the Company&amp;#x2019;s intellectual property may be subordinated to a qualified institutional lender.&amp;nbsp;Under the terms of the Loan Agreement, the Company may be eligible for forgiveness of up to &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;$2,000,000&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; of the &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;principal amount of the loan if the Company achieves certain job creation and retention milestones by March 1, 2018.&amp;nbsp;&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;Conversely, i&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;f the Company is unable to meet these job creation &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;milestones, namely, hiring &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;40&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; full time employees with a specified average annual salary within the allotted timeframe &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;and &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;retaining those employees for a &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;two&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;-&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;year period &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;or &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;does not maintain the Company&amp;#x2019;s Connecticut operations for a period of&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;10&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; years, the DECD may require early repayment of a portion or all of the loan&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; plus a penalty of &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;5%&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;.&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Arial Unicode MS;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp; &amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Arial Unicode MS;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;As discussed above, a&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;n initial disbursement of &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;$2,000,000&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; was made to the Company on April 15, 2016 under the Loan Agreement.&amp;nbsp;The Loan Agreement provides that the remaining &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;$2,000,000&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; will be disbursed&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;if and when the Company achieves certain future milestones. The loan may be prepaid at any time without premium or penalty&lt;/font&gt;&lt;a name="T7"&gt;&lt;/a&gt;&lt;a name="T8"&gt;&lt;/a&gt;&lt;a name="T9"&gt;&lt;/a&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:36pt;border-top:1pt none #D9D9D9 ;line-height:100%;font-family:Arial Unicode MS;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;"&gt;Operating Leases&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-indent:36pt;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;The Company leases facilities to support its business of discovering, developing and commercializing diagnostic tests in the fields of gynecologic disease&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;. The Company&amp;#x2019;s&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; principal facility&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;,&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;including&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;the &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;CLIA laboratory &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;used by ASPiRA LABS, is &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;located in Austin, Texas&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;,&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;the &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;CLIA laboratory &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;used by ASPiRA IVD is located &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;in Trumbull, Connecticut. &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;The&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; Austin, Texas lease include&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;s&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; an aggregate annual base rent of &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;$85,000&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; and annual estimated common area charges, taxes and insurance of &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;$46,000&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; and&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; expires on &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;January 31, 2019.&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; &amp;nbsp; &amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-indent:36pt;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;In October 2015, the Company entered a lease agreement for a facility in Trumbull, Connecticut. The lease required initial payments for the buildout of leasehold improvements to the office space, which were approximately &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;$596,000&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;. The term of the lease is &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;five&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; years beginning after the initial date of occupancy &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;i&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;n January 2016 and a rent abatement period of &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;five&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; months. The lease includes an aggregate annual base rent of &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;$32,000&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; and annual estimated common area charges, taxes and insurance of &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;$95,000&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;. &amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-indent:36pt;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;Building rent&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; for the three months ended&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; June 30, 2017&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;201&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;6&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; totaled &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;$62,000&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;$53,000&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;, respectively. &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;Building rent&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; for the &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;six &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;months ended&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; June 30, 2017&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;201&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;6&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; totaled &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;$123,000&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;$104,000&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;, respectively. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-indent:36pt;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;"&gt;Capital Lease&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-indent:36pt;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;In April 2015, the Company leased &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;a&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; laboratory instrument for a total initial payment of &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;$125,000&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; and ongoing payments of approximately &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;$3,500&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; per month for &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;36&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; months after delivery. The agreement also requires minimum annual purchases of reagents from the manufacturer of the equipment. The laboratory instrument was placed into service on July 1, 2015. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-indent:36pt;font-family:Calibri;font-size: 11pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;The accumulated amortization of assets under capital lease obligations was &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;$155,000&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;$77,000&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; as of June 30&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;, 201&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;7&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; and 201&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;6&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;, respectively. The net book value of assets under capital lease obligations was &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;$77,000&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;$155,000&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; as&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; of&lt;/font&gt;&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;June 30, 2017 and 2016, respectively&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;. &amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-indent:36pt;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;"&gt;Non-cancelable Royalty Obligations&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:36pt;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Arial Unicode MS;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;The Company is a party to an amended research collaboration agreement with The Johns Hopkins University School of Medicine &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;under which the Company licenses certain of its intellectual property&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;. Under the terms of the amended research collaboration agreement, Vermillion is required to pay the greater of &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;4%&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; royalties on net sales of diagnostic tests using the assigned patents or annual minimum royalties of &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;$57,500&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;. Royalty expense for the three months ended &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;June 30, 2017&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; and 201&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;6&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; totalled &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;$34,000&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;$22,000&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;,&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; respectively. &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;Royalty expense for the &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;six &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;months ended &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;June 30, 2017&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; and 201&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;6&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; totalled &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;$63,000&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;$42,000&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;,&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; respectively.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt 0pt;text-indent:36pt;border-top:1pt none #D9D9D9 ;line-height:100%;font-family:Arial Unicode MS;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;
	&lt;/div&gt; &lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="As_Of_12_31_2016" unitRef="Unit13" decimals="INF">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="As_Of_2_17_2017" unitRef="Unit13" decimals="INF">1.40</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="As_Of_6_30_2017" unitRef="Unit13" decimals="INF">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockSharesAuthorized contextRef="As_Of_12_31_2016" unitRef="Unit1" decimals="INF">150000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesAuthorized contextRef="As_Of_6_30_2017" unitRef="Unit1" decimals="INF">150000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesIssued contextRef="As_Of_12_31_2016" unitRef="Unit1" decimals="INF">52328492</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesIssued contextRef="As_Of_2_17_2017" unitRef="Unit1" decimals="INF">3747125</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesIssued contextRef="As_Of_6_30_2017" unitRef="Unit1" decimals="INF">56164082</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesOutstanding contextRef="As_Of_12_31_2016" unitRef="Unit1" decimals="INF">52328492</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockSharesOutstanding contextRef="As_Of_6_30_2017" unitRef="Unit1" decimals="INF">56164082</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockValue contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="-3">52000</us-gaap:CommonStockValue>
  <us-gaap:CommonStockValue contextRef="As_Of_2_17_2017" unitRef="Unit12" decimals="0">4296000</us-gaap:CommonStockValue>
  <us-gaap:CommonStockValue contextRef="As_Of_6_30_2017" unitRef="Unit12" decimals="-3">56000</us-gaap:CommonStockValue>
  <us-gaap:CompensationAndEmployeeBenefitPlansTextBlock contextRef="Duration_1_1_2017_To_6_30_2017">&lt;div&gt; &lt;div style="margin-left:0pt;margin-right:0pt;"&gt;
		&lt;p style="margin:0pt 0pt 6pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;"&gt;4.&amp;nbsp;&amp;nbsp;&amp;nbsp;STOCKHOLDERS&amp;#x2019; EQUITY&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 10pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;"&gt;2017 Private Placement&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; &amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp; &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 10pt;text-indent:36pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;On February 17, 2017, the Company completed a private placement pursuant to which certain investors purchased &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;3,747,125&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; shares of Vermillion common stock at a price of &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;$1.40&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; per share. Vermillion also issued warrants to purchase shares of Vermillion common stock at a price of &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;$0.125&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; per warrant share in the private placement. Net proceeds of the private placement were approximately &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;5,127,000&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; after deducting offering expenses. The warrants are exercisable for &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;2,810,338&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; shares of Vermillion common stock at &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;$1.80&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; per share. &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;The warrants may be exercised from time to time beginning August 17, 2017 and expire on the fifth anniversary of the date of issuance &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;or, if earlier, five business days after Vermillion delivers notice that the closing price per share of its common stock exceeded the exercise price for 20 consecutive trading days during the exercise period&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 3pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;The sale&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; of common stock and issuance of warrants qualified for equity treatment under GAAP. The respective values of the warrants and common stock were calculated using their relative fair values and classified under common stock and additional paid-in capital. The value ascribed to the warrants is &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;$804,000&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; and to the common stock is approximately &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;$4,296,000&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 3pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 3pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;"&gt;2010 Stock Incentive Plan&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 6pt;text-indent:36pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;The Company&amp;#x2019;s employees, directors, and consultants are eligible to receive awards under the Vermillion, Inc. &lt;/font&gt;&lt;a name="_cp_text_4_18"&gt;&lt;/a&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;Second Amended and Restated &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;2010 Stock Incentive Plan (the &amp;#x201C;2010 Plan&amp;#x201D;). The 2010 Plan permits the granting of a variety of awards, including stock options, share appreciation rights, restricted shares, restricted share units, unrestricted shares, deferred share units, performance and cash-settled awards, and dividend equivalent rights. The 2010 Plan provides for issuance of up to &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;8,122,983&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; shares of Vermillion common stock, subject to adjustment as provided in the 2010 Plan.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 3pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;"&gt;Stock-Based Compensation&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-indent:36pt;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;During the &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;six&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;June 30&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;, 2017&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;, the Company awarded to Vermillion&amp;#x2019;s non-employee directors &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;131,250&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; shares of restricted stock under the 2010 Plan having a fair value of approximately &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;$281,000&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; as payment for services to be rendered in 2017.&amp;nbsp;These shares of restricted stock vest&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;ed&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;50%&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; on June 1, 201&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;7, and will vest &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;25%&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; on&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; each of &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;September 1, 2017&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;December 1, 2017&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;. The Company also issued to certain consultants &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;22,841&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; shares of restricted stock under the 2010 Plan having a fair value of approximately &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;$39,000&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-indent:36pt;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-indent:36pt;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;During the &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;three &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;months ended &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;June 30&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;, 2017&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;, the Company issued to certain consultants &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;9,213&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; shares of restricted stock under the 2010 Plan having a fair value of approximately &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;$19,000&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;.&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; The Company &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;did not&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; make any awards of restricted stock to non-employee directors during the three months ended June 30, 201&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;7&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;.&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-indent:36pt;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-indent:36pt;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;During the &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;six&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;June 30&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;, 2017&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;, the Company also granted certain consultants options to purchase &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;70,000&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; shares of Vermillion common stock with an exercise price of &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;$2.14&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; per share.&amp;nbsp;&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;The Company also granted certain officers and employees options to &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;purchase approximately &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;916,000&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; shares of Vermillion common stock with an exercise price of &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;$2.14&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; per share.&amp;nbsp;&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;These stock options generally vest &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;25%&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; on each of the four&amp;nbsp;anniversaries of the grant date.&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; In addition, the C&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;ompany granted certain officers and employees options to purchase &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;250,000&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; shares of Vermillion common stock with an exercise price of &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;approximately &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;$2.14&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; per&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; share with performance-based vesting based on certain metrics through December 31, 2017. &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;These options vest &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;25%&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; on each of the four&amp;nbsp;anniversaries of the grant date if the performance-based metrics are met.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-indent:36pt;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-indent:36pt;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;During the three months ended June 30, 201&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;7&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;, the Company granted certain officers and employees options to purchase &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;14,500&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; shares of Vermillion common stock with an exercise price of &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;$1.83&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; per share.&amp;nbsp;These stock options vest &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;25%&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; on each of the four&amp;nbsp;anniversaries of the vesting commencement date for each such stock option.&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-indent:36pt;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 6pt;text-indent:36pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;The allocation of employee stock-based compensation expense by functional area for the three &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;and six &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;months ended &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;June 30&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;, 2017 and 2016 was as follows:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Calibri;line-height:107.92%;font-size: 1pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:38.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size: 1pt"&gt;
						&lt;font style="display: inline;font-size:1pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:38.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="5" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:10pt;"&gt;Three Months Ended June 30,&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="5" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:10pt;"&gt;Six Months Ended June 30,&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:38.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;border-bottom:1pt solid #000000 ;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-weight:bold;color:#000000;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:10pt;"&gt;(in thousands)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.82%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.82%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:38.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;Cost of revenue&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.36%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.10%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;20&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.36%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.10%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;22&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.36%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.10%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;40&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.36%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.10%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;46&amp;nbsp;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:38.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;Research and development &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;2&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;22&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;5&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;53&amp;nbsp;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:38.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;Sales and marketing &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;38&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;14&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;70&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;56&amp;nbsp;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:38.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;General and administrative&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;283&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;320&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;414&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;425&amp;nbsp;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:38.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;Total &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.36%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.10%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;343&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.36%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.10%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;378&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.36%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.10%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;529&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.36%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.10%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;580&amp;nbsp;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:38.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.36%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.10%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.36%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.10%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.36%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.10%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.36%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.10%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt 0pt 8pt;font-family:Calibri;line-height:107.92%;font-size: 11pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Calibri;line-height:107.92%;font-size: 1pt"&gt;
			&lt;font style="display: inline;font-size:1pt;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;
	&lt;/div&gt; &lt;/div&gt;</us-gaap:CompensationAndEmployeeBenefitPlansTextBlock>
  <us-gaap:CostOfGoodsAndServicesSold id="Item-0012" contextRef="Duration_1_1_2016_To_6_30_2016" unitRef="Unit12" decimals="-3">1115000</us-gaap:CostOfGoodsAndServicesSold>
  <us-gaap:CostOfGoodsAndServicesSold id="Item-0010" contextRef="Duration_4_1_2016_To_6_30_2016" unitRef="Unit12" decimals="-3">587000</us-gaap:CostOfGoodsAndServicesSold>
  <us-gaap:CostOfGoodsAndServicesSold id="Item-0011" contextRef="Duration_1_1_2017_To_6_30_2017" unitRef="Unit12" decimals="-3">1421000</us-gaap:CostOfGoodsAndServicesSold>
  <us-gaap:CostOfGoodsAndServicesSold id="Item-0009" contextRef="Duration_4_1_2017_To_6_30_2017" unitRef="Unit12" decimals="-3">694000</us-gaap:CostOfGoodsAndServicesSold>
  <us-gaap:CostOfGoodsSold id="Item-0004" contextRef="Duration_1_1_2016_To_6_30_2016" unitRef="Unit12" decimals="-3">1055000</us-gaap:CostOfGoodsSold>
  <us-gaap:CostOfGoodsSold id="Item-0002" contextRef="Duration_4_1_2016_To_6_30_2016" unitRef="Unit12" decimals="-3">527000</us-gaap:CostOfGoodsSold>
  <us-gaap:CostOfGoodsSold id="Item-0003" contextRef="Duration_1_1_2017_To_6_30_2017" unitRef="Unit12" decimals="-3">850000</us-gaap:CostOfGoodsSold>
  <us-gaap:CostOfGoodsSold id="Item-0001" contextRef="Duration_4_1_2017_To_6_30_2017" unitRef="Unit12" decimals="-3">428000</us-gaap:CostOfGoodsSold>
  <us-gaap:CostOfServices id="Item-0008" contextRef="Duration_1_1_2016_To_6_30_2016" unitRef="Unit12" decimals="-3">60000</us-gaap:CostOfServices>
  <us-gaap:CostOfServices id="Item-0006" contextRef="Duration_4_1_2016_To_6_30_2016" unitRef="Unit12" decimals="-3">60000</us-gaap:CostOfServices>
  <us-gaap:CostOfServices id="Item-0007" contextRef="Duration_1_1_2017_To_6_30_2017" unitRef="Unit12" decimals="-3">571000</us-gaap:CostOfServices>
  <us-gaap:CostOfServices id="Item-0005" contextRef="Duration_4_1_2017_To_6_30_2017" unitRef="Unit12" decimals="-3">266000</us-gaap:CostOfServices>
  <us-gaap:DebtDisclosureTextBlock contextRef="Duration_1_1_2017_To_6_30_2017">&lt;div&gt; &lt;div style="margin-left:0pt;margin-right:0pt;"&gt;
		&lt;p style="margin:0pt 0pt 8pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-indent:36pt;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;"&gt;2.&amp;nbsp;&amp;nbsp;&amp;nbsp;AGREEMENTS WITH QUEST DIAGNOSTICS INCORPORATED&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:36pt;line-height:100%;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt 0pt;text-indent:36pt;line-height:100%;font-family:Arial Unicode MS;font-size: 12pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;In March 2015, the Company entered into a commercial agreement with Quest Diagnostics&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;,&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;a name="_cp_text_1_39"&gt;&lt;/a&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;Incorporated (&amp;#x201C;Quest Diagnostics&amp;#x201D;)&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;. Pursuant to this agreement&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;, &amp;nbsp;&lt;/font&gt;&lt;a name="_cp_text_1_40"&gt;&lt;/a&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;all OVA1 U.S. testing services for &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;Quest Diagnostics &lt;/font&gt;&lt;a name="_cp_text_1_42"&gt;&lt;/a&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;customers were transferred to&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;Vermillion&amp;#x2019;s&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;wholly-owned subsidiary, ASPiRA LABS,&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;as of August 2015. Pursuant to this agreement, as amended as of March 11, 2017, Quest Diagnostics has agreed to provide &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;blood draw and logistics support by transporting specimens from its clients to ASPiRA LABS for testing through at least March 11, 201&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;8&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; in exchange for a market value fee. Per the terms of &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;this&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; agreement, the Company will not offer to existing or future Quest Diagnostics customers tests that Quest Diagnostics offers. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;
	&lt;/div&gt; &lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
  <us-gaap:DebtInstrumentFaceAmount contextRef="As_Of_3_22_2016_us-gaap_DebtInstrumentAxis_vrml_DecdMember" unitRef="Unit12" decimals="INF">4000000</us-gaap:DebtInstrumentFaceAmount>
  <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="As_Of_3_22_2016_us-gaap_DebtInstrumentAxis_vrml_DecdMember" unitRef="Unit14" decimals="INF">0.02</us-gaap:DebtInstrumentInterestRateStatedPercentage>
  <us-gaap:DebtInstrumentMaturityDate contextRef="Duration_1_1_2017_To_6_30_2017_us-gaap_DebtInstrumentAxis_vrml_DecdMember">2026-04-15</us-gaap:DebtInstrumentMaturityDate>
  <us-gaap:DebtInstrumentTerm contextRef="Duration_1_1_2017_To_6_30_2017_us-gaap_DebtInstrumentAxis_vrml_DecdMember">P10Y</us-gaap:DebtInstrumentTerm>
  <us-gaap:DebtInstrumentUnusedBorrowingCapacityAmount contextRef="As_Of_3_22_2016_us-gaap_DebtInstrumentAxis_vrml_DecdMember" unitRef="Unit12" decimals="INF">2000000</us-gaap:DebtInstrumentUnusedBorrowingCapacityAmount>
  <us-gaap:DepreciationDepletionAndAmortization contextRef="Duration_1_1_2016_To_6_30_2016" unitRef="Unit12" decimals="-3">323000</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:DepreciationDepletionAndAmortization contextRef="Duration_1_1_2017_To_6_30_2017" unitRef="Unit12" decimals="-3">401000</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="Duration_1_1_2016_To_6_30_2016" unitRef="Unit13" decimals="2">-0.17</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="Duration_4_1_2016_To_6_30_2016" unitRef="Unit13" decimals="2">-0.07</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="Duration_1_1_2017_To_6_30_2017" unitRef="Unit13" decimals="2">-0.09</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="Duration_4_1_2017_To_6_30_2017" unitRef="Unit13" decimals="2">-0.04</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareTextBlock contextRef="Duration_1_1_2017_To_6_30_2017">&lt;div&gt; &lt;div style="margin-left:0pt;margin-right:0pt;"&gt;
		&lt;p style="margin:0pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;"&gt;5.&amp;nbsp;&amp;nbsp; &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;"&gt;LOSS PER SHARE&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 8pt;text-indent:36pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;The Company calculates basic loss per share using the weighted ave&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;rage number of shares &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;of Vermillion common stock &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;outstanding during the period. Because the Company is in a net loss position, diluted loss per share is calculated using the &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;weighted average number of shares of Vermillion common stock outstanding and excludes the effects of &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;11,662,280&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; an&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;d &amp;nbsp;&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;7,808,044&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; po&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;tential shares of&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; Vermillion&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; common stock as of &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;June 30, 2017&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; and 201&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;6&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;, respectively, that are anti-dilutive. Potential shares of &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;Vermillion &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;common stock include incremental shares of &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;Vermillion &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;common stock issuable upon the exercise of outstanding warrants, stock options and unvested restricted stock units.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;
	&lt;/div&gt; &lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
  <us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="Duration_1_1_2016_To_6_30_2016" unitRef="Unit12" decimals="-3">-3000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
  <us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="Duration_1_1_2017_To_6_30_2017" unitRef="Unit12" decimals="-3">-4000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
  <us-gaap:GeneralAndAdministrativeExpense id="Item-0024" contextRef="Duration_1_1_2016_To_6_30_2016" unitRef="Unit12" decimals="-3">3350000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:GeneralAndAdministrativeExpense id="Item-0022" contextRef="Duration_4_1_2016_To_6_30_2016" unitRef="Unit12" decimals="-3">1691000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:GeneralAndAdministrativeExpense id="Item-0023" contextRef="Duration_1_1_2017_To_6_30_2017" unitRef="Unit12" decimals="-3">2648000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:GeneralAndAdministrativeExpense id="Item-0021" contextRef="Duration_4_1_2017_To_6_30_2017" unitRef="Unit12" decimals="-3">1241000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:GrossProfit contextRef="Duration_1_1_2016_To_6_30_2016" unitRef="Unit12" decimals="-3">99000</us-gaap:GrossProfit>
  <us-gaap:GrossProfit contextRef="Duration_4_1_2016_To_6_30_2016" unitRef="Unit12" decimals="-3">122000</us-gaap:GrossProfit>
  <us-gaap:GrossProfit contextRef="Duration_1_1_2017_To_6_30_2017" unitRef="Unit12" decimals="-3">203000</us-gaap:GrossProfit>
  <us-gaap:GrossProfit contextRef="Duration_4_1_2017_To_6_30_2017" unitRef="Unit12" decimals="-3">204000</us-gaap:GrossProfit>
  <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="Duration_1_1_2016_To_6_30_2016" unitRef="Unit12" decimals="-3">-835000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
  <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="Duration_1_1_2017_To_6_30_2017" unitRef="Unit12" decimals="-3">-504000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
  <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="Duration_1_1_2016_To_6_30_2016" unitRef="Unit12" decimals="-3">156000</us-gaap:IncreaseDecreaseInAccountsReceivable>
  <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="Duration_1_1_2017_To_6_30_2017" unitRef="Unit12" decimals="-3">-61000</us-gaap:IncreaseDecreaseInAccountsReceivable>
  <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="Duration_1_1_2016_To_6_30_2016" unitRef="Unit12" decimals="-3">16000</us-gaap:IncreaseDecreaseInDeferredRevenue>
  <us-gaap:IncreaseDecreaseInInventories contextRef="Duration_1_1_2016_To_6_30_2016" unitRef="Unit12" decimals="-3">-7000</us-gaap:IncreaseDecreaseInInventories>
  <us-gaap:IncreaseDecreaseInInventories contextRef="Duration_1_1_2017_To_6_30_2017" unitRef="Unit12" decimals="-3">9000</us-gaap:IncreaseDecreaseInInventories>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="Duration_1_1_2016_To_6_30_2016" unitRef="Unit12" decimals="-3">-233000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="Duration_1_1_2017_To_6_30_2017" unitRef="Unit12" decimals="-3">-218000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:InterestIncomeExpenseNet contextRef="Duration_1_1_2016_To_6_30_2016" unitRef="Unit12" decimals="-3">-5000</us-gaap:InterestIncomeExpenseNet>
  <us-gaap:InterestIncomeExpenseNet contextRef="Duration_4_1_2016_To_6_30_2016" unitRef="Unit12" decimals="-3">-8000</us-gaap:InterestIncomeExpenseNet>
  <us-gaap:InterestIncomeExpenseNet contextRef="Duration_1_1_2017_To_6_30_2017" unitRef="Unit12" decimals="-3">-22000</us-gaap:InterestIncomeExpenseNet>
  <us-gaap:InterestIncomeExpenseNet contextRef="Duration_4_1_2017_To_6_30_2017" unitRef="Unit12" decimals="-3">-10000</us-gaap:InterestIncomeExpenseNet>
  <us-gaap:InterestPaidNet contextRef="Duration_1_1_2016_To_6_30_2016" unitRef="Unit12" decimals="-3">10000</us-gaap:InterestPaidNet>
  <us-gaap:InterestPaidNet contextRef="Duration_1_1_2017_To_6_30_2017" unitRef="Unit12" decimals="-3">24000</us-gaap:InterestPaidNet>
  <us-gaap:InventoryNet contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="-3">93000</us-gaap:InventoryNet>
  <us-gaap:InventoryNet contextRef="As_Of_6_30_2017" unitRef="Unit12" decimals="-3">102000</us-gaap:InventoryNet>
  <us-gaap:LeaseExpirationDate1 contextRef="Duration_1_1_2017_To_6_30_2017_us-gaap_LeaseArrangementTypeAxis_vrml_AustinTexasFacilityMember">2019-01-31</us-gaap:LeaseExpirationDate1>
  <us-gaap:LeaseholdImprovementsGross contextRef="As_Of_10_31_2015_us-gaap_LeaseArrangementTypeAxis_vrml_TrumbullConnecticutFacilityMember" unitRef="Unit12" decimals="0">596000</us-gaap:LeaseholdImprovementsGross>
  <us-gaap:LesseeLeasingArrangementsOperatingLeasesTermOfContract contextRef="Duration_1_1_2017_To_6_30_2017_us-gaap_LeaseArrangementTypeAxis_vrml_TrumbullConnecticutFacilityMember">P5Y</us-gaap:LesseeLeasingArrangementsOperatingLeasesTermOfContract>
  <us-gaap:Liabilities contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="-3">4257000</us-gaap:Liabilities>
  <us-gaap:Liabilities contextRef="As_Of_6_30_2017" unitRef="Unit12" decimals="-3">3646000</us-gaap:Liabilities>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="-3">8019000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="As_Of_6_30_2017" unitRef="Unit12" decimals="-3">8173000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:LiabilitiesCurrent contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="-3">2561000</us-gaap:LiabilitiesCurrent>
  <us-gaap:LiabilitiesCurrent contextRef="As_Of_6_30_2017" unitRef="Unit12" decimals="-3">2061000</us-gaap:LiabilitiesCurrent>
  <us-gaap:LongTermDebtNoncurrent contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="-3">1667000</us-gaap:LongTermDebtNoncurrent>
  <us-gaap:LongTermDebtNoncurrent contextRef="As_Of_6_30_2017" unitRef="Unit12" decimals="-3">1538000</us-gaap:LongTermDebtNoncurrent>
  <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations contextRef="Duration_1_1_2016_To_6_30_2016" unitRef="Unit12" decimals="-3">1929000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
  <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations contextRef="Duration_1_1_2017_To_6_30_2017" unitRef="Unit12" decimals="-3">5020000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
  <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations contextRef="Duration_1_1_2016_To_6_30_2016" unitRef="Unit12" decimals="-3">-1054000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
  <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations contextRef="Duration_1_1_2017_To_6_30_2017" unitRef="Unit12" decimals="-3">-43000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
  <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="Duration_1_1_2016_To_6_30_2016" unitRef="Unit12" decimals="-3">-8455000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
  <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="Duration_1_1_2017_To_6_30_2017" unitRef="Unit12" decimals="-3">-4191000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
  <us-gaap:NetIncomeLoss contextRef="Duration_1_1_2016_To_6_30_2016" unitRef="Unit12" decimals="-3">-8646000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="Duration_4_1_2016_To_6_30_2016" unitRef="Unit12" decimals="-3">-3749000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="Duration_1_1_2017_To_6_30_2017" unitRef="Unit12" decimals="-3">-5033000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="Duration_4_1_2017_To_6_30_2017" unitRef="Unit12" decimals="-3">-2360000</us-gaap:NetIncomeLoss>
  <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="Duration_1_1_2017_To_6_30_2017">&lt;div&gt; &lt;div style="margin-left:0pt;margin-right:0pt;"&gt;
		&lt;p style="margin:0pt 0pt 8pt;text-indent:36pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;text-decoration:underline;background-color: #FFFFFF;"&gt;Recent Accounting Pronouncements&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:36pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;In March 2016, the &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;Financial Accounting Standards Board&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;(&amp;#x201C;FASB&amp;#x201D;) &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;issued ASU 2016-09, Improvements to Employee Share-Based Payment Accounting (&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;Topic 718), Compensation - Stock Compensation&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; (&amp;#x201C;ASU 2016-09&amp;#x201D;)&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;. The new guidance simplifies several aspects of the accounting for share-based payments, including immediate recognition of all excess tax benefits and deficiencies in the income statement, changing the threshold to qualify for equity classification up to the employees' maximum statutory tax rates, allowing an entity-wide accounting policy election to either estimate the number of awards that are expected to vest or account for forfeitures as they occur, and clarifying the classification on the statement of cash flows for the excess tax benefit and employee taxes paid when an employer withholds shares for tax-withholding purposes. ASU 2016-09 is effective for annual reporting periods beginning after December 15, 2016 and interim periods within that reporting period. The adoption of this standard is not expected to have a material effect on our financial statements&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:36pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 8pt;text-indent:36pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;In May 2014, the FASB issued ASU No. 2014-09&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;, Revenue from Contracts with Customers (Topic 606) (&amp;#x201C;ASU 2014-09&amp;#x201D;), which&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; removes inconsistencies and weaknesses in revenue requirements, provides a more robust framework for addressing revenue issues, improves comparability of revenue recognition practices across entities, industries, jurisdictions and capital markets, provides more useful information to users of financial statements through improved disclosure requirements and simplifies the preparation of financial statements by reducing the number of requirements to which an entity must refer. This guidance requires that an entity depict the consideration by applying a five-step analysis in determining when and how revenue is recognized. The new model will require revenue recognition to depict the transfer of promised goods or services to customers in an amount that reflects the consideration a company expects to receive in exchange for those goods or services. On April 1, 2015, the FASB voted for a one-year deferral of the effective date of the new revenue recognition standard, ASU No. 2014-09.&amp;nbsp;On July 15, 2015, the FASB affirmed these changes, which requires public entities to apply the amendments in ASU 2014-09 for annual reporting beginning after December 15, 2017. Early adoption is permitted beginning after December 31, 2016, the original effective date in ASU 2014-09.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 8pt;text-indent:36pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; The Company is in the early stages of its analysis of the effect &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;ASU 2014-09&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; will have on its Service Revenue, but expects to complete its analysis during the second half of 2017.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 8pt;text-indent:36pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;The Company is also in the early stages of its analysis of&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; the effect ASU 2014-09 will have on &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;its Product Revenue and also expects to complete this analysis in the second half of 2017. Revenue that is recognized upon the ultimate receipt of cash under the Company&amp;#x2019;s existing revenue recognition policy will have to be reassessed under the new standard. The next step in the Company&amp;#x2019;s implementation process is to review its patient account population to determine the appropriate distribution of patient accounts &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;text-decoration:underline;"&gt;by payer&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; &amp;nbsp;(&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-style:italic;font-size:10pt;"&gt;i.e.&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;, Medicare, patient pay, other third-party payer, &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-style:italic;font-size:10pt;"&gt;etc&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;.) into portfolios with similar collection experience that, when evaluated for collectability, will result in a materially consistent revenue amount for such portfolios as if each patient account were evaluated on a contract-by-contract basis.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 8pt;text-indent:36pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;The Company has not yet determined if it plans to utilize the full retrospective or modified retrospective method of adoption, but anticipates adopting the new standard in the first quarter of 2018.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:36pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;
	&lt;/div&gt; &lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
  <us-gaap:NonoperatingIncomeExpense contextRef="Duration_1_1_2016_To_6_30_2016" unitRef="Unit12" decimals="-3">16000</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:NonoperatingIncomeExpense contextRef="Duration_4_1_2016_To_6_30_2016" unitRef="Unit12" decimals="-3">20000</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:NonoperatingIncomeExpense contextRef="Duration_1_1_2017_To_6_30_2017" unitRef="Unit12" decimals="-3">-9000</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:NonoperatingIncomeExpense contextRef="Duration_4_1_2017_To_6_30_2017" unitRef="Unit12" decimals="-3">-4000</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:OperatingExpenses contextRef="Duration_1_1_2016_To_6_30_2016" unitRef="Unit12" decimals="-3">8756000</us-gaap:OperatingExpenses>
  <us-gaap:OperatingExpenses contextRef="Duration_4_1_2016_To_6_30_2016" unitRef="Unit12" decimals="-3">3883000</us-gaap:OperatingExpenses>
  <us-gaap:OperatingExpenses contextRef="Duration_1_1_2017_To_6_30_2017" unitRef="Unit12" decimals="-3">5205000</us-gaap:OperatingExpenses>
  <us-gaap:OperatingExpenses contextRef="Duration_4_1_2017_To_6_30_2017" unitRef="Unit12" decimals="-3">2550000</us-gaap:OperatingExpenses>
  <us-gaap:OperatingIncomeLoss contextRef="Duration_1_1_2016_To_6_30_2016" unitRef="Unit12" decimals="-3">-8657000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss contextRef="Duration_4_1_2016_To_6_30_2016" unitRef="Unit12" decimals="-3">-3761000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss contextRef="Duration_1_1_2017_To_6_30_2017" unitRef="Unit12" decimals="-3">-5002000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss contextRef="Duration_4_1_2017_To_6_30_2017" unitRef="Unit12" decimals="-3">-2346000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingLeasesRentExpenseNet contextRef="Duration_1_1_2016_To_6_30_2016" unitRef="Unit12" decimals="0">104000</us-gaap:OperatingLeasesRentExpenseNet>
  <us-gaap:OperatingLeasesRentExpenseNet contextRef="Duration_4_1_2016_To_6_30_2016" unitRef="Unit12" decimals="0">53000</us-gaap:OperatingLeasesRentExpenseNet>
  <us-gaap:OperatingLeasesRentExpenseNet contextRef="Duration_1_1_2017_To_6_30_2017" unitRef="Unit12" decimals="0">123000</us-gaap:OperatingLeasesRentExpenseNet>
  <us-gaap:OperatingLeasesRentExpenseNet contextRef="Duration_4_1_2017_To_6_30_2017" unitRef="Unit12" decimals="0">62000</us-gaap:OperatingLeasesRentExpenseNet>
  <us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock contextRef="Duration_1_1_2017_To_6_30_2017">&lt;div&gt; &lt;div style="margin-left:0pt;margin-right:0pt;"&gt;
		&lt;p style="margin:0pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;"&gt;1.&amp;nbsp;&amp;nbsp; &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;"&gt;ORGANIZATION, BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING AND REPORTING POLICIES&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 8pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;"&gt;Organization &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:4.5pt 0pt 0pt 4.5pt;text-indent:31.5pt;line-height:100%;font-family:Arial Unicode MS;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;Vermillion, Inc. (&amp;#x201C;Vermillion&amp;#x201D;; Vermillion and its wholly-owned subsidiaries are collectively referred to as the &amp;#x201C;Company&lt;/font&gt;&lt;a name="_cp_text_1_15"&gt;&lt;/a&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;,&amp;#x201D; &amp;#x201C;we&amp;#x201D; or &amp;#x201C;our&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;&amp;#x201D;&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;) i&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;s incorporated in the state of Delaware, and is engaged in the business of developing and commercializing diagnostic tests for gynecologic disease. The Company sells OVA1&amp;#x2122; and Overa&amp;#x2122; risk of malignancy test&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;s&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; for ovarian cancer (&amp;#x201C;OVA1&amp;#x201D; and &amp;#x201C;Overa&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;,&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;&amp;#x201D;&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; respectively&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;) through Vermillion&amp;#x2019;s wholly-owned&amp;nbsp;Clinical Laboratory Improvement Amendments of 1988 (&amp;#x201C;CLIA&amp;#x201D;) certified clinical laboratory, ASPiRA LABS, Inc. (&amp;#x201C;ASPiRA LABS&amp;#x201D;). &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;The Company also offers in-vitro diagnostic (&amp;#x201C;IVD&amp;#x201D;) trial services to third-party customers through its wholly-owned subsidiary, ASPiRA IVD, Inc. (&amp;#x201C;ASPiRA IVD&amp;#x201D;), which commenced operations in June 2016. &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;ASPiRA IVD is a specialized, CLIA certified, laboratory provider dedicated to meeting the unique testing needs of IVD manufacturers seeking to commercialize&amp;nbsp;high-complexity&amp;nbsp;assays. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:9pt 0pt 3pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;"&gt;Going Concern&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 6pt;text-indent:36pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;The Company has incurred significant net losses and negative cash flows from operations since inception, and as a result has an accumulated deficit of approximat&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;ely &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;390&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;,589&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;,000&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; &amp;nbsp;a&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;t &amp;nbsp;&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;June 30&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;, 2017. The Company also expects to incur a net loss and negative cash flows from operations for the remainder of 2017. The Company&amp;#x2019;s management believes that successful achievement of the Company&amp;#x2019;s business objectives will require additional financing.&amp;nbsp;Given these conditions, there is substantial doubt about the Company&amp;#x2019;s ability to continue as a going concern. The condensed consolidated financial statements have been prepared on a going concern basis and do not include any adjustments that might result from these uncertainties. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 6pt;text-indent:36pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;The Company expects to raise capital through a variety of sources, which may include &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;the exercise of common stock warrants, &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;equity &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;offerings, debt financing&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;, collaborati&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;ons&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;, licensing arrangements, &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;grants and government funding and strategic alliances&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;. However, additional funding may not be available when needed or on terms acceptable to the Company. If the Company is unable to obtain additional capital, it may not be able to continue sales and marketing, research and development, or other operations on the scope or scale of current activity and that could have a material adverse effect on &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;the Company&amp;#x2019;s&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; business, results of operations and financial condition.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 6pt;text-indent:36pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;As discussed in Note &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;4&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;, on February 17, 2017, the Company completed a private placement pursuant to which certain investors purchased Vermillion common stock and warrants to purchase shares of&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; Vermillion&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; common stock for net proceeds of approximately &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;5,127,000&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; after deducting offering expenses.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 6pt;text-indent:36pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;As discussed in Note 3, in March 2016, the Company entered into an agreement (the &amp;#x201C;Loan Agreement&amp;#x201D;) pursuant to which it may borrow up to &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;$4,000,000&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; from the State of Connecticut Department of Economic and Community Development (the &amp;#x201C;DECD&amp;#x201D;). &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;An initial disbursement of &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;$2,000,000&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; was made to the Company in April 2016 under the Loan Agreement.&amp;nbsp;The Loan Agreement provides that the remaining &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;$2,000,000&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; will be disbursed if and when the Company achieves certain future milestones.&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;text-indent:36pt;line-height:100%;font-family:Arial Unicode MS;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 8pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;"&gt;Basis of Presentation &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:6pt 0pt;text-indent:36pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&amp;#x201C;GAAP&amp;#x201D;) for interim financial information and with the instructions to Form 10-Q and Article 8-03 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management of the Company, all adjustments, consisting of normal recurring adjustments necessary for the fair statement of results for the periods presented, have been included. The results of operations of any interim period are not necessarily indicative of the results of operations for the full year or any other interim period. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 6pt;text-indent:36pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;The unaudited condensed consolidated financial statements and related disclosures have been prepared with the presumption that users of the interim unaudited condensed consolidated financial statements have read or have access to the audited consolidated financial statements for the preceding fiscal year. The condensed consolidated balance sheet at December&amp;nbsp;31,&amp;nbsp;2016 included in this report has been derived from the audited consolidated financial statements at that date but does not include all the information and footnotes required by GAAP. Accordingly, these unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended December 31, 2016, included in Vermillion&amp;#x2019;s Annual Report on Form 10-K which was filed with the Securities and Exchange Commission on March 3&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;1&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;, 2017 (the &amp;#x201C;2016 Annual Report&amp;#x201D;).&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:6pt 0pt 0pt;line-height:100%;text-indent:36pt;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimated results.&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:6pt 0pt 0pt;line-height:100%;text-indent:36pt;font-family:Calibri;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 8pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;"&gt;Significant Acco&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;"&gt;unting and Reporting Policies &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 2.25pt 10pt;line-height:normal;text-indent:26pt;text-align:justify;text-justify:inter-ideograph;border-bottom:1pt none #D9D9D9 ;font-family:Arial Unicode MS;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;background-color: #FFFFFF;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 2.25pt 10pt;line-height:normal;text-indent: -10pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Arial Unicode MS;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;background-color: #FFFFFF;"&gt;Revenue Recognition&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 2.25pt 10pt;line-height:normal;text-indent: -10pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Arial Unicode MS;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;background-color: #FFFFFF;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 2.25pt 10pt;line-height:normal;text-indent: -10pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Arial Unicode MS;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;text-decoration:underline;background-color: #FFFFFF;"&gt;Product Revenue&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 2.25pt 10pt;line-height:normal;text-indent: -10pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Arial Unicode MS;font-size: 8pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:8.5pt;background-color: #FFFFFF;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:normal;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Arial Unicode MS;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;background-color: #FFFFFF;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;background-color: #FFFFFF;;font-size: 10pt;font-family:Arial Unicode MS;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;background-color: #FFFFFF;"&gt;The Company has adopted ASC 954-605,&lt;/font&gt;&lt;font style="font-family:Times New Roman;display: inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-style:italic;color:#000000;font-size:10pt;background-color: #FFFFFF;"&gt;Health Care Entities&amp;#x2014;Revenue Recognition, &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;background-color: #FFFFFF;"&gt;as &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;revenue from laboratory services has become significant to the Company&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;background-color: #FFFFFF;"&gt;.&lt;/font&gt;&lt;font style="font-family:Times New Roman;display: inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;background-color: #FFFFFF;"&gt;The Company's product revenue is generated by performing diagnostic services using its OVA1 and Overa tests, and the service is completed upon the delivery of test results to the prescribing physician. The Company recognizes revenue related to billings for Medicare and commercial payers on an accrual basis, net of contractual and other adjustments, when amounts that will ultimately be realized can be estimated. Until a contract has been negotiated with a commercial payer or governmental program, the OVA1 and Overa tests may or may not be covered by these entities' existing reimbursement policies. In addition, patients do not enter into direct agreements with the Company that commit them to pay any portion of the cost of the tests in the event that their insurance declines to reimburse the Company. In the absence of an agreement with the patient or other clearly enforceable legal right to demand payment from the patient, the related revenue is only recognized upon cash receipt.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:normal;border-top:1pt none #D9D9D9 ;font-family:Arial Unicode MS;font-size: 8pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:8.5pt;background-color: #FFFFFF;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:36pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;Estimates of amounts that the Company will ultimately realize require significant judgment by management. Some patients have out-of-pocket costs for amounts not covered by their insurance carrier, and the Company may bill the patient directly for these amounts in the form of co-payments and co-insurance in accordance with the patient&amp;#x2019;s health plan. Some payers may not cover the OVA1 and Overa tests as ordered by the prescribing physician under their reimbursement policies. The Company pursues reimbursement from such patients on a case-by-case basis. In the absence of contracted reimbursement coverage or the ability to estimate the amount that will ultimately be realized for the Company's services, revenue is recognized when cash is received.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:36pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;background-color: #FFFFFF;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 8pt;text-indent:36pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;See discussion of &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;FASB ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606) (&amp;#x201C;ASU No. 2014-09&amp;#x201D;)&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; included in Recent Accounting Pronouncements below&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;. &amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 8pt;text-indent:36pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 2.25pt 10pt;line-height:normal;text-indent: -10pt;text-align:justify;text-justify:inter-ideograph;border-bottom:1pt none #D9D9D9 ;font-family:Arial Unicode MS;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;background-color: #FFFFFF;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 2.25pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Arial Unicode MS;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;text-decoration:underline;background-color: #FFFFFF;"&gt;Service Revenue&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 2.25pt 10pt;line-height:normal;text-indent: -10pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;font-family:Arial Unicode MS;font-size: 8pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:8.5pt;background-color: #FFFFFF;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 6pt;text-indent:36pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;The Company&amp;#x2019;s service revenue is generated by performing IVD trial services for third-party customers. In accordance with SAB Topic 13, service revenue is recognized when the following revenue recognition criteria are met: (1)&amp;nbsp;persuasive evidence of an arrangement exists; (2)&amp;nbsp;delivery has occurred or services have been rendered; (3)&amp;nbsp;the fee is fixed or determinable; and (4)&amp;nbsp;collectability is reasonably assured.&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 6pt;text-indent:36pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;See discussion of ASU No. 2014-09 included in Recent Accounting Pronouncements below&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 6pt;text-indent:36pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;background-color: #FFFFFF;"&gt;The Company has made no &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;background-color: #FFFFFF;"&gt;other &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;background-color: #FFFFFF;"&gt;significant&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; changes in its critical accounting policies and estimates from those disclosed in the 2016 Annual Report&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;.&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 8pt;text-indent:36pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;text-decoration:underline;background-color: #FFFFFF;"&gt;Recent Accounting Pronouncements&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:36pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;In March 2016, the &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;Financial Accounting Standards Board&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;(&amp;#x201C;FASB&amp;#x201D;) &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;issued ASU 2016-09, Improvements to Employee Share-Based Payment Accounting (&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;Topic 718), Compensation - Stock Compensation&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; (&amp;#x201C;ASU 2016-09&amp;#x201D;)&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;. The new guidance simplifies several aspects of the accounting for share-based payments, including immediate recognition of all excess tax benefits and deficiencies in the income statement, changing the threshold to qualify for equity classification up to the employees' maximum statutory tax rates, allowing an entity-wide accounting policy election to either estimate the number of awards that are expected to vest or account for forfeitures as they occur, and clarifying the classification on the statement of cash flows for the excess tax benefit and employee taxes paid when an employer withholds shares for tax-withholding purposes. ASU 2016-09 is effective for annual reporting periods beginning after December 15, 2016 and interim periods within that reporting period. The adoption of this standard is not expected to have a material effect on our financial statements&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:36pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 8pt;text-indent:36pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;In May 2014, the FASB issued ASU No. 2014-09&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;, Revenue from Contracts with Customers (Topic 606) (&amp;#x201C;ASU 2014-09&amp;#x201D;), which&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; removes inconsistencies and weaknesses in revenue requirements, provides a more robust framework for addressing revenue issues, improves comparability of revenue recognition practices across entities, industries, jurisdictions and capital markets, provides more useful information to users of financial statements through improved disclosure requirements and simplifies the preparation of financial statements by reducing the number of requirements to which an entity must refer. This guidance requires that an entity depict the consideration by applying a five-step analysis in determining when and how revenue is recognized. The new model will require revenue recognition to depict the transfer of promised goods or services to customers in an amount that reflects the consideration a company expects to receive in exchange for those goods or services. On April 1, 2015, the FASB voted for a one-year deferral of the effective date of the new revenue recognition standard, ASU No. 2014-09.&amp;nbsp;On July 15, 2015, the FASB affirmed these changes, which requires public entities to apply the amendments in ASU 2014-09 for annual reporting beginning after December 15, 2017. Early adoption is permitted beginning after December 31, 2016, the original effective date in ASU 2014-09.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 8pt;text-indent:36pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; The Company is in the early stages of its analysis of the effect &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;ASU 2014-09&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; will have on its Service Revenue, but expects to complete its analysis during the second half of 2017.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 8pt;text-indent:36pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;The Company is also in the early stages of its analysis of&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; the effect ASU 2014-09 will have on &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;its Product Revenue and also expects to complete this analysis in the second half of 2017. Revenue that is recognized upon the ultimate receipt of cash under the Company&amp;#x2019;s existing revenue recognition policy will have to be reassessed under the new standard. The next step in the Company&amp;#x2019;s implementation process is to review its patient account population to determine the appropriate distribution of patient accounts &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;text-decoration:underline;"&gt;by payer&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; &amp;nbsp;(&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-style:italic;font-size:10pt;"&gt;i.e.&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;, Medicare, patient pay, other third-party payer, &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-style:italic;font-size:10pt;"&gt;etc&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;.) into portfolios with similar collection experience that, when evaluated for collectability, will result in a materially consistent revenue amount for such portfolios as if each patient account were evaluated on a contract-by-contract basis.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 8pt;text-indent:36pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;The Company has not yet determined if it plans to utilize the full retrospective or modified retrospective method of adoption, but anticipates adopting the new standard in the first quarter of 2018.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:36pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;
	&lt;/div&gt; &lt;/div&gt;</us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock>
  <us-gaap:OtherAssetsNoncurrent contextRef="As_Of_6_30_2017" unitRef="Unit12" decimals="-3">11000</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:OtherLiabilitiesCurrent contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="-3">34000</us-gaap:OtherLiabilitiesCurrent>
  <us-gaap:OtherLiabilitiesCurrent contextRef="As_Of_6_30_2017" unitRef="Unit12" decimals="-3">32000</us-gaap:OtherLiabilitiesCurrent>
  <us-gaap:OtherLiabilitiesNoncurrent contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="-3">29000</us-gaap:OtherLiabilitiesNoncurrent>
  <us-gaap:OtherLiabilitiesNoncurrent contextRef="As_Of_6_30_2017" unitRef="Unit12" decimals="-3">47000</us-gaap:OtherLiabilitiesNoncurrent>
  <us-gaap:PaymentsForRent contextRef="Duration_10_1_2015_To_10_31_2015_us-gaap_LeaseArrangementTypeAxis_vrml_TrumbullConnecticutFacilityMember" unitRef="Unit12" decimals="0">32000</us-gaap:PaymentsForRent>
  <us-gaap:PaymentsForRent contextRef="Duration_1_1_2017_To_6_30_2017_us-gaap_LeaseArrangementTypeAxis_vrml_AustinTexasFacilityMember" unitRef="Unit12" decimals="0">85000</us-gaap:PaymentsForRent>
  <us-gaap:PaymentsForRoyalties contextRef="Duration_1_1_2017_To_6_30_2017" unitRef="Unit12" decimals="0">57500</us-gaap:PaymentsForRoyalties>
  <us-gaap:PaymentsToAcquireMachineryAndEquipment contextRef="Duration_4_1_2015_To_4_30_2015_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_AssetsHeldUnderCapitalLeasesMember" unitRef="Unit12" decimals="0">125000</us-gaap:PaymentsToAcquireMachineryAndEquipment>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="Duration_1_1_2016_To_6_30_2016" unitRef="Unit12" decimals="-3">1054000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="Duration_1_1_2017_To_6_30_2017" unitRef="Unit12" decimals="-3">43000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="-3">498000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="As_Of_6_30_2017" unitRef="Unit12" decimals="-3">269000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:ProceedsFromIssuanceOfDebt contextRef="Duration_1_1_2016_To_6_30_2016" unitRef="Unit12" decimals="-3">1966000</us-gaap:ProceedsFromIssuanceOfDebt>
  <us-gaap:ProceedsFromIssuanceOfDebt contextRef="Duration_4_15_2016_To_4_15_2016_us-gaap_DebtInstrumentAxis_vrml_DecdMember" unitRef="Unit12" decimals="0">2000000</us-gaap:ProceedsFromIssuanceOfDebt>
  <us-gaap:ProceedsFromIssuanceOfPrivatePlacement contextRef="Duration_1_1_2017_To_6_30_2017" unitRef="Unit12" decimals="-3">5127000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
  <us-gaap:ProceedsFromStockOptionsExercised contextRef="Duration_1_1_2016_To_6_30_2016" unitRef="Unit12" decimals="-3">5000</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="As_Of_6_30_2016_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_AssetsHeldUnderCapitalLeasesMember" unitRef="Unit12" decimals="0">155000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="-3">1911000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="As_Of_6_30_2017" unitRef="Unit12" decimals="-3">1549000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="As_Of_6_30_2017_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_AssetsHeldUnderCapitalLeasesMember" unitRef="Unit12" decimals="0">77000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:RepaymentsOfDebt contextRef="Duration_1_1_2016_To_6_30_2016" unitRef="Unit12" decimals="-3">28000</us-gaap:RepaymentsOfDebt>
  <us-gaap:RepaymentsOfDebt contextRef="Duration_1_1_2017_To_6_30_2017" unitRef="Unit12" decimals="-3">92000</us-gaap:RepaymentsOfDebt>
  <us-gaap:RepaymentsOfDebtAndCapitalLeaseObligations contextRef="Duration_1_1_2016_To_6_30_2016" unitRef="Unit12" decimals="-3">14000</us-gaap:RepaymentsOfDebtAndCapitalLeaseObligations>
  <us-gaap:RepaymentsOfDebtAndCapitalLeaseObligations contextRef="Duration_1_1_2017_To_6_30_2017" unitRef="Unit12" decimals="-3">15000</us-gaap:RepaymentsOfDebtAndCapitalLeaseObligations>
  <us-gaap:ResearchAndDevelopmentExpense id="Item-0016" contextRef="Duration_1_1_2016_To_6_30_2016" unitRef="Unit12" decimals="-3">1498000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense id="Item-0014" contextRef="Duration_4_1_2016_To_6_30_2016" unitRef="Unit12" decimals="-3">564000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense id="Item-0015" contextRef="Duration_1_1_2017_To_6_30_2017" unitRef="Unit12" decimals="-3">493000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense id="Item-0013" contextRef="Duration_4_1_2017_To_6_30_2017" unitRef="Unit12" decimals="-3">268000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="-3">-385556000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="As_Of_6_30_2017" unitRef="Unit12" decimals="-3">-390589000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="Duration_1_1_2017_To_6_30_2017">&lt;div&gt; &lt;div style="margin-left:0pt;margin-right:0pt;"&gt;
		&lt;p style="margin:0pt 0pt 2.25pt 10pt;line-height:normal;text-indent: -10pt;text-align:justify;text-justify:inter-ideograph;border-bottom:1pt none #D9D9D9 ;font-family:Arial Unicode MS;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;background-color: #FFFFFF;"&gt;Revenue Recognition&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 2.25pt 10pt;line-height:normal;text-indent: -10pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Arial Unicode MS;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;background-color: #FFFFFF;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 2.25pt 10pt;line-height:normal;text-indent: -10pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Arial Unicode MS;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;text-decoration:underline;background-color: #FFFFFF;"&gt;Product Revenue&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 2.25pt 10pt;line-height:normal;text-indent: -10pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Arial Unicode MS;font-size: 8pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:8.5pt;background-color: #FFFFFF;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:normal;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Arial Unicode MS;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;background-color: #FFFFFF;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;background-color: #FFFFFF;;font-size: 10pt;font-family:Arial Unicode MS;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;background-color: #FFFFFF;"&gt;The Company has adopted ASC 954-605,&lt;/font&gt;&lt;font style="font-family:Times New Roman;display: inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-style:italic;color:#000000;font-size:10pt;background-color: #FFFFFF;"&gt;Health Care Entities&amp;#x2014;Revenue Recognition, &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;background-color: #FFFFFF;"&gt;as &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;revenue from laboratory services has become significant to the Company&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;background-color: #FFFFFF;"&gt;.&lt;/font&gt;&lt;font style="font-family:Times New Roman;display: inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;background-color: #FFFFFF;"&gt;The Company's product revenue is generated by performing diagnostic services using its OVA1 and Overa tests, and the service is completed upon the delivery of test results to the prescribing physician. The Company recognizes revenue related to billings for Medicare and commercial payers on an accrual basis, net of contractual and other adjustments, when amounts that will ultimately be realized can be estimated. Until a contract has been negotiated with a commercial payer or governmental program, the OVA1 and Overa tests may or may not be covered by these entities' existing reimbursement policies. In addition, patients do not enter into direct agreements with the Company that commit them to pay any portion of the cost of the tests in the event that their insurance declines to reimburse the Company. In the absence of an agreement with the patient or other clearly enforceable legal right to demand payment from the patient, the related revenue is only recognized upon cash receipt.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:normal;border-top:1pt none #D9D9D9 ;font-family:Arial Unicode MS;font-size: 8pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:8.5pt;background-color: #FFFFFF;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:36pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;Estimates of amounts that the Company will ultimately realize require significant judgment by management. Some patients have out-of-pocket costs for amounts not covered by their insurance carrier, and the Company may bill the patient directly for these amounts in the form of co-payments and co-insurance in accordance with the patient&amp;#x2019;s health plan. Some payers may not cover the OVA1 and Overa tests as ordered by the prescribing physician under their reimbursement policies. The Company pursues reimbursement from such patients on a case-by-case basis. In the absence of contracted reimbursement coverage or the ability to estimate the amount that will ultimately be realized for the Company's services, revenue is recognized when cash is received.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:36pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;background-color: #FFFFFF;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 8pt;text-indent:36pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;See discussion of &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;FASB ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606) (&amp;#x201C;ASU No. 2014-09&amp;#x201D;)&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; included in Recent Accounting Pronouncements below&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;. &amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 8pt;text-indent:36pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 2.25pt 10pt;line-height:normal;text-indent: -10pt;text-align:justify;text-justify:inter-ideograph;border-bottom:1pt none #D9D9D9 ;font-family:Arial Unicode MS;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;background-color: #FFFFFF;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 2.25pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Arial Unicode MS;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;text-decoration:underline;background-color: #FFFFFF;"&gt;Service Revenue&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 2.25pt 10pt;line-height:normal;text-indent: -10pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;font-family:Arial Unicode MS;font-size: 8pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:8.5pt;background-color: #FFFFFF;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 6pt;text-indent:36pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;The Company&amp;#x2019;s service revenue is generated by performing IVD trial services for third-party customers. In accordance with SAB Topic 13, service revenue is recognized when the following revenue recognition criteria are met: (1)&amp;nbsp;persuasive evidence of an arrangement exists; (2)&amp;nbsp;delivery has occurred or services have been rendered; (3)&amp;nbsp;the fee is fixed or determinable; and (4)&amp;nbsp;collectability is reasonably assured.&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 6pt;text-indent:36pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;See discussion of ASU No. 2014-09 included in Recent Accounting Pronouncements below&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 8pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;background-color: #FFFFFF;"&gt;The Company has made no &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;background-color: #FFFFFF;"&gt;other &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;background-color: #FFFFFF;"&gt;significant&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; changes in its critical accounting policies and estimates from those disclosed in the 2016 Annual Report&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;
	&lt;/div&gt; &lt;/div&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
  <us-gaap:Revenues contextRef="Duration_1_1_2016_To_6_30_2016" unitRef="Unit12" decimals="-3">1214000</us-gaap:Revenues>
  <us-gaap:Revenues contextRef="Duration_4_1_2016_To_6_30_2016" unitRef="Unit12" decimals="-3">709000</us-gaap:Revenues>
  <us-gaap:Revenues contextRef="Duration_1_1_2017_To_6_30_2017" unitRef="Unit12" decimals="-3">1624000</us-gaap:Revenues>
  <us-gaap:Revenues contextRef="Duration_4_1_2017_To_6_30_2017" unitRef="Unit12" decimals="-3">898000</us-gaap:Revenues>
  <us-gaap:RoyaltyExpense contextRef="Duration_1_1_2016_To_6_30_2016" unitRef="Unit12" decimals="0">42000</us-gaap:RoyaltyExpense>
  <us-gaap:RoyaltyExpense contextRef="Duration_4_1_2016_To_6_30_2016" unitRef="Unit12" decimals="0">22000</us-gaap:RoyaltyExpense>
  <us-gaap:RoyaltyExpense contextRef="Duration_1_1_2017_To_6_30_2017" unitRef="Unit12" decimals="0">63000</us-gaap:RoyaltyExpense>
  <us-gaap:RoyaltyExpense contextRef="Duration_4_1_2017_To_6_30_2017" unitRef="Unit12" decimals="0">34000</us-gaap:RoyaltyExpense>
  <us-gaap:SalesRevenueGoodsNet contextRef="Duration_1_1_2016_To_6_30_2016" unitRef="Unit12" decimals="-3">1059000</us-gaap:SalesRevenueGoodsNet>
  <us-gaap:SalesRevenueGoodsNet contextRef="Duration_4_1_2016_To_6_30_2016" unitRef="Unit12" decimals="-3">554000</us-gaap:SalesRevenueGoodsNet>
  <us-gaap:SalesRevenueGoodsNet contextRef="Duration_1_1_2017_To_6_30_2017" unitRef="Unit12" decimals="-3">1538000</us-gaap:SalesRevenueGoodsNet>
  <us-gaap:SalesRevenueGoodsNet contextRef="Duration_4_1_2017_To_6_30_2017" unitRef="Unit12" decimals="-3">860000</us-gaap:SalesRevenueGoodsNet>
  <us-gaap:SalesRevenueServicesNet contextRef="Duration_1_1_2016_To_6_30_2016" unitRef="Unit12" decimals="-3">155000</us-gaap:SalesRevenueServicesNet>
  <us-gaap:SalesRevenueServicesNet contextRef="Duration_4_1_2016_To_6_30_2016" unitRef="Unit12" decimals="-3">155000</us-gaap:SalesRevenueServicesNet>
  <us-gaap:SalesRevenueServicesNet contextRef="Duration_1_1_2017_To_6_30_2017" unitRef="Unit12" decimals="-3">86000</us-gaap:SalesRevenueServicesNet>
  <us-gaap:SalesRevenueServicesNet contextRef="Duration_4_1_2017_To_6_30_2017" unitRef="Unit12" decimals="-3">38000</us-gaap:SalesRevenueServicesNet>
  <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="Duration_1_1_2017_To_6_30_2017">&lt;div&gt; &lt;div style="margin-left:0pt;margin-right:0pt;"&gt;
		&lt;div style="width:100%"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:38.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size: 1pt"&gt;
						&lt;font style="display: inline;font-size:1pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:38.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="5" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:10pt;"&gt;Three Months Ended June 30,&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="5" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:10pt;"&gt;Six Months Ended June 30,&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:38.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;border-bottom:1pt solid #000000 ;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-weight:bold;color:#000000;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:10pt;"&gt;(in thousands)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.82%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.82%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:38.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;Cost of revenue&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.36%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.10%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;20&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.36%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.10%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;22&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.36%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.10%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;40&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.36%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.10%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;46&amp;nbsp;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:38.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;Research and development &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;2&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;22&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;5&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;53&amp;nbsp;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:38.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;Sales and marketing &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;38&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;14&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;70&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;56&amp;nbsp;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:38.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;General and administrative&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;283&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;320&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;414&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;425&amp;nbsp;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:38.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;Total &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.36%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.10%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;343&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.36%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.10%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;378&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.36%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.10%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;529&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.36%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.10%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;580&amp;nbsp;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:38.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.36%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.10%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.36%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.10%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.36%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.10%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.36%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.10%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt 0pt 8pt;font-family:Calibri;line-height:107.92%;font-size: 11pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;
	&lt;/div&gt; &lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
  <us-gaap:SellingAndMarketingExpense id="Item-0020" contextRef="Duration_1_1_2016_To_6_30_2016" unitRef="Unit12" decimals="-3">3908000</us-gaap:SellingAndMarketingExpense>
  <us-gaap:SellingAndMarketingExpense id="Item-0018" contextRef="Duration_4_1_2016_To_6_30_2016" unitRef="Unit12" decimals="-3">1628000</us-gaap:SellingAndMarketingExpense>
  <us-gaap:SellingAndMarketingExpense id="Item-0019" contextRef="Duration_1_1_2017_To_6_30_2017" unitRef="Unit12" decimals="-3">2064000</us-gaap:SellingAndMarketingExpense>
  <us-gaap:SellingAndMarketingExpense id="Item-0017" contextRef="Duration_4_1_2017_To_6_30_2017" unitRef="Unit12" decimals="-3">1041000</us-gaap:SellingAndMarketingExpense>
  <us-gaap:ShareBasedCompensation contextRef="Duration_1_1_2016_To_6_30_2016" unitRef="Unit12" decimals="-3">600000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation contextRef="Duration_1_1_2017_To_6_30_2017" unitRef="Unit12" decimals="-3">671000</us-gaap:ShareBasedCompensation>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage contextRef="Duration_1_1_2017_To_6_30_2017_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_vrml_StockOptionPlanTwentyTenMember_us-gaap_TitleOfIndividualAxis_vrml_NonEmployeeDirectorsMember_us-gaap_VestingAxis_vrml_VestingPercentageDateBMember" unitRef="Unit14" decimals="INF">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage contextRef="Duration_1_1_2017_To_6_30_2017_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_vrml_StockOptionPlanTwentyTenMember_us-gaap_TitleOfIndividualAxis_vrml_NonEmployeeDirectorsMember_us-gaap_VestingAxis_vrml_VestingPercentageDateCMember" unitRef="Unit14" decimals="INF">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage contextRef="Duration_1_1_2017_To_6_30_2017_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_vrml_StockOptionPlanTwentyTenMember_us-gaap_TitleOfIndividualAxis_vrml_NonEmployeeDirectorsMember_us-gaap_VestingAxis_vrml_VestingPercentageDateMember" unitRef="Unit14" decimals="INF">0.5</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage contextRef="Duration_1_1_2017_To_6_30_2017_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_vrml_StockOptionPlanTwentyTenMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_vrml_ExercisePriceCMember_us-gaap_TitleOfIndividualAxis_vrml_CertainOfficersAndEmployeesMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember" unitRef="Unit14" decimals="2">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage contextRef="Duration_1_1_2017_To_6_30_2017_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_vrml_StockOptionPlanTwentyTenMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_vrml_ExercisePriceDMember_us-gaap_TitleOfIndividualAxis_vrml_CertainOfficersAndEmployeesMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember" unitRef="Unit14" decimals="INF">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage contextRef="Duration_4_1_2017_To_6_30_2017_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_vrml_StockOptionPlanTwentyTenMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_vrml_ExercisePriceEMember_us-gaap_TitleOfIndividualAxis_vrml_CertainOfficersAndEmployeesMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember" unitRef="Unit14" decimals="INF">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="Duration_1_1_2017_To_6_30_2017_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_vrml_StockOptionPlanTwentyTenMember_us-gaap_TitleOfIndividualAxis_vrml_CertainConsultantsMember" unitRef="Unit1" decimals="INF">22841</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice contextRef="As_Of_6_30_2017_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_vrml_StockOptionPlanTwentyTenMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_vrml_ExercisePriceBMember_us-gaap_TitleOfIndividualAxis_vrml_CertainConsultantsMember" unitRef="Unit13" decimals="2">2.14</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice contextRef="As_Of_6_30_2017_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_vrml_StockOptionPlanTwentyTenMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_vrml_ExercisePriceCMember_us-gaap_TitleOfIndividualAxis_vrml_CertainOfficersAndEmployeesMember" unitRef="Unit13" decimals="2">2.14</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice contextRef="As_Of_6_30_2017_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_vrml_StockOptionPlanTwentyTenMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_vrml_ExercisePriceEMember_us-gaap_TitleOfIndividualAxis_vrml_CertainOfficersAndEmployeesMember" unitRef="Unit13" decimals="2">1.83</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice contextRef="As_Of_6_30_2017_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_PlanNameAxis_vrml_StockOptionPlanTwentyTenMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_vrml_ExercisePriceDMember_us-gaap_TitleOfIndividualAxis_vrml_CertainOfficersAndEmployeesMember" unitRef="Unit13" decimals="2">2.14</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted contextRef="Duration_1_1_2017_To_6_30_2017_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_vrml_StockOptionPlanTwentyTenMember_us-gaap_TitleOfIndividualAxis_vrml_NonEmployeeDirectorsMember" unitRef="Unit1" decimals="INF">131250</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted contextRef="Duration_4_1_2017_To_6_30_2017_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_vrml_StockOptionPlanTwentyTenMember_us-gaap_TitleOfIndividualAxis_vrml_CertainConsultantsMember" unitRef="Unit1" decimals="INF">9213</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted contextRef="Duration_4_1_2017_To_6_30_2017_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_vrml_StockOptionPlanTwentyTenMember_us-gaap_TitleOfIndividualAxis_vrml_NonEmployeeDirectorsMember" unitRef="Unit1" decimals="INF">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="As_Of_6_30_2017_us-gaap_PlanNameAxis_vrml_StockOptionPlanTwentyTenMember" unitRef="Unit1" decimals="INF">8122983</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="Duration_1_1_2017_To_6_30_2017_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_vrml_StockOptionPlanTwentyTenMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_vrml_ExercisePriceBMember_us-gaap_TitleOfIndividualAxis_vrml_CertainConsultantsMember" unitRef="Unit1" decimals="INF">70000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="Duration_1_1_2017_To_6_30_2017_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_vrml_StockOptionPlanTwentyTenMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_vrml_ExercisePriceCMember_us-gaap_TitleOfIndividualAxis_vrml_CertainOfficersAndEmployeesMember" unitRef="Unit1" decimals="INF">916000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="Duration_1_1_2017_To_6_30_2017_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_PlanNameAxis_vrml_StockOptionPlanTwentyTenMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_vrml_ExercisePriceDMember_us-gaap_TitleOfIndividualAxis_vrml_CertainOfficersAndEmployeesMember" unitRef="Unit1" decimals="INF">250000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="Duration_4_1_2017_To_6_30_2017_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_vrml_StockOptionPlanTwentyTenMember_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_vrml_ExercisePriceEMember_us-gaap_TitleOfIndividualAxis_vrml_CertainOfficersAndEmployeesMember" unitRef="Unit1" decimals="INF">14500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShortTermBorrowings contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="-3">182000</us-gaap:ShortTermBorrowings>
  <us-gaap:ShortTermBorrowings contextRef="As_Of_6_30_2017" unitRef="Unit12" decimals="-3">188000</us-gaap:ShortTermBorrowings>
  <us-gaap:StockholdersEquity contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="-3">3762000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="As_Of_6_30_2017" unitRef="Unit12" decimals="-3">4527000</us-gaap:StockholdersEquity>
  <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="Duration_1_1_2017_To_6_30_2017_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_vrml_StockOptionPlanTwentyTenMember_us-gaap_TitleOfIndividualAxis_vrml_CertainConsultantsMember" unitRef="Unit12" decimals="0">39000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="Duration_1_1_2016_To_6_30_2016" unitRef="Unit1" decimals="0">52132288</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="Duration_4_1_2016_To_6_30_2016" unitRef="Unit1" decimals="0">52151440</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="Duration_1_1_2017_To_6_30_2017" unitRef="Unit1" decimals="0">55123977</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="Duration_4_1_2017_To_6_30_2017" unitRef="Unit1" decimals="0">56113917</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <vrml:DebtInstrumentAmountEligibleForForgiveness contextRef="As_Of_3_22_2016_us-gaap_DebtInstrumentAxis_vrml_DecdMember" unitRef="Unit12" decimals="0">2000000</vrml:DebtInstrumentAmountEligibleForForgiveness>
  <vrml:DebtInstrumentCovenantNoncompliancePenalty contextRef="Duration_1_1_2017_To_6_30_2017_us-gaap_DebtInstrumentAxis_vrml_DecdMember" unitRef="Unit14" decimals="2">0.05</vrml:DebtInstrumentCovenantNoncompliancePenalty>
  <vrml:DebtInstrumentDebtCovenantJobCreationNumberOfEmployees contextRef="Duration_1_1_2017_To_6_30_2017_us-gaap_DebtInstrumentAxis_vrml_DecdMember" unitRef="Unit15" decimals="INF">40</vrml:DebtInstrumentDebtCovenantJobCreationNumberOfEmployees>
  <vrml:DebtInstrumentDebtCovenantJobCreationPeriod contextRef="Duration_1_1_2017_To_6_30_2017_us-gaap_DebtInstrumentAxis_vrml_DecdMember">P2Y</vrml:DebtInstrumentDebtCovenantJobCreationPeriod>
  <vrml:FairValueOfWarrantsIssued contextRef="As_Of_2_17_2017" unitRef="Unit12" decimals="0">804000</vrml:FairValueOfWarrantsIssued>
  <vrml:GoingConcernPolicyTextBlock contextRef="Duration_1_1_2017_To_6_30_2017">&lt;div&gt; &lt;div style="margin-left:0pt;margin-right:0pt;"&gt;
		&lt;p style="margin:9pt 0pt 3pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;"&gt;Going Concern&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 6pt;text-indent:36pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;The Company has incurred significant net losses and negative cash flows from operations since inception, and as a result has an accumulated deficit of approximat&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;ely &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;390&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;,589&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;,000&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; &amp;nbsp;a&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;t &amp;nbsp;&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;June 30&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;, 2017. The Company also expects to incur a net loss and negative cash flows from operations for the remainder of 2017. The Company&amp;#x2019;s management believes that successful achievement of the Company&amp;#x2019;s business objectives will require additional financing.&amp;nbsp;Given these conditions, there is substantial doubt about the Company&amp;#x2019;s ability to continue as a going concern. The condensed consolidated financial statements have been prepared on a going concern basis and do not include any adjustments that might result from these uncertainties. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 6pt;text-indent:36pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;The Company expects to raise capital through a variety of sources, which may include &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;the exercise of common stock warrants, &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;equity &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;offerings, debt financing&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;, collaborati&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;ons&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;, licensing arrangements, &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;grants and government funding and strategic alliances&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;. However, additional funding may not be available when needed or on terms acceptable to the Company. If the Company is unable to obtain additional capital, it may not be able to continue sales and marketing, research and development, or other operations on the scope or scale of current activity and that could have a material adverse effect on &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;the Company&amp;#x2019;s&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; business, results of operations and financial condition.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 6pt;text-indent:36pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;As discussed in Note &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;4&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;, on February 17, 2017, the Company completed a private placement pursuant to which certain investors purchased Vermillion common stock and warrants to purchase shares of&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; Vermillion&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; common stock for net proceeds of approximately &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;5,127,000&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; after deducting offering expenses.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 6pt;text-indent:36pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;As discussed in Note 3, in March 2016, the Company entered into an agreement (the &amp;#x201C;Loan Agreement&amp;#x201D;) pursuant to which it may borrow up to &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;$4,000,000&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; from the State of Connecticut Department of Economic and Community Development (the &amp;#x201C;DECD&amp;#x201D;). &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;An initial disbursement of &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;$2,000,000&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; was made to the Company in April 2016 under the Loan Agreement.&amp;nbsp;The Loan Agreement provides that the remaining &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;$2,000,000&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; will be disbursed if and when the Company achieves certain future milestones.&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt;text-indent:36pt;line-height:100%;font-family:Arial Unicode MS;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;
	&lt;/div&gt; &lt;/div&gt;</vrml:GoingConcernPolicyTextBlock>
  <vrml:LesseeLeasingArrangementsOperatingLeasesRentAbatementPeriod contextRef="Duration_1_1_2017_To_6_30_2017_us-gaap_LeaseArrangementTypeAxis_vrml_TrumbullConnecticutFacilityMember">P5M</vrml:LesseeLeasingArrangementsOperatingLeasesRentAbatementPeriod>
  <vrml:NumberOfPaymentsForPurchaseProductionOfAssets contextRef="Duration_1_1_2017_To_6_30_2017_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_AssetsHeldUnderCapitalLeasesMember">P36M</vrml:NumberOfPaymentsForPurchaseProductionOfAssets>
  <vrml:NumberOfPurchasedLaboratoryInstruments contextRef="Duration_4_1_2015_To_4_30_2015_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_AssetsHeldUnderCapitalLeasesMember" unitRef="Unit16" decimals="INF">1</vrml:NumberOfPurchasedLaboratoryInstruments>
  <vrml:OperatingLeasesOtherOccupancyCosts contextRef="Duration_10_1_2015_To_10_31_2015_us-gaap_LeaseArrangementTypeAxis_vrml_TrumbullConnecticutFacilityMember" unitRef="Unit12" decimals="0">95000</vrml:OperatingLeasesOtherOccupancyCosts>
  <vrml:OperatingLeasesOtherOccupancyCosts contextRef="Duration_1_1_2017_To_6_30_2017_us-gaap_LeaseArrangementTypeAxis_vrml_AustinTexasFacilityMember" unitRef="Unit12" decimals="0">46000</vrml:OperatingLeasesOtherOccupancyCosts>
  <vrml:OrganizationPolicyTextBlock contextRef="Duration_1_1_2017_To_6_30_2017">&lt;div&gt; &lt;div style="margin-left:0pt;margin-right:0pt;"&gt;
		&lt;p style="margin:0pt 0pt 8pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;"&gt;Organization &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:4.5pt 0pt 0pt 4.5pt;text-indent:31.5pt;line-height:100%;font-family:Arial Unicode MS;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;Vermillion, Inc. (&amp;#x201C;Vermillion&amp;#x201D;; Vermillion and its wholly-owned subsidiaries are collectively referred to as the &amp;#x201C;Company&lt;/font&gt;&lt;a name="_cp_text_1_15"&gt;&lt;/a&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;,&amp;#x201D; &amp;#x201C;we&amp;#x201D; or &amp;#x201C;our&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;&amp;#x201D;&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;) i&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;s incorporated in the state of Delaware, and is engaged in the business of developing and commercializing diagnostic tests for gynecologic disease. The Company sells OVA1&amp;#x2122; and Overa&amp;#x2122; risk of malignancy test&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;s&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; for ovarian cancer (&amp;#x201C;OVA1&amp;#x201D; and &amp;#x201C;Overa&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;,&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;&amp;#x201D;&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt; respectively&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;) through Vermillion&amp;#x2019;s wholly-owned&amp;nbsp;Clinical Laboratory Improvement Amendments of 1988 (&amp;#x201C;CLIA&amp;#x201D;) certified clinical laboratory, ASPiRA LABS, Inc. (&amp;#x201C;ASPiRA LABS&amp;#x201D;). &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;The Company also offers in-vitro diagnostic (&amp;#x201C;IVD&amp;#x201D;) trial services to third-party customers through its wholly-owned subsidiary, ASPiRA IVD, Inc. (&amp;#x201C;ASPiRA IVD&amp;#x201D;), which commenced operations in June 2016. &lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;ASPiRA IVD is a specialized, CLIA certified, laboratory provider dedicated to meeting the unique testing needs of IVD manufacturers seeking to commercialize&amp;nbsp;high-complexity&amp;nbsp;assays. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;
	&lt;/div&gt; &lt;/div&gt;</vrml:OrganizationPolicyTextBlock>
  <vrml:PercentageOfRoyaltyPaid contextRef="Duration_1_1_2017_To_6_30_2017" unitRef="Unit14" decimals="2">0.04</vrml:PercentageOfRoyaltyPaid>
  <vrml:PriceOfSharesToBeIssuedUnderWarrants contextRef="As_Of_2_17_2017" unitRef="Unit13" decimals="INF">0.125</vrml:PriceOfSharesToBeIssuedUnderWarrants>
  <vrml:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedFairValue contextRef="Duration_1_1_2017_To_6_30_2017_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_vrml_StockOptionPlanTwentyTenMember_us-gaap_TitleOfIndividualAxis_vrml_NonEmployeeDirectorsMember" unitRef="Unit12" decimals="0">281000</vrml:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedFairValue>
  <vrml:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedFairValue contextRef="Duration_4_1_2017_To_6_30_2017_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_vrml_StockOptionPlanTwentyTenMember_us-gaap_TitleOfIndividualAxis_vrml_CertainConsultantsMember" unitRef="Unit12" decimals="0">19000</vrml:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedFairValue>
  <vrml:SignificantAccountingAndReportingPoliciesPolicyTextBlock contextRef="Duration_1_1_2017_To_6_30_2017">&lt;div&gt; &lt;div style="margin-left:0pt;margin-right:0pt;"&gt;
		&lt;p style="margin:0pt 0pt 8pt;font-family:Calibri;line-height:107.92%;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;"&gt;Significant Acco&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;"&gt;unting and Reporting Policies&lt;/font&gt;
		&lt;/p&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;
	&lt;/div&gt; &lt;/div&gt;</vrml:SignificantAccountingAndReportingPoliciesPolicyTextBlock>
  <!--Extensible List Section-->
  <!--Footnote Section-->
  <link:footnoteLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:href="#Item-0012" xlink:label="Item-0012_lbl" />
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-0012_lbl" xlink:to="Footnote-01" order="1" />
    <link:loc xlink:type="locator" xlink:href="#Item-0010" xlink:label="Item-0010_lbl" />
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-0010_lbl" xlink:to="Footnote-01" order="1" />
    <link:loc xlink:type="locator" xlink:href="#Item-0011" xlink:label="Item-0011_lbl" />
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-0011_lbl" xlink:to="Footnote-01" order="1" />
    <link:loc xlink:type="locator" xlink:href="#Item-0009" xlink:label="Item-0009_lbl" />
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-0009_lbl" xlink:to="Footnote-01" order="1" />
    <link:loc xlink:type="locator" xlink:href="#Item-0004" xlink:label="Item-0004_lbl" />
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-0004_lbl" xlink:to="Footnote-01" order="1" />
    <link:loc xlink:type="locator" xlink:href="#Item-0002" xlink:label="Item-0002_lbl" />
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-0002_lbl" xlink:to="Footnote-01" order="1" />
    <link:loc xlink:type="locator" xlink:href="#Item-0003" xlink:label="Item-0003_lbl" />
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-0003_lbl" xlink:to="Footnote-01" order="1" />
    <link:loc xlink:type="locator" xlink:href="#Item-0001" xlink:label="Item-0001_lbl" />
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-0001_lbl" xlink:to="Footnote-01" order="1" />
    <link:loc xlink:type="locator" xlink:href="#Item-0008" xlink:label="Item-0008_lbl" />
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-0008_lbl" xlink:to="Footnote-01" order="1" />
    <link:loc xlink:type="locator" xlink:href="#Item-0006" xlink:label="Item-0006_lbl" />
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-0006_lbl" xlink:to="Footnote-01" order="1" />
    <link:loc xlink:type="locator" xlink:href="#Item-0007" xlink:label="Item-0007_lbl" />
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-0007_lbl" xlink:to="Footnote-01" order="1" />
    <link:loc xlink:type="locator" xlink:href="#Item-0005" xlink:label="Item-0005_lbl" />
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-0005_lbl" xlink:to="Footnote-01" order="1" />
    <link:loc xlink:type="locator" xlink:href="#Item-0024" xlink:label="Item-0024_lbl" />
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-0024_lbl" xlink:to="Footnote-04" order="1" />
    <link:loc xlink:type="locator" xlink:href="#Item-0022" xlink:label="Item-0022_lbl" />
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-0022_lbl" xlink:to="Footnote-04" order="1" />
    <link:loc xlink:type="locator" xlink:href="#Item-0023" xlink:label="Item-0023_lbl" />
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-0023_lbl" xlink:to="Footnote-04" order="1" />
    <link:loc xlink:type="locator" xlink:href="#Item-0021" xlink:label="Item-0021_lbl" />
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-0021_lbl" xlink:to="Footnote-04" order="1" />
    <link:loc xlink:type="locator" xlink:href="#Item-0016" xlink:label="Item-0016_lbl" />
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-0016_lbl" xlink:to="Footnote-02" order="1" />
    <link:loc xlink:type="locator" xlink:href="#Item-0014" xlink:label="Item-0014_lbl" />
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-0014_lbl" xlink:to="Footnote-02" order="1" />
    <link:loc xlink:type="locator" xlink:href="#Item-0015" xlink:label="Item-0015_lbl" />
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-0015_lbl" xlink:to="Footnote-02" order="1" />
    <link:loc xlink:type="locator" xlink:href="#Item-0013" xlink:label="Item-0013_lbl" />
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-0013_lbl" xlink:to="Footnote-02" order="1" />
    <link:loc xlink:type="locator" xlink:href="#Item-0020" xlink:label="Item-0020_lbl" />
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-0020_lbl" xlink:to="Footnote-03" order="1" />
    <link:loc xlink:type="locator" xlink:href="#Item-0018" xlink:label="Item-0018_lbl" />
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-0018_lbl" xlink:to="Footnote-03" order="1" />
    <link:loc xlink:type="locator" xlink:href="#Item-0019" xlink:label="Item-0019_lbl" />
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-0019_lbl" xlink:to="Footnote-03" order="1" />
    <link:loc xlink:type="locator" xlink:href="#Item-0017" xlink:label="Item-0017_lbl" />
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-0017_lbl" xlink:to="Footnote-03" order="1" />
    <link:footnote xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:label="Footnote-01" xml:lang="en-US">(1)  Cost of revenue$40$22$79$46</link:footnote>
    <link:footnote xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:label="Footnote-04" xml:lang="en-US">(4)  General and administrative 295 319 510 445</link:footnote>
    <link:footnote xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:label="Footnote-02" xml:lang="en-US">(2)  Research and development 2 22 5 53</link:footnote>
    <link:footnote xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:label="Footnote-03" xml:lang="en-US">(3)  Sales and marketing 40 14 77 56</link:footnote>
  </link:footnoteLink>
</xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>c617-20170630.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created by Certent Disclosure Management 6.8.4.2 -->
<!--Based on XBRL 2.1-->
<!--Created on: 8/11/2017 2:59:16 PM-->
<!--Modified on: 8/11/2017 2:59:16 PM-->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" targetNamespace="http://www.vermillion.com/20170630" elementFormDefault="qualified" attributeFormDefault="unqualified" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:vrml="http://www.vermillion.com/20170630" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2017-01-31" xmlns:us-types="http://fasb.org/us-types/2017-01-31" xmlns:country="http://xbrl.sec.gov/country/2017-01-31">
  <annotation>
    <appinfo>
      <link:roleType roleURI="http://www.vermillion.com/role/StatementCondensedConsolidatedBalanceSheets" id="StatementCondensedConsolidatedBalanceSheets">
        <link:definition>00100 - Statement - Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vermillion.com/role/StatementCondensedConsolidatedStatementsOfOperations" id="StatementCondensedConsolidatedStatementsOfOperations">
        <link:definition>00200 - Statement - Condensed Consolidated Statements Of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vermillion.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" id="StatementCondensedConsolidatedStatementsOfCashFlows">
        <link:definition>00400 - Statement - Condensed Consolidated Statements Of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vermillion.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>00090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vermillion.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" id="StatementCondensedConsolidatedBalanceSheetsParenthetical">
        <link:definition>00105 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vermillion.com/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical" id="StatementCondensedConsolidatedStatementsOfOperationsParenthetical">
        <link:definition>00205 - Statement - Condensed Consolidated Statements Of Operations (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vermillion.com/role/DisclosureOrganizationBasisOfPresentationAndSignificantAccountingAndReportingPolicies" id="DisclosureOrganizationBasisOfPresentationAndSignificantAccountingAndReportingPolicies">
        <link:definition>10101 - Disclosure - Organization, Basis Of Presentation And Significant Accounting And Reporting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vermillion.com/role/DisclosureAgreementsWithQuestDiagnosticsIncorporated" id="DisclosureAgreementsWithQuestDiagnosticsIncorporated">
        <link:definition>10201 - Disclosure - Agreements With Quest Diagnostics Incorporated</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vermillion.com/role/DisclosureCommitmentsAndContingencies" id="DisclosureCommitmentsAndContingencies">
        <link:definition>10301 - Disclosure - Commitments And Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vermillion.com/role/DisclosureStockholdersEquity" id="DisclosureStockholdersEquity">
        <link:definition>10401 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vermillion.com/role/DisclosureLossPerShare" id="DisclosureLossPerShare">
        <link:definition>10501 - Disclosure - Loss Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vermillion.com/role/DisclosureOrganizationBasisOfPresentationAndSignificantAccountingAndReportingPoliciesPolicy" id="DisclosureOrganizationBasisOfPresentationAndSignificantAccountingAndReportingPoliciesPolicy">
        <link:definition>20102 - Disclosure - Organization, Basis Of Presentation And Significant Accounting And Reporting Policies (Policy)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vermillion.com/role/DisclosureStockholdersEquityTables" id="DisclosureStockholdersEquityTables">
        <link:definition>30403 - Disclosure - Stockholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vermillion.com/role/DisclosureOrganizationBasisOfPresentationAndSignificantAccountingAndReportingPoliciesDetails" id="DisclosureOrganizationBasisOfPresentationAndSignificantAccountingAndReportingPoliciesDetails">
        <link:definition>40101 - Disclosure - Organization, Basis Of Presentation And Significant Accounting And Reporting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vermillion.com/role/DisclosureCommitmentsAndContingenciesDetails" id="DisclosureCommitmentsAndContingenciesDetails">
        <link:definition>40301 - Disclosure - Commitments And Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vermillion.com/role/DisclosureStockholdersEquityNarrativeDetails" id="DisclosureStockholdersEquityNarrativeDetails">
        <link:definition>40401 - Disclosure - Stockholders' Equity (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vermillion.com/role/DisclosureStockholdersEquityAllocationOfEmployeeStockBasedCompensationExpenseByFunctionalAreaDetails" id="DisclosureStockholdersEquityAllocationOfEmployeeStockBasedCompensationExpenseByFunctionalAreaDetails">
        <link:definition>40402 - Disclosure - Stockholders' Equity (Allocation of Employee Stock-Based Compensation Expense By Functional Area) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vermillion.com/role/DisclosureLossPerShareDetails" id="DisclosureLossPerShareDetails">
        <link:definition>40501 - Disclosure - Loss Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:href="c617-20170630_cal.xml" xlink:title="Calculation Links, all" />
      <link:linkbaseRef xlink:type="simple" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:href="c617-20170630_def.xml" xlink:title="Definition Links, all" />
      <link:linkbaseRef xlink:type="simple" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:href="c617-20170630_lab.xml" xlink:title="Label Links, all" />
      <link:linkbaseRef xlink:type="simple" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:href="c617-20170630_pre.xml" xlink:title="Presentation Links, all" />
    </appinfo>
  </annotation>
  <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
  <import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
  <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
  <import namespace="http://xbrl.sec.gov/dei/2014-01-31" schemaLocation="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd" />
  <import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <import namespace="http://fasb.org/us-gaap/2017-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd" />
  <element name="BasisOfPresentationAndSignificantAccountingPoliciesTable" id="vrml_BasisOfPresentationAndSignificantAccountingPoliciesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" />
  <element name="OperatingLeasesOtherOccupancyCosts" id="vrml_OperatingLeasesOtherOccupancyCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" />
  <element name="OrganizationConsolidationAndSummaryOfSignificantAccountingPoliciesLineItems" id="vrml_OrganizationConsolidationAndSummaryOfSignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
  <element name="StockOptionPlanTwentyTenMember" id="vrml_StockOptionPlanTwentyTenMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
  <element id="vrml_DocumentAndEntityInformationAbstract" name="DocumentAndEntityInformationAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="vrml_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedFairValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedFairValue" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <element id="vrml_VestingPercentageDateMember" name="VestingPercentageDateMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="vrml_VestingPercentageDateBMember" name="VestingPercentageDateBMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="vrml_VestingPercentageDateCMember" name="VestingPercentageDateCMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="vrml_EmployeeStockBasedCompensationMember" name="EmployeeStockBasedCompensationMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="vrml_ExercisePriceBMember" name="ExercisePriceBMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="vrml_ExercisePriceCMember" name="ExercisePriceCMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="vrml_ExercisePriceDMember" name="ExercisePriceDMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="vrml_ExercisePriceEMember" name="ExercisePriceEMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="vrml_NumberOfPaymentsForPurchaseProductionOfAssets" name="NumberOfPaymentsForPurchaseProductionOfAssets" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="vrml_NumberOfPurchasedLaboratoryInstruments" name="NumberOfPurchasedLaboratoryInstruments" nillable="true" type="xbrli:positiveIntegerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="vrml_FairValueOfWarrantsIssued" name="FairValueOfWarrantsIssued" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <element id="vrml_OrganizationPolicyTextBlock" name="OrganizationPolicyTextBlock" nillable="true" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="vrml_AustinTexasFacilityMember" name="AustinTexasFacilityMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="vrml_PercentageOfRoyaltyPaid" name="PercentageOfRoyaltyPaid" nillable="true" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="vrml_CommitmentsAndContingenciesTable" name="CommitmentsAndContingenciesTable" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" abstract="true" xbrli:periodType="duration" />
  <element id="vrml_CommitmentsAndContingenciesLineItems" name="CommitmentsAndContingenciesLineItems" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="vrml_TrumbullConnecticutFacilityMember" name="TrumbullConnecticutFacilityMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="vrml_LesseeLeasingArrangementsOperatingLeasesRentAbatementPeriod" name="LesseeLeasingArrangementsOperatingLeasesRentAbatementPeriod" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="vrml_CertainConsultantsMember" name="CertainConsultantsMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="vrml_DecdMember" name="DecdMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="vrml_DebtInstrumentAmountEligibleForForgiveness" name="DebtInstrumentAmountEligibleForForgiveness" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <element id="vrml_NonEmployeeDirectorsMember" name="NonEmployeeDirectorsMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="vrml_CertainOfficersAndEmployeesMember" name="CertainOfficersAndEmployeesMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="vrml_GoingConcernPolicyTextBlock" name="GoingConcernPolicyTextBlock" nillable="true" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="vrml_DebtInstrumentCovenantNoncompliancePenalty" name="DebtInstrumentCovenantNoncompliancePenalty" nillable="true" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="vrml_SignificantAccountingAndReportingPoliciesPolicyTextBlock" name="SignificantAccountingAndReportingPoliciesPolicyTextBlock" nillable="true" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="vrml_DebtInstrumentDebtCovenantJobCreationNumberOfEmployees" name="DebtInstrumentDebtCovenantJobCreationNumberOfEmployees" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="vrml_DebtInstrumentDebtCovenantJobCreationPeriod" name="DebtInstrumentDebtCovenantJobCreationPeriod" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="vrml_PriceOfSharesToBeIssuedUnderWarrants" name="PriceOfSharesToBeIssuedUnderWarrants" nillable="true" type="num:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>c617-20170630_cal.xml
<DESCRIPTION>EX-101.CAL
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created by Certent Disclosure Management 6.8.4.2 -->
<!--Based on XBRL 2.1-->
<!--Created on: 8/11/2017 2:59:16 PM-->
<!--Modified on: 8/11/2017 2:59:16 PM-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="c617-20170630.xsd#StatementCondensedConsolidatedBalanceSheets" roleURI="http://www.vermillion.com/role/StatementCondensedConsolidatedBalanceSheets" />
  <roleRef xlink:type="simple" xlink:href="c617-20170630.xsd#StatementCondensedConsolidatedStatementsOfOperations" roleURI="http://www.vermillion.com/role/StatementCondensedConsolidatedStatementsOfOperations" />
  <roleRef xlink:type="simple" xlink:href="c617-20170630.xsd#StatementCondensedConsolidatedStatementsOfCashFlows" roleURI="http://www.vermillion.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" />
  <calculationLink xlink:role="http://www.vermillion.com/role/StatementCondensedConsolidatedBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - Condensed Consolidated Balance Sheets">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_636380603560554792" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent_636380603560554792" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_636380603560554792" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_636380603560554792" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_636380603560554792" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent_636380603560564793" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_636380603560554792" xlink:to="us-gaap_AccountsReceivableNetCurrent_636380603560564793" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_636380603560564793" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_636380603560554792" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_636380603560564793" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet_636380603560564793" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_636380603560554792" xlink:to="us-gaap_InventoryNet_636380603560564793" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_636380603560564793" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_636380603560564793" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent_636380603560564793" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent_636380603560564793" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_636380603560564793" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity_636380603560564793" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_636380603560564793" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_636380603560564793" xlink:to="us-gaap_CommonStockValue_636380603560564793" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital_636380603560564793" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_636380603560564793" xlink:to="us-gaap_AdditionalPaidInCapital_636380603560564793" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_636380603560564793" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_636380603560564793" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_636380603560564793" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_636380603560564793" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities_636380603560564793" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_636380603560564793" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_636380603560564793" xlink:to="us-gaap_LiabilitiesCurrent_636380603560564793" order="1" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_636380603560564793" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_636380603560564793" xlink:to="us-gaap_AccruedLiabilitiesCurrent_636380603560564793" order="1" use="optional" weight="1" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermBorrowings" xlink:label="us-gaap_ShortTermBorrowings_636380603560564793" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_636380603560564793" xlink:to="us-gaap_ShortTermBorrowings_636380603560564793" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_636380603560564793" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_636380603560564793" xlink:to="us-gaap_AccountsPayableCurrent_636380603560564793" order="3" use="optional" weight="1" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent_636380603560564793" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_636380603560564793" xlink:to="us-gaap_OtherLiabilitiesCurrent_636380603560564793" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_636380603560574794" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_636380603560564793" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_636380603560574794" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent_636380603560574794" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_636380603560564793" xlink:to="us-gaap_LongTermDebtNoncurrent_636380603560574794" order="3" use="optional" weight="1" priority="4" />
  </calculationLink>
  <calculationLink xlink:role="http://www.vermillion.com/role/StatementCondensedConsolidatedStatementsOfOperations" xlink:type="extended" xlink:title="00200 - Statement - Condensed Consolidated Statements Of Operations">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="us-gaap_InterestIncomeExpenseNet_636380603560694806" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_InterestIncomeExpenseNet_636380603560694806" order="1" use="optional" weight="1" priority="7" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense_636380603560694806" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NonoperatingIncomeExpense_636380603560694806" order="2" use="optional" weight="1" priority="7" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_636380603560694806" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_636380603560694806" order="3" use="optional" weight="1" priority="7" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit_636380603560694806" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_636380603560694806" xlink:to="us-gaap_GrossProfit_636380603560694806" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues_636380603560694806" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GrossProfit_636380603560694806" xlink:to="us-gaap_Revenues_636380603560694806" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="us-gaap_SalesRevenueGoodsNet_636380603560694806" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Revenues_636380603560694806" xlink:to="us-gaap_SalesRevenueGoodsNet_636380603560694806" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueServicesNet" xlink:label="us-gaap_SalesRevenueServicesNet_636380603560694806" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Revenues_636380603560694806" xlink:to="us-gaap_SalesRevenueServicesNet_636380603560694806" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold_636380603560694806" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GrossProfit_636380603560694806" xlink:to="us-gaap_CostOfGoodsAndServicesSold_636380603560694806" order="2" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CostOfServices" xlink:label="us-gaap_CostOfServices_636380603560694806" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostOfGoodsAndServicesSold_636380603560694806" xlink:to="us-gaap_CostOfServices_636380603560694806" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CostOfGoodsSold" xlink:label="us-gaap_CostOfGoodsSold_636380603560694806" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostOfGoodsAndServicesSold_636380603560694806" xlink:to="us-gaap_CostOfGoodsSold_636380603560694806" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses_636380603560694806" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_636380603560694806" xlink:to="us-gaap_OperatingExpenses_636380603560694806" order="2" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_636380603560694806" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_636380603560694806" xlink:to="us-gaap_ResearchAndDevelopmentExpense_636380603560694806" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SellingAndMarketingExpense" xlink:label="us-gaap_SellingAndMarketingExpense_636380603560694806" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_636380603560694806" xlink:to="us-gaap_SellingAndMarketingExpense_636380603560694806" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_636380603560694806" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_636380603560694806" xlink:to="us-gaap_GeneralAndAdministrativeExpense_636380603560694806" order="3" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.vermillion.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="00400 - Statement - Condensed Consolidated Statements Of Cash Flows">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_636380603560694806" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_636380603560694806" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_636380603560704807" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_636380603560694806" xlink:to="us-gaap_NetIncomeLoss_636380603560704807" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_636380603560704807" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_636380603560694806" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_636380603560704807" order="2" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization_636380603560704807" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_636380603560694806" xlink:to="us-gaap_DepreciationDepletionAndAmortization_636380603560704807" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_636380603560704807" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_636380603560694806" xlink:to="us-gaap_ShareBasedCompensation_636380603560704807" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_636380603560704807" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_636380603560694806" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_636380603560704807" order="5" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_636380603560704807" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_636380603560694806" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_636380603560704807" order="6" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_636380603560704807" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_636380603560694806" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_636380603560704807" order="7" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_636380603560704807" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_636380603560694806" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue_636380603560704807" order="8" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories_636380603560704807" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_636380603560694806" xlink:to="us-gaap_IncreaseDecreaseInInventories_636380603560704807" order="9" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_636380603560704807" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_636380603560704807" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_636380603560704807" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_636380603560704807" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_636380603560704807" order="1" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_636380603560704807" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_636380603560704807" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_636380603560704807" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_636380603560704807" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_636380603560704807" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt_636380603560704807" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_636380603560704807" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt_636380603560704807" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepaymentsOfDebt" xlink:label="us-gaap_RepaymentsOfDebt_636380603560704807" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_636380603560704807" xlink:to="us-gaap_RepaymentsOfDebt_636380603560704807" order="3" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_636380603560704807" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_636380603560704807" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_636380603560704807" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations" xlink:label="us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations_636380603560704807" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_636380603560704807" xlink:to="us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations_636380603560704807" order="5" use="optional" weight="-1" priority="2" />
  </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>c617-20170630_def.xml
<DESCRIPTION>EX-101.DEF
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created by Certent Disclosure Management 6.8.4.2 -->
<!--Based on XBRL 2.1-->
<!--Created on: 8/11/2017 2:59:16 PM-->
<!--Modified on: 8/11/2017 2:59:16 PM-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="c617-20170630.xsd#StatementCondensedConsolidatedStatementsOfOperationsParenthetical" roleURI="http://www.vermillion.com/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical" />
  <roleRef xlink:type="simple" xlink:href="c617-20170630.xsd#DisclosureOrganizationBasisOfPresentationAndSignificantAccountingAndReportingPoliciesDetails" roleURI="http://www.vermillion.com/role/DisclosureOrganizationBasisOfPresentationAndSignificantAccountingAndReportingPoliciesDetails" />
  <roleRef xlink:type="simple" xlink:href="c617-20170630.xsd#DisclosureCommitmentsAndContingenciesDetails" roleURI="http://www.vermillion.com/role/DisclosureCommitmentsAndContingenciesDetails" />
  <roleRef xlink:type="simple" xlink:href="c617-20170630.xsd#DisclosureStockholdersEquityNarrativeDetails" roleURI="http://www.vermillion.com/role/DisclosureStockholdersEquityNarrativeDetails" />
  <roleRef xlink:type="simple" xlink:href="c617-20170630.xsd#DisclosureStockholdersEquityAllocationOfEmployeeStockBasedCompensationExpenseByFunctionalAreaDetails" roleURI="http://www.vermillion.com/role/DisclosureStockholdersEquityAllocationOfEmployeeStockBasedCompensationExpenseByFunctionalAreaDetails" />
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
  <definitionLink xlink:role="http://www.vermillion.com/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical" xlink:type="extended" xlink:title="00205 - Statement - Condensed Consolidated Statements Of Operations (Parenthetical)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_636380603560714808" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_636380603560714808" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CostOfSalesMember" xlink:label="us-gaap_CostOfSalesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_CostOfSalesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SellingAndMarketingExpenseMember" xlink:label="us-gaap_SellingAndMarketingExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_SellingAndMarketingExpenseMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.vermillion.com/role/DisclosureOrganizationBasisOfPresentationAndSignificantAccountingAndReportingPoliciesDetails" xlink:type="extended" xlink:title="40101 - Disclosure - Organization, Basis Of Presentation And Significant Accounting And Reporting Policies (Details)">
    <loc xlink:type="locator" xlink:href="c617-20170630.xsd#vrml_BasisOfPresentationAndSignificantAccountingPoliciesTable" xlink:label="vrml_BasisOfPresentationAndSignificantAccountingPoliciesTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="vrml_BasisOfPresentationAndSignificantAccountingPoliciesTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_636380603560724809" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain_636380603560724809" use="optional" />
    <loc xlink:type="locator" xlink:href="c617-20170630.xsd#vrml_DecdMember" xlink:label="vrml_DecdMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="vrml_DecdMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="c617-20170630.xsd#vrml_OrganizationConsolidationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:label="vrml_OrganizationConsolidationAndSummaryOfSignificantAccountingPoliciesLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="vrml_OrganizationConsolidationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="vrml_BasisOfPresentationAndSignificantAccountingPoliciesTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="vrml_OrganizationConsolidationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="vrml_OrganizationConsolidationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="vrml_OrganizationConsolidationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="vrml_OrganizationConsolidationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount" xlink:label="us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="vrml_OrganizationConsolidationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.vermillion.com/role/DisclosureCommitmentsAndContingenciesDetails" xlink:type="extended" xlink:title="40301 - Disclosure - Commitments And Contingencies (Details)">
    <loc xlink:type="locator" xlink:href="c617-20170630.xsd#vrml_CommitmentsAndContingenciesTable" xlink:label="vrml_CommitmentsAndContingenciesTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="vrml_CommitmentsAndContingenciesTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_636380603560734810" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_636380603560734810" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsHeldUnderCapitalLeasesMember" xlink:label="us-gaap_AssetsHeldUnderCapitalLeasesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_AssetsHeldUnderCapitalLeasesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="vrml_CommitmentsAndContingenciesTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="c617-20170630.xsd#vrml_DecdMember" xlink:label="vrml_DecdMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="vrml_DecdMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseArrangementTypeAxis" xlink:label="us-gaap_LeaseArrangementTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="vrml_CommitmentsAndContingenciesTable" xlink:to="us-gaap_LeaseArrangementTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="us-gaap_LeaseArrangementTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_LeaseArrangementTypeAxis" xlink:to="us-gaap_LeaseArrangementTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="us-gaap_LeaseArrangementTypeDomain_636380603560734810" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_LeaseArrangementTypeAxis" xlink:to="us-gaap_LeaseArrangementTypeDomain_636380603560734810" use="optional" />
    <loc xlink:type="locator" xlink:href="c617-20170630.xsd#vrml_AustinTexasFacilityMember" xlink:label="vrml_AustinTexasFacilityMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_LeaseArrangementTypeDomain" xlink:to="vrml_AustinTexasFacilityMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="c617-20170630.xsd#vrml_TrumbullConnecticutFacilityMember" xlink:label="vrml_TrumbullConnecticutFacilityMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LeaseArrangementTypeDomain" xlink:to="vrml_TrumbullConnecticutFacilityMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="c617-20170630.xsd#vrml_CommitmentsAndContingenciesLineItems" xlink:label="vrml_CommitmentsAndContingenciesLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="vrml_CommitmentsAndContingenciesLineItems" xlink:to="vrml_CommitmentsAndContingenciesTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="vrml_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="vrml_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="vrml_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="c617-20170630.xsd#vrml_DebtInstrumentAmountEligibleForForgiveness" xlink:label="vrml_DebtInstrumentAmountEligibleForForgiveness" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="vrml_CommitmentsAndContingenciesLineItems" xlink:to="vrml_DebtInstrumentAmountEligibleForForgiveness" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="c617-20170630.xsd#vrml_DebtInstrumentDebtCovenantJobCreationNumberOfEmployees" xlink:label="vrml_DebtInstrumentDebtCovenantJobCreationNumberOfEmployees" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="vrml_CommitmentsAndContingenciesLineItems" xlink:to="vrml_DebtInstrumentDebtCovenantJobCreationNumberOfEmployees" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="c617-20170630.xsd#vrml_DebtInstrumentDebtCovenantJobCreationPeriod" xlink:label="vrml_DebtInstrumentDebtCovenantJobCreationPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="vrml_CommitmentsAndContingenciesLineItems" xlink:to="vrml_DebtInstrumentDebtCovenantJobCreationPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="us-gaap_DebtInstrumentTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="vrml_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_DebtInstrumentTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="c617-20170630.xsd#vrml_DebtInstrumentCovenantNoncompliancePenalty" xlink:label="vrml_DebtInstrumentCovenantNoncompliancePenalty" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="vrml_CommitmentsAndContingenciesLineItems" xlink:to="vrml_DebtInstrumentCovenantNoncompliancePenalty" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="vrml_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount" xlink:label="us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="vrml_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsForRent" xlink:label="us-gaap_PaymentsForRent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="vrml_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_PaymentsForRent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="c617-20170630.xsd#vrml_OperatingLeasesOtherOccupancyCosts" xlink:label="vrml_OperatingLeasesOtherOccupancyCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="vrml_CommitmentsAndContingenciesLineItems" xlink:to="vrml_OperatingLeasesOtherOccupancyCosts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:label="us-gaap_LeaseExpirationDate1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="vrml_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_LeaseExpirationDate1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseholdImprovementsGross" xlink:label="us-gaap_LeaseholdImprovementsGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="vrml_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_LeaseholdImprovementsGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract" xlink:label="us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="vrml_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="c617-20170630.xsd#vrml_LesseeLeasingArrangementsOperatingLeasesRentAbatementPeriod" xlink:label="vrml_LesseeLeasingArrangementsOperatingLeasesRentAbatementPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="vrml_CommitmentsAndContingenciesLineItems" xlink:to="vrml_LesseeLeasingArrangementsOperatingLeasesRentAbatementPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="us-gaap_OperatingLeasesRentExpenseNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="vrml_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_OperatingLeasesRentExpenseNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="c617-20170630.xsd#vrml_NumberOfPurchasedLaboratoryInstruments" xlink:label="vrml_NumberOfPurchasedLaboratoryInstruments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="vrml_CommitmentsAndContingenciesLineItems" xlink:to="vrml_NumberOfPurchasedLaboratoryInstruments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireMachineryAndEquipment" xlink:label="us-gaap_PaymentsToAcquireMachineryAndEquipment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="20" xlink:from="vrml_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_PaymentsToAcquireMachineryAndEquipment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalLeasesContingentRentalPaymentsDue" xlink:label="us-gaap_CapitalLeasesContingentRentalPaymentsDue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="21" xlink:from="vrml_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_CapitalLeasesContingentRentalPaymentsDue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="c617-20170630.xsd#vrml_NumberOfPaymentsForPurchaseProductionOfAssets" xlink:label="vrml_NumberOfPaymentsForPurchaseProductionOfAssets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="22" xlink:from="vrml_CommitmentsAndContingenciesLineItems" xlink:to="vrml_NumberOfPaymentsForPurchaseProductionOfAssets" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="23" xlink:from="vrml_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="24" xlink:from="vrml_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="c617-20170630.xsd#vrml_PercentageOfRoyaltyPaid" xlink:label="vrml_PercentageOfRoyaltyPaid" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="25" xlink:from="vrml_CommitmentsAndContingenciesLineItems" xlink:to="vrml_PercentageOfRoyaltyPaid" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsForRoyalties" xlink:label="us-gaap_PaymentsForRoyalties" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="26" xlink:from="vrml_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_PaymentsForRoyalties" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RoyaltyExpense" xlink:label="us-gaap_RoyaltyExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="27" xlink:from="vrml_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_RoyaltyExpense" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.vermillion.com/role/DisclosureStockholdersEquityNarrativeDetails" xlink:type="extended" xlink:title="40401 - Disclosure - Stockholders' Equity (Narrative) (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_636380603560784815" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_636380603560784815" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="c617-20170630.xsd#vrml_StockOptionPlanTwentyTenMember" xlink:label="vrml_StockOptionPlanTwentyTenMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="vrml_StockOptionPlanTwentyTenMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="us-gaap_TitleOfIndividualAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_TitleOfIndividualAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_636380603560784815" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_636380603560784815" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="c617-20170630.xsd#vrml_NonEmployeeDirectorsMember" xlink:label="vrml_NonEmployeeDirectorsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="vrml_NonEmployeeDirectorsMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="c617-20170630.xsd#vrml_CertainConsultantsMember" xlink:label="vrml_CertainConsultantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="vrml_CertainConsultantsMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="c617-20170630.xsd#vrml_CertainOfficersAndEmployeesMember" xlink:label="vrml_CertainOfficersAndEmployeesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="vrml_CertainOfficersAndEmployeesMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_636380603560784815" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_636380603560784815" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_PerformanceSharesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_VestingAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain_636380603560794816" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain_636380603560794816" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" use="optional" />
    <loc xlink:type="locator" xlink:href="c617-20170630.xsd#vrml_VestingPercentageDateMember" xlink:label="vrml_VestingPercentageDateMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_VestingDomain" xlink:to="vrml_VestingPercentageDateMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="c617-20170630.xsd#vrml_VestingPercentageDateBMember" xlink:label="vrml_VestingPercentageDateBMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_VestingDomain" xlink:to="vrml_VestingPercentageDateBMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="c617-20170630.xsd#vrml_VestingPercentageDateCMember" xlink:label="vrml_VestingPercentageDateCMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_VestingDomain" xlink:to="vrml_VestingPercentageDateCMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_636380603560804817" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_636380603560804817" use="optional" />
    <loc xlink:type="locator" xlink:href="c617-20170630.xsd#vrml_ExercisePriceBMember" xlink:label="vrml_ExercisePriceBMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="vrml_ExercisePriceBMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="c617-20170630.xsd#vrml_ExercisePriceCMember" xlink:label="vrml_ExercisePriceCMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="vrml_ExercisePriceCMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="c617-20170630.xsd#vrml_ExercisePriceDMember" xlink:label="vrml_ExercisePriceDMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="vrml_ExercisePriceDMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="c617-20170630.xsd#vrml_ExercisePriceEMember" xlink:label="vrml_ExercisePriceEMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="vrml_ExercisePriceEMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockSharesIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="c617-20170630.xsd#vrml_PriceOfSharesToBeIssuedUnderWarrants" xlink:label="vrml_PriceOfSharesToBeIssuedUnderWarrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="vrml_PriceOfSharesToBeIssuedUnderWarrants" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="c617-20170630.xsd#vrml_FairValueOfWarrantsIssued" xlink:label="vrml_FairValueOfWarrantsIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="vrml_FairValueOfWarrantsIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="c617-20170630.xsd#vrml_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedFairValue" xlink:label="vrml_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="vrml_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.vermillion.com/role/DisclosureStockholdersEquityAllocationOfEmployeeStockBasedCompensationExpenseByFunctionalAreaDetails" xlink:type="extended" xlink:title="40402 - Disclosure - Stockholders' Equity (Allocation of Employee Stock-Based Compensation Expense By Functional Area) (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="c617-20170630.xsd#vrml_EmployeeStockBasedCompensationMember" xlink:label="vrml_EmployeeStockBasedCompensationMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="vrml_EmployeeStockBasedCompensationMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CostOfSalesMember" xlink:label="us-gaap_CostOfSalesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_CostOfSalesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SellingAndMarketingExpenseMember" xlink:label="us-gaap_SellingAndMarketingExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_SellingAndMarketingExpenseMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="1" use="optional" />
  </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>c617-20170630_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created by Certent Disclosure Management 6.8.4.2 -->
<!--Based on XBRL 2.1-->
<!--Created on: 8/11/2017 2:59:16 PM-->
<!--Modified on: 8/11/2017 2:59:16 PM-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
  <labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="c617-20170630.xsd#vrml_DocumentAndEntityInformationAbstract" xlink:label="vrml_DocumentAndEntityInformationAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vrml_DocumentAndEntityInformationAbstract" xlink:to="vrml_DocumentAndEntityInformationAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vrml_DocumentAndEntityInformationAbstract_lbl" xml:lang="en-US">Document And Entity Information [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vrml_DocumentAndEntityInformationAbstract_lbl" xml:lang="en-US">Document And Entity Information [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Condensed Consolidated Balance Sheets [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">Assets [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">Assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Assets Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current assets:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash And Cash Equivalents At Carrying Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents, end of year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents, beginning of year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US">Accounts Receivable Net Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US">Accounts receivable</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid Expense And Other Assets Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid expenses and other current assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US">Inventory, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US">Inventories</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Assets Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property Plant And Equipment Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property and equipment, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Net book value</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US">Other Assets, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US">Other assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">Liabilities And Stockholders Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">Liabilities and Stockholders' Equity</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Liabilities Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current liabilities:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts Payable Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued Liabilities Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermBorrowings" xlink:label="us-gaap_ShortTermBorrowings" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermBorrowings" xlink:to="us-gaap_ShortTermBorrowings_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermBorrowings_lbl" xml:lang="en-US">Short Term Borrowings</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShortTermBorrowings_lbl" xml:lang="en-US">Short-term debt</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xml:lang="en-US">Other Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xml:lang="en-US">Other current liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Liabilities Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xml:lang="en-US">Non-current liabilities:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtNoncurrent" xlink:to="us-gaap_LongTermDebtNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtNoncurrent_lbl" xml:lang="en-US">Long-term Debt, Excluding Current Maturities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebtNoncurrent_lbl" xml:lang="en-US">Long-term debt</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xml:lang="en-US">Other Liabilities, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xml:lang="en-US">Other non-current liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments And Contingencies</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and contingencies (Note 3)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders' Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders' equity:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common Stock Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock, par value $0.001 per share, 150,000,000 shares authorized at June 30, 2017 and December 31, 2016; 56,164,082 and 52,328,492 shares issued and outstanding at June 30, 2017 and December 31, 2016, respectively</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock value</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional Paid In Capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid-in capital</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Retained Earnings Accumulated Deficit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Stockholders Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total stockholders' equity</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Liabilities And Stockholders Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total liabilities and stockholders' equity</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common Stock Par Or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Price per share</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common Stock Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common Stock Shares Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common Stock Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Condensed Consolidated Statements Of Operations [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenuesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenuesAbstract_lbl" xml:lang="en-US">Revenues [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenuesAbstract_lbl" xml:lang="en-US">Revenue:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="us-gaap_SalesRevenueGoodsNet" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueGoodsNet" xlink:to="us-gaap_SalesRevenueGoodsNet_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalesRevenueGoodsNet_lbl" xml:lang="en-US">Sales Revenue Goods Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SalesRevenueGoodsNet_lbl" xml:lang="en-US">Product</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueServicesNet" xlink:label="us-gaap_SalesRevenueServicesNet" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueServicesNet" xlink:to="us-gaap_SalesRevenueServicesNet_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalesRevenueServicesNet_lbl" xml:lang="en-US">Sales Revenue, Services, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SalesRevenueServicesNet_lbl" xml:lang="en-US">Service</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">Revenues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">Total revenue</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CostOfGoodsSoldAbstract" xlink:label="us-gaap_CostOfGoodsSoldAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsSoldAbstract" xlink:to="us-gaap_CostOfGoodsSoldAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfGoodsSoldAbstract_lbl" xml:lang="en-US">Cost Of Goods Sold [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CostOfGoodsSoldAbstract_lbl" xml:lang="en-US">Cost of revenue:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CostOfGoodsSold" xlink:label="us-gaap_CostOfGoodsSold" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsSold" xlink:to="us-gaap_CostOfGoodsSold_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfGoodsSold_lbl" xml:lang="en-US">Cost Of Goods Sold</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CostOfGoodsSold_lbl" xml:lang="en-US">Product</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CostOfServices" xlink:label="us-gaap_CostOfServices" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfServices" xlink:to="us-gaap_CostOfServices_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfServices_lbl" xml:lang="en-US">Cost of Services</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CostOfServices_lbl" xml:lang="en-US">Service</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsAndServicesSold" xlink:to="us-gaap_CostOfGoodsAndServicesSold_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfGoodsAndServicesSold_lbl" xml:lang="en-US">Cost Of Goods And Services Sold</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CostOfGoodsAndServicesSold_lbl" xml:lang="en-US">Total cost of revenue</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GrossProfit_lbl" xml:lang="en-US">Gross Profit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_GrossProfit_lbl" xml:lang="en-US">Gross profit</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating Expenses [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating expenses:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research And Development Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SellingAndMarketingExpense" xlink:label="us-gaap_SellingAndMarketingExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingAndMarketingExpense" xlink:to="us-gaap_SellingAndMarketingExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingAndMarketingExpense_lbl" xml:lang="en-US">Selling And Marketing Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SellingAndMarketingExpense_lbl" xml:lang="en-US">Sales and marketing</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General And Administrative Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Operating Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total operating expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Operating Income Loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Loss from operations</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="us-gaap_InterestIncomeExpenseNet" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNet" xlink:to="us-gaap_InterestIncomeExpenseNet_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestIncomeExpenseNet_lbl" xml:lang="en-US">Investment Income Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestIncomeExpenseNet_lbl" xml:lang="en-US">Interest income (expense), net</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Nonoperating Income Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Other income (expense), net</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net Income Loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US">Earnings Per Share Basic And Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US">Net loss per share - basic and diluted</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xml:lang="en-US">Weighted Average Number Of Share Outstanding Basic And Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xml:lang="en-US">Weighted average common shares used to compute basic and diluted net loss per common share</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Income Statement Location [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US">Income Statement Location [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US">Employee Service Share-based Compensation, Allocation of Recognized Period Costs, Report Line [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research And Development Expense [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research And Development [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SellingAndMarketingExpenseMember" xlink:label="us-gaap_SellingAndMarketingExpenseMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingAndMarketingExpenseMember" xlink:to="us-gaap_SellingAndMarketingExpenseMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingAndMarketingExpenseMember_lbl" xml:lang="en-US">Selling And Marketing Expense [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SellingAndMarketingExpenseMember_lbl" xml:lang="en-US">Sales And Marketing [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US">General And Administrative Expense [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US">General And Administrative [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Allocated Share Based Compensation Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Stock-based compensation expense</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Condensed Consolidated Statements Of Cash Flows [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Net Cash Provided By Used In Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from operating activities:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US">Depreciation Depletion And Amortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US">Depreciation and amortization</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Share Based Compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation expense</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xml:lang="en-US">Gain Loss On Sale Of Property Plant Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xml:lang="en-US">Loss on sale and disposal of property and equipment</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Increase Decrease In Operating Capital [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US">Increase Decrease In Accounts Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US">Accounts receivable</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Increase Decrease In Prepaid Deferred Expense And Other Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Prepaid expenses and other assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US">Increase (Decrease) in Inventories</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US">Inventories</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Increase Decrease In Accounts Payable And Accrued Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Accounts payable, accrued liabilities and other liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xml:lang="en-US">Increase Decrease In Deferred Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xml:lang="en-US">Deferred revenue</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_lbl" xml:lang="en-US">Net Cash Provided By Used In Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_lbl" xml:lang="en-US">Net cash used in operating activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Net Cash Provided By Used In Investing Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from investing activities:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Payments To Acquire Property Plant And Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchase of property and equipment</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_lbl" xml:lang="en-US">Net Cash Provided By Used In Investing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_lbl" xml:lang="en-US">Net cash used in investing activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Net Cash Provided By Used In Financing Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from financing activities:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xml:lang="en-US">Proceeds From Issuance Of Private Placement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xml:lang="en-US">Proceeds from private placement offering of common stock, net of issuance costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xml:lang="en-US">Proceeds from issuance of private placement</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt_lbl" xml:lang="en-US">Proceeds from Issuance of Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt_lbl" xml:lang="en-US">Initial proceeds from loan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt_lbl" xml:lang="en-US">Proceeds from issuance of DECD loan, net of issuance costs</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepaymentsOfDebt" xlink:label="us-gaap_RepaymentsOfDebt" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfDebt" xlink:to="us-gaap_RepaymentsOfDebt_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfDebt_lbl" xml:lang="en-US">Repayments of Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfDebt_lbl" xml:lang="en-US">Principal repayment of DECD loan</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations" xlink:label="us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations" xlink:to="us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations_lbl" xml:lang="en-US">Repayments of Debt and Capital Lease Obligations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations_lbl" xml:lang="en-US">Repayment of capital lease obligations</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US">Proceeds From Stock Options Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US">Proceeds from issuance of common stock from exercise of stock options</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_lbl" xml:lang="en-US">Net Cash Provided By Used In Financing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_lbl" xml:lang="en-US">Net cash provided by financing activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xml:lang="en-US">Cash And Cash Equivalents Period Increase Decrease</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xml:lang="en-US">Net increase (decrease) in cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental disclosure of cash flow information:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Interest Paid Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Cash paid during the period for interest</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Organization, Basis Of Presentation And Significant Accounting And Reporting Policies [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:label="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:to="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Organization Consolidation Basis Of Presentation Business Description And Accounting Policies [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Organization, Basis Of Presentation And Significant Accounting And Reporting Policies</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US">Agreements With Quest Diagnostics Incorporated [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US">Debt Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US">Agreements With Quest Diagnostics Incorporated</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments And Contingencies [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">Commitments And Contingencies Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">Commitments And Contingencies</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:to="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl" xml:lang="en-US">Compensation And Employee Benefit Plans [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl" xml:lang="en-US">Stockholders' Equity</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US">Loss Per Share [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US">Earnings Per Share [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US">Loss Per Share</label>
    <loc xlink:type="locator" xlink:href="c617-20170630.xsd#vrml_OrganizationPolicyTextBlock" xlink:label="vrml_OrganizationPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vrml_OrganizationPolicyTextBlock" xlink:to="vrml_OrganizationPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vrml_OrganizationPolicyTextBlock_lbl" xml:lang="en-US">Organization policy.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vrml_OrganizationPolicyTextBlock_lbl" xml:lang="en-US">Organization Policy [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vrml_OrganizationPolicyTextBlock_lbl" xml:lang="en-US">Organization</label>
    <loc xlink:type="locator" xlink:href="c617-20170630.xsd#vrml_GoingConcernPolicyTextBlock" xlink:label="vrml_GoingConcernPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vrml_GoingConcernPolicyTextBlock" xlink:to="vrml_GoingConcernPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vrml_GoingConcernPolicyTextBlock_lbl" xml:lang="en-US">Going Concern [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vrml_GoingConcernPolicyTextBlock_lbl" xml:lang="en-US">Going Concern [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vrml_GoingConcernPolicyTextBlock_lbl" xml:lang="en-US">Going Concern</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Basis Of Accounting Policy Policy [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Basis of Presentation</label>
    <loc xlink:type="locator" xlink:href="c617-20170630.xsd#vrml_SignificantAccountingAndReportingPoliciesPolicyTextBlock" xlink:label="vrml_SignificantAccountingAndReportingPoliciesPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vrml_SignificantAccountingAndReportingPoliciesPolicyTextBlock" xlink:to="vrml_SignificantAccountingAndReportingPoliciesPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vrml_SignificantAccountingAndReportingPoliciesPolicyTextBlock_lbl" xml:lang="en-US">Significant Accounting And Reporting Policies [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vrml_SignificantAccountingAndReportingPoliciesPolicyTextBlock_lbl" xml:lang="en-US">Significant Accounting And Reporting Policies [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vrml_SignificantAccountingAndReportingPoliciesPolicyTextBlock_lbl" xml:lang="en-US">Significant Accounting and Reporting Policies</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xml:lang="en-US">Revenue Recognition, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xml:lang="en-US">Revenue Recognition</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Other Significant Accounting And Reporting Policies Policy [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recent Accounting Pronouncements</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US">Allocation of Stock-Based Compensation Expense by Functional Area</label>
    <loc xlink:type="locator" xlink:href="c617-20170630.xsd#vrml_BasisOfPresentationAndSignificantAccountingPoliciesTable" xlink:label="vrml_BasisOfPresentationAndSignificantAccountingPoliciesTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vrml_BasisOfPresentationAndSignificantAccountingPoliciesTable" xlink:to="vrml_BasisOfPresentationAndSignificantAccountingPoliciesTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vrml_BasisOfPresentationAndSignificantAccountingPoliciesTable_lbl" xml:lang="en-US">Basis Of Presentation And Significant Accounting Policies [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vrml_BasisOfPresentationAndSignificantAccountingPoliciesTable_lbl" xml:lang="en-US">Basis Of Presentation And Significant Accounting Policies [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vrml_BasisOfPresentationAndSignificantAccountingPoliciesTable_lbl" xml:lang="en-US">Basis Of Presentation And Significant Accounting Policies [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xml:lang="en-US">Debt Instrument [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xml:lang="en-US">Debt Instrument Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xml:lang="en-US">Debt Instrument, Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="c617-20170630.xsd#vrml_DecdMember" xlink:label="vrml_DecdMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vrml_DecdMember" xlink:to="vrml_DecdMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vrml_DecdMember_lbl" xml:lang="en-US">DECD [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vrml_DecdMember_lbl" xml:lang="en-US">Decd [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vrml_DecdMember_lbl" xml:lang="en-US">DECD [Member]</label>
    <loc xlink:type="locator" xlink:href="c617-20170630.xsd#vrml_OrganizationConsolidationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:label="vrml_OrganizationConsolidationAndSummaryOfSignificantAccountingPoliciesLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vrml_OrganizationConsolidationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="vrml_OrganizationConsolidationAndSummaryOfSignificantAccountingPoliciesLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vrml_OrganizationConsolidationAndSummaryOfSignificantAccountingPoliciesLineItems_lbl" xml:lang="en-US">Organization Consolidation And Summary Of Significant Accounting Policies [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vrml_OrganizationConsolidationAndSummaryOfSignificantAccountingPoliciesLineItems_lbl" xml:lang="en-US">Organization Consolidation And Summary Of Significant Accounting Policies [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vrml_OrganizationConsolidationAndSummaryOfSignificantAccountingPoliciesLineItems_lbl" xml:lang="en-US">Organization Consolidation And Summary Of Significant Accounting Policies [Line Items]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US">Debt Instrument, Face Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US">Total borrowing amount</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount" xlink:label="us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount" xlink:to="us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount_lbl" xml:lang="en-US">Debt Instrument, Unused Borrowing Capacity, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount_lbl" xml:lang="en-US">Remaining loan amount</label>
    <loc xlink:type="locator" xlink:href="c617-20170630.xsd#vrml_CommitmentsAndContingenciesTable" xlink:label="vrml_CommitmentsAndContingenciesTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vrml_CommitmentsAndContingenciesTable" xlink:to="vrml_CommitmentsAndContingenciesTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vrml_CommitmentsAndContingenciesTable_lbl" xml:lang="en-US">Commitments And Contingencies [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vrml_CommitmentsAndContingenciesTable_lbl" xml:lang="en-US">Commitments And Contingencies [Table]</label>
    <loc xlink:type="locator" xlink:href="c617-20170630.xsd#vrml_CommitmentsAndContingenciesLineItems" xlink:label="vrml_CommitmentsAndContingenciesLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vrml_CommitmentsAndContingenciesLineItems" xlink:to="vrml_CommitmentsAndContingenciesLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vrml_CommitmentsAndContingenciesLineItems_lbl" xml:lang="en-US">Commitments And Contingencies [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vrml_CommitmentsAndContingenciesLineItems_lbl" xml:lang="en-US">Commitments And Contingencies [Line Items]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US">Fixed rate per annum</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDate" xlink:to="us-gaap_DebtInstrumentMaturityDate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xml:lang="en-US">Debt Instrument, Maturity Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xml:lang="en-US">Maturity date</label>
    <loc xlink:type="locator" xlink:href="c617-20170630.xsd#vrml_DebtInstrumentAmountEligibleForForgiveness" xlink:label="vrml_DebtInstrumentAmountEligibleForForgiveness" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vrml_DebtInstrumentAmountEligibleForForgiveness" xlink:to="vrml_DebtInstrumentAmountEligibleForForgiveness_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vrml_DebtInstrumentAmountEligibleForForgiveness_lbl" xml:lang="en-US">Debt Instrument, Amount Eligible For Forgiveness</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vrml_DebtInstrumentAmountEligibleForForgiveness_lbl" xml:lang="en-US">Debt Instrument, Amount Eligible For Forgiveness</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vrml_DebtInstrumentAmountEligibleForForgiveness_lbl" xml:lang="en-US">Amount eligible for forgiveness</label>
    <loc xlink:type="locator" xlink:href="c617-20170630.xsd#vrml_DebtInstrumentDebtCovenantJobCreationNumberOfEmployees" xlink:label="vrml_DebtInstrumentDebtCovenantJobCreationNumberOfEmployees" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vrml_DebtInstrumentDebtCovenantJobCreationNumberOfEmployees" xlink:to="vrml_DebtInstrumentDebtCovenantJobCreationNumberOfEmployees_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vrml_DebtInstrumentDebtCovenantJobCreationNumberOfEmployees_lbl" xml:lang="en-US">Debt Instrument, Debt Covenant, Job Creation, Number Of Employees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vrml_DebtInstrumentDebtCovenantJobCreationNumberOfEmployees_lbl" xml:lang="en-US">Debt Instrument, Debt Covenant, Job Creation, Number Of Employees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vrml_DebtInstrumentDebtCovenantJobCreationNumberOfEmployees_lbl" xml:lang="en-US">Job creation, number of employees</label>
    <loc xlink:type="locator" xlink:href="c617-20170630.xsd#vrml_DebtInstrumentDebtCovenantJobCreationPeriod" xlink:label="vrml_DebtInstrumentDebtCovenantJobCreationPeriod" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vrml_DebtInstrumentDebtCovenantJobCreationPeriod" xlink:to="vrml_DebtInstrumentDebtCovenantJobCreationPeriod_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vrml_DebtInstrumentDebtCovenantJobCreationPeriod_lbl" xml:lang="en-US">Debt Instrument, Debt Covenant, Job Creation, Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vrml_DebtInstrumentDebtCovenantJobCreationPeriod_lbl" xml:lang="en-US">Debt Instrument, Debt Covenant, Job Creation, Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vrml_DebtInstrumentDebtCovenantJobCreationPeriod_lbl" xml:lang="en-US">Job creation, term</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="us-gaap_DebtInstrumentTerm" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTerm" xlink:to="us-gaap_DebtInstrumentTerm_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentTerm_lbl" xml:lang="en-US">Debt Instrument, Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentTerm_lbl" xml:lang="en-US">Debt, maturity term</label>
    <loc xlink:type="locator" xlink:href="c617-20170630.xsd#vrml_DebtInstrumentCovenantNoncompliancePenalty" xlink:label="vrml_DebtInstrumentCovenantNoncompliancePenalty" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vrml_DebtInstrumentCovenantNoncompliancePenalty" xlink:to="vrml_DebtInstrumentCovenantNoncompliancePenalty_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vrml_DebtInstrumentCovenantNoncompliancePenalty_lbl" xml:lang="en-US">Debt Instrument, Covenant Noncompliance Penalty</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vrml_DebtInstrumentCovenantNoncompliancePenalty_lbl" xml:lang="en-US">Debt Instrument, Covenant Noncompliance Penalty</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vrml_DebtInstrumentCovenantNoncompliancePenalty_lbl" xml:lang="en-US">Debt penalty</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsForRent" xlink:label="us-gaap_PaymentsForRent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRent" xlink:to="us-gaap_PaymentsForRent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForRent_lbl" xml:lang="en-US">Payments For Rent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsForRent_lbl" xml:lang="en-US">Annual base rent</label>
    <loc xlink:type="locator" xlink:href="c617-20170630.xsd#vrml_OperatingLeasesOtherOccupancyCosts" xlink:label="vrml_OperatingLeasesOtherOccupancyCosts" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vrml_OperatingLeasesOtherOccupancyCosts" xlink:to="vrml_OperatingLeasesOtherOccupancyCosts_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vrml_OperatingLeasesOtherOccupancyCosts_lbl" xml:lang="en-US">Operating Leases, Other Occupancy Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vrml_OperatingLeasesOtherOccupancyCosts_lbl" xml:lang="en-US">Operating Leases Other Occupancy Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vrml_OperatingLeasesOtherOccupancyCosts_lbl" xml:lang="en-US">Annual estimated common area charges, taxes and insurance</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:label="us-gaap_LeaseExpirationDate1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseExpirationDate1" xlink:to="us-gaap_LeaseExpirationDate1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseExpirationDate1_lbl" xml:lang="en-US">Lease Expiration Date 1</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseExpirationDate1_lbl" xml:lang="en-US">Lease expiration date</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseholdImprovementsGross" xlink:label="us-gaap_LeaseholdImprovementsGross" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsGross" xlink:to="us-gaap_LeaseholdImprovementsGross_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseholdImprovementsGross_lbl" xml:lang="en-US">Leasehold Improvements, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseholdImprovementsGross_lbl" xml:lang="en-US">Leasehold improvements</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract" xlink:label="us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract" xlink:to="us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract_lbl" xml:lang="en-US">Lessee Leasing Arrangements, Operating Leases, Term of Contract</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract_lbl" xml:lang="en-US">Lease term</label>
    <loc xlink:type="locator" xlink:href="c617-20170630.xsd#vrml_LesseeLeasingArrangementsOperatingLeasesRentAbatementPeriod" xlink:label="vrml_LesseeLeasingArrangementsOperatingLeasesRentAbatementPeriod" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vrml_LesseeLeasingArrangementsOperatingLeasesRentAbatementPeriod" xlink:to="vrml_LesseeLeasingArrangementsOperatingLeasesRentAbatementPeriod_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vrml_LesseeLeasingArrangementsOperatingLeasesRentAbatementPeriod_lbl" xml:lang="en-US">Lessee Leasing Arrangements, Operating Leases, Rent Abatement Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vrml_LesseeLeasingArrangementsOperatingLeasesRentAbatementPeriod_lbl" xml:lang="en-US">Lessee Leasing Arrangements, Operating Leases, Rent Abatement Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vrml_LesseeLeasingArrangementsOperatingLeasesRentAbatementPeriod_lbl" xml:lang="en-US">Rent abatement period</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="us-gaap_OperatingLeasesRentExpenseNet" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesRentExpenseNet" xlink:to="us-gaap_OperatingLeasesRentExpenseNet_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesRentExpenseNet_lbl" xml:lang="en-US">Operating Leases, Rent Expense, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesRentExpenseNet_lbl" xml:lang="en-US">Operating leases rental expense</label>
    <loc xlink:type="locator" xlink:href="c617-20170630.xsd#vrml_NumberOfPurchasedLaboratoryInstruments" xlink:label="vrml_NumberOfPurchasedLaboratoryInstruments" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vrml_NumberOfPurchasedLaboratoryInstruments" xlink:to="vrml_NumberOfPurchasedLaboratoryInstruments_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vrml_NumberOfPurchasedLaboratoryInstruments_lbl" xml:lang="en-US">Number of purchased laboratory instruments.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vrml_NumberOfPurchasedLaboratoryInstruments_lbl" xml:lang="en-US">Number of purchased laboratory instruments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vrml_NumberOfPurchasedLaboratoryInstruments_lbl" xml:lang="en-US">Number of purchased laboratory instruments</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireMachineryAndEquipment" xlink:label="us-gaap_PaymentsToAcquireMachineryAndEquipment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireMachineryAndEquipment" xlink:to="us-gaap_PaymentsToAcquireMachineryAndEquipment_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireMachineryAndEquipment_lbl" xml:lang="en-US">Payments to Acquire Machinery and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsToAcquireMachineryAndEquipment_lbl" xml:lang="en-US">Initial payment of laboratory equipment</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalLeasesContingentRentalPaymentsDue" xlink:label="us-gaap_CapitalLeasesContingentRentalPaymentsDue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeasesContingentRentalPaymentsDue" xlink:to="us-gaap_CapitalLeasesContingentRentalPaymentsDue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalLeasesContingentRentalPaymentsDue_lbl" xml:lang="en-US">Monthly Payment For Acquisition For Equipemnt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CapitalLeasesContingentRentalPaymentsDue_lbl" xml:lang="en-US">Monthly payment for acquisition for equipment</label>
    <loc xlink:type="locator" xlink:href="c617-20170630.xsd#vrml_NumberOfPaymentsForPurchaseProductionOfAssets" xlink:label="vrml_NumberOfPaymentsForPurchaseProductionOfAssets" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vrml_NumberOfPaymentsForPurchaseProductionOfAssets" xlink:to="vrml_NumberOfPaymentsForPurchaseProductionOfAssets_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vrml_NumberOfPaymentsForPurchaseProductionOfAssets_lbl" xml:lang="en-US">Number of payments for purchase production of assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vrml_NumberOfPaymentsForPurchaseProductionOfAssets_lbl" xml:lang="en-US">Number of payments for purchase production of assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Accumulated Depreciation Depletion And Amortization Property Plant And Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Accumulated amortization</label>
    <loc xlink:type="locator" xlink:href="c617-20170630.xsd#vrml_PercentageOfRoyaltyPaid" xlink:label="vrml_PercentageOfRoyaltyPaid" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vrml_PercentageOfRoyaltyPaid" xlink:to="vrml_PercentageOfRoyaltyPaid_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vrml_PercentageOfRoyaltyPaid_lbl" xml:lang="en-US">Percentage Of Royalty Paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vrml_PercentageOfRoyaltyPaid_lbl" xml:lang="en-US">Percentage Of Royalty Paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vrml_PercentageOfRoyaltyPaid_lbl" xml:lang="en-US">Percent of royalty paid</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsForRoyalties" xlink:label="us-gaap_PaymentsForRoyalties" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRoyalties" xlink:to="us-gaap_PaymentsForRoyalties_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForRoyalties_lbl" xml:lang="en-US">Payments for Royalties</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsForRoyalties_lbl" xml:lang="en-US">Minimum royalty payment</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RoyaltyExpense" xlink:label="us-gaap_RoyaltyExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RoyaltyExpense" xlink:to="us-gaap_RoyaltyExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RoyaltyExpense_lbl" xml:lang="en-US">Royalty Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RoyaltyExpense_lbl" xml:lang="en-US">Royalty expense</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US">Plan Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US">Plan Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="c617-20170630.xsd#vrml_StockOptionPlanTwentyTenMember" xlink:label="vrml_StockOptionPlanTwentyTenMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vrml_StockOptionPlanTwentyTenMember" xlink:to="vrml_StockOptionPlanTwentyTenMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vrml_StockOptionPlanTwentyTenMember_lbl" xml:lang="en-US">Stock Option Plan 2010 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vrml_StockOptionPlanTwentyTenMember_lbl" xml:lang="en-US">Stock Option Plan Twenty Ten [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vrml_StockOptionPlanTwentyTenMember_lbl" xml:lang="en-US">2010 Stock Incentive Plan [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="us-gaap_TitleOfIndividualAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TitleOfIndividualAxis_lbl" xml:lang="en-US">Title of Individual [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xml:lang="en-US">Title Of Individual With Relationship To Entity [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xml:lang="en-US">Title of Individual with Relationship to Entity [Domain]</label>
    <loc xlink:type="locator" xlink:href="c617-20170630.xsd#vrml_NonEmployeeDirectorsMember" xlink:label="vrml_NonEmployeeDirectorsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vrml_NonEmployeeDirectorsMember" xlink:to="vrml_NonEmployeeDirectorsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vrml_NonEmployeeDirectorsMember_lbl" xml:lang="en-US">Non-Employee Directors [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vrml_NonEmployeeDirectorsMember_lbl" xml:lang="en-US">Non Employee Directors [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vrml_NonEmployeeDirectorsMember_lbl" xml:lang="en-US">Non-Employee Directors [Member]</label>
    <loc xlink:type="locator" xlink:href="c617-20170630.xsd#vrml_CertainConsultantsMember" xlink:label="vrml_CertainConsultantsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vrml_CertainConsultantsMember" xlink:to="vrml_CertainConsultantsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vrml_CertainConsultantsMember_lbl" xml:lang="en-US">Certain Consultants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vrml_CertainConsultantsMember_lbl" xml:lang="en-US">Certain Consultants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vrml_CertainConsultantsMember_lbl" xml:lang="en-US">Certain Consultants [Member]</label>
    <loc xlink:type="locator" xlink:href="c617-20170630.xsd#vrml_CertainOfficersAndEmployeesMember" xlink:label="vrml_CertainOfficersAndEmployeesMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vrml_CertainOfficersAndEmployeesMember" xlink:to="vrml_CertainOfficersAndEmployeesMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vrml_CertainOfficersAndEmployeesMember_lbl" xml:lang="en-US">Certain Officers And Employees [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vrml_CertainOfficersAndEmployeesMember_lbl" xml:lang="en-US">Certain Officers And Employees [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vrml_CertainOfficersAndEmployeesMember_lbl" xml:lang="en-US">Certain Officers And Employees [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl" xml:lang="en-US">Exercise Price Range [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_lbl" xml:lang="en-US">Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_lbl" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Domain]</label>
    <loc xlink:type="locator" xlink:href="c617-20170630.xsd#vrml_ExercisePriceBMember" xlink:label="vrml_ExercisePriceBMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vrml_ExercisePriceBMember" xlink:to="vrml_ExercisePriceBMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vrml_ExercisePriceBMember_lbl" xml:lang="en-US">Exercise Price B [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vrml_ExercisePriceBMember_lbl" xml:lang="en-US">Exercise Price B [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vrml_ExercisePriceBMember_lbl" xml:lang="en-US">$2.14 [Member]</label>
    <loc xlink:type="locator" xlink:href="c617-20170630.xsd#vrml_ExercisePriceCMember" xlink:label="vrml_ExercisePriceCMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vrml_ExercisePriceCMember" xlink:to="vrml_ExercisePriceCMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vrml_ExercisePriceCMember_lbl" xml:lang="en-US">Exercise Price C [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vrml_ExercisePriceCMember_lbl" xml:lang="en-US">Exercise Price C [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vrml_ExercisePriceCMember_lbl" xml:lang="en-US">$2.14 [Member]</label>
    <loc xlink:type="locator" xlink:href="c617-20170630.xsd#vrml_ExercisePriceDMember" xlink:label="vrml_ExercisePriceDMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vrml_ExercisePriceDMember" xlink:to="vrml_ExercisePriceDMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vrml_ExercisePriceDMember_lbl" xml:lang="en-US">Exercise Price D [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vrml_ExercisePriceDMember_lbl" xml:lang="en-US">Exercise Price D [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vrml_ExercisePriceDMember_lbl" xml:lang="en-US">$2.14 [Member]</label>
    <loc xlink:type="locator" xlink:href="c617-20170630.xsd#vrml_ExercisePriceEMember" xlink:label="vrml_ExercisePriceEMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vrml_ExercisePriceEMember" xlink:to="vrml_ExercisePriceEMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vrml_ExercisePriceEMember_lbl" xml:lang="en-US">Exercise Price E [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vrml_ExercisePriceEMember_lbl" xml:lang="en-US">Exercise Price E [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vrml_ExercisePriceEMember_lbl" xml:lang="en-US">$1.83 [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
    <loc xlink:type="locator" xlink:href="c617-20170630.xsd#vrml_PriceOfSharesToBeIssuedUnderWarrants" xlink:label="vrml_PriceOfSharesToBeIssuedUnderWarrants" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vrml_PriceOfSharesToBeIssuedUnderWarrants" xlink:to="vrml_PriceOfSharesToBeIssuedUnderWarrants_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vrml_PriceOfSharesToBeIssuedUnderWarrants_lbl" xml:lang="en-US">Price Of Shares To Be Issued Under Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vrml_PriceOfSharesToBeIssuedUnderWarrants_lbl" xml:lang="en-US">Price Of Shares To Be Issued Under Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vrml_PriceOfSharesToBeIssuedUnderWarrants_lbl" xml:lang="en-US">Issued a warrant to purchase common stock with a cost</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US">Class Of Warrant Or Right Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US">Warrants outstanding to purchase shares</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Class Of Warrant Or Right Exercise Price Of Warrants Or Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Exercise price of warrants</label>
    <loc xlink:type="locator" xlink:href="c617-20170630.xsd#vrml_FairValueOfWarrantsIssued" xlink:label="vrml_FairValueOfWarrantsIssued" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vrml_FairValueOfWarrantsIssued" xlink:to="vrml_FairValueOfWarrantsIssued_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vrml_FairValueOfWarrantsIssued_lbl" xml:lang="en-US">Represents fair value of warrants issued.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vrml_FairValueOfWarrantsIssued_lbl" xml:lang="en-US">Fair Value Of Warrants Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vrml_FairValueOfWarrantsIssued_lbl" xml:lang="en-US">Fair value of warrants issued</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US">Shares available for grant</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl" xml:lang="en-US">Restricted shares awarded</label>
    <loc xlink:type="locator" xlink:href="c617-20170630.xsd#vrml_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedFairValue" xlink:label="vrml_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedFairValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vrml_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedFairValue" xlink:to="vrml_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedFairValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vrml_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedFairValue_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted, Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vrml_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedFairValue_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted, Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vrml_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedFairValue_lbl" xml:lang="en-US">Fair value of restricted shares awarded</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Stock options granted</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl" xml:lang="en-US">Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl" xml:lang="en-US">Stock options granted, average exercise price</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US">Restricted share units granted</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xml:lang="en-US">Stock Issued During Period Value Restricted Stock Award Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xml:lang="en-US">Fair value of restricted share units</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xml:lang="en-US">Vesting percentage</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xml:lang="en-US">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</label>
    <loc xlink:type="locator" xlink:href="c617-20170630.xsd#vrml_EmployeeStockBasedCompensationMember" xlink:label="vrml_EmployeeStockBasedCompensationMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vrml_EmployeeStockBasedCompensationMember" xlink:to="vrml_EmployeeStockBasedCompensationMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vrml_EmployeeStockBasedCompensationMember_lbl" xml:lang="en-US">Employee Stock-Based Compensation [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vrml_EmployeeStockBasedCompensationMember_lbl" xml:lang="en-US">Employee Stock Based Compensation [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vrml_EmployeeStockBasedCompensationMember_lbl" xml:lang="en-US">Employee Stock-Based Compensation [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US">Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US">Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Antidilutive securities excluded from computation of earnings per share</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CostOfSalesMember" xlink:label="us-gaap_CostOfSalesMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfSalesMember" xlink:to="us-gaap_CostOfSalesMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfSalesMember_lbl" xml:lang="en-US">Cost Of Sales [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CostOfSalesMember_lbl" xml:lang="en-US">Cost Of Revenue [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xml:lang="en-US">Property Plant And Equipment Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsHeldUnderCapitalLeasesMember" xlink:label="us-gaap_AssetsHeldUnderCapitalLeasesMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsHeldUnderCapitalLeasesMember" xlink:to="us-gaap_AssetsHeldUnderCapitalLeasesMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsHeldUnderCapitalLeasesMember_lbl" xml:lang="en-US">Assets Held Under Capital Leases [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsHeldUnderCapitalLeasesMember_lbl" xml:lang="en-US">Assets Under Capital Leases [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseArrangementTypeAxis" xlink:label="us-gaap_LeaseArrangementTypeAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseArrangementTypeAxis" xlink:to="us-gaap_LeaseArrangementTypeAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseArrangementTypeAxis_lbl" xml:lang="en-US">Lease Arrangement, Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="us-gaap_LeaseArrangementTypeDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseArrangementTypeDomain" xlink:to="us-gaap_LeaseArrangementTypeDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseArrangementTypeDomain_lbl" xml:lang="en-US">Lease Arrangement Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseArrangementTypeDomain_lbl" xml:lang="en-US">Lease Arrangement, Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="c617-20170630.xsd#vrml_AustinTexasFacilityMember" xlink:label="vrml_AustinTexasFacilityMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vrml_AustinTexasFacilityMember" xlink:to="vrml_AustinTexasFacilityMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vrml_AustinTexasFacilityMember_lbl" xml:lang="en-US">Austin, Texas facility.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vrml_AustinTexasFacilityMember_lbl" xml:lang="en-US">Austin Texas Facility [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vrml_AustinTexasFacilityMember_lbl" xml:lang="en-US">Austin, Texas facility [Member]</label>
    <loc xlink:type="locator" xlink:href="c617-20170630.xsd#vrml_TrumbullConnecticutFacilityMember" xlink:label="vrml_TrumbullConnecticutFacilityMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vrml_TrumbullConnecticutFacilityMember" xlink:to="vrml_TrumbullConnecticutFacilityMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vrml_TrumbullConnecticutFacilityMember_lbl" xml:lang="en-US">Trumbull, Connecticut Facility [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vrml_TrumbullConnecticutFacilityMember_lbl" xml:lang="en-US">Trumbull Connecticut Facility [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vrml_TrumbullConnecticutFacilityMember_lbl" xml:lang="en-US">Trumbull, Connecticut Facility [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US">Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US">Award Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockMember_lbl" xml:lang="en-US">Restricted Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedStockMember_lbl" xml:lang="en-US">Restricted Stock [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US">Employee Stock Option [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US">Stock Option [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PerformanceSharesMember" xlink:to="us-gaap_PerformanceSharesMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PerformanceSharesMember_lbl" xml:lang="en-US">Performance Shares [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PerformanceSharesMember_lbl" xml:lang="en-US">Performance Shares [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VestingAxis_lbl" xml:lang="en-US">Vesting [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_VestingDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VestingDomain_lbl" xml:lang="en-US">Vesting [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_VestingDomain_lbl" xml:lang="en-US">Vesting [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xml:lang="en-US">Share Based Compensation Award Tranche One [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xml:lang="en-US">Share-based Compensation Award, Tranche One [Member]</label>
    <loc xlink:type="locator" xlink:href="c617-20170630.xsd#vrml_VestingPercentageDateMember" xlink:label="vrml_VestingPercentageDateMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vrml_VestingPercentageDateMember" xlink:to="vrml_VestingPercentageDateMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vrml_VestingPercentageDateMember_lbl" xml:lang="en-US">Vesting Percentage Date A [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vrml_VestingPercentageDateMember_lbl" xml:lang="en-US">Vesting Percentage Date [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vrml_VestingPercentageDateMember_lbl" xml:lang="en-US">June 1, 2016 [Member]</label>
    <loc xlink:type="locator" xlink:href="c617-20170630.xsd#vrml_VestingPercentageDateBMember" xlink:label="vrml_VestingPercentageDateBMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vrml_VestingPercentageDateBMember" xlink:to="vrml_VestingPercentageDateBMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vrml_VestingPercentageDateBMember_lbl" xml:lang="en-US">Vesting Percentage Date B [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vrml_VestingPercentageDateBMember_lbl" xml:lang="en-US">Vesting Percentage Date B [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vrml_VestingPercentageDateBMember_lbl" xml:lang="en-US">September 1, 2016 [Member]</label>
    <loc xlink:type="locator" xlink:href="c617-20170630.xsd#vrml_VestingPercentageDateCMember" xlink:label="vrml_VestingPercentageDateCMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vrml_VestingPercentageDateCMember" xlink:to="vrml_VestingPercentageDateCMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="vrml_VestingPercentageDateCMember_lbl" xml:lang="en-US">Vesting Percentage Date C [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="vrml_VestingPercentageDateCMember_lbl" xml:lang="en-US">Vesting Percentage Date C [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="vrml_VestingPercentageDateCMember_lbl" xml:lang="en-US">December 1, 2017 [Member]</label>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>c617-20170630_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created by Certent Disclosure Management 6.8.4.2 -->
<!--Based on XBRL 2.1-->
<!--Created on: 8/11/2017 2:59:16 PM-->
<!--Modified on: 8/11/2017 2:59:16 PM-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="c617-20170630.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.vermillion.com/role/DocumentDocumentAndEntityInformation" />
  <roleRef xlink:type="simple" xlink:href="c617-20170630.xsd#StatementCondensedConsolidatedBalanceSheets" roleURI="http://www.vermillion.com/role/StatementCondensedConsolidatedBalanceSheets" />
  <roleRef xlink:type="simple" xlink:href="c617-20170630.xsd#StatementCondensedConsolidatedBalanceSheetsParenthetical" roleURI="http://www.vermillion.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" />
  <roleRef xlink:type="simple" xlink:href="c617-20170630.xsd#StatementCondensedConsolidatedStatementsOfOperations" roleURI="http://www.vermillion.com/role/StatementCondensedConsolidatedStatementsOfOperations" />
  <roleRef xlink:type="simple" xlink:href="c617-20170630.xsd#StatementCondensedConsolidatedStatementsOfOperationsParenthetical" roleURI="http://www.vermillion.com/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical" />
  <roleRef xlink:type="simple" xlink:href="c617-20170630.xsd#StatementCondensedConsolidatedStatementsOfCashFlows" roleURI="http://www.vermillion.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" />
  <roleRef xlink:type="simple" xlink:href="c617-20170630.xsd#DisclosureOrganizationBasisOfPresentationAndSignificantAccountingAndReportingPolicies" roleURI="http://www.vermillion.com/role/DisclosureOrganizationBasisOfPresentationAndSignificantAccountingAndReportingPolicies" />
  <roleRef xlink:type="simple" xlink:href="c617-20170630.xsd#DisclosureAgreementsWithQuestDiagnosticsIncorporated" roleURI="http://www.vermillion.com/role/DisclosureAgreementsWithQuestDiagnosticsIncorporated" />
  <roleRef xlink:type="simple" xlink:href="c617-20170630.xsd#DisclosureCommitmentsAndContingencies" roleURI="http://www.vermillion.com/role/DisclosureCommitmentsAndContingencies" />
  <roleRef xlink:type="simple" xlink:href="c617-20170630.xsd#DisclosureStockholdersEquity" roleURI="http://www.vermillion.com/role/DisclosureStockholdersEquity" />
  <roleRef xlink:type="simple" xlink:href="c617-20170630.xsd#DisclosureLossPerShare" roleURI="http://www.vermillion.com/role/DisclosureLossPerShare" />
  <roleRef xlink:type="simple" xlink:href="c617-20170630.xsd#DisclosureOrganizationBasisOfPresentationAndSignificantAccountingAndReportingPoliciesPolicy" roleURI="http://www.vermillion.com/role/DisclosureOrganizationBasisOfPresentationAndSignificantAccountingAndReportingPoliciesPolicy" />
  <roleRef xlink:type="simple" xlink:href="c617-20170630.xsd#DisclosureStockholdersEquityTables" roleURI="http://www.vermillion.com/role/DisclosureStockholdersEquityTables" />
  <roleRef xlink:type="simple" xlink:href="c617-20170630.xsd#DisclosureOrganizationBasisOfPresentationAndSignificantAccountingAndReportingPoliciesDetails" roleURI="http://www.vermillion.com/role/DisclosureOrganizationBasisOfPresentationAndSignificantAccountingAndReportingPoliciesDetails" />
  <roleRef xlink:type="simple" xlink:href="c617-20170630.xsd#DisclosureCommitmentsAndContingenciesDetails" roleURI="http://www.vermillion.com/role/DisclosureCommitmentsAndContingenciesDetails" />
  <roleRef xlink:type="simple" xlink:href="c617-20170630.xsd#DisclosureStockholdersEquityNarrativeDetails" roleURI="http://www.vermillion.com/role/DisclosureStockholdersEquityNarrativeDetails" />
  <roleRef xlink:type="simple" xlink:href="c617-20170630.xsd#DisclosureStockholdersEquityAllocationOfEmployeeStockBasedCompensationExpenseByFunctionalAreaDetails" roleURI="http://www.vermillion.com/role/DisclosureStockholdersEquityAllocationOfEmployeeStockBasedCompensationExpenseByFunctionalAreaDetails" />
  <roleRef xlink:type="simple" xlink:href="c617-20170630.xsd#DisclosureLossPerShareDetails" roleURI="http://www.vermillion.com/role/DisclosureLossPerShareDetails" />
  <presentationLink xlink:role="http://www.vermillion.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity Information">
    <loc xlink:type="locator" xlink:href="c617-20170630.xsd#vrml_DocumentAndEntityInformationAbstract" xlink:label="vrml_DocumentAndEntityInformationAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType_636380603560864823" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vrml_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentType_636380603560864823" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_636380603560864823" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vrml_DocumentAndEntityInformationAbstract" xlink:to="dei_AmendmentFlag_636380603560864823" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_636380603560864823" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vrml_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentPeriodEndDate_636380603560864823" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus_636380603560864823" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vrml_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentFiscalYearFocus_636380603560864823" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus_636380603560864823" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vrml_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentFiscalPeriodFocus_636380603560864823" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_636380603560874824" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vrml_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityRegistrantName_636380603560874824" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_636380603560874824" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vrml_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityCentralIndexKey_636380603560874824" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate_636380603560874824" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vrml_DocumentAndEntityInformationAbstract" xlink:to="dei_CurrentFiscalYearEndDate_636380603560874824" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory_636380603560874824" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vrml_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityFilerCategory_636380603560874824" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding_636380603560874824" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vrml_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding_636380603560874824" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.vermillion.com/role/StatementCondensedConsolidatedBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - Condensed Consolidated Balance Sheets">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract_636380603560874824" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract_636380603560874824" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract_636380603560874824" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_636380603560874824" xlink:to="us-gaap_AssetsCurrentAbstract_636380603560874824" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_636380603560874824" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_636380603560874824" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_636380603560874824" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent_636380603560874824" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_636380603560874824" xlink:to="us-gaap_AccountsReceivableNetCurrent_636380603560874824" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_636380603560874824" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_636380603560874824" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_636380603560874824" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet_636380603560874824" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_636380603560874824" xlink:to="us-gaap_InventoryNet_636380603560874824" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_636380603560874824" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_636380603560874824" xlink:to="us-gaap_AssetsCurrent_636380603560874824" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_636380603560874824" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_636380603560874824" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_636380603560874824" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent_636380603560874824" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_636380603560874824" xlink:to="us-gaap_OtherAssetsNoncurrent_636380603560874824" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets_636380603560874824" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_636380603560874824" xlink:to="us-gaap_Assets_636380603560874824" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_636380603560874824" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_636380603560874824" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract_636380603560874824" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_636380603560874824" xlink:to="us-gaap_LiabilitiesCurrentAbstract_636380603560874824" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_636380603560874824" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_636380603560874824" xlink:to="us-gaap_AccountsPayableCurrent_636380603560874824" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_636380603560874824" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_636380603560874824" xlink:to="us-gaap_AccruedLiabilitiesCurrent_636380603560874824" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermBorrowings" xlink:label="us-gaap_ShortTermBorrowings_636380603560884825" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_636380603560874824" xlink:to="us-gaap_ShortTermBorrowings_636380603560884825" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent_636380603560884825" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_636380603560874824" xlink:to="us-gaap_OtherLiabilitiesCurrent_636380603560884825" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_636380603560884825" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_636380603560874824" xlink:to="us-gaap_LiabilitiesCurrent_636380603560884825" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_636380603560884825" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_636380603560874824" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_636380603560884825" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent_636380603560884825" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract_636380603560884825" xlink:to="us-gaap_LongTermDebtNoncurrent_636380603560884825" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_636380603560884825" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract_636380603560884825" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_636380603560884825" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_636380603560884825" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract_636380603560884825" xlink:to="us-gaap_Liabilities_636380603560884825" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies_636380603560884825" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_636380603560874824" xlink:to="us-gaap_CommitmentsAndContingencies_636380603560884825" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract_636380603560884825" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_636380603560874824" xlink:to="us-gaap_StockholdersEquityAbstract_636380603560884825" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_636380603560884825" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_636380603560884825" xlink:to="us-gaap_CommonStockValue_636380603560884825" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital_636380603560884825" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_636380603560884825" xlink:to="us-gaap_AdditionalPaidInCapital_636380603560884825" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_636380603560884825" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_636380603560884825" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_636380603560884825" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_636380603560884825" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_636380603560884825" xlink:to="us-gaap_StockholdersEquity_636380603560884825" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_636380603560884825" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_636380603560874824" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_636380603560884825" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.vermillion.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended" xlink:title="00105 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_636380603560894826" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_636380603560894826" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_636380603560894826" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized_636380603560894826" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_636380603560894826" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued_636380603560894826" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_636380603560894826" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding_636380603560894826" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.vermillion.com/role/StatementCondensedConsolidatedStatementsOfOperations" xlink:type="extended" xlink:title="00200 - Statement - Condensed Consolidated Statements Of Operations">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract_636380603560894826" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_RevenuesAbstract_636380603560894826" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="us-gaap_SalesRevenueGoodsNet_636380603560894826" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract_636380603560894826" xlink:to="us-gaap_SalesRevenueGoodsNet_636380603560894826" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueServicesNet" xlink:label="us-gaap_SalesRevenueServicesNet_636380603560894826" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract_636380603560894826" xlink:to="us-gaap_SalesRevenueServicesNet_636380603560894826" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues_636380603560894826" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract_636380603560894826" xlink:to="us-gaap_Revenues_636380603560894826" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CostOfGoodsSoldAbstract" xlink:label="us-gaap_CostOfGoodsSoldAbstract_636380603560894826" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_CostOfGoodsSoldAbstract_636380603560894826" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CostOfGoodsSold" xlink:label="us-gaap_CostOfGoodsSold_636380603560894826" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostOfGoodsSoldAbstract_636380603560894826" xlink:to="us-gaap_CostOfGoodsSold_636380603560894826" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CostOfServices" xlink:label="us-gaap_CostOfServices_636380603560894826" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostOfGoodsSoldAbstract_636380603560894826" xlink:to="us-gaap_CostOfServices_636380603560894826" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold_636380603560894826" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostOfGoodsSoldAbstract_636380603560894826" xlink:to="us-gaap_CostOfGoodsAndServicesSold_636380603560894826" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit_636380603560894826" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_GrossProfit_636380603560894826" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract_636380603560894826" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_636380603560894826" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_636380603560894826" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_636380603560894826" xlink:to="us-gaap_ResearchAndDevelopmentExpense_636380603560894826" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SellingAndMarketingExpense" xlink:label="us-gaap_SellingAndMarketingExpense_636380603560894826" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_636380603560894826" xlink:to="us-gaap_SellingAndMarketingExpense_636380603560894826" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_636380603560894826" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_636380603560894826" xlink:to="us-gaap_GeneralAndAdministrativeExpense_636380603560894826" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses_636380603560904827" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_636380603560894826" xlink:to="us-gaap_OperatingExpenses_636380603560904827" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_636380603560904827" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_636380603560894826" xlink:to="us-gaap_OperatingIncomeLoss_636380603560904827" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="us-gaap_InterestIncomeExpenseNet_636380603560904827" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_636380603560894826" xlink:to="us-gaap_InterestIncomeExpenseNet_636380603560904827" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense_636380603560904827" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_636380603560894826" xlink:to="us-gaap_NonoperatingIncomeExpense_636380603560904827" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_636380603560904827" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_636380603560894826" xlink:to="us-gaap_NetIncomeLoss_636380603560904827" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_636380603560904827" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_636380603560894826" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_636380603560904827" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_636380603560904827" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_636380603560894826" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_636380603560904827" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.vermillion.com/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical" xlink:type="extended" xlink:title="00205 - Statement - Condensed Consolidated Statements Of Operations (Parenthetical)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_636380603560904827" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_StatementTable_636380603560904827" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_636380603560904827" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_636380603560904827" xlink:to="us-gaap_IncomeStatementLocationAxis_636380603560904827" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_636380603560904827" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis_636380603560904827" xlink:to="us-gaap_IncomeStatementLocationDomain_636380603560904827" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CostOfSalesMember" xlink:label="us-gaap_CostOfSalesMember_636380603560904827" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_636380603560904827" xlink:to="us-gaap_CostOfSalesMember_636380603560904827" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_636380603560904827" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_636380603560904827" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_636380603560904827" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SellingAndMarketingExpenseMember" xlink:label="us-gaap_SellingAndMarketingExpenseMember_636380603560904827" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_636380603560904827" xlink:to="us-gaap_SellingAndMarketingExpenseMember_636380603560904827" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_636380603560904827" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_636380603560904827" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_636380603560904827" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_636380603560904827" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_636380603560904827" xlink:to="us-gaap_StatementLineItems_636380603560904827" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_636380603560904827" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_636380603560904827" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_636380603560904827" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.vermillion.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="00400 - Statement - Condensed Consolidated Statements Of Cash Flows">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_636380603560914828" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_636380603560914828" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_636380603560914828" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_636380603560914828" xlink:to="us-gaap_NetIncomeLoss_636380603560914828" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_636380603560914828" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_636380603560914828" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_636380603560914828" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization_636380603560914828" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_636380603560914828" xlink:to="us-gaap_DepreciationDepletionAndAmortization_636380603560914828" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_636380603560914828" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_636380603560914828" xlink:to="us-gaap_ShareBasedCompensation_636380603560914828" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_636380603560914828" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_636380603560914828" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_636380603560914828" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_636380603560914828" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_636380603560914828" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_636380603560914828" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_636380603560914828" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_636380603560914828" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_636380603560914828" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_636380603560914828" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_636380603560914828" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_636380603560914828" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories_636380603560914828" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_636380603560914828" xlink:to="us-gaap_IncreaseDecreaseInInventories_636380603560914828" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_636380603560914828" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_636380603560914828" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_636380603560914828" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_636380603560914828" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_636380603560914828" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue_636380603560914828" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_636380603560914828" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_636380603560914828" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_636380603560914828" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_636380603560914828" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_636380603560914828" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_636380603560914828" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_636380603560914828" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_636380603560914828" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_636380603560914828" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_636380603560914828" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_636380603560914828" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_636380603560914828" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_636380603560914828" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_636380603560914828" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_636380603560914828" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_636380603560914828" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/netLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt_636380603560924829" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_636380603560914828" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt_636380603560924829" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepaymentsOfDebt" xlink:label="us-gaap_RepaymentsOfDebt_636380603560924829" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_636380603560914828" xlink:to="us-gaap_RepaymentsOfDebt_636380603560924829" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations" xlink:label="us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations_636380603560924829" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_636380603560914828" xlink:to="us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations_636380603560924829" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_636380603560924829" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_636380603560914828" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_636380603560924829" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_636380603560924829" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_636380603560914828" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_636380603560924829" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_636380603560924829" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_636380603560924829" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_636380603560924829" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_636380603560924829" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_6363806035609248291" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_6363806035609248291" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_636380603560924829" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_636380603560924829" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet_636380603560924829" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract_636380603560924829" xlink:to="us-gaap_InterestPaidNet_636380603560924829" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="9" />
  </presentationLink>
  <presentationLink xlink:role="http://www.vermillion.com/role/DisclosureOrganizationBasisOfPresentationAndSignificantAccountingAndReportingPolicies" xlink:type="extended" xlink:title="10101 - Disclosure - Organization, Basis Of Presentation And Significant Accounting And Reporting Policies">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:label="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_636380603560924829" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_636380603560924829" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.vermillion.com/role/DisclosureAgreementsWithQuestDiagnosticsIncorporated" xlink:type="extended" xlink:title="10201 - Disclosure - Agreements With Quest Diagnostics Incorporated">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock_636380603560934830" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock_636380603560934830" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.vermillion.com/role/DisclosureCommitmentsAndContingencies" xlink:type="extended" xlink:title="10301 - Disclosure - Commitments And Contingencies">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_636380603560934830" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_636380603560934830" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.vermillion.com/role/DisclosureStockholdersEquity" xlink:type="extended" xlink:title="10401 - Disclosure - Stockholders' Equity">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_636380603560934830" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_636380603560934830" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.vermillion.com/role/DisclosureLossPerShare" xlink:type="extended" xlink:title="10501 - Disclosure - Loss Per Share">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock_636380603560934830" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock_636380603560934830" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.vermillion.com/role/DisclosureOrganizationBasisOfPresentationAndSignificantAccountingAndReportingPoliciesPolicy" xlink:type="extended" xlink:title="20102 - Disclosure - Organization, Basis Of Presentation And Significant Accounting And Reporting Policies (Policy)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_635693696872816526" />
    <loc xlink:type="locator" xlink:href="c617-20170630.xsd#vrml_OrganizationPolicyTextBlock" xlink:label="vrml_OrganizationPolicyTextBlock_636380603560934830" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_635693696872816526" xlink:to="vrml_OrganizationPolicyTextBlock_636380603560934830" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="c617-20170630.xsd#vrml_GoingConcernPolicyTextBlock" xlink:label="vrml_GoingConcernPolicyTextBlock_636380603560934830" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_635693696872816526" xlink:to="vrml_GoingConcernPolicyTextBlock_636380603560934830" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_636380603560934830" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_635693696872816526" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_636380603560934830" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="c617-20170630.xsd#vrml_SignificantAccountingAndReportingPoliciesPolicyTextBlock" xlink:label="vrml_SignificantAccountingAndReportingPoliciesPolicyTextBlock_636380603560934830" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_635693696872816526" xlink:to="vrml_SignificantAccountingAndReportingPoliciesPolicyTextBlock_636380603560934830" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_636380603560934830" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_635693696872816526" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_636380603560934830" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_636380603560934830" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_635693696872816526" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_636380603560934830" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.vermillion.com/role/DisclosureStockholdersEquityTables" xlink:type="extended" xlink:title="30403 - Disclosure - Stockholders' Equity (Tables)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_636380603560934830" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_636380603560934830" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.vermillion.com/role/DisclosureOrganizationBasisOfPresentationAndSignificantAccountingAndReportingPoliciesDetails" xlink:type="extended" xlink:title="40101 - Disclosure - Organization, Basis Of Presentation And Significant Accounting And Reporting Policies (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="c617-20170630.xsd#vrml_BasisOfPresentationAndSignificantAccountingPoliciesTable" xlink:label="vrml_BasisOfPresentationAndSignificantAccountingPoliciesTable_636380603560944831" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="vrml_BasisOfPresentationAndSignificantAccountingPoliciesTable_636380603560944831" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_636380603560944831" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vrml_BasisOfPresentationAndSignificantAccountingPoliciesTable_636380603560944831" xlink:to="us-gaap_DebtInstrumentAxis_636380603560944831" order="1" use="optional" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_636380603560944831" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_636380603560944831" xlink:to="us-gaap_DebtInstrumentNameDomain_636380603560944831" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="c617-20170630.xsd#vrml_DecdMember" xlink:label="vrml_DecdMember_636380603560944831" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_636380603560944831" xlink:to="vrml_DecdMember_636380603560944831" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="c617-20170630.xsd#vrml_OrganizationConsolidationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:label="vrml_OrganizationConsolidationAndSummaryOfSignificantAccountingPoliciesLineItems_636380603560944831" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vrml_BasisOfPresentationAndSignificantAccountingPoliciesTable_636380603560944831" xlink:to="vrml_OrganizationConsolidationAndSummaryOfSignificantAccountingPoliciesLineItems_636380603560944831" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_636380603560944831" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vrml_OrganizationConsolidationAndSummaryOfSignificantAccountingPoliciesLineItems_636380603560944831" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_636380603560944831" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_636380603560944831" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vrml_OrganizationConsolidationAndSummaryOfSignificantAccountingPoliciesLineItems_636380603560944831" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_636380603560944831" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount_636380603560944831" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vrml_OrganizationConsolidationAndSummaryOfSignificantAccountingPoliciesLineItems_636380603560944831" xlink:to="us-gaap_DebtInstrumentFaceAmount_636380603560944831" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt_636380603560944831" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vrml_OrganizationConsolidationAndSummaryOfSignificantAccountingPoliciesLineItems_636380603560944831" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt_636380603560944831" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount" xlink:label="us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount_636380603560944831" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vrml_OrganizationConsolidationAndSummaryOfSignificantAccountingPoliciesLineItems_636380603560944831" xlink:to="us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount_636380603560944831" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.vermillion.com/role/DisclosureCommitmentsAndContingenciesDetails" xlink:type="extended" xlink:title="40301 - Disclosure - Commitments And Contingencies (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="c617-20170630.xsd#vrml_CommitmentsAndContingenciesTable" xlink:label="vrml_CommitmentsAndContingenciesTable_636380603560944831" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="vrml_CommitmentsAndContingenciesTable_636380603560944831" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_636380603560944831" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vrml_CommitmentsAndContingenciesTable_636380603560944831" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_636380603560944831" order="1" use="optional" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_636380603560944831" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_636380603560944831" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_636380603560944831" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsHeldUnderCapitalLeasesMember" xlink:label="us-gaap_AssetsHeldUnderCapitalLeasesMember_636380603560944831" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_636380603560944831" xlink:to="us-gaap_AssetsHeldUnderCapitalLeasesMember_636380603560944831" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_636380603560944831" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vrml_CommitmentsAndContingenciesTable_636380603560944831" xlink:to="us-gaap_DebtInstrumentAxis_636380603560944831" order="2" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_636380603560944831" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_636380603560944831" xlink:to="us-gaap_DebtInstrumentNameDomain_636380603560944831" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="c617-20170630.xsd#vrml_DecdMember" xlink:label="vrml_DecdMember_636380603560954832" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_636380603560944831" xlink:to="vrml_DecdMember_636380603560954832" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseArrangementTypeAxis" xlink:label="us-gaap_LeaseArrangementTypeAxis_636380603560954832" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vrml_CommitmentsAndContingenciesTable_636380603560944831" xlink:to="us-gaap_LeaseArrangementTypeAxis_636380603560954832" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="us-gaap_LeaseArrangementTypeDomain_636380603560954832" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseArrangementTypeAxis_636380603560954832" xlink:to="us-gaap_LeaseArrangementTypeDomain_636380603560954832" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="c617-20170630.xsd#vrml_AustinTexasFacilityMember" xlink:label="vrml_AustinTexasFacilityMember_636380603560954832" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseArrangementTypeDomain_636380603560954832" xlink:to="vrml_AustinTexasFacilityMember_636380603560954832" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="c617-20170630.xsd#vrml_TrumbullConnecticutFacilityMember" xlink:label="vrml_TrumbullConnecticutFacilityMember_636380603560954832" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseArrangementTypeDomain_636380603560954832" xlink:to="vrml_TrumbullConnecticutFacilityMember_636380603560954832" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="c617-20170630.xsd#vrml_CommitmentsAndContingenciesLineItems" xlink:label="vrml_CommitmentsAndContingenciesLineItems_636380603560954832" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vrml_CommitmentsAndContingenciesTable_636380603560944831" xlink:to="vrml_CommitmentsAndContingenciesLineItems_636380603560954832" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount_636380603560954832" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vrml_CommitmentsAndContingenciesLineItems_636380603560954832" xlink:to="us-gaap_DebtInstrumentFaceAmount_636380603560954832" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_636380603560954832" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vrml_CommitmentsAndContingenciesLineItems_636380603560954832" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_636380603560954832" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate_636380603560954832" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vrml_CommitmentsAndContingenciesLineItems_636380603560954832" xlink:to="us-gaap_DebtInstrumentMaturityDate_636380603560954832" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="c617-20170630.xsd#vrml_DebtInstrumentAmountEligibleForForgiveness" xlink:label="vrml_DebtInstrumentAmountEligibleForForgiveness_636380603560954832" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vrml_CommitmentsAndContingenciesLineItems_636380603560954832" xlink:to="vrml_DebtInstrumentAmountEligibleForForgiveness_636380603560954832" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="c617-20170630.xsd#vrml_DebtInstrumentDebtCovenantJobCreationNumberOfEmployees" xlink:label="vrml_DebtInstrumentDebtCovenantJobCreationNumberOfEmployees_636380603560954832" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vrml_CommitmentsAndContingenciesLineItems_636380603560954832" xlink:to="vrml_DebtInstrumentDebtCovenantJobCreationNumberOfEmployees_636380603560954832" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="c617-20170630.xsd#vrml_DebtInstrumentDebtCovenantJobCreationPeriod" xlink:label="vrml_DebtInstrumentDebtCovenantJobCreationPeriod_636380603560954832" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vrml_CommitmentsAndContingenciesLineItems_636380603560954832" xlink:to="vrml_DebtInstrumentDebtCovenantJobCreationPeriod_636380603560954832" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="us-gaap_DebtInstrumentTerm_636380603560954832" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vrml_CommitmentsAndContingenciesLineItems_636380603560954832" xlink:to="us-gaap_DebtInstrumentTerm_636380603560954832" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="c617-20170630.xsd#vrml_DebtInstrumentCovenantNoncompliancePenalty" xlink:label="vrml_DebtInstrumentCovenantNoncompliancePenalty_636380603560954832" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vrml_CommitmentsAndContingenciesLineItems_636380603560954832" xlink:to="vrml_DebtInstrumentCovenantNoncompliancePenalty_636380603560954832" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt_636380603560954832" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vrml_CommitmentsAndContingenciesLineItems_636380603560954832" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt_636380603560954832" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount" xlink:label="us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount_636380603560964833" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vrml_CommitmentsAndContingenciesLineItems_636380603560954832" xlink:to="us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount_636380603560964833" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsForRent" xlink:label="us-gaap_PaymentsForRent_636380603560964833" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vrml_CommitmentsAndContingenciesLineItems_636380603560954832" xlink:to="us-gaap_PaymentsForRent_636380603560964833" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="c617-20170630.xsd#vrml_OperatingLeasesOtherOccupancyCosts" xlink:label="vrml_OperatingLeasesOtherOccupancyCosts_636380603560964833" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vrml_CommitmentsAndContingenciesLineItems_636380603560954832" xlink:to="vrml_OperatingLeasesOtherOccupancyCosts_636380603560964833" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:label="us-gaap_LeaseExpirationDate1_636380603560964833" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vrml_CommitmentsAndContingenciesLineItems_636380603560954832" xlink:to="us-gaap_LeaseExpirationDate1_636380603560964833" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseholdImprovementsGross" xlink:label="us-gaap_LeaseholdImprovementsGross_636380603560964833" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vrml_CommitmentsAndContingenciesLineItems_636380603560954832" xlink:to="us-gaap_LeaseholdImprovementsGross_636380603560964833" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract" xlink:label="us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract_636380603560964833" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vrml_CommitmentsAndContingenciesLineItems_636380603560954832" xlink:to="us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract_636380603560964833" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="c617-20170630.xsd#vrml_LesseeLeasingArrangementsOperatingLeasesRentAbatementPeriod" xlink:label="vrml_LesseeLeasingArrangementsOperatingLeasesRentAbatementPeriod_636380603560964833" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vrml_CommitmentsAndContingenciesLineItems_636380603560954832" xlink:to="vrml_LesseeLeasingArrangementsOperatingLeasesRentAbatementPeriod_636380603560964833" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="us-gaap_OperatingLeasesRentExpenseNet_636380603560964833" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vrml_CommitmentsAndContingenciesLineItems_636380603560954832" xlink:to="us-gaap_OperatingLeasesRentExpenseNet_636380603560964833" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="c617-20170630.xsd#vrml_NumberOfPurchasedLaboratoryInstruments" xlink:label="vrml_NumberOfPurchasedLaboratoryInstruments_636380603560964833" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vrml_CommitmentsAndContingenciesLineItems_636380603560954832" xlink:to="vrml_NumberOfPurchasedLaboratoryInstruments_636380603560964833" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireMachineryAndEquipment" xlink:label="us-gaap_PaymentsToAcquireMachineryAndEquipment_636380603560964833" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vrml_CommitmentsAndContingenciesLineItems_636380603560954832" xlink:to="us-gaap_PaymentsToAcquireMachineryAndEquipment_636380603560964833" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalLeasesContingentRentalPaymentsDue" xlink:label="us-gaap_CapitalLeasesContingentRentalPaymentsDue_636380603560974834" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vrml_CommitmentsAndContingenciesLineItems_636380603560954832" xlink:to="us-gaap_CapitalLeasesContingentRentalPaymentsDue_636380603560974834" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="c617-20170630.xsd#vrml_NumberOfPaymentsForPurchaseProductionOfAssets" xlink:label="vrml_NumberOfPaymentsForPurchaseProductionOfAssets_636380603560974834" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vrml_CommitmentsAndContingenciesLineItems_636380603560954832" xlink:to="vrml_NumberOfPaymentsForPurchaseProductionOfAssets_636380603560974834" order="21" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_636380603560974834" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vrml_CommitmentsAndContingenciesLineItems_636380603560954832" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_636380603560974834" order="22" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_636380603560974834" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vrml_CommitmentsAndContingenciesLineItems_636380603560954832" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_636380603560974834" order="23" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="c617-20170630.xsd#vrml_PercentageOfRoyaltyPaid" xlink:label="vrml_PercentageOfRoyaltyPaid_636380603560974834" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vrml_CommitmentsAndContingenciesLineItems_636380603560954832" xlink:to="vrml_PercentageOfRoyaltyPaid_636380603560974834" order="24" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsForRoyalties" xlink:label="us-gaap_PaymentsForRoyalties_636380603560974834" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vrml_CommitmentsAndContingenciesLineItems_636380603560954832" xlink:to="us-gaap_PaymentsForRoyalties_636380603560974834" order="25" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RoyaltyExpense" xlink:label="us-gaap_RoyaltyExpense_636380603560974834" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vrml_CommitmentsAndContingenciesLineItems_636380603560954832" xlink:to="us-gaap_RoyaltyExpense_636380603560974834" order="26" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.vermillion.com/role/DisclosureStockholdersEquityNarrativeDetails" xlink:type="extended" xlink:title="40401 - Disclosure - Stockholders' Equity (Narrative) (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_636380603560984835" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_636380603560984835" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_636380603560984835" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_636380603560984835" xlink:to="us-gaap_PlanNameAxis_636380603560984835" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_636380603560984835" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_636380603560984835" xlink:to="us-gaap_PlanNameDomain_636380603560984835" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="c617-20170630.xsd#vrml_StockOptionPlanTwentyTenMember" xlink:label="vrml_StockOptionPlanTwentyTenMember_636380603560984835" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_636380603560984835" xlink:to="vrml_StockOptionPlanTwentyTenMember_636380603560984835" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="us-gaap_TitleOfIndividualAxis_636380603560984835" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_636380603560984835" xlink:to="us-gaap_TitleOfIndividualAxis_636380603560984835" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_636380603560984835" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualAxis_636380603560984835" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_636380603560984835" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="c617-20170630.xsd#vrml_NonEmployeeDirectorsMember" xlink:label="vrml_NonEmployeeDirectorsMember_636380603560984835" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_636380603560984835" xlink:to="vrml_NonEmployeeDirectorsMember_636380603560984835" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="c617-20170630.xsd#vrml_CertainConsultantsMember" xlink:label="vrml_CertainConsultantsMember_636380603560984835" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_636380603560984835" xlink:to="vrml_CertainConsultantsMember_636380603560984835" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="c617-20170630.xsd#vrml_CertainOfficersAndEmployeesMember" xlink:label="vrml_CertainOfficersAndEmployeesMember_636380603560984835" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_636380603560984835" xlink:to="vrml_CertainOfficersAndEmployeesMember_636380603560984835" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_636380603560984835" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_636380603560984835" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_636380603560984835" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_636380603560984835" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_636380603560984835" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_636380603560984835" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="c617-20170630.xsd#vrml_ExercisePriceBMember" xlink:label="vrml_ExercisePriceBMember_636380603560984835" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_636380603560984835" xlink:to="vrml_ExercisePriceBMember_636380603560984835" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="c617-20170630.xsd#vrml_ExercisePriceCMember" xlink:label="vrml_ExercisePriceCMember_636380603560984835" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_636380603560984835" xlink:to="vrml_ExercisePriceCMember_636380603560984835" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="c617-20170630.xsd#vrml_ExercisePriceDMember" xlink:label="vrml_ExercisePriceDMember_636380603560984835" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_636380603560984835" xlink:to="vrml_ExercisePriceDMember_636380603560984835" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="c617-20170630.xsd#vrml_ExercisePriceEMember" xlink:label="vrml_ExercisePriceEMember_636380603560984835" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_636380603560984835" xlink:to="vrml_ExercisePriceEMember_636380603560984835" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_636380603560984835" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_636380603560984835" xlink:to="us-gaap_AwardTypeAxis_636380603560984835" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_636380603560984835" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_636380603560984835" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_636380603560984835" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember_636380603560994836" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_636380603560984835" xlink:to="us-gaap_RestrictedStockMember_636380603560994836" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_636380603560994836" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_636380603560984835" xlink:to="us-gaap_EmployeeStockOptionMember_636380603560994836" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember_636380603560994836" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_636380603560984835" xlink:to="us-gaap_PerformanceSharesMember_636380603560994836" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis_636380603560994836" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_636380603560984835" xlink:to="us-gaap_VestingAxis_636380603560994836" order="5" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain_636380603560994836" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis_636380603560994836" xlink:to="us-gaap_VestingDomain_636380603560994836" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_636380603560994836" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain_636380603560994836" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember_636380603560994836" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="c617-20170630.xsd#vrml_VestingPercentageDateMember" xlink:label="vrml_VestingPercentageDateMember_636380603560994836" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain_636380603560994836" xlink:to="vrml_VestingPercentageDateMember_636380603560994836" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="c617-20170630.xsd#vrml_VestingPercentageDateBMember" xlink:label="vrml_VestingPercentageDateBMember_636380603560994836" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain_636380603560994836" xlink:to="vrml_VestingPercentageDateBMember_636380603560994836" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="c617-20170630.xsd#vrml_VestingPercentageDateCMember" xlink:label="vrml_VestingPercentageDateCMember_636380603560994836" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain_636380603560994836" xlink:to="vrml_VestingPercentageDateCMember_636380603560994836" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_636380603560994836" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_636380603560984835" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_636380603560994836" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_636380603560994836" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_636380603560994836" xlink:to="us-gaap_CommonStockSharesIssued_636380603560994836" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_636380603560994836" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_636380603560994836" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_636380603560994836" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="c617-20170630.xsd#vrml_PriceOfSharesToBeIssuedUnderWarrants" xlink:label="vrml_PriceOfSharesToBeIssuedUnderWarrants_636380603560994836" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_636380603560994836" xlink:to="vrml_PriceOfSharesToBeIssuedUnderWarrants_636380603560994836" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_636380603561004837" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_636380603560994836" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_636380603561004837" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_636380603561004837" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_636380603560994836" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_636380603561004837" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_636380603561004837" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_636380603560994836" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_636380603561004837" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="c617-20170630.xsd#vrml_FairValueOfWarrantsIssued" xlink:label="vrml_FairValueOfWarrantsIssued_636380603561004837" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_636380603560994836" xlink:to="vrml_FairValueOfWarrantsIssued_636380603561004837" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_636380603561004837" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_636380603560994836" xlink:to="us-gaap_CommonStockValue_636380603561004837" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_636380603561004837" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_636380603560994836" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_636380603561004837" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_636380603561004837" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_636380603560994836" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_636380603561004837" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="c617-20170630.xsd#vrml_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedFairValue" xlink:label="vrml_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedFairValue_636380603561004837" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_636380603560994836" xlink:to="vrml_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedFairValue_636380603561004837" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_636380603561004837" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_636380603560994836" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_636380603561004837" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_636380603561014838" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_636380603560994836" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_636380603561014838" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_636380603561014838" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_636380603560994836" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_636380603561014838" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_636380603561014838" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_636380603560994836" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_636380603561014838" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_636380603561014838" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_636380603560994836" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_636380603561014838" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
  </presentationLink>
  <presentationLink xlink:role="http://www.vermillion.com/role/DisclosureStockholdersEquityAllocationOfEmployeeStockBasedCompensationExpenseByFunctionalAreaDetails" xlink:type="extended" xlink:title="40402 - Disclosure - Stockholders' Equity (Allocation of Employee Stock-Based Compensation Expense By Functional Area) (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_636380603561014838" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_636380603561014838" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_636380603561014838" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_636380603561014838" xlink:to="us-gaap_PlanNameAxis_636380603561014838" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_636380603561014838" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_636380603561014838" xlink:to="us-gaap_PlanNameDomain_636380603561014838" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="c617-20170630.xsd#vrml_EmployeeStockBasedCompensationMember" xlink:label="vrml_EmployeeStockBasedCompensationMember_636380603561014838" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_636380603561014838" xlink:to="vrml_EmployeeStockBasedCompensationMember_636380603561014838" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_636380603561024839" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_636380603561014838" xlink:to="us-gaap_IncomeStatementLocationAxis_636380603561024839" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_636380603561024839" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis_636380603561024839" xlink:to="us-gaap_IncomeStatementLocationDomain_636380603561024839" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CostOfSalesMember" xlink:label="us-gaap_CostOfSalesMember_636380603561024839" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_636380603561024839" xlink:to="us-gaap_CostOfSalesMember_636380603561024839" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_636380603561024839" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_636380603561024839" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_636380603561024839" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SellingAndMarketingExpenseMember" xlink:label="us-gaap_SellingAndMarketingExpenseMember_636380603561024839" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_636380603561024839" xlink:to="us-gaap_SellingAndMarketingExpenseMember_636380603561024839" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_636380603561024839" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_636380603561024839" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_636380603561024839" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_636380603561024839" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_636380603561014838" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_636380603561024839" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_636380603561024839" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_636380603561024839" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_636380603561024839" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.vermillion.com/role/DisclosureLossPerShareDetails" xlink:type="extended" xlink:title="40501 - Disclosure - Loss Per Share (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_636380603561024839" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_636380603561024839" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6794196080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jul. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vrml_DocumentAndEntityInformationAbstract', window );"><strong>Document And Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">VERMILLION, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000926617<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Smaller Reporting Company<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,164,082<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrml_DocumentAndEntityInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Document And Entity Information [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrml_DocumentAndEntityInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrml_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6794616480">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 6,028,000<span></span>
</td>
<td class="nump">$ 5,242,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">214,000<span></span>
</td>
<td class="nump">275,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">269,000<span></span>
</td>
<td class="nump">498,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">102,000<span></span>
</td>
<td class="nump">93,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">6,613,000<span></span>
</td>
<td class="nump">6,108,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">1,549,000<span></span>
</td>
<td class="nump">1,911,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">11,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">8,173,000<span></span>
</td>
<td class="nump">8,019,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">300,000<span></span>
</td>
<td class="nump">881,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="nump">1,541,000<span></span>
</td>
<td class="nump">1,464,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Short-term debt</a></td>
<td class="nump">188,000<span></span>
</td>
<td class="nump">182,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">32,000<span></span>
</td>
<td class="nump">34,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">2,061,000<span></span>
</td>
<td class="nump">2,561,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Non-current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt</a></td>
<td class="nump">1,538,000<span></span>
</td>
<td class="nump">1,667,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other non-current liabilities</a></td>
<td class="nump">47,000<span></span>
</td>
<td class="nump">29,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">3,646,000<span></span>
</td>
<td class="nump">4,257,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 3)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, par value $0.001 per share, 150,000,000 shares authorized at June 30, 2017 and December 31, 2016; 56,164,082 and 52,328,492 shares issued and outstanding at June 30, 2017 and December 31, 2016, respectively</a></td>
<td class="nump">56,000<span></span>
</td>
<td class="nump">52,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">395,060,000<span></span>
</td>
<td class="nump">389,266,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(390,589,000)<span></span>
</td>
<td class="num">(385,556,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">4,527,000<span></span>
</td>
<td class="nump">3,762,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 8,173,000<span></span>
</td>
<td class="nump">$ 8,019,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6801-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3044-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82911808&amp;loc=d3e14326-108349<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68049868&amp;loc=d3e3927-108312<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6904-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6911-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6794013520">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Condensed Consolidated Balance Sheets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">150,000,000<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">56,164,082<span></span>
</td>
<td class="nump">52,328,492<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">56,164,082<span></span>
</td>
<td class="nump">52,328,492<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6795227472">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements Of Operations - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 860<span></span>
</td>
<td class="nump">$ 554<span></span>
</td>
<td class="nump">$ 1,538<span></span>
</td>
<td class="nump">$ 1,059<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueServicesNet', window );">Service</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">38<span></span>
</td>
<td class="nump">155<span></span>
</td>
<td class="nump">86<span></span>
</td>
<td class="nump">155<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">898<span></span>
</td>
<td class="nump">709<span></span>
</td>
<td class="nump">1,624<span></span>
</td>
<td class="nump">1,214<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsSoldAbstract', window );"><strong>Cost of revenue:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsSold', window );">Product</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">428<span></span>
</td>
<td class="nump">527<span></span>
</td>
<td class="nump">850<span></span>
</td>
<td class="nump">1,055<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfServices', window );">Service</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">266<span></span>
</td>
<td class="nump">60<span></span>
</td>
<td class="nump">571<span></span>
</td>
<td class="nump">60<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Total cost of revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">694<span></span>
</td>
<td class="nump">587<span></span>
</td>
<td class="nump">1,421<span></span>
</td>
<td class="nump">1,115<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">204<span></span>
</td>
<td class="nump">122<span></span>
</td>
<td class="nump">203<span></span>
</td>
<td class="nump">99<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">268<span></span>
</td>
<td class="nump">564<span></span>
</td>
<td class="nump">493<span></span>
</td>
<td class="nump">1,498<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingAndMarketingExpense', window );">Sales and marketing</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">1,041<span></span>
</td>
<td class="nump">1,628<span></span>
</td>
<td class="nump">2,064<span></span>
</td>
<td class="nump">3,908<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="nump">1,241<span></span>
</td>
<td class="nump">1,691<span></span>
</td>
<td class="nump">2,648<span></span>
</td>
<td class="nump">3,350<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,550<span></span>
</td>
<td class="nump">3,883<span></span>
</td>
<td class="nump">5,205<span></span>
</td>
<td class="nump">8,756<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(2,346)<span></span>
</td>
<td class="num">(3,761)<span></span>
</td>
<td class="num">(5,002)<span></span>
</td>
<td class="num">(8,657)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNet', window );">Interest income (expense), net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(10)<span></span>
</td>
<td class="num">(8)<span></span>
</td>
<td class="num">(22)<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(4)<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="num">(9)<span></span>
</td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (2,360)<span></span>
</td>
<td class="num">$ (3,749)<span></span>
</td>
<td class="num">$ (5,033)<span></span>
</td>
<td class="num">$ (8,646)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share - basic and diluted</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (0.04)<span></span>
</td>
<td class="num">$ (0.07)<span></span>
</td>
<td class="num">$ (0.09)<span></span>
</td>
<td class="num">$ (0.17)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average common shares used to compute basic and diluted net loss per common share</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">56,113,917<span></span>
</td>
<td class="nump">52,151,440<span></span>
</td>
<td class="nump">55,123,977<span></span>
</td>
<td class="nump">52,132,288<span></span>
</td>
</tr>
<tr><td colspan="6"></td></tr>
<tr><td colspan="6"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">(1)  Cost of revenue$40$22$79$46</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">(2)  Research and development 2 22 5 53</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top">(3)  Sales and marketing 40 14 77 56</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[4]</td>
<td style="vertical-align: top;" valign="top">(4)  General and administrative 295 319 510 445</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs related to goods produced and sold during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsSoldAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsSoldAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs related to services rendered by an entity during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of operating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.10)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueGoodsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesRevenueGoodsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueServicesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue during the period from services rendered in the normal course of business, after deducting allowances and discounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesRevenueServicesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingAndMarketingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total amount of expenses directly related to the marketing or selling of products or services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingAndMarketingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6777744416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements Of Operations (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost Of Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 40<span></span>
</td>
<td class="nump">$ 22<span></span>
</td>
<td class="nump">$ 79<span></span>
</td>
<td class="nump">$ 46<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research And Development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">22<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="nump">53<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember', window );">Sales And Marketing [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">40<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="nump">77<span></span>
</td>
<td class="nump">56<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General And Administrative [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 295<span></span>
</td>
<td class="nump">$ 319<span></span>
</td>
<td class="nump">$ 510<span></span>
</td>
<td class="nump">$ 445<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6795225744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements Of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (5,033)<span></span>
</td>
<td class="num">$ (8,646)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">401<span></span>
</td>
<td class="nump">323<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">671<span></span>
</td>
<td class="nump">600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss on sale and disposal of property and equipment</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="nump">61<span></span>
</td>
<td class="num">(156)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="nump">218<span></span>
</td>
<td class="nump">233<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories</a></td>
<td class="num">(9)<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable, accrued liabilities and other liabilities</a></td>
<td class="num">(504)<span></span>
</td>
<td class="num">(835)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations', window );">Net cash used in operating activities</a></td>
<td class="num">(4,191)<span></span>
</td>
<td class="num">(8,455)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(43)<span></span>
</td>
<td class="num">(1,054)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations', window );">Net cash used in investing activities</a></td>
<td class="num">(43)<span></span>
</td>
<td class="num">(1,054)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from private placement offering of common stock, net of issuance costs</a></td>
<td class="nump">5,127<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from issuance of DECD loan, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,966<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Principal repayment of DECD loan</a></td>
<td class="num">(92)<span></span>
</td>
<td class="num">(28)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations', window );">Repayment of capital lease obligations</a></td>
<td class="num">(15)<span></span>
</td>
<td class="num">(14)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from issuance of common stock from exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations', window );">Net cash provided by financing activities</a></td>
<td class="nump">5,020<span></span>
</td>
<td class="nump">1,929<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="nump">786<span></span>
</td>
<td class="num">(7,580)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents, beginning of year</a></td>
<td class="nump">5,242<span></span>
</td>
<td class="nump">18,642<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents, end of year</a></td>
<td class="nump">6,028<span></span>
</td>
<td class="nump">11,062<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid during the period for interest</a></td>
<td class="nump">$ 24<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3044-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period, excluding the portion taken into income, in the liability reflecting revenue yet to be earned for which cash or other forms of consideration was received or recorded as a receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid, after deduction of cash paid for capitalized interest, for interest. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3574-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3574-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of stock options granted under share-based compensation arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=SL79508275-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow during the period from the repayment of aggregate short-term and long-term debt and payment of capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6785662064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization, Basis Of Presentation And Significant Accounting And Reporting Policies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Basis Of Presentation And Significant Accounting And Reporting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock', window );">Organization, Basis Of Presentation And Significant Accounting And Reporting Policies</a></td>
<td class="text"><div> <div style="margin-left:0pt;margin-right:0pt;">
		<p style="margin:0pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">1.&nbsp;&nbsp; </font><font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">ORGANIZATION, BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING AND REPORTING POLICIES</font>
		</p>
		<p style="margin:0pt 0pt 8pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;">Organization </font>
		</p>
		<p style="margin:4.5pt 0pt 0pt 4.5pt;text-indent:31.5pt;line-height:100%;font-family:Arial Unicode MS;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">Vermillion, Inc. (&#x201C;Vermillion&#x201D;; Vermillion and its wholly-owned subsidiaries are collectively referred to as the &#x201C;Company</font><a name="_cp_text_1_15"></a><font style="display: inline;font-family:Times New Roman;font-size:10pt;">,&#x201D; &#x201C;we&#x201D; or &#x201C;our</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">&#x201D;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">) i</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">s incorporated in the state of Delaware, and is engaged in the business of developing and commercializing diagnostic tests for gynecologic disease. The Company sells OVA1&#x2122; and Overa&#x2122; risk of malignancy test</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">s</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> for ovarian cancer (&#x201C;OVA1&#x201D; and &#x201C;Overa</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">,</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">&#x201D;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> respectively</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">) through Vermillion&#x2019;s wholly-owned&nbsp;Clinical Laboratory Improvement Amendments of 1988 (&#x201C;CLIA&#x201D;) certified clinical laboratory, ASPiRA LABS, Inc. (&#x201C;ASPiRA LABS&#x201D;). </font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">The Company also offers in-vitro diagnostic (&#x201C;IVD&#x201D;) trial services to third-party customers through its wholly-owned subsidiary, ASPiRA IVD, Inc. (&#x201C;ASPiRA IVD&#x201D;), which commenced operations in June 2016. </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">ASPiRA IVD is a specialized, CLIA certified, laboratory provider dedicated to meeting the unique testing needs of IVD manufacturers seeking to commercialize&nbsp;high-complexity&nbsp;assays. </font>
		</p>
		<p style="margin:9pt 0pt 3pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;">Going Concern</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">The Company has incurred significant net losses and negative cash flows from operations since inception, and as a result has an accumulated deficit of approximat</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">ely </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">$</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">390</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">,589</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">,000</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> &nbsp;a</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">t &nbsp;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">June 30</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">, 2017. The Company also expects to incur a net loss and negative cash flows from operations for the remainder of 2017. The Company&#x2019;s management believes that successful achievement of the Company&#x2019;s business objectives will require additional financing.&nbsp;Given these conditions, there is substantial doubt about the Company&#x2019;s ability to continue as a going concern. The condensed consolidated financial statements have been prepared on a going concern basis and do not include any adjustments that might result from these uncertainties. </font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">The Company expects to raise capital through a variety of sources, which may include </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">the exercise of common stock warrants, </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">equity </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">offerings, debt financing</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">, collaborati</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">ons</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">, licensing arrangements, </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">grants and government funding and strategic alliances</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">. However, additional funding may not be available when needed or on terms acceptable to the Company. If the Company is unable to obtain additional capital, it may not be able to continue sales and marketing, research and development, or other operations on the scope or scale of current activity and that could have a material adverse effect on </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">the Company&#x2019;s</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> business, results of operations and financial condition.</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">As discussed in Note </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">4</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">, on February 17, 2017, the Company completed a private placement pursuant to which certain investors purchased Vermillion common stock and warrants to purchase shares of</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> Vermillion</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> common stock for net proceeds of approximately </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">$</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">5,127,000</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> after deducting offering expenses.</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">As discussed in Note 3, in March 2016, the Company entered into an agreement (the &#x201C;Loan Agreement&#x201D;) pursuant to which it may borrow up to </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">$4,000,000</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> from the State of Connecticut Department of Economic and Community Development (the &#x201C;DECD&#x201D;). </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">An initial disbursement of </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">$2,000,000</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> was made to the Company in April 2016 under the Loan Agreement.&nbsp;The Loan Agreement provides that the remaining </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">$2,000,000</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> will be disbursed if and when the Company achieves certain future milestones.</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:5pt 0pt;text-indent:36pt;line-height:100%;font-family:Arial Unicode MS;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 8pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;">Basis of Presentation </font>
		</p>
		<p style="margin:6pt 0pt;text-indent:36pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201C;GAAP&#x201D;) for interim financial information and with the instructions to Form 10-Q and Article 8-03 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management of the Company, all adjustments, consisting of normal recurring adjustments necessary for the fair statement of results for the periods presented, have been included. The results of operations of any interim period are not necessarily indicative of the results of operations for the full year or any other interim period. </font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">The unaudited condensed consolidated financial statements and related disclosures have been prepared with the presumption that users of the interim unaudited condensed consolidated financial statements have read or have access to the audited consolidated financial statements for the preceding fiscal year. The condensed consolidated balance sheet at December&nbsp;31,&nbsp;2016 included in this report has been derived from the audited consolidated financial statements at that date but does not include all the information and footnotes required by GAAP. Accordingly, these unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended December 31, 2016, included in Vermillion&#x2019;s Annual Report on Form 10-K which was filed with the Securities and Exchange Commission on March 3</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">1</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">, 2017 (the &#x201C;2016 Annual Report&#x201D;).</font>
		</p>
		<p style="margin:6pt 0pt 0pt;line-height:100%;text-indent:36pt;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimated results.</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:6pt 0pt 0pt;line-height:100%;text-indent:36pt;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 8pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;">Significant Acco</font><font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;">unting and Reporting Policies </font>
		</p>
		<p style="margin:0pt 0pt 2.25pt 10pt;line-height:normal;text-indent:26pt;text-align:justify;text-justify:inter-ideograph;border-bottom:1pt none #D9D9D9 ;font-family:Arial Unicode MS;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;background-color: #FFFFFF;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 2.25pt 10pt;line-height:normal;text-indent: -10pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Arial Unicode MS;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;background-color: #FFFFFF;">Revenue Recognition</font>
		</p>
		<p style="margin:0pt 0pt 2.25pt 10pt;line-height:normal;text-indent: -10pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Arial Unicode MS;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;background-color: #FFFFFF;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 2.25pt 10pt;line-height:normal;text-indent: -10pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Arial Unicode MS;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;text-decoration:underline;background-color: #FFFFFF;">Product Revenue</font>
		</p>
		<p style="margin:0pt 0pt 2.25pt 10pt;line-height:normal;text-indent: -10pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Arial Unicode MS;font-size: 8pt">
			<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:8.5pt;background-color: #FFFFFF;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:normal;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Arial Unicode MS;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;background-color: #FFFFFF;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;background-color: #FFFFFF;;font-size: 10pt;font-family:Arial Unicode MS;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;background-color: #FFFFFF;">The Company has adopted ASC 954-605,</font><font style="font-family:Times New Roman;display: inline;">&nbsp;</font><font style="display: inline;font-family:Times New Roman;font-style:italic;color:#000000;font-size:10pt;background-color: #FFFFFF;">Health Care Entities&#x2014;Revenue Recognition, </font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;background-color: #FFFFFF;">as </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">revenue from laboratory services has become significant to the Company</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;background-color: #FFFFFF;">.</font><font style="font-family:Times New Roman;display: inline;">&nbsp;</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;background-color: #FFFFFF;">The Company's product revenue is generated by performing diagnostic services using its OVA1 and Overa tests, and the service is completed upon the delivery of test results to the prescribing physician. The Company recognizes revenue related to billings for Medicare and commercial payers on an accrual basis, net of contractual and other adjustments, when amounts that will ultimately be realized can be estimated. Until a contract has been negotiated with a commercial payer or governmental program, the OVA1 and Overa tests may or may not be covered by these entities' existing reimbursement policies. In addition, patients do not enter into direct agreements with the Company that commit them to pay any portion of the cost of the tests in the event that their insurance declines to reimburse the Company. In the absence of an agreement with the patient or other clearly enforceable legal right to demand payment from the patient, the related revenue is only recognized upon cash receipt.</font>
		</p>
		<p style="margin:0pt;line-height:normal;border-top:1pt none #D9D9D9 ;font-family:Arial Unicode MS;font-size: 8pt">
			<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:8.5pt;background-color: #FFFFFF;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">Estimates of amounts that the Company will ultimately realize require significant judgment by management. Some patients have out-of-pocket costs for amounts not covered by their insurance carrier, and the Company may bill the patient directly for these amounts in the form of co-payments and co-insurance in accordance with the patient&#x2019;s health plan. Some payers may not cover the OVA1 and Overa tests as ordered by the prescribing physician under their reimbursement policies. The Company pursues reimbursement from such patients on a case-by-case basis. In the absence of contracted reimbursement coverage or the ability to estimate the amount that will ultimately be realized for the Company's services, revenue is recognized when cash is received.</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;background-color: #FFFFFF;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 8pt;text-indent:36pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">&nbsp;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">See discussion of </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">FASB ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606) (&#x201C;ASU No. 2014-09&#x201D;)</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> included in Recent Accounting Pronouncements below</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">. &nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 8pt;text-indent:36pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 2.25pt 10pt;line-height:normal;text-indent: -10pt;text-align:justify;text-justify:inter-ideograph;border-bottom:1pt none #D9D9D9 ;font-family:Arial Unicode MS;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;background-color: #FFFFFF;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 2.25pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Arial Unicode MS;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;text-decoration:underline;background-color: #FFFFFF;">Service Revenue</font>
		</p>
		<p style="margin:0pt 0pt 2.25pt 10pt;line-height:normal;text-indent: -10pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;font-family:Arial Unicode MS;font-size: 8pt">
			<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:8.5pt;background-color: #FFFFFF;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">The Company&#x2019;s service revenue is generated by performing IVD trial services for third-party customers. In accordance with SAB Topic 13, service revenue is recognized when the following revenue recognition criteria are met: (1)&nbsp;persuasive evidence of an arrangement exists; (2)&nbsp;delivery has occurred or services have been rendered; (3)&nbsp;the fee is fixed or determinable; and (4)&nbsp;collectability is reasonably assured.</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">See discussion of ASU No. 2014-09 included in Recent Accounting Pronouncements below</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">.</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;background-color: #FFFFFF;">The Company has made no </font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;background-color: #FFFFFF;">other </font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;background-color: #FFFFFF;">significant</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> changes in its critical accounting policies and estimates from those disclosed in the 2016 Annual Report</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">.</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 8pt;text-indent:36pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;text-decoration:underline;background-color: #FFFFFF;">Recent Accounting Pronouncements</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">In March 2016, the </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">Financial Accounting Standards Board</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">&nbsp;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">(&#x201C;FASB&#x201D;) </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">issued ASU 2016-09, Improvements to Employee Share-Based Payment Accounting (</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">Topic 718), Compensation - Stock Compensation</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> (&#x201C;ASU 2016-09&#x201D;)</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">. The new guidance simplifies several aspects of the accounting for share-based payments, including immediate recognition of all excess tax benefits and deficiencies in the income statement, changing the threshold to qualify for equity classification up to the employees' maximum statutory tax rates, allowing an entity-wide accounting policy election to either estimate the number of awards that are expected to vest or account for forfeitures as they occur, and clarifying the classification on the statement of cash flows for the excess tax benefit and employee taxes paid when an employer withholds shares for tax-withholding purposes. ASU 2016-09 is effective for annual reporting periods beginning after December 15, 2016 and interim periods within that reporting period. The adoption of this standard is not expected to have a material effect on our financial statements</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">.</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 8pt;text-indent:36pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">In May 2014, the FASB issued ASU No. 2014-09</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">, Revenue from Contracts with Customers (Topic 606) (&#x201C;ASU 2014-09&#x201D;), which</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> removes inconsistencies and weaknesses in revenue requirements, provides a more robust framework for addressing revenue issues, improves comparability of revenue recognition practices across entities, industries, jurisdictions and capital markets, provides more useful information to users of financial statements through improved disclosure requirements and simplifies the preparation of financial statements by reducing the number of requirements to which an entity must refer. This guidance requires that an entity depict the consideration by applying a five-step analysis in determining when and how revenue is recognized. The new model will require revenue recognition to depict the transfer of promised goods or services to customers in an amount that reflects the consideration a company expects to receive in exchange for those goods or services. On April 1, 2015, the FASB voted for a one-year deferral of the effective date of the new revenue recognition standard, ASU No. 2014-09.&nbsp;On July 15, 2015, the FASB affirmed these changes, which requires public entities to apply the amendments in ASU 2014-09 for annual reporting beginning after December 15, 2017. Early adoption is permitted beginning after December 31, 2016, the original effective date in ASU 2014-09.</font>
		</p>
		<p style="margin:0pt 0pt 8pt;text-indent:36pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;"> The Company is in the early stages of its analysis of the effect </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">ASU 2014-09</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> will have on its Service Revenue, but expects to complete its analysis during the second half of 2017.</font>
		</p>
		<p style="margin:0pt 0pt 8pt;text-indent:36pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">The Company is also in the early stages of its analysis of</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> the effect ASU 2014-09 will have on </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">its Product Revenue and also expects to complete this analysis in the second half of 2017. Revenue that is recognized upon the ultimate receipt of cash under the Company&#x2019;s existing revenue recognition policy will have to be reassessed under the new standard. The next step in the Company&#x2019;s implementation process is to review its patient account population to determine the appropriate distribution of patient accounts </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;text-decoration:underline;">by payer</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> &nbsp;(</font><font style="display: inline;font-family:Times New Roman;font-style:italic;font-size:10pt;">i.e.</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">, Medicare, patient pay, other third-party payer, </font><font style="display: inline;font-family:Times New Roman;font-style:italic;font-size:10pt;">etc</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">.) into portfolios with similar collection experience that, when evaluated for collectability, will result in a materially consistent revenue amount for such portfolios as if each patient account were evaluated on a contract-by-contract basis.</font>
		</p>
		<p style="margin:0pt 0pt 8pt;text-indent:36pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">The Company has not yet determined if it plans to utilize the full retrospective or modified retrospective method of adoption, but anticipates adopting the new standard in the first quarter of 2018.</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p><font size="1"> </font></p>
	</div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -URI http://asc.fasb.org/topic&amp;trid=2122394<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6617736576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Agreements With Quest Diagnostics Incorporated<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Agreements With Quest Diagnostics Incorporated [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Agreements With Quest Diagnostics Incorporated</a></td>
<td class="text"><div> <div style="margin-left:0pt;margin-right:0pt;">
		<p style="margin:0pt 0pt 8pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-indent:36pt;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">2.&nbsp;&nbsp;&nbsp;AGREEMENTS WITH QUEST DIAGNOSTICS INCORPORATED</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;line-height:100%;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:5pt 0pt 0pt;text-indent:36pt;line-height:100%;font-family:Arial Unicode MS;font-size: 12pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">In March 2015, the Company entered into a commercial agreement with Quest Diagnostics</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">,</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">&nbsp;</font><a name="_cp_text_1_39"></a><font style="display: inline;font-family:Times New Roman;font-size:10pt;">Incorporated (&#x201C;Quest Diagnostics&#x201D;)</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">. Pursuant to this agreement</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">, &nbsp;</font><a name="_cp_text_1_40"></a><font style="display: inline;font-family:Times New Roman;font-size:10pt;">all OVA1 U.S. testing services for </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">Quest Diagnostics </font><a name="_cp_text_1_42"></a><font style="display: inline;font-family:Times New Roman;font-size:10pt;">customers were transferred to</font><font style="display: inline;font-family:Times New Roman;">&nbsp;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">Vermillion&#x2019;s</font><font style="display: inline;font-family:Times New Roman;">&nbsp;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">wholly-owned subsidiary, ASPiRA LABS,</font><font style="display: inline;font-family:Times New Roman;">&nbsp;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">as of August 2015. Pursuant to this agreement, as amended as of March 11, 2017, Quest Diagnostics has agreed to provide </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">blood draw and logistics support by transporting specimens from its clients to ASPiRA LABS for testing through at least March 11, 201</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">8</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> in exchange for a market value fee. Per the terms of </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">this</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> agreement, the Company will not offer to existing or future Quest Diagnostics customers tests that Quest Diagnostics offers. </font>
		</p>
		<p><font size="1"> </font></p>
	</div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6785677296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments And Contingencies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments And Contingencies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments And Contingencies</a></td>
<td class="text"><div> <div style="margin-left:0pt;margin-right:0pt;">
		<p style="margin:0pt;line-height:100%;text-indent:36pt;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:10pt;">3.</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"> &nbsp; </font><font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">COMMITMENT</font><font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">S</font><font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;"> AND CONTINGENCIES</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;">Development Loan</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Arial Unicode MS;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">On March 22, 2016, the Company entered into the </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">Loan </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">Agreement, pursuant to which the Company may borrow up to </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">$4,000,000</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> from the DECD.&nbsp;Proceeds from the </font><a name="_cp_text_1_48"></a><font style="display: inline;font-family:Times New Roman;font-size:10pt;">$2,000,000</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> April 2016 initial disbursement under the Loan Agreement </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">were</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> utilized primarily to fund the build-out, information technology infrastructure and other costs related to the Company&#x2019;s Trumbull, Connecticut facility and operations.&nbsp;The loan bears interest at a fixed rate of </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">2.0%</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> per annum and requires equal monthly payments of principal and interest until maturity, which occurs on </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">April 15, 2026</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">.&nbsp;As security for the loan, the Company has granted the DECD a blanket security interest in the Company&#x2019;s personal and intellectual property.&nbsp;The DECD&#x2019;s security interest in the Company&#x2019;s intellectual property may be subordinated to a qualified institutional lender.&nbsp;Under the terms of the Loan Agreement, the Company may be eligible for forgiveness of up to </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">$2,000,000</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> of the </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">principal amount of the loan if the Company achieves certain job creation and retention milestones by March 1, 2018.&nbsp;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">Conversely, i</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">f the Company is unable to meet these job creation </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">milestones, namely, hiring </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">40</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> full time employees with a specified average annual salary within the allotted timeframe </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">and </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">retaining those employees for a </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">two</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">-</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">year period </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">or </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">does not maintain the Company&#x2019;s Connecticut operations for a period of</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">&nbsp;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">10</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> years, the DECD may require early repayment of a portion or all of the loan</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> plus a penalty of </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">5%</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">.</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Arial Unicode MS;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">&nbsp; &nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Arial Unicode MS;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">As discussed above, a</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">n initial disbursement of </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">$2,000,000</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> was made to the Company on April 15, 2016 under the Loan Agreement.&nbsp;The Loan Agreement provides that the remaining </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">$2,000,000</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> will be disbursed</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">&nbsp;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">if and when the Company achieves certain future milestones. The loan may be prepaid at any time without premium or penalty</font><a name="T7"></a><a name="T8"></a><a name="T9"></a><font style="display: inline;font-family:Times New Roman;font-size:10pt;">.</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;border-top:1pt none #D9D9D9 ;line-height:100%;font-family:Arial Unicode MS;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;">Operating Leases</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-indent:36pt;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">The Company leases facilities to support its business of discovering, developing and commercializing diagnostic tests in the fields of gynecologic disease</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">. The Company&#x2019;s</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> principal facility</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">,</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">&nbsp;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">including</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">&nbsp;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">the </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">CLIA laboratory </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">used by ASPiRA LABS, is </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">located in Austin, Texas</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">,</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> and </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">the </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">CLIA laboratory </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">used by ASPiRA IVD is located </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">in Trumbull, Connecticut. </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">The</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> Austin, Texas lease include</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">s</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> an aggregate annual base rent of </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">$85,000</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> and annual estimated common area charges, taxes and insurance of </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">$46,000</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> and</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> expires on </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">January 31, 2019.</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> &nbsp; &nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-indent:36pt;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">In October 2015, the Company entered a lease agreement for a facility in Trumbull, Connecticut. The lease required initial payments for the buildout of leasehold improvements to the office space, which were approximately </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">$596,000</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">. The term of the lease is </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">five</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> years beginning after the initial date of occupancy </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">i</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">n January 2016 and a rent abatement period of </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">five</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> months. The lease includes an aggregate annual base rent of </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">$32,000</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> and annual estimated common area charges, taxes and insurance of </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">$95,000</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">. &nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-indent:36pt;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">Building rent</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> for the three months ended</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> June 30, 2017</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> and </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">201</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">6</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> totaled </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">$62,000</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> and </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">$53,000</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">, respectively. </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">Building rent</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> for the </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">six </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">months ended</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> June 30, 2017</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> and </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">201</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">6</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> totaled </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">$123,000</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> and </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">$104,000</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">, respectively. </font>
		</p>
		<p style="margin:0pt;line-height:100%;text-indent:36pt;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;">Capital Lease</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-indent:36pt;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">In April 2015, the Company leased </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">a</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> laboratory instrument for a total initial payment of </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">$125,000</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> and ongoing payments of approximately </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">$3,500</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> per month for </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">36</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> months after delivery. The agreement also requires minimum annual purchases of reagents from the manufacturer of the equipment. The laboratory instrument was placed into service on July 1, 2015. </font>
		</p>
		<p style="margin:0pt;line-height:100%;text-indent:36pt;font-family:Calibri;font-size: 11pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">The accumulated amortization of assets under capital lease obligations was </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">$155,000</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> and </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">$77,000</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> as of June 30</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">, 201</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">7</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> and 201</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">6</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">, respectively. The net book value of assets under capital lease obligations was </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">$77,000</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> and </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">$155,000</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> as</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> of</font><font style="display: inline;">&nbsp;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">June 30, 2017 and 2016, respectively</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">. &nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-indent:36pt;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;">Non-cancelable Royalty Obligations</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Arial Unicode MS;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">The Company is a party to an amended research collaboration agreement with The Johns Hopkins University School of Medicine </font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">under which the Company licenses certain of its intellectual property</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">. Under the terms of the amended research collaboration agreement, Vermillion is required to pay the greater of </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">4%</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> royalties on net sales of diagnostic tests using the assigned patents or annual minimum royalties of </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">$57,500</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">. Royalty expense for the three months ended </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">June 30, 2017</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> and 201</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">6</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> totalled </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">$34,000</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> and </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">$22,000</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">,</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> respectively. </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">Royalty expense for the </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">six </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">months ended </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">June 30, 2017</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> and 201</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">6</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> totalled </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">$63,000</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> and </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">$42,000</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">,</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> respectively.</font>
		</p>
		<p style="margin:5pt 0pt 0pt;text-indent:36pt;border-top:1pt none #D9D9D9 ;line-height:100%;font-family:Arial Unicode MS;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">&nbsp;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">&nbsp;</font>
		</p>
		<p><font size="1"> </font></p>
	</div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6624750064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock', window );">Stockholders' Equity</a></td>
<td class="text"><div> <div style="margin-left:0pt;margin-right:0pt;">
		<p style="margin:0pt 0pt 6pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">4.&nbsp;&nbsp;&nbsp;STOCKHOLDERS&#x2019; EQUITY</font>
		</p>
		<p style="margin:0pt 0pt 10pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;">2017 Private Placement</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font>
		</p>
		<p style="margin:0pt 0pt 10pt;text-indent:36pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">On February 17, 2017, the Company completed a private placement pursuant to which certain investors purchased </font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">3,747,125</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> shares of Vermillion common stock at a price of </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">$1.40</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> per share. Vermillion also issued warrants to purchase shares of Vermillion common stock at a price of </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">$0.125</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> per warrant share in the private placement. Net proceeds of the private placement were approximately </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">$</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">5,127,000</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> after deducting offering expenses. The warrants are exercisable for </font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">2,810,338</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> shares of Vermillion common stock at </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">$1.80</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> per share. </font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">The warrants may be exercised from time to time beginning August 17, 2017 and expire on the fifth anniversary of the date of issuance </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">or, if earlier, five business days after Vermillion delivers notice that the closing price per share of its common stock exceeded the exercise price for 20 consecutive trading days during the exercise period</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">.</font>
		</p>
		<p style="margin:0pt 0pt 3pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">The sale</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> of common stock and issuance of warrants qualified for equity treatment under GAAP. The respective values of the warrants and common stock were calculated using their relative fair values and classified under common stock and additional paid-in capital. The value ascribed to the warrants is </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">$804,000</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> and to the common stock is approximately </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">$4,296,000</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">.</font>
		</p>
		<p style="margin:0pt 0pt 3pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 3pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;">2010 Stock Incentive Plan</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">The Company&#x2019;s employees, directors, and consultants are eligible to receive awards under the Vermillion, Inc. </font><a name="_cp_text_4_18"></a><font style="display: inline;font-family:Times New Roman;font-size:10pt;">Second Amended and Restated </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">2010 Stock Incentive Plan (the &#x201C;2010 Plan&#x201D;). The 2010 Plan permits the granting of a variety of awards, including stock options, share appreciation rights, restricted shares, restricted share units, unrestricted shares, deferred share units, performance and cash-settled awards, and dividend equivalent rights. The 2010 Plan provides for issuance of up to </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">8,122,983</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> shares of Vermillion common stock, subject to adjustment as provided in the 2010 Plan.</font>
		</p>
		<p style="margin:0pt 0pt 3pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;">Stock-Based Compensation</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-indent:36pt;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">During the </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">six</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> months ended </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">June 30</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">, 2017</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">, the Company awarded to Vermillion&#x2019;s non-employee directors </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">131,250</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> shares of restricted stock under the 2010 Plan having a fair value of approximately </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">$281,000</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> as payment for services to be rendered in 2017.&nbsp;These shares of restricted stock vest</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">ed</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">&nbsp;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">50%</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> on June 1, 201</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">7, and will vest </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">25%</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> on</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> each of </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">September 1, 2017</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> and </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">December 1, 2017</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">. The Company also issued to certain consultants </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">22,841</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> shares of restricted stock under the 2010 Plan having a fair value of approximately </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">$39,000</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">.</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-indent:36pt;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-indent:36pt;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">During the </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">three </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">months ended </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">June 30</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">, 2017</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">, the Company issued to certain consultants </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">9,213</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> shares of restricted stock under the 2010 Plan having a fair value of approximately </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">$19,000</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">.</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> The Company </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">did not</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> make any awards of restricted stock to non-employee directors during the three months ended June 30, 201</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">7</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">.&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-indent:36pt;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-indent:36pt;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">During the </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">six</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> months ended </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">June 30</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">, 2017</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">, the Company also granted certain consultants options to purchase </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">70,000</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> shares of Vermillion common stock with an exercise price of </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">$2.14</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> per share.&nbsp;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">&nbsp;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">The Company also granted certain officers and employees options to </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">purchase approximately </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">916,000</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> shares of Vermillion common stock with an exercise price of </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">$2.14</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> per share.&nbsp;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">These stock options generally vest </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">25%</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> on each of the four&nbsp;anniversaries of the grant date.</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">&nbsp;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> In addition, the C</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">ompany granted certain officers and employees options to purchase </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">250,000</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> shares of Vermillion common stock with an exercise price of </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">approximately </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">$2.14</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> per</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> share with performance-based vesting based on certain metrics through December 31, 2017. </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">These options vest </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">25%</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> on each of the four&nbsp;anniversaries of the grant date if the performance-based metrics are met.</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-indent:36pt;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-indent:36pt;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">During the three months ended June 30, 201</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">7</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">, the Company granted certain officers and employees options to purchase </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">14,500</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> shares of Vermillion common stock with an exercise price of </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">$1.83</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> per share.&nbsp;These stock options vest </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">25%</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> on each of the four&nbsp;anniversaries of the vesting commencement date for each such stock option.&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-indent:36pt;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">The allocation of employee stock-based compensation expense by functional area for the three </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">and six </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">months ended </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">June 30</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">, 2017 and 2016 was as follows:</font>
		</p>
		<p style="margin:0pt;font-family:Calibri;line-height:107.92%;font-size: 1pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:38.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size: 1pt">
						<font style="display: inline;font-size:1pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:38.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;color:#000000;font-size:10pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="5" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:10pt;">Three Months Ended June 30,</font></p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="5" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:10pt;">Six Months Ended June 30,</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:38.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;border-bottom:1pt solid #000000 ;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:10pt;">&#xFEFF;</font><font style="display: inline;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:10pt;">(in thousands)</font></p>
				</td>
				<td valign="top" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:10pt;">2017</font></p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:10pt;">2016</font></p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:10pt;">2017</font></p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:10pt;">2016</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:38.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;color:#000000;font-size:10pt;">&#xFEFF;</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">Cost of revenue</font></p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.10%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">20&nbsp;
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.10%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">22&nbsp;
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.10%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">40&nbsp;
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.10%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">46&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:38.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;color:#000000;font-size:10pt;">&#xFEFF;</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">Research and development </font></p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">2&nbsp;
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">22&nbsp;
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">5&nbsp;
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">53&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:38.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;color:#000000;font-size:10pt;">&#xFEFF;</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">Sales and marketing </font></p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">38&nbsp;
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">14&nbsp;
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">70&nbsp;
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">56&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:38.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;color:#000000;font-size:10pt;">&#xFEFF;</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">General and administrative</font></p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">283&nbsp;
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">320&nbsp;
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">414&nbsp;
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">425&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:38.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;color:#000000;font-size:10pt;">&#xFEFF;</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">Total </font></p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.10%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">343&nbsp;
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.10%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">378&nbsp;
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.10%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">529&nbsp;
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.10%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">580&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:38.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;color:#000000;font-size:10pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.10%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.10%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.10%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.10%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt 0pt 8pt;font-family:Calibri;line-height:107.92%;font-size: 11pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;font-family:Calibri;line-height:107.92%;font-size: 1pt">
			<font style="display: inline;font-size:1pt;">&#xFEFF;</font>
		</p>
		<p><font size="1"> </font></p>
	</div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI http://asc.fasb.org/topic&amp;trid=2235017<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 712<br> -URI http://asc.fasb.org/topic&amp;trid=2197446<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 710<br> -URI http://asc.fasb.org/topic&amp;trid=2127225<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndEmployeeBenefitPlansTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6785658192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Loss Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Loss Per Share</a></td>
<td class="text"><div> <div style="margin-left:0pt;margin-right:0pt;">
		<p style="margin:0pt 0pt 6pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">5.&nbsp;&nbsp; </font><font style="display: inline;font-family:Times New Roman;font-weight:bold;font-size:10pt;">LOSS PER SHARE</font>
		</p>
		<p style="margin:0pt 0pt 8pt;text-indent:36pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">The Company calculates basic loss per share using the weighted ave</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">rage number of shares </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">of Vermillion common stock </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">outstanding during the period. Because the Company is in a net loss position, diluted loss per share is calculated using the </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">weighted average number of shares of Vermillion common stock outstanding and excludes the effects of </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">11,662,280</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> an</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">d &nbsp;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">7,808,044</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> po</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">tential shares of</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> Vermillion</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> common stock as of </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">June 30, 2017</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> and 201</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">6</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">, respectively, that are anti-dilutive. Potential shares of </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">Vermillion </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">common stock include incremental shares of </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">Vermillion </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">common stock issuable upon the exercise of outstanding warrants, stock options and unvested restricted stock units.</font>
		</p>
		<p><font size="1"> </font></p>
	</div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6784638000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization, Basis Of Presentation And Significant Accounting And Reporting Policies (Policy)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Basis Of Presentation And Significant Accounting And Reporting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vrml_OrganizationPolicyTextBlock', window );">Organization</a></td>
<td class="text"><div> <div style="margin-left:0pt;margin-right:0pt;">
		<p style="margin:0pt 0pt 8pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;">Organization </font>
		</p>
		<p style="margin:4.5pt 0pt 0pt 4.5pt;text-indent:31.5pt;line-height:100%;font-family:Arial Unicode MS;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">Vermillion, Inc. (&#x201C;Vermillion&#x201D;; Vermillion and its wholly-owned subsidiaries are collectively referred to as the &#x201C;Company</font><a name="_cp_text_1_15"></a><font style="display: inline;font-family:Times New Roman;font-size:10pt;">,&#x201D; &#x201C;we&#x201D; or &#x201C;our</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">&#x201D;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">) i</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">s incorporated in the state of Delaware, and is engaged in the business of developing and commercializing diagnostic tests for gynecologic disease. The Company sells OVA1&#x2122; and Overa&#x2122; risk of malignancy test</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">s</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> for ovarian cancer (&#x201C;OVA1&#x201D; and &#x201C;Overa</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">,</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">&#x201D;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> respectively</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">) through Vermillion&#x2019;s wholly-owned&nbsp;Clinical Laboratory Improvement Amendments of 1988 (&#x201C;CLIA&#x201D;) certified clinical laboratory, ASPiRA LABS, Inc. (&#x201C;ASPiRA LABS&#x201D;). </font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">The Company also offers in-vitro diagnostic (&#x201C;IVD&#x201D;) trial services to third-party customers through its wholly-owned subsidiary, ASPiRA IVD, Inc. (&#x201C;ASPiRA IVD&#x201D;), which commenced operations in June 2016. </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">ASPiRA IVD is a specialized, CLIA certified, laboratory provider dedicated to meeting the unique testing needs of IVD manufacturers seeking to commercialize&nbsp;high-complexity&nbsp;assays. </font>
		</p>
		<p><font size="1"> </font></p>
	</div> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vrml_GoingConcernPolicyTextBlock', window );">Going Concern</a></td>
<td class="text"><div> <div style="margin-left:0pt;margin-right:0pt;">
		<p style="margin:9pt 0pt 3pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;">Going Concern</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">The Company has incurred significant net losses and negative cash flows from operations since inception, and as a result has an accumulated deficit of approximat</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">ely </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">$</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">390</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">,589</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">,000</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> &nbsp;a</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">t &nbsp;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">June 30</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">, 2017. The Company also expects to incur a net loss and negative cash flows from operations for the remainder of 2017. The Company&#x2019;s management believes that successful achievement of the Company&#x2019;s business objectives will require additional financing.&nbsp;Given these conditions, there is substantial doubt about the Company&#x2019;s ability to continue as a going concern. The condensed consolidated financial statements have been prepared on a going concern basis and do not include any adjustments that might result from these uncertainties. </font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">The Company expects to raise capital through a variety of sources, which may include </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">the exercise of common stock warrants, </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">equity </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">offerings, debt financing</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">, collaborati</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">ons</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">, licensing arrangements, </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">grants and government funding and strategic alliances</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">. However, additional funding may not be available when needed or on terms acceptable to the Company. If the Company is unable to obtain additional capital, it may not be able to continue sales and marketing, research and development, or other operations on the scope or scale of current activity and that could have a material adverse effect on </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">the Company&#x2019;s</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> business, results of operations and financial condition.</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">As discussed in Note </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">4</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">, on February 17, 2017, the Company completed a private placement pursuant to which certain investors purchased Vermillion common stock and warrants to purchase shares of</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> Vermillion</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> common stock for net proceeds of approximately </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">$</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">5,127,000</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> after deducting offering expenses.</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">As discussed in Note 3, in March 2016, the Company entered into an agreement (the &#x201C;Loan Agreement&#x201D;) pursuant to which it may borrow up to </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">$4,000,000</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> from the State of Connecticut Department of Economic and Community Development (the &#x201C;DECD&#x201D;). </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">An initial disbursement of </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">$2,000,000</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> was made to the Company in April 2016 under the Loan Agreement.&nbsp;The Loan Agreement provides that the remaining </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">$2,000,000</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> will be disbursed if and when the Company achieves certain future milestones.</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:5pt 0pt;text-indent:36pt;line-height:100%;font-family:Arial Unicode MS;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p><font size="1"> </font></p>
	</div> </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div> <div style="margin-left:0pt;margin-right:0pt;">
		<p style="margin:0pt 0pt 8pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;">Basis of Presentation </font>
		</p>
		<p style="margin:6pt 0pt;text-indent:36pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201C;GAAP&#x201D;) for interim financial information and with the instructions to Form 10-Q and Article 8-03 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management of the Company, all adjustments, consisting of normal recurring adjustments necessary for the fair statement of results for the periods presented, have been included. The results of operations of any interim period are not necessarily indicative of the results of operations for the full year or any other interim period. </font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">The unaudited condensed consolidated financial statements and related disclosures have been prepared with the presumption that users of the interim unaudited condensed consolidated financial statements have read or have access to the audited consolidated financial statements for the preceding fiscal year. The condensed consolidated balance sheet at December&nbsp;31,&nbsp;2016 included in this report has been derived from the audited consolidated financial statements at that date but does not include all the information and footnotes required by GAAP. Accordingly, these unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended December 31, 2016, included in Vermillion&#x2019;s Annual Report on Form 10-K which was filed with the Securities and Exchange Commission on March 3</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">1</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">, 2017 (the &#x201C;2016 Annual Report&#x201D;).</font>
		</p>
		<p style="margin:6pt 0pt 0pt;line-height:100%;text-indent:36pt;font-family:Calibri;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimated results.</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">&nbsp;</font>
		</p>
		<p><font size="1"> </font></p>
	</div> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vrml_SignificantAccountingAndReportingPoliciesPolicyTextBlock', window );">Significant Accounting and Reporting Policies</a></td>
<td class="text"><div> <div style="margin-left:0pt;margin-right:0pt;">
		<p style="margin:0pt 0pt 8pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;">Significant Acco</font><font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;font-size:10pt;">unting and Reporting Policies</font>
		</p>
		<p><font size="1"> </font></p>
	</div> </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div> <div style="margin-left:0pt;margin-right:0pt;">
		<p style="margin:0pt 0pt 2.25pt 10pt;line-height:normal;text-indent: -10pt;text-align:justify;text-justify:inter-ideograph;border-bottom:1pt none #D9D9D9 ;font-family:Arial Unicode MS;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;background-color: #FFFFFF;">Revenue Recognition</font>
		</p>
		<p style="margin:0pt 0pt 2.25pt 10pt;line-height:normal;text-indent: -10pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Arial Unicode MS;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;background-color: #FFFFFF;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 2.25pt 10pt;line-height:normal;text-indent: -10pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Arial Unicode MS;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;text-decoration:underline;background-color: #FFFFFF;">Product Revenue</font>
		</p>
		<p style="margin:0pt 0pt 2.25pt 10pt;line-height:normal;text-indent: -10pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Arial Unicode MS;font-size: 8pt">
			<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:8.5pt;background-color: #FFFFFF;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:normal;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Arial Unicode MS;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;background-color: #FFFFFF;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;background-color: #FFFFFF;;font-size: 10pt;font-family:Arial Unicode MS;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;background-color: #FFFFFF;">The Company has adopted ASC 954-605,</font><font style="font-family:Times New Roman;display: inline;">&nbsp;</font><font style="display: inline;font-family:Times New Roman;font-style:italic;color:#000000;font-size:10pt;background-color: #FFFFFF;">Health Care Entities&#x2014;Revenue Recognition, </font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;background-color: #FFFFFF;">as </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">revenue from laboratory services has become significant to the Company</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;background-color: #FFFFFF;">.</font><font style="font-family:Times New Roman;display: inline;">&nbsp;</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;background-color: #FFFFFF;">The Company's product revenue is generated by performing diagnostic services using its OVA1 and Overa tests, and the service is completed upon the delivery of test results to the prescribing physician. The Company recognizes revenue related to billings for Medicare and commercial payers on an accrual basis, net of contractual and other adjustments, when amounts that will ultimately be realized can be estimated. Until a contract has been negotiated with a commercial payer or governmental program, the OVA1 and Overa tests may or may not be covered by these entities' existing reimbursement policies. In addition, patients do not enter into direct agreements with the Company that commit them to pay any portion of the cost of the tests in the event that their insurance declines to reimburse the Company. In the absence of an agreement with the patient or other clearly enforceable legal right to demand payment from the patient, the related revenue is only recognized upon cash receipt.</font>
		</p>
		<p style="margin:0pt;line-height:normal;border-top:1pt none #D9D9D9 ;font-family:Arial Unicode MS;font-size: 8pt">
			<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:8.5pt;background-color: #FFFFFF;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">Estimates of amounts that the Company will ultimately realize require significant judgment by management. Some patients have out-of-pocket costs for amounts not covered by their insurance carrier, and the Company may bill the patient directly for these amounts in the form of co-payments and co-insurance in accordance with the patient&#x2019;s health plan. Some payers may not cover the OVA1 and Overa tests as ordered by the prescribing physician under their reimbursement policies. The Company pursues reimbursement from such patients on a case-by-case basis. In the absence of contracted reimbursement coverage or the ability to estimate the amount that will ultimately be realized for the Company's services, revenue is recognized when cash is received.</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;background-color: #FFFFFF;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 8pt;text-indent:36pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">&nbsp;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">See discussion of </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">FASB ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606) (&#x201C;ASU No. 2014-09&#x201D;)</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> included in Recent Accounting Pronouncements below</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">. &nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 8pt;text-indent:36pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 2.25pt 10pt;line-height:normal;text-indent: -10pt;text-align:justify;text-justify:inter-ideograph;border-bottom:1pt none #D9D9D9 ;font-family:Arial Unicode MS;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;background-color: #FFFFFF;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 2.25pt;line-height:normal;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Arial Unicode MS;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;text-decoration:underline;background-color: #FFFFFF;">Service Revenue</font>
		</p>
		<p style="margin:0pt 0pt 2.25pt 10pt;line-height:normal;text-indent: -10pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;font-family:Arial Unicode MS;font-size: 8pt">
			<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:8.5pt;background-color: #FFFFFF;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">The Company&#x2019;s service revenue is generated by performing IVD trial services for third-party customers. In accordance with SAB Topic 13, service revenue is recognized when the following revenue recognition criteria are met: (1)&nbsp;persuasive evidence of an arrangement exists; (2)&nbsp;delivery has occurred or services have been rendered; (3)&nbsp;the fee is fixed or determinable; and (4)&nbsp;collectability is reasonably assured.</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:36pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">See discussion of ASU No. 2014-09 included in Recent Accounting Pronouncements below</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">.</font>
		</p>
		<p style="margin:0pt 0pt 8pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;background-color: #FFFFFF;">The Company has made no </font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;background-color: #FFFFFF;">other </font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;background-color: #FFFFFF;">significant</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> changes in its critical accounting policies and estimates from those disclosed in the 2016 Annual Report</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">.</font>
		</p>
		<p><font size="1"> </font></p>
	</div> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div> <div style="margin-left:0pt;margin-right:0pt;">
		<p style="margin:0pt 0pt 8pt;text-indent:36pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;text-decoration:underline;background-color: #FFFFFF;">Recent Accounting Pronouncements</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">In March 2016, the </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">Financial Accounting Standards Board</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">&nbsp;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">(&#x201C;FASB&#x201D;) </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">issued ASU 2016-09, Improvements to Employee Share-Based Payment Accounting (</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">Topic 718), Compensation - Stock Compensation</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> (&#x201C;ASU 2016-09&#x201D;)</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">. The new guidance simplifies several aspects of the accounting for share-based payments, including immediate recognition of all excess tax benefits and deficiencies in the income statement, changing the threshold to qualify for equity classification up to the employees' maximum statutory tax rates, allowing an entity-wide accounting policy election to either estimate the number of awards that are expected to vest or account for forfeitures as they occur, and clarifying the classification on the statement of cash flows for the excess tax benefit and employee taxes paid when an employer withholds shares for tax-withholding purposes. ASU 2016-09 is effective for annual reporting periods beginning after December 15, 2016 and interim periods within that reporting period. The adoption of this standard is not expected to have a material effect on our financial statements</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">.</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 8pt;text-indent:36pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">In May 2014, the FASB issued ASU No. 2014-09</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">, Revenue from Contracts with Customers (Topic 606) (&#x201C;ASU 2014-09&#x201D;), which</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> removes inconsistencies and weaknesses in revenue requirements, provides a more robust framework for addressing revenue issues, improves comparability of revenue recognition practices across entities, industries, jurisdictions and capital markets, provides more useful information to users of financial statements through improved disclosure requirements and simplifies the preparation of financial statements by reducing the number of requirements to which an entity must refer. This guidance requires that an entity depict the consideration by applying a five-step analysis in determining when and how revenue is recognized. The new model will require revenue recognition to depict the transfer of promised goods or services to customers in an amount that reflects the consideration a company expects to receive in exchange for those goods or services. On April 1, 2015, the FASB voted for a one-year deferral of the effective date of the new revenue recognition standard, ASU No. 2014-09.&nbsp;On July 15, 2015, the FASB affirmed these changes, which requires public entities to apply the amendments in ASU 2014-09 for annual reporting beginning after December 15, 2017. Early adoption is permitted beginning after December 31, 2016, the original effective date in ASU 2014-09.</font>
		</p>
		<p style="margin:0pt 0pt 8pt;text-indent:36pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;"> The Company is in the early stages of its analysis of the effect </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">ASU 2014-09</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> will have on its Service Revenue, but expects to complete its analysis during the second half of 2017.</font>
		</p>
		<p style="margin:0pt 0pt 8pt;text-indent:36pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">The Company is also in the early stages of its analysis of</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> the effect ASU 2014-09 will have on </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">its Product Revenue and also expects to complete this analysis in the second half of 2017. Revenue that is recognized upon the ultimate receipt of cash under the Company&#x2019;s existing revenue recognition policy will have to be reassessed under the new standard. The next step in the Company&#x2019;s implementation process is to review its patient account population to determine the appropriate distribution of patient accounts </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;text-decoration:underline;">by payer</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> &nbsp;(</font><font style="display: inline;font-family:Times New Roman;font-style:italic;font-size:10pt;">i.e.</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">, Medicare, patient pay, other third-party payer, </font><font style="display: inline;font-family:Times New Roman;font-style:italic;font-size:10pt;">etc</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">.) into portfolios with similar collection experience that, when evaluated for collectability, will result in a materially consistent revenue amount for such portfolios as if each patient account were evaluated on a contract-by-contract basis.</font>
		</p>
		<p style="margin:0pt 0pt 8pt;text-indent:36pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">The Company has not yet determined if it plans to utilize the full retrospective or modified retrospective method of adoption, but anticipates adopting the new standard in the first quarter of 2018.</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p><font size="1"> </font></p>
	</div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.B.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18726-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrml_GoingConcernPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Going Concern [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrml_GoingConcernPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrml_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrml_OrganizationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Organization policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrml_OrganizationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrml_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrml_SignificantAccountingAndReportingPoliciesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Significant Accounting And Reporting Policies [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrml_SignificantAccountingAndReportingPoliciesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrml_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6785583968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Allocation of Stock-Based Compensation Expense by Functional Area</a></td>
<td class="text"><div> <div style="margin-left:0pt;margin-right:0pt;">
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:38.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size: 1pt">
						<font style="display: inline;font-size:1pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:38.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;color:#000000;font-size:10pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="5" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:10pt;">Three Months Ended June 30,</font></p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="5" valign="bottom" style="width:00.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:10pt;">Six Months Ended June 30,</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:38.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;border-bottom:1pt solid #000000 ;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:10pt;">&#xFEFF;</font><font style="display: inline;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:10pt;">(in thousands)</font></p>
				</td>
				<td valign="top" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:10pt;">2017</font></p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:10pt;">2016</font></p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:10pt;">2017</font></p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:00.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-weight:bold;color:#000000;font-size:10pt;">2016</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:38.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;color:#000000;font-size:10pt;">&#xFEFF;</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">Cost of revenue</font></p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.10%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">20&nbsp;
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.10%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">22&nbsp;
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.10%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">40&nbsp;
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.10%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">46&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:38.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;color:#000000;font-size:10pt;">&#xFEFF;</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">Research and development </font></p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">2&nbsp;
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">22&nbsp;
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">5&nbsp;
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">53&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:38.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;color:#000000;font-size:10pt;">&#xFEFF;</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">Sales and marketing </font></p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">38&nbsp;
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">14&nbsp;
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">70&nbsp;
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">56&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:38.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;color:#000000;font-size:10pt;">&#xFEFF;</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">General and administrative</font></p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">283&nbsp;
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">320&nbsp;
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">414&nbsp;
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">425&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:38.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;color:#000000;font-size:10pt;">&#xFEFF;</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">Total </font></p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.10%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">343&nbsp;
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.10%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">378&nbsp;
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.10%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">529&nbsp;
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.10%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:12.75pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">580&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:38.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;font-size: 10pt">
						<font style="display: inline;color:#000000;font-size:10pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.10%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.10%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.10%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.10%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:12.75pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;font-family:Calibri;line-height:107.92%;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt 0pt 8pt;font-family:Calibri;line-height:107.92%;font-size: 11pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p><font size="1"> </font></p>
	</div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6794290048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization, Basis Of Presentation And Significant Accounting And Reporting Policies (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 15, 2016</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Mar. 22, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vrml_OrganizationConsolidationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization Consolidation And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (390,589,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (385,556,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from issuance of private placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,127,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Initial proceeds from loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,966,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=vrml_DecdMember', window );">DECD [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vrml_OrganizationConsolidationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization Consolidation And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Total borrowing amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Initial proceeds from loan</a></td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount', window );">Remaining loan amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=64930739&amp;loc=d3e28878-108400<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28551-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unused borrowing capacity under the long-term financing arrangement that is available to the entity as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrml_OrganizationConsolidationAndSummaryOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Organization Consolidation And Summary Of Significant Accounting Policies [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrml_OrganizationConsolidationAndSummaryOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrml_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=vrml_DecdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=vrml_DecdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6796781616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments And Contingencies (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Apr. 15, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 31, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 30, 2015 </div>
<div>USD ($) </div>
<div>item</div>
</th>
<th class="th">
<div>Jun. 30, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2017 </div>
<div>USD ($) </div>
<div>employee</div>
</th>
<th class="th">
<div>Jun. 30, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 22, 2016 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vrml_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Initial proceeds from loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,966,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesRentExpenseNet', window );">Operating leases rental expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 62,000<span></span>
</td>
<td class="nump">$ 53,000<span></span>
</td>
<td class="nump">$ 123,000<span></span>
</td>
<td class="nump">104,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Net book value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,549,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,549,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,911,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vrml_PercentageOfRoyaltyPaid', window );">Percent of royalty paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRoyalties', window );">Minimum royalty payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 57,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Royalty expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,000<span></span>
</td>
<td class="nump">22,000<span></span>
</td>
<td class="nump">63,000<span></span>
</td>
<td class="nump">42,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseArrangementTypeAxis=vrml_AustinTexasFacilityMember', window );">Austin, Texas facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vrml_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRent', window );">Annual base rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vrml_OperatingLeasesOtherOccupancyCosts', window );">Annual estimated common area charges, taxes and insurance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 46,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Lease expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jan. 31,  2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseArrangementTypeAxis=vrml_TrumbullConnecticutFacilityMember', window );">Trumbull, Connecticut Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vrml_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRent', window );">Annual base rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vrml_OperatingLeasesOtherOccupancyCosts', window );">Annual estimated common area charges, taxes and insurance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseholdImprovementsGross', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 596,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract', window );">Lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vrml_LesseeLeasingArrangementsOperatingLeasesRentAbatementPeriod', window );">Rent abatement period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=vrml_DecdMember', window );">DECD [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vrml_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Total borrowing amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Fixed rate per annum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Apr. 15,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vrml_DebtInstrumentAmountEligibleForForgiveness', window );">Amount eligible for forgiveness</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vrml_DebtInstrumentDebtCovenantJobCreationNumberOfEmployees', window );">Job creation, number of employees | employee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vrml_DebtInstrumentDebtCovenantJobCreationPeriod', window );">Job creation, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt, maturity term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vrml_DebtInstrumentCovenantNoncompliancePenalty', window );">Debt penalty</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Initial proceeds from loan</a></td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount', window );">Remaining loan amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_AssetsHeldUnderCapitalLeasesMember', window );">Assets Under Capital Leases [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vrml_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vrml_NumberOfPurchasedLaboratoryInstruments', window );">Number of purchased laboratory instruments | item</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMachineryAndEquipment', window );">Initial payment of laboratory equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesContingentRentalPaymentsDue', window );">Monthly payment for acquisition for equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vrml_NumberOfPaymentsForPurchaseProductionOfAssets', window );">Number of payments for purchase production of assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">36 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">155,000<span></span>
</td>
<td class="nump">77,000<span></span>
</td>
<td class="nump">$ 155,000<span></span>
</td>
<td class="nump">77,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Net book value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 77,000<span></span>
</td>
<td class="nump">$ 155,000<span></span>
</td>
<td class="nump">$ 77,000<span></span>
</td>
<td class="nump">$ 155,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasesContingentRentalPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due based upon the occurrence of an event specified in the contractual terms.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=84164817&amp;loc=d3e45280-112737<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeasesContingentRentalPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=64930739&amp;loc=d3e28878-108400<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28551-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unused borrowing capacity under the long-term financing arrangement that is available to the entity as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseExpirationDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date which lease or group of leases is set to expire, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseExpirationDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseholdImprovementsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of additions or improvements to assets held under a lease arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6812-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseholdImprovementsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesRentExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41499-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesRentExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash payments to lessor's for use of assets under operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for royalties during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMachineryAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for acquisition of machinery and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMachineryAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrml_CommitmentsAndContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commitments And Contingencies [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrml_CommitmentsAndContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrml_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrml_DebtInstrumentAmountEligibleForForgiveness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Amount Eligible For Forgiveness</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrml_DebtInstrumentAmountEligibleForForgiveness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrml_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrml_DebtInstrumentCovenantNoncompliancePenalty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant Noncompliance Penalty</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrml_DebtInstrumentCovenantNoncompliancePenalty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrml_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrml_DebtInstrumentDebtCovenantJobCreationNumberOfEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Debt Covenant, Job Creation, Number Of Employees</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrml_DebtInstrumentDebtCovenantJobCreationNumberOfEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrml_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrml_DebtInstrumentDebtCovenantJobCreationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Debt Covenant, Job Creation, Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrml_DebtInstrumentDebtCovenantJobCreationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrml_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrml_LesseeLeasingArrangementsOperatingLeasesRentAbatementPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee Leasing Arrangements, Operating Leases, Rent Abatement Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrml_LesseeLeasingArrangementsOperatingLeasesRentAbatementPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrml_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrml_NumberOfPaymentsForPurchaseProductionOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of payments for purchase production of assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrml_NumberOfPaymentsForPurchaseProductionOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrml_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrml_NumberOfPurchasedLaboratoryInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of purchased laboratory instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrml_NumberOfPurchasedLaboratoryInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrml_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:positiveIntegerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrml_OperatingLeasesOtherOccupancyCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Leases, Other Occupancy Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrml_OperatingLeasesOtherOccupancyCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrml_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrml_PercentageOfRoyaltyPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage Of Royalty Paid</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrml_PercentageOfRoyaltyPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrml_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseArrangementTypeAxis=vrml_AustinTexasFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseArrangementTypeAxis=vrml_AustinTexasFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseArrangementTypeAxis=vrml_TrumbullConnecticutFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseArrangementTypeAxis=vrml_TrumbullConnecticutFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=vrml_DecdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=vrml_DecdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_AssetsHeldUnderCapitalLeasesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_AssetsHeldUnderCapitalLeasesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6795097728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Narrative) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Feb. 17, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">56,164,082<span></span>
</td>
<td class="nump">56,164,082<span></span>
</td>
<td class="nump">3,747,125<span></span>
</td>
<td class="nump">52,328,492<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Price per share</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 1.40<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vrml_PriceOfSharesToBeIssuedUnderWarrants', window );">Issued a warrant to purchase common stock with a cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from issuance of private placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,127,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding to purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,810,338<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vrml_FairValueOfWarrantsIssued', window );">Fair value of warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 804,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock value</a></td>
<td class="nump">$ 56,000<span></span>
</td>
<td class="nump">$ 56,000<span></span>
</td>
<td class="nump">$ 4,296,000<span></span>
</td>
<td class="nump">$ 52,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=vrml_StockOptionPlanTwentyTenMember', window );">2010 Stock Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for grant</a></td>
<td class="nump">8,122,983<span></span>
</td>
<td class="nump">8,122,983<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=vrml_StockOptionPlanTwentyTenMember', window );">2010 Stock Incentive Plan [Member] | Non-Employee Directors [Member] | Restricted Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Restricted shares awarded</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">131,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vrml_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedFairValue', window );">Fair value of restricted shares awarded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 281,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=vrml_StockOptionPlanTwentyTenMember', window );">2010 Stock Incentive Plan [Member] | Non-Employee Directors [Member] | Restricted Stock [Member] | June 1, 2016 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=vrml_StockOptionPlanTwentyTenMember', window );">2010 Stock Incentive Plan [Member] | Non-Employee Directors [Member] | Restricted Stock [Member] | September 1, 2016 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=vrml_StockOptionPlanTwentyTenMember', window );">2010 Stock Incentive Plan [Member] | Non-Employee Directors [Member] | Restricted Stock [Member] | December 1, 2017 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=vrml_StockOptionPlanTwentyTenMember', window );">2010 Stock Incentive Plan [Member] | Certain Consultants [Member] | Restricted Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Restricted shares awarded</a></td>
<td class="nump">9,213<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vrml_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedFairValue', window );">Fair value of restricted shares awarded</a></td>
<td class="nump">$ 19,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Restricted share units granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,841<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Fair value of restricted share units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 39,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=vrml_StockOptionPlanTwentyTenMember', window );">2010 Stock Incentive Plan [Member] | Certain Consultants [Member] | $2.14 [Member] | Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Stock options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Stock options granted, average exercise price</a></td>
<td class="nump">$ 2.14<span></span>
</td>
<td class="nump">$ 2.14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=vrml_StockOptionPlanTwentyTenMember', window );">2010 Stock Incentive Plan [Member] | Certain Officers And Employees [Member] | $2.14 [Member] | Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Stock options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">916,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Stock options granted, average exercise price</a></td>
<td class="nump">2.14<span></span>
</td>
<td class="nump">$ 2.14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=vrml_StockOptionPlanTwentyTenMember', window );">2010 Stock Incentive Plan [Member] | Certain Officers And Employees [Member] | $2.14 [Member] | Stock Option [Member] | Share-based Compensation Award, Tranche One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=vrml_StockOptionPlanTwentyTenMember', window );">2010 Stock Incentive Plan [Member] | Certain Officers And Employees [Member] | $2.14 [Member] | Stock Option [Member] | Share-based Compensation Award, Tranche One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=vrml_StockOptionPlanTwentyTenMember', window );">2010 Stock Incentive Plan [Member] | Certain Officers And Employees [Member] | $2.14 [Member] | Performance Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Stock options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Stock options granted, average exercise price</a></td>
<td class="nump">$ 2.14<span></span>
</td>
<td class="nump">$ 2.14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=vrml_StockOptionPlanTwentyTenMember', window );">2010 Stock Incentive Plan [Member] | Certain Officers And Employees [Member] | $1.83 [Member] | Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Stock options granted</a></td>
<td class="nump">14,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Stock options granted, average exercise price</a></td>
<td class="nump">$ 1.83<span></span>
</td>
<td class="nump">$ 1.83<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=vrml_StockOptionPlanTwentyTenMember', window );">2010 Stock Incentive Plan [Member] | Certain Officers And Employees [Member] | $1.83 [Member] | Stock Option [Member] | Share-based Compensation Award, Tranche One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net number of non-option equity instruments granted to participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of share-based compensation awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate value of stock related to Restricted Stock Awards issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrml_FairValueOfWarrantsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents fair value of warrants issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrml_FairValueOfWarrantsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrml_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrml_PriceOfSharesToBeIssuedUnderWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price Of Shares To Be Issued Under Warrants</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrml_PriceOfSharesToBeIssuedUnderWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrml_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vrml_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted, Fair Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vrml_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vrml_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=vrml_StockOptionPlanTwentyTenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=vrml_StockOptionPlanTwentyTenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=vrml_NonEmployeeDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=vrml_NonEmployeeDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=vrml_VestingPercentageDateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=vrml_VestingPercentageDateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=vrml_VestingPercentageDateBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=vrml_VestingPercentageDateBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=vrml_VestingPercentageDateCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=vrml_VestingPercentageDateCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=vrml_CertainConsultantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=vrml_CertainConsultantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=vrml_ExercisePriceBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=vrml_ExercisePriceBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=vrml_CertainOfficersAndEmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=vrml_CertainOfficersAndEmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=vrml_ExercisePriceCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=vrml_ExercisePriceCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=vrml_ExercisePriceDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=vrml_ExercisePriceDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=vrml_ExercisePriceEMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=vrml_ExercisePriceEMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6784813856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Allocation of Employee Stock-Based Compensation Expense By Functional Area) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost Of Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 40<span></span>
</td>
<td class="nump">$ 22<span></span>
</td>
<td class="nump">$ 79<span></span>
</td>
<td class="nump">$ 46<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research And Development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">22<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="nump">53<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember', window );">Sales And Marketing [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">40<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="nump">77<span></span>
</td>
<td class="nump">56<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General And Administrative [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">295<span></span>
</td>
<td class="nump">319<span></span>
</td>
<td class="nump">510<span></span>
</td>
<td class="nump">445<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=vrml_EmployeeStockBasedCompensationMember', window );">Employee Stock-Based Compensation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">343<span></span>
</td>
<td class="nump">378<span></span>
</td>
<td class="nump">529<span></span>
</td>
<td class="nump">580<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=vrml_EmployeeStockBasedCompensationMember', window );">Employee Stock-Based Compensation [Member] | Cost Of Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">20<span></span>
</td>
<td class="nump">22<span></span>
</td>
<td class="nump">40<span></span>
</td>
<td class="nump">46<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=vrml_EmployeeStockBasedCompensationMember', window );">Employee Stock-Based Compensation [Member] | Research And Development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">22<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="nump">53<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=vrml_EmployeeStockBasedCompensationMember', window );">Employee Stock-Based Compensation [Member] | Sales And Marketing [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">38<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="nump">70<span></span>
</td>
<td class="nump">56<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=vrml_EmployeeStockBasedCompensationMember', window );">Employee Stock-Based Compensation [Member] | General And Administrative [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 283<span></span>
</td>
<td class="nump">$ 320<span></span>
</td>
<td class="nump">$ 414<span></span>
</td>
<td class="nump">$ 425<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=vrml_EmployeeStockBasedCompensationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=vrml_EmployeeStockBasedCompensationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6620712736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss Per Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Loss Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share</a></td>
<td class="nump">11,662,280<span></span>
</td>
<td class="nump">7,808,044<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>30
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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M?_C=A'UOW<']8^.KH&K@UUVH+U!+ P04    " !B@ M+F5R<(Q &  "<)P
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MG!84+LI,5WHNA@XR+!3OQNX832VZ_ -02P,$%     @ 8H +2^O:IGJ$ P
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M4-^'H] CO$2I.P:]['CO"6AR]#XXE*G16\&/#D:YZGLFDQ/GSV;PN<Z1;X"
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MH?+A^ G/=ARST?"FFWX0F[]Q_A=02P,$%     @ 8H +2^QL(6ZT 0  T@,
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MLYG&;#(<]O,/8LLW+GX#4$L#!!0    ( &* "TN^BJ"]M $  -(#   9
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M=3885-IN=V8OQ_DR&EKTT^@D\_S._P!02P,$%     @ 8H +2URN'2RV 0
MT@,  !D   !X;"]W;W)K<VAE971S+W-H965T,3,N>&UL;5/;;MP@$/T5Q >$
M7=;91"O;4C91U$J-M$K4]IFUQQ<%&!?P.OG[ '9<-_4+,,,Y9RX,Z8#FU38
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M,Z;1K<_H2_NX]CK=GBYRO6NZ4]&>5\,7SN&B,0?[]38\?4)>_@902P,$%
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M1?K=$AJ;1GI@QDS?48V'@UGEB%5+*^>853Z#58%9%8!5H_P"L,H":_T%IE4
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MX Y=:4L!XAT$Z<JO'EL4!,F*,?;!14%Z3BZ@_0VPOP'O>0\ VDQ W*$J;29
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M\F>#0J7,=J?WPO6_,Q3OI]%&\_\E^P=02P,$%     @ 8H +2_+8;W&=)P
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MO)\2VB<]<4DA"".%([K$LXX*\@>Z/J\BY91ZRR(89\2QP6(=PKI-&E7!%P(
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MFFU0/41SDK_K*R+VS6_WNDCSLTNG;8>^:^+@K]:,R&H?A\"WZ50#=:NZZ^[
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M+-(\^7#D/7MV/0^G0BI7VU?PWV4_?2^P\:Q RM@@<((]D,8UT1J4N#6.F^S
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MQ5?Y!8VU'4LKM/N+Y-/[Q;X^:W^PIM]02P$"% ,4    " !B@ M+'R// \
M   3 @  "P              @ $     7W)E;',O+G)E;'-02P$"% ,4
M" !B@ M+9O,+8((   "Q    $               @ 'I    9&]C4')O<',O
M87!P+GAM;%!+ 0(4 Q0    ( &* "TO(]"?Z[@   "L"   1
M  "  9D!  !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( &* "TN97)PC
M$ 8  )PG   3              "  ;8"  !X;"]T:&5M92]T:&5M93$N>&UL
M4$L! A0#%     @ 8H +2S9]T<Y7 @  K@<  !@              ( !]P@
M 'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( &* "TOKVJ9Z
MA ,  &<0   8              "  80+  !X;"]W;W)K<VAE971S+W-H965T
M,BYX;6Q02P$"% ,4    " !B@ M+M)'^8?8!  ")!0  &
M@ $^#P  >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%     @ 8H +
M2]9KR^"Q!   UQ8  !@              ( !:A$  'AL+W=O<FMS:&5E=',O
M<VAE970T+GAM;%!+ 0(4 Q0    ( &* "TNKV7%:? (  +((   8
M      "  5$6  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q02P$"% ,4
M" !B@ M+G+:K"KT#  "A$   &               @ $#&0  >&PO=V]R:W-H
M965T<R]S:&5E=#8N>&UL4$L! A0#%     @ 8H +2U&FOB"Q 0  T@,  !@
M             ( !]AP  'AL+W=O<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4
M Q0    ( &* "TO?RO(<LP$  -(#   8              "  =T>  !X;"]W
M;W)K<VAE971S+W-H965T."YX;6Q02P$"% ,4    " !B@ M+[&PA;K0!  #2
M P  &               @ '&(   >&PO=V]R:W-H965T<R]S:&5E=#DN>&UL
M4$L! A0#%     @ 8H +2[Z*H+VT 0  T@,  !D              ( !L"(
M 'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q02P$"% ,4    " !B@ M+-0?/
MAK0!  #2 P  &0              @ &;)   >&PO=V]R:W-H965T<R]S:&5E
M=#$Q+GAM;%!+ 0(4 Q0    ( &* "TL!L%L=]0$  ,L%   9
M  "  88F  !X;"]W;W)K<VAE971S+W-H965T,3(N>&UL4$L! A0#%     @
M8H +2URN'2RV 0  T@,  !D              ( !LB@  'AL+W=O<FMS:&5E
M=',O<VAE970Q,RYX;6Q02P$"% ,4    " !B@ M+'E$(C#\"  !N!P  &0
M            @ &?*@  >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4
M Q0    ( &* "TN<&N#6/P0  $X6   9              "  14M  !X;"]W
M;W)K<VAE971S+W-H965T,34N>&UL4$L! A0#%     @ 8H +2]AYE)&K!
MBQD  !D              ( !BS$  'AL+W=O<FMS:&5E=',O<VAE970Q-BYX
M;6Q02P$"% ,4    " !B@ M+029BLG<#  "!$   &0              @ %M
M-@  >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    ( &* "TOP
M;8F<XP$  &L$   9              "  1LZ  !X;"]W;W)K<VAE971S+W-H
M965T,3@N>&UL4$L! A0#%     @ 8H +2_+8;W&=)P  \KH  !0
M     ( !-3P  'AL+W-H87)E9%-T<FEN9W,N>&UL4$L! A0#%     @ 8H +
M2V8X^1\_ @  (PL   T              ( !!&0  'AL+W-T>6QE<RYX;6Q0
M2P$"% ,4    " !B@ M+4EWO>QP"  !I#   #P              @ %N9@
M>&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ 8H +2W\!('DJ 0  .PP  !H
M             ( !MV@  'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L!
M A0#%     @ 8H +2Y6 &TAA 0  : T  !,              ( !&6H  %M#
G;VYT96YT7U1Y<&5S72YX;6Q02P4&     !L &P O!P  JVL

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.4.0.3
 *
 */

var Show = {};
Show.LastAR = null,

Show.hideAR = function(){
	Show.LastAR.style.display = 'none';
};

Show.showAR = function ( link, id, win ){
	if( Show.LastAR ){
		Show.hideAR();
	}

	var ref = link;
	do {
		ref = ref.nextSibling;
	} while (ref && ref.nodeName != 'TABLE');

	if (!ref || ref.nodeName != 'TABLE') {
		var tmp = win ?
			win.document.getElementById(id) :
			document.getElementById(id);

		if( tmp ){
			ref = tmp.cloneNode(true);
			ref.id = '';
			link.parentNode.appendChild(ref);
		}
	}

	if( ref ){
		ref.style.display = 'block';
		Show.LastAR = ref;
	}
};

Show.toggleNext = function( link ){
	var ref = link;

	do{
		ref = ref.nextSibling;
	}while( ref.nodeName != 'DIV' );

	if( ref.style &&
		ref.style.display &&
		ref.style.display == 'none' ){
		ref.style.display = 'block';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '+', '-' );
		}else{
			link.innerText = link.innerText.replace( '+', '-' );
		}
	}else{
		ref.style.display = 'none';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '-', '+' );
		}else{
			link.innerText = link.innerText.replace( '-', '+' );
		}
	}
};
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='UTF-8'?>
<FilingSummary>
  <Version>3.7.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>77</ContextCount>
  <ElementCount>122</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>24</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="c617-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vermillion.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="c617-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00100 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vermillion.com/role/StatementCondensedConsolidatedBalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="c617-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00105 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vermillion.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="c617-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00200 - Statement - Condensed Consolidated Statements Of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vermillion.com/role/StatementCondensedConsolidatedStatementsOfOperations</Role>
      <ShortName>Condensed Consolidated Statements Of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="c617-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00205 - Statement - Condensed Consolidated Statements Of Operations (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vermillion.com/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical</Role>
      <ShortName>Condensed Consolidated Statements Of Operations (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="c617-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00400 - Statement - Condensed Consolidated Statements Of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vermillion.com/role/StatementCondensedConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Condensed Consolidated Statements Of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="c617-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>10101 - Disclosure - Organization, Basis Of Presentation And Significant Accounting And Reporting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vermillion.com/role/DisclosureOrganizationBasisOfPresentationAndSignificantAccountingAndReportingPolicies</Role>
      <ShortName>Organization, Basis Of Presentation And Significant Accounting And Reporting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="c617-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>10201 - Disclosure - Agreements With Quest Diagnostics Incorporated</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vermillion.com/role/DisclosureAgreementsWithQuestDiagnosticsIncorporated</Role>
      <ShortName>Agreements With Quest Diagnostics Incorporated</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="c617-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>10301 - Disclosure - Commitments And Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vermillion.com/role/DisclosureCommitmentsAndContingencies</Role>
      <ShortName>Commitments And Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="c617-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>10401 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vermillion.com/role/DisclosureStockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="c617-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>10501 - Disclosure - Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vermillion.com/role/DisclosureLossPerShare</Role>
      <ShortName>Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="c617-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>20102 - Disclosure - Organization, Basis Of Presentation And Significant Accounting And Reporting Policies (Policy)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vermillion.com/role/DisclosureOrganizationBasisOfPresentationAndSignificantAccountingAndReportingPoliciesPolicy</Role>
      <ShortName>Organization, Basis Of Presentation And Significant Accounting And Reporting Policies (Policy)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.vermillion.com/role/DisclosureOrganizationBasisOfPresentationAndSignificantAccountingAndReportingPolicies</ParentRole>
      <Position>12</Position>
    </Report>
    <Report instance="c617-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>30403 - Disclosure - Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vermillion.com/role/DisclosureStockholdersEquityTables</Role>
      <ShortName>Stockholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.vermillion.com/role/DisclosureStockholdersEquity</ParentRole>
      <Position>13</Position>
    </Report>
    <Report instance="c617-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>40101 - Disclosure - Organization, Basis Of Presentation And Significant Accounting And Reporting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vermillion.com/role/DisclosureOrganizationBasisOfPresentationAndSignificantAccountingAndReportingPoliciesDetails</Role>
      <ShortName>Organization, Basis Of Presentation And Significant Accounting And Reporting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vermillion.com/role/DisclosureOrganizationBasisOfPresentationAndSignificantAccountingAndReportingPoliciesPolicy</ParentRole>
      <Position>14</Position>
    </Report>
    <Report instance="c617-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>40301 - Disclosure - Commitments And Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vermillion.com/role/DisclosureCommitmentsAndContingenciesDetails</Role>
      <ShortName>Commitments And Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vermillion.com/role/DisclosureCommitmentsAndContingencies</ParentRole>
      <Position>15</Position>
    </Report>
    <Report instance="c617-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>40401 - Disclosure - Stockholders' Equity (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vermillion.com/role/DisclosureStockholdersEquityNarrativeDetails</Role>
      <ShortName>Stockholders' Equity (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vermillion.com/role/DisclosureStockholdersEquityTables</ParentRole>
      <Position>16</Position>
    </Report>
    <Report instance="c617-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>40402 - Disclosure - Stockholders' Equity (Allocation of Employee Stock-Based Compensation Expense By Functional Area) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vermillion.com/role/DisclosureStockholdersEquityAllocationOfEmployeeStockBasedCompensationExpenseByFunctionalAreaDetails</Role>
      <ShortName>Stockholders' Equity (Allocation of Employee Stock-Based Compensation Expense By Functional Area) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vermillion.com/role/DisclosureStockholdersEquityTables</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="c617-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>40501 - Disclosure - Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vermillion.com/role/DisclosureLossPerShareDetails</Role>
      <ShortName>Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vermillion.com/role/DisclosureLossPerShare</ParentRole>
      <Position>18</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>c617-20170630.xml</File>
    <File>c617-20170630.xsd</File>
    <File>c617-20170630_cal.xml</File>
    <File>c617-20170630_def.xml</File>
    <File>c617-20170630_lab.xml</File>
    <File>c617-20170630_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies/>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>36
<FILENAME>0000926617-17-000049-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000926617-17-000049-xbrl.zip
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MP!\.D&A6,FTFEN;%G;<M#WDC)[!@X)!P@ #XS>^!+>1PPC8;K!<@EU#C=F9
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M&XS[@675X+%M8V=<(_#)@!H8TIO*(>/3KQ3+8FC20FKT&74]>?3"/'%F0<F
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MD_M/CM+QZTI'%SD/8=*4THF $$K'C[-6QL *0C@OU.=I,W@F[XM&N' &KW'
M7'A&AV)YA-SCU1*3#LV3T'PF\,C"3Z'=+%(*B#C^QS0'-YWO:,U&B8JW\*W
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M5YC_+=K8HXB/^^YB+%#D] O)'],LRL/(,"5[1A$9WK,3(37\)6Y4O8%^#%Z
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MCPZ<;GM ATH>16''*CVO"BZN'5S\PFSFXDV0MDFH.>8V]WR7^OSQ$"NJWY1
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M29/#Q7<E30K#]TP43'ZD@,<XZ&+RQ_331:OI;AE#TM(QI%4!I.4QHG@!DQ4
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MNDZC-\GWN/_0@Q?,(_1_W'@KI=,QLXW^8'&35"_,$HKD:M3931X<2$6(>,?
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MGU)KBJU[N!U'.O&=4,V99.0\Y0=\$T-J[)C,RC8VSZ.YR&*+P8.]97L#B0?
M^YBC,35T4&VE0[;8:3;>>5QF6J:210 YEFR(/;=B2HR<IMDR P1'8E%3 6D$
M8#1C;OIC<AVU)),]#]HI$?7H^&%*"@4=R.JB58(I;FNC<=N:1+^;86LZ/\1:
M'HHB[5N;%7RIGF?7>+.,-8TT?QHB.AAP=\S,J&6\C/!$[;]CGID$?;#9XBTG
M+I9#W@A3<>)KB; =6R+2\@V458;)R3&Y%+F-L:4!3#1!-O/%><6BGR<])D2?
M'I?#>[')$:,S"^%+@JW[H2LSF5P\25L5& ;F&<I</NE2A!L[PXBJ;R+Z=2>:
M6LH:F48HHY<S)[(UT;0EM>_C=E 9U*2Z,'@,&[# F-8@OB3BX-EIAIO$O1OK
ML91:\J;X-2V ,E17&]N!U<Y46<I^(3,WD\1L)7RGM"Y=Q%/Q<$)]94]0X_*&
M*/LQRM&.O=:D)6;NT7 JW3['Y)*.>H)$+',0N95H&*+V349'_13IHDC//R-V
MP6+@]F( T#@2Y@P-K3Q'^-4\U+V/',9%W$9YN9&?/W$F46,X825(.R3,#<6F
MRZ""$1] 5[ ,86^']M;,..HJEA:'O 6_X+$[9O>JW1:)#5!TO'!5APU^S-2>
MM-3B(INX# 0Q6@L+)-(9"P+1A=\0L0H#S#?4!C-^EH4N:%<-8*<ZH=L)_@:W
MJ!M?">S80OZX7&1&H! )*XC8([4"&EFDV:R$6F2<BZMTT(J.@SC6E,3^8E+4
M%9K8(M8IDL(3J/#BM@&HAR15/-[%3W@K40)':(-++UHDD8=_AXGD;TJ]XI$W
MQM.FS$_DFVC=RWU1)"!$) @V45L1MUITF0_N<7C1J:B[<DQY!6CVR9B!!V.*
M\&IH9TL3".^&,OA$-KP23R(G-"7AXQH([H*_^4< VRR^*JM;1=FB16:W/8SU
MX4@+!?.L9(A_*3Z8_#%Y+?SPR[O JP\IG9RE;U0_CSOUP0?14O=ZD&ZH^RF\
M^N-"5(((.O=L,SE(BIH>W0/R/UF.\>/CO_\;(;_$4Z$P[8D>9M\=.[I<!;<E
MO'_+!A^.>M[#]>"A\]!L/*"Y<H17@,HGV%!6TX^P#@YL$\O[<%1O'GW4M$:C
MD5I+W@0Y,'Q-FJ>=+X1"TQ^:&H+160E&LS4/QOP<VP*R/CJ:^LOA6$J9#7"B
MGRZ%95WZ%,0HK9.MH G/2KW/CGL["\)%((VQ!ZWQ('#2?KAW\$,S_!0.\O 5
M+RKO)>F#]],)ZX&I_/#HCJV'>S<8]T'6IJX,^$P-H3>_B5C$TK4UYH@^ _(V
MZY'+.<'EQ!A><S4]3 .V8?]3;[-5=-O;K<*94DM$D=9?RBI0VB?M1:!$L^7#
M<^_T#!'C^H:M[VWF3D$Z7L(WD_%"9+=2O-,*(4Q8!YQ ,+;\Z0UH:#\]V*=I
MC/?H72GW_L$L\U?T#LYEI%J0RUN/!IJ>3X3EZUJ!BX5+6$JQ3IIBJX6-UFBW
MEH.^$ PEX&_ <$(Z-8L!'D\#N'DINWS">RE]6(B>:YUVLX"NGK ("-='I-XY
M?2F \KJESZXSOO+P AN#70\N\';%(MGUM-.9@7/1M"\##Z1+.X8O^1")#/SA
ME6BAC\R42/$+9ICKB0Q=IN@5M9(;>87837R#6(&;K*WI)VN .@O"8K!%\M*U
M;-][&5XW:A;))NV%X.9./0=IOLSXSI;ML<YKZ9[VW&H7@O^BA6X@[K33&?]"
M&5 ;>#SMUJR(4PW3*W'$R=QN77.=MRQ*BBM><NM9!3@[U0L V5":G>HO  30
MER;(==_BP_"FC2*U7&LIB(N!4 +\AOC5V@4!+R^BA?=35[R%]@CAYH>C*Y^-
MZPV!ST)Q?SK+J4L V1;FU@*86]NIN\XLPR@ N;T<S9L:[J=-]2 WEV-Y0Y#U
MS@L8 Z]Q8^8E=3%GPNL91C .1,^G"Y$]_$)]6V]VV^UV9P:\57,6 ./ZV*LW
M3QOM[ND+012G'*F6BR)N.HVCIIMPZ$>,ZJ8CO/!W-AR>M/ ,/XNF7F=Q'+HT
M->('5-I?-30_8.KM6[N2MT*VJJ%YU="\:FA>-32O&IJ7JO=SL<JW:FA>-30O
M 5-7#<VKAN950_.JH7G5T+QJ:!YKX*JA>=70O&IHOK=;N@0QP?TH+-A1=Z6J
MH7G5T'R/-\@>G1 <4KRS:FB^?P<P54/S/77*2MHH.$\F5PW-JX;F54/SM]S0
MO/O:%*CZEU?]R\O<OWRWA><KTR!SLR:+S5#7YW+4Y22;3+U=LO-)8S:)=/.9
MM\QL[^B%+7K#J;MS2>FY,XLJVVF4"ET0O1M''ULS-1.9>3:'87/"8\%<L3!L
M5>#<::K PV8PS+1,6 ;#';68%[+*%VR1.%NO]/+BX>Q>S)MP6Y"V+(68*6<N
M$J)MZV&:7=5(VE2:=!HO@"B,.13.3#-UC NF? %<VW&4>KBVXZMN9S?HVA"L
M)<R^&"QCQ,S 8M>#Z-Z%\%5Q^X*X?"%]TT$/O'K9)OYZ<!N[_3>B._HY'M^^
M<CU(ZH=/W/1'8#8V_A[G1OHBJ<)@EA7F4:)4%Y^]"36BS^'OPY@9NO9TXK&S
MZ(_W<F!PL1K',/A<BF;6[?+=^*/\;))'$;C#"3"(>I2%M]D][G;_OE805LRX
M>8@V?"X1F/-XWE6A@>^\CWQ-6',V#S6UX.6N+*"KO8$WFYT0SY#Q_H&S$3=-
M9F=\W;2KNZZW*WV*E6<?6<\B]#1\<S.:-K3CKE[1= .:SH+PEYGP5@$4:78J
MBI2((II^K#4JBI2((I74*B%%*JE5*HI44JML%*FD5@DI4DFM4E&DDEIEHT@E
MM4I(D4IJE8HBE=3:(47D9S?S^>!"F?KQ27LW%%N8F?.7U>'*I8DE5?1REV2,
MMQI1(?U@<=Z$ AG:1RLH F 731%QA0()N:P$)$EE.!NB!'@G>VVC1//5&_-^
MY#)&OL&3D4<N;<Q(_&< >&PVYCM@5/M4)5-4.W</B%2BG7O'GPO8MQM:4< /
M;\^$>GGUU\P&V!FW;<912XVT'7+V3R)IUPD\:IO>?#GG)FIHGE_?E@Y:BU]+
MIJ'TK314OHZI5-1KJBC,G-J5%?E"^I=W"Y?3C*PVZ0%MTD[EZE5[M-JCI=ZC
ME2*M-FFU24N^23=3I(=Z@G5^?HDAA#=UAJ6D)EM,>QXV 75SFK@<K*GV:BRD
M5NIOD<_QRNIX+_?RRS;<WXK?8OF)(:4D;0Y^UFM\D-+A HCW1P#"DTLG'X[D
M?T,EF>R:2F8=8ARWDG&5C"LY:57+.+V2<96,VX>-4,FX2L9M)^-:E1U7R;B]
MV B5C*MDW)8RKK-*QAU$!'>_]DMIX[31A=^B*Z697/F]I)OCWFK-*BY;8?M0
M:^AV'"LX##.Z,I8K 5(2;+\U 5))D$J"[!%U]@#;;TR"M"L!4@F0_:'.'F#[
MK0F0YIN(DQU*Q+FT$331#5R$SP Y/YBXZ^4 @V=EXJ.WK)(J.I1#697EN*?9
M/0Q#N#K2KN11)8_V7QYIK4H>5?+HL.FV!W2HY%$HCTZJE+]*'ATXW?: #I4\
MBL*.57I>%5Q<.[CXA=G,Q7ND;9-0<\QM[OEXX]_C(594ORF!J$(Q;=8@XTVA
M6X7^>1&Z52?8=%<>;[TUH5!9MY40J83(1F<+A]+WH!(BE1 I"[K?FA!I'<J)
M0"5$*B%2%G2_.2&BK\SW/8BP69FBQ0<94+MW?&I5^7D'*Q@+;_&@PW/3"?H6
M>TGGV;W<Q(??Y$$E<57[YJT#"?!5!]N5H*L$727H%@JZDRK#N1)T>[(7*D%7
M";JM,X/TTTK058)N/_9")>@J0;>UH.NN/%8^B&#N?FV9%X9L]S^"^L;CI$L$
M2H5O!?*_PK=B_JZD225-#A3?E32II,E!8[N2)I4T.5A\5]*DDB:'B^]*FA2&
M[YDHF/Q( 8]QT,7DC^FGBU;3W3*&I*5C2*L"2,MC1/$")AF LQE_,.N'(TT,
MM"1'+[URDO[PR[O JP\IG9S=&2-F!A:['ER.)Y8S9>R.N8_<8'<CZK)/U&/F
MN3.>,-NC/G?LGF4YAOCK>G#+#&=H R3F#7.Y8^)-QMX]>_8_P3L_/O[[OQ'R
M2SP-LV#IPYYM?HMZ_UT^XZB,<//#T97/QO5&0V\<$0,6 F/<LL&'HXO %7,]
M:/ _O'_[X=YYZ#PT&^+#$0EL+E_\%?[0]"-B,H./J>5].*HWCSXV3QM=V$.I
MQ2Z$8AMHM>X":%M;0:MU=*70GB['[4D:VI.5T.J-3DLEM"?+<;LAM%JCI6T'
M;>XN*))).T+.IR#+G?'%4&V(L,Z)MAU4_3F)X;K4'C*\*N?3-'GEAD[QJ]X3
M=4WQK]^8AU2X11'K@4 QX"D=L@T6]1 "\B#&NY].6.^9>_&WMS"!RPV?F7<^
MR*=O;-QG;OSTQJ+V=SJ6/WETQ]:#>.MZ@O/AP_LG &AZS^R9']YS'Z7GE0VB
ME9L!M9(1OCMV)%0ON,L,WW&]F5^'JTY^$WZ1(.""^NR3_-4LU5IIJEU]_WST
ML7&LMV>(5C1!*IKOAN;G%<W?',W7)WE%\13%8\LUH6115,_7>^);KQ?X(\=%
M^_=7&YRLF1&]3]/+9U@L]]@-L".[15PE\V>>G:_/:^?,]2D'ZWL OW,],&"B
MU2]CN>7+D5@%8H(O<&VOPX5Z)78.C@DO]HT)#U[[Y?HZA\Z&EQ4;KLV&\]#/
M3?%I=HK+/P+N3Z]L,)("_-*[]D?,O1]16]++^P)#^-Z5+8,Z^VR7A?QQ#HL*
M+!]7E4_..6KJ>K>EK7)^B\=U013^3+G[&[4"UO.\8"PGRFRQ#$U[WL/UX.V(
MET_%LT]SQC+2C[56 <RSDHP5N^R795[QS=OAFR*MF%5\HQUWFQ7?2*Y@[L!Q
MQV"]R?.K63NPY%Q3I MV8-+FNQ/:3',VE;"AV%X;JHL#B"M-5:VIZ>V5!S5%
M(/AU";F-+[Q''L>IKA4APRLBONYNW*N-&."2K@>A$GNDW,*,F<^.*^992PMO
MBOZ5".QJNGY:B#FS8GD%(3'7C__B.IY71995^MQSC'.R3A;%BPA:<<QAN-WS
MNE?K5+Q3N5!;< Y8W@?*.=71DVK>T5KM';..X_KWS!U_<ES7>>+VT,LQ\33]
MH:FMF:_:U6>8?VZ";2#8(*FSV]T0 &2-D6,!EWC2N'X9!IHGG1D4S$VP!0#K
M(Z#5UD\VG__*\P)FPDZ7Z4? +2)^,^-G"=XJ6+64UQ_/H+8A,L?G\+HIWK*H
M_Q]1.\#,WB-SZ9!EO)/KP/< ."R]@.W-#9 F%]P*5@6UEB<:SZRHK6M-7>]V
MDT5M!Y&Z5:V5-3^_JK;6:C7*NZJUTJ]G5]76].;IR4EY5[56%O[LJCJ:UCS5
M"EH5;N^S"];WD_A(;^P$MG]I\2&7CC[\_Y _,IMY>8JF^:#KDN$B03(S7"Q%
M+IAAKB<W]$:8S;\A> O7=.[ "R"WOCNV 7:!Q=$NOX&OK!G=L:9@WGR)\WE_
MC7;N^I:!NG!]^"GZX3^=_KG+Q"HB5HB-JMVLM3UGI;7R:;DNV)NN>_N<FS46
M^_%&_[]-5I-.2A&_BL]ZK@?_0UUI< JEF+.[] < ;J45 UNFVV@E.V;A#"DH
MOC@@$T"C@]UMWS@6-Z9QS=DF(O@CUL.E:^/@[VQ1H*RYQ*K$\+.LHLR4*>;5
M$IZ&M83-(OI1O:1_FWCV)"?J@U48SH(#G7$?H#'RK])$!),0P^N4)BZHI>Q$
M?<XX^&6V?];LE (AL_<<C!A!EXO:4S*B'@QC!*X+/.WQH<W!O<-8N,U\8H%-
M!Z/A!:,V&XJK18E!O1'!<E:/#%QG3)P)DTSGP<\!?S@:$P9L3=Y,"K\GX+."
M,2HFHS:AAA&, XNBKC49S,=]X@P(G4Q<YQFVB3]7WEGDZIDUG:\?+7*"^0Z!
M18X.=KK2\6OM[JG:"4#V*9V )$745.E$/IDIUU8UT3\#FY&F8KH3U!'')"T<
M0&$YA#U/F.%[Q'>DH(#M',F&M27#P'&)#P.[;$Q1-+JXW^?F"^O#X?O3]QX!
M0*F, Y$^LSA[A"7X(PH+#@P##,A!8($D&>$#\1*,Z"\:JQ^ ;$*;V.G_#HOA
M.-83MRP Z(^ NXQ@%P $E5IDP,$H,$ ?'"?4_8)&*P[OB50=^:Y7PV_@QQQ$
M7]!'V]WG, "V,_ )[3N!OQ@BVN<6!D, JZC!N1TP*2J'0A494A5)].",6*<K
MC [1%E2(SA!0F!&F]@42/!"Q0(D^ V@G+IM0E.J./3LLZ8-_(:EG.L1V?*2L
M%9@  E+=Q$:Y<CB!\#&JJ4B&"])*3 0X& 8;?,Z\8_*F]&9J5[B4(UO0"1H8
M@!K7"88C0/DC=3D#$@-C>D[@ L_6R-.(&R-@[6F,<;42"B!F8;P7X0 O90SL
MX&'8ACR%YF9-+0Q,1OV4SN$,!@R#5+ 6$RS[9 \K%IF&8UFPT5',J5V?[2E>
M"5C&(&)01M D *^:-8:"_X0<&F*7%%L(\D$@8B#B:W&C/1MR W21=*_5(N*8
M_,-Y HWBUC(J(80(]RU*RSX(RBB[ K8T"%N;,1-%K8O2UF?NV$,K%^Q@\0H(
MB90B."97&56%^B.PHQ>=/DK4].RA9*D1,)/3$(0_B-6'1ZW06!]'#1YJ*+49
M=4'F"&$/*[.<"6*Y)F!%_976TXY0<L0SX#M\P3-@3"$XT$$ -%-4GKB=<3BA
M' PGL$RI=BA,#&M'C41-P"'(' 8;T_!Q7.5R+D_-JK4S(ZNB%NI&#S&5PB;B
M*%'2L=UP?/"*LN<1&,((/+19@)F_.[YB1==2+!Z!@3^SOAM0=TJT$VDKUS*;
M6 0 &=IE%$PO_@@[@<"DAC1.)X'K!>A6PX:5-D!H.@%(8(QBOAV^8XSPK)/\
M!@($K%,N&IRD-#8R5*2U<:3H%\03Q\+ ?FH9/H%+[3R91:/O@ ['Q'4,D+)>
M-E2PY]Y\NZ;I)^H]8CH N0SBWPP,5 LDLI>$&0N>A?=&95*SAG]^$PH2ST6R
M6YKA/2'B;=AK&+<:NDQNYY_PM433G+__ZL#S7O0\>7+Q_N><O1\J\KXXM"?!
M!)^H9>(6\IAZ/HN<0W*''BGNU'/'MM'C-L 9OD"'U(^<]4M0B,X8+3N0:H#R
M,0;-I_!2;*/,H_GB\OPB@]QCM7CKH7SFTJOG7A\(&<<:U-)+WPV]GBC&6<Q9
M"Q4W10^4F"4V!1BG&+'!YUDV3P5([N<>HKQ^Y&84M$FB/RAV#@-Y&$ "0SSB
M#! 4 ZFB1S)8E,319)C*BY7^(/ #EQ&8"W6_/2M_BP9U09AR/3'?EF)^7L1G
MQ7GC[QFP>L(-^-7FA@/L]>UN=X+^E;M,KCJP2QWK?07?@;&OC*+?G<I[\ZZE
M#V$/\1GS;O%XLQ^&^+8_+Q6#I::)DY7$J>F]&XS[@66E!/9G:H@@97R8VOX6
MKN\%D*?6'YT=A[E]WF?'O0DMVAO7$;8*-MWLP5S^5L?A, K XT\QE<K'A,4_
M CZ1F85SF5IREG\P2^94GDNG6RXC1D"S$V%@(]CSUAP9^U]E_,AQTV4O2U-0
MVKC85KC8MJK%SIQA=^:S.6<QL71%*13,\(AH$'%M& &(2F,J.JHNH'4CM7[X
MT-2R"'@I?Z\XM3]M)X?VJY=0Q'I?L)M[>-6=#4*'>INMLM79=I7ND-K\3YE&
M4<8<A9?V.W[M'(4T@K<Y:VD=MZ/^U?"/^)35Z9KXJJ1:/0D]U,B5;1R3G])^
M02HPD?(.T@$+89AQV&I/(\>RIG7GR<:$AZ#O<9/C08U'J,M$0%\>$%I3L%?!
M2T8'$-T_C\PZ(U' <=9*H,2F8UCR@S%Y0 0CI[>/8AN"*HE0I=>=@?*)91XY
M;N:I$[CJ+<]P;J43_4S4GL"(+!G'G:!FDP$$$2B/W-P+9M$G8""9\\(]PNPA
M'28O)@?0@R@*'QUQ8+ +3^A@X_^)WP$[#FT0KN 9^PR5 P; AE-06H[EX$D(
M+ 7E<?:HWF.6Y9'KWWI:A')-U]^+":XQUS3SK<N]'PC)6/3J1VDNIE*+0,61
M!SS.P!-7\$$-/"=RLQ(BC1FQ$1 SF1<$EI1&D0]CI^%AQR22D8KW='28GB??
M,8LB+<P3)_<<9N,&**K$$B578XQ'R,A$#_YM2CL;-H%VVNUF>>7\ZU4O&\)#
MOYT/.&9@1&-;\=@UTKN[X;<]\K7WZ2Y/.Z4>JPI>K;Z@<RZO1\2 4:S5'[GO
M.FFYDX'^ZK=LR(WXP@CPY)T)G@P=<=>L8W!O2@RP/)TQCAP1;['635 'DRS!
MW"P(41Z%$)VPU\WTJ1M(7)$OA:$KU>'!&#P4^93@OA!RG)DU@ER4,$XMQ3!1
M:$Q$Y(&9?&EBC)DXLQ7Z HST/P(FI#)^94<''S@50!,,J($1), R^.$_Q*^<
MC"9AR788@2U7E\=3S^ 'I++C/(].UTS<41$E6>(RI!R+I!WD]>#6F6)N_0WE
M+ZD]R<GO;X4@+9@L#0Z6348]%NZ=3TQF:PL_.DK@WB0YO)G36%/3HWJ#=69+
M :>N T><IK[/M7'KMSF9JW+I:HE?O ,LEX&F^]&Z9MMZ1^WTU0B:9-GW# ,K
MI.2U++<,O O1(1]E(7BD51A%01@EA7V"Z"_60-@<'DE^X8[$#$ B#G@MS;PM
MBTHN_X]Z_?+9QW1"3%'[RCV?W#$1$*_7XS<^.XYOXQG\S"/ \X^S0?CP*WP@
MS^(K'T3-AR.&XX+5=!1^ZSI(II'O3\[>O7MZ>CI^[KO6L>,.W^F-1O,=/GZ'
M+QZ)P:/A =3,J.*"+\>-!AVYN,/^&MW+I$??@P7'K.2^)OW!ZEM'Y%UFZ CR
MGIN=@KI&- S\N0+L\(UW:.75HQ&CG^,9^QP0X53.AZ,(K_6&=D3$57C(#S-0
M;H: Q@($-,J @,8.$* M0(!6!@1HZA'0.,U'0..T! B(@%"*@-8"!+3*@(#6
M#A"P0 @VRB $&SL0@HWF @0TRX" Y@X0L$ (-LH@!!N[$(+=!0CHE@$!W1T@
MH+,  9TR(*"S P2<+$# 21D0<+(#!+07(*!=!@2TU2- 7V 'Z&6P _0E=D"K
M* 0LL /T,M@!^A([H# $++ #]#+8 ?H2.Z P!"RP _0RV 'Z$CN@* 1H"]2@
M5@8UJ"U1@WI1"%@@!+4R"$%MB1 L# $+U*!6!C6H+5&#A2%@@1#4RB $M25"
ML"@$Z M"8GH90F+ZDI!8LR@.6. ,:65PAK0ESE!A"%@0$M/*$!+3EH3$"D/
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M?M[F?QZTJ]*SWM CX]3D5;^"-ZJ@'1VT[=Y6W&G-B]6?-_OX'U!+ P04
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M6S!8^$6KY4IG<H./QTB"V(6S=],9A=@HQOF5^EM9#Y4*U9*E(].A@LH\RH(
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M5-6Q4U+Z<Y/UQ]+?/_\?4$L#!!0    ( &* "TM]KQCWJ"T  +J7 @ 5
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M?TO=NXQ' SL %/1+!2.A8+PF5*7@U*.32'WOK7?![NHXU%2OV^ C>!T><>H
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M^,<D;IVLVC @6KA6A9:=2ZEQK%T#16X[P$#J' O">1 MOY\.08T#TP'2E%)
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M2QO%;+MPG'',U-H+&LGL5!E_9WQ!X')AGLLH&B>UUA<D;_^E#6<]^_..,L+
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M6S_0.>:" _/0=YQ>GZ)@R'VRWS[LP_ \CB+J9X&_S\R^:,&$X)/6JI2^:>3
M\5%+6"VK*?@6I,8YD_TK?7>H,@BZZ'UYYE]GQB4_Y-H:%B='-$@+>1G0QIJ]
M3C#_\KS=>GN YVG:3JPQC!?&4M6-L4K1: 5[69^];9^:QD.;<O2FZ(!NZW0K
MM$<[[MT [:W$%#?E:\X)^\[0+(%VG2QM/$DGUH<G]*WHHWMKVMUG!2W.$*$%
M7O=Q*>'L3JI!H;OF*Y)L<7>.)X&.D#1;52376KF&'CF15:6 -"7UF!@ON52.
MQ)18GC]KAVOZ776P@C[C"3Y-UG&R]:(\1U5_N*BD1CJIUX-OG,[+2><_D=?A
M:)]55]3%D^6XUCX9_/DL/K^?JEED-RAP+%L"LF[-M:]GM^!6V\H;P-@KZQR'
M=DE\1(/Z:ZL7H0T"K%]<NV(I?W/4)=H82-%W?OABD2TJ_4=Z$U'M?-Q)@E/[
M-#HE+;9?9.RN[*JHL778+!$; $(*86*0Y_V15)6^K2$>SK#1=< Y6^[UU>L5
M%UXF]RTS.<+9F@7\\E1-0XMSGF8$I!RC*Q8"/&2)=(@VG@:(!V?=E?CSGCGC
MZ8(P=_HPFU.>=?3*,]?<\JR+7YXYYYAGO>SZS"7/=%*%'LZIU^,+LTS^_>PN
M>M[11<]=<]'S+BYZ[IR+GO>R[W.77-1)%7JXJ%Z/"^K7/?0/4OCYW]>L/?9O
M]B_V!\3)?_K_4$L#!!0    ( &* "TOM;_>)@AT  "X) @ 5    8S8Q-RTR
M,#$W,#8S,%]P<F4N>&UL[5UM<]LXDOY^5?<?>-X/-UMUCB6_Q4Y-=DNV[)SO
MG$AK>V;V/DW1%"1A0Y$:D%2L^?4'\$4B)0($2$"$(-=N53PV **??@ T&D#W
MSW]_F[G6 J  ^M[GH^Z'SI$%/,<?06_R^2@*CNW @?#H[W_[]W_[^3^.C_]Y
M\_1HC7PGF@$OM!P$[!",K->E=0M02'[5AX'C^D&$@/75]NP)B M>?KCZ</[A
MU#H^3MNYL0-<S_>LN,'3#]W57V[3-GWODW5UTNV>G':Z'ZW33Q?7G[J7UO#K
MJN!7W,<QK"SI0N_[*_Z:A>7T@L]'TS"<?SHY^?'CQX>W5^1^\-$$5^R<G60%
MCY*2G]X"6"C]XRPKVSWYY]?'9V<*9O8Q](+0]IQU+=),6;WN]?7U2?Q77#2
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M/<JXL$C9[@E09W5+K22H=Z.VBL/R' _+EI]52+\T*!\>$Y.TD(M6#QY&+R)
M]MX@[67J=D%M*"1?T^47TCC$9U"DY>?*10&^V3.09"'F4O>ZN#9*%U1,E48K
M)-3UG*(/G%%IWNR-OVJNM@KT-R;U"K&43M-=!8>-F\O=<S2;V6@Y&#-GKT=*
M FS9S6M#'973_$Y ,S&YX!/9+WA@E-T\P9A$L\@E%_[[ ,,$Z:&>JBKJ13S5
MY"CS%M="R$0K=><A#0^/;0U04CJO:;$ONL?B]V8$82YS>5W\T%DEA(N"X_G6
MMUW*0F8>'I<$D5&:94:+3?PO'I9L=.,CY/](LJ_8#G'S\T]4S!8.G6]-H=I-
MT+O6'BF*G6"(OE5L]R1"^U>+%*\"XYO4$X2J.MI, XW?&=87E\.MV]+^FYK>
MXV;Y@K_-<.ASU-1&]?4U5VI&U));7]<^52(B#]/+SU%3&PXTU9\ $RJD;_TP
M0 YMDA2S_PW<T2]XR4;Y\-!!Z9D"?\7](4V%JK=)4U-X0SACS'&QI,5$[%BX
MS$.FE9_K_5CXD(^%+[!0ISJI3<ZQ<"J67L?"<D9OO.ST$++QW)6M9HQ)F59<
M&QK(G)J%A&6XGEO>X)6)P9RBZ16T47,M%?%IF"&IKI-U+R)Y$%_ FQW<VPY)
MG+ZDS]W4PGNA7(9V-B9S,3EU5>T+7L=>(]?%DY@'G! Z45BMXLI*AJFZGKRM
MOQ87=\$^LFYL\=331O$RUNEF4C-.]UI>L)7<'-!8UVP]U;T2L NC_4('@F2Q
MW9_L$,0/&L@K*H?H=D)+G,'?P(&02!@"I3>6M+@;\-4.(]*=/D:#BT;Y"@="
MFTJ1];J01/7U%#Q=\5QZY\()Q$OPO8_P_R=P 4@H]')?$&]MXT@A0WZEEXR$
M#1@NAI#_NO6Q3+87_H__>HM K+1O$3&UU\]_.=C"V](A,*<1%DIO"LEZL<(E
M;_("O#9UDNH'S!<& ++R4^KDORYB\@+0C,M6(06-(XF@J K2?378&7'-&1G?
MO_F>X^,)$9(;O$/\*W<=[9P^9;!J&T<&&?*G#+DRZ5F&LNOT!G"FIL@I3:[U
MV.3L_3WY2XSJF1E$:HI!YKSKF$2MH;V,P<4[PR= ?W-8+&4L17CDS&B@R<T+
MVH/\)#N\-TFN\@W"*=ZW.4XTQ]/G,@YI56:B5-<R3O5-Y,ZHH,;QVN8EG+NW
M.42Q&HDWL4N9%LJ*&D<086$S5JCQL[9Y;X>$WWN8S1$VW6-(OR!_RPU;7<%L
MAO"+G/'$J">=CR ( "!(D$B!ZSL4P<842QP!@S&!F_'FK%YC!O-+&AP9]Q2_
MYFQHQ/ *3&RUWFL:/8_NLVW0G'&<4@)(QBHU3MV6?#0E6& K '@!^ :HX3E9
M=8SC4GVI,\*H<?O*FH:R4Z]AA)PI"1V,OT220/MHN?8GE.ZG^&H:1XBFLF>T
M4./K;>MI<^I;>/%[SA\11."KC57@ ;3,/^"K<,"P*QM') GB9UPRRB%<>*:Y
M0C8D,Z[M9F#U(]I5*=[J14 _8D#/S>!3(P"RVW9J_,#"5D[5HK5V:68S\1#Y
MH\A)HD\G[W^9:Q=/ \8Q11($&5>:.HM=39R#A:"-6 0')LXP,'=!&KVH-R-1
M^-.<B;1WZI2)25;SQM%Q)P!E9&WJSBZFQFG]@CH5!/K^C57%6&X)"YWQI:FC
M6QI?*$OA^O;\8/SD+\D-DZ$-2UU$E*+&Z5Q8V$S7FEP-EG_X'<L/M^X)LXH:
MQPIA83-6J'$CM[1>I$,A=5U1^% L9"P3.,3,.*#&Z;NCP)#;V<6^V8@X,Q=
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MVFX$\(H00U)-)5K-=UJ)@B/)$J;%I[F49$'%)^+I8A"\^#<@&37Q"?QO)$P
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M"1&-W.7XV_\#4$L! A0#%     @ 8H +2XFT0-5*8P  I^($ !$
M     ( !     &,V,3<M,C Q-S V,S N>&UL4$L! A0#%     @ 8H +2^&2
MFMUN"0  J$P  !$              ( !>6,  &,V,3<M,C Q-S V,S N>'-D
M4$L! A0#%     @ 8H +2WQ?D"8;"   BFX  !4              ( !%FT
M &,V,3<M,C Q-S V,S!?8V%L+GAM;%!+ 0(4 Q0    ( &* "TM3%5P\/1
M ._F   5              "  61U  !C-C$W+3(P,3<P-C,P7V1E9BYX;6Q0
M2P$"% ,4    " !B@ M+?:\8]Z@M  "ZEP( %0              @ '4A0
M8S8Q-RTR,#$W,#8S,%]L86(N>&UL4$L! A0#%     @ 8H +2^UO]XF"'0
M+@D" !4              ( !K[,  &,V,3<M,C Q-S V,S!?<')E+GAM;%!+
4!08     !@ & (H!  !DT0     !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
